%PDF-1.3
%âãÏÓ
1 0 obj
<<
/Producer (pypdf)
>>
endobj
2 0 obj
<<
/Type /Pages
/Count 8
/Kids [ 4 0 R 64 0 R 122 0 R 159 0 R 188 0 R 226 0 R 251 0 R 256 0 R ]
>>
endobj
3 0 obj
<<
/Type /Catalog
/Pages 2 0 R
>>
endobj
4 0 obj
<<
/Annots [ 5 0 R 6 0 R 7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R 13 0 R 14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R ]
/Contents 24 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 29 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F5 39 0 R
/F6 42 0 R
/F7 45 0 R
/F8 50 0 R
/F9 55 0 R
>>
/XObject <<
/Im1 58 0 R
/Xi0 59 0 R
/Xi1 60 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 61 0 R
/Type /Page
/Parent 2 0 R
>>
endobj
5 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib79)
/Rect [ 134 269 218 277 ]
/Subtype /Link
/Type /Annot
>>
endobj
6 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib86)
/Rect [ 225 269 290 277 ]
/Subtype /Link
/Type /Annot
>>
endobj
7 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib86)
/Rect [ 51 257 112 266 ]
/Subtype /Link
/Type /Annot
>>
endobj
8 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib52)
/Rect [ 118 257 181 266 ]
/Subtype /Link
/Type /Annot
>>
endobj
9 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib65)
/Rect [ 226 246 284 255 ]
/Subtype /Link
/Type /Annot
>>
endobj
10 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib10)
/Rect [ 209 190 290 199 ]
/Subtype /Link
/Type /Annot
>>
endobj
11 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib10)
/Rect [ 51 179 75 187 ]
/Subtype /Link
/Type /Annot
>>
endobj
12 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib5)
/Rect [ 154 156 209 165 ]
/Subtype /Link
/Type /Annot
>>
endobj
13 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib65)
/Rect [ 113 145 172 154 ]
/Subtype /Link
/Type /Annot
>>
endobj
14 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib14)
/Rect [ 341 269 460 277 ]
/Subtype /Link
/Type /Annot
>>
endobj
15 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib39)
/Rect [ 334 168 424 176 ]
/Subtype /Link
/Type /Annot
>>
endobj
16 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib8)
/Rect [ 433 168 541 176 ]
/Subtype /Link
/Type /Annot
>>
endobj
17 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib82)
/Rect [ 517 123 547 131 ]
/Subtype /Link
/Type /Annot
>>
endobj
18 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib82)
/Rect [ 308 112 327 120 ]
/Subtype /Link
/Type /Annot
>>
endobj
19 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib39)
/Rect [ 334 112 416 120 ]
/Subtype /Link
/Type /Annot
>>
endobj
20 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib79)
/Rect [ 516 89 547 98 ]
/Subtype /Link
/Type /Annot
>>
endobj
21 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib79)
/Rect [ 308 78 353 86 ]
/Subtype /Link
/Type /Annot
>>
endobj
22 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib7)
/Rect [ 469 56 541 64 ]
/Subtype /Link
/Type /Annot
>>
endobj
23 0 obj
<<
/A <<
/S /URI
/URI (http\072\057\057crossmark\056crossref\056org\057dialog\057\077doi\07510\0561038\0452Fbjp\0562008\056307\046domain\075pdf\046date\137stamp\0752009\05501\05529)
>>
/Border [ 0 0 0 ]
/C [ 0 0 1 ]
/Rect [ 519 794 595 779 ]
/Subtype /Link
>>
endobj
24 0 obj
<<
/Length 15177
>>
stream
q
q

0 0 0 rg
/GS1 gs
1 i 
50.797 447.477 496.176 -0.454 re
f
BT
/F1 1 Tf
19.9253 0 0 19.9253 50.7968 696.5857 Tm
0 Tc
0 Tw
(REVIEW)Tj
20.4233 0 0 20.4233 50.7968 659.225 Tm
[(PDE4)-336.5(inhibitor)-8.5(s:)-334.1(current)-337.2(status)]TJ
/F2 1 Tf
10.959 0 0 10.959 50.7968 629.2912 Tm
[(D)-331.2(Spina)]TJ
/F3 1 Tf
8.7174 0 0 8.7174 50.7968 603.4392 Tm
[(King’)50.4(s)-335.4(College)-338.2(London)-332.8(School)-337.6(of)-331.1(Biomedical)-339.1(and)-336(Health)-334.1(Science,)-335.8(Pharmaceutical)-342(Science)-334.2(Research)-327.1(Division,)-342.6(Sackler)-334.7(Institute)-335(of)]TJ
0 -1.2617 TD
[(Pulmonar)-17.1(y)-333.9(Pharmacology)69(,)-333.3(London,)-334.4(UK)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 50.7968 562.0534 Tm
[(Phosphodiesterase4)-271.8(inhibitors)-268.9(are)-265.6(currently)-267.3(under)-263.2(development)-270.7(for)-267.2(the)-264.8(treatment)-264.5(of)-268.8(respiratory)-267(diseases)-267.6(including)-261.6(asthma)-265.2(and)]TJ
0 -1.1634 TD
[(chronic)-300.6(obstructive)-310.3(pulmonary)-299.1(disease.)-304.7(The)-296.1(rationale)-306(for)-298.8(the)-302.8(development)-302.3(of)-300.4(this)-302.6(drug)-301.6(class)-300.8(stems)-295.6(from)-301.7(our)-302.3(understanding)-307.3(of)]TJ
0 -1.1697 TD
[(the)-328.1(role)-327.7(of)-332(PDE4)-328.8(in)-322.4(suppressing)-332.4(the)-328.1(function)-333.9(of)-325.7(a)-328.3(range)-328.9(of)-325.7(inflammatory)-334.1(and)-322(resident)-331.9(cells)-329.3(thought)-331.1(to)-324.3(contribute)-335.7(toward)-326.5(the)]TJ
0 -1.1634 TD
[(pathogenesis)-482.4(of)-477.4(these)-482.6(diseases.)-476.1(Similarly,)-484.1(numerous)-480.7(preclinical)]TJ
/F5 1 Tf
29.0348 0 TD
[(in)-477.2(vivo)]TJ
/F4 1 Tf
3.4017 0 TD
[   (studies)-482.1(have)-472.4(shown)-478.7(that)-481.9(PDE4)-480.6(inhibitors)-477.6(suppress)]
TJ
-32.4365 -1.1697 TD
[(characteristic)-266.8(features)-257.4(of)-262.5(these)-261.3(diseases,)-261.1(namely,)-256.6(cell)-259.1(recruitment,)-264.7(activation)-265.3(of)-256.1(inflammatory)-264.6(cells)-259.8(and)-258.8(physiological)-267.2(changes)-255.4(in)]TJ
0 -1.1634 TD
[(lung)-270.2(function)-277(in)-271.9(response)-273(to)-267.4(a)-271.4(range)-272(of)-268.8(insults)-276.2(to)-273.7(the)-271.1(airways.)-267.2(These)-273.6(potentially)-270.7(beneficial)-274.5(actions)-275.3(of)-268.8(PDE4)-271.9(inhibitors)-275.3(have)-270.1(been)]TJ
0 -1.1697 TD
[(successfully)-382.5(translated)-384(in)-379.3(phase)-375.4(II)-377.8(and)-378.9(III)-383.4(clinical)-379.3(trials)-378.9(with)-380.8(roflumilast)-383.2(and)-378.9(cilomilast.)-384.2(However,)-379.9(dose)-380.6(limiting)-379.4(side)-378.5(effects)-384(of)]TJ
0 -1.1634 TD
[(nausea,)-452.6(diarrhoea)-451.5(and)-454.8(headache)-446.1(have)-453.4(tempered)-451.3(the)-454.5(enthusiasm)-455.2(of)-445.8(this)-454.3(drug)-453.4(class)-452.6(for)-450.6(the)-448.2(treatment)-454.2(of)-452.1(these)-451(respiratory)]TJ
0 -1.1697 TD
[(diseases.)-337(A)-328.1(number)-329.2(of)-332(strategies)-331.8(are)-335.2(currently)-330.5(being)-333.5(pursued)-333.1(in)-328.8(attempts)-330.5(to)-330.6(improve)-336(clinical)-328.7(efficacy)-333.9(and)-328.3(reduce)-331.4(side)-334.2(effects,)]TJ
0 -1.1634 TD
[(including)-337.5(delivery)-339(via)-333.7(the)-334.4(inhaled)-338(route,)-334.3(and/or)-337.1(development)-333.9(of)-338.3(non-emetic)-333.6(PDE4)-335.2(inhibitors)-338.5(and)-334.6(mixed)-341.1(PDE)-331.8(inhibitors.)]TJ
/F5    1 Tf
9.4646 0 0 9.4646 50.7968 456.718 Tm
[(British)-336.1(Journal)-332.4(of)-337.1(Pharmacology)]
TJ
/F4 1 Tf
13.7111 0 TD
(\(2008\))Tj
/F1 1 Tf
3.3364 0 TD
(155,)Tj
/F4 1 Tf
2.3421 0 TD
[(308–315;)-335.3(doi:10.1038/bjp.2008.307;)-347.9(published)-335.2(online)-334.9(28)-335.5(July)-335.8(2008)]TJ
/F1 1 Tf
8.4682 0 0 8.4682 50.7968 435.5715 Tm
(Keywords:)Tj
/F4 1 Tf
8.9663 0 0 8.9663 96.3212 435.5715 Tm
[(asthma;)-334.5(COPD;)-340(cilomilast;)-333.6(roflumilast;)-345.1(PDE4;)-335(inflammation;)-336(emesis)]TJ
/F1 1 Tf
8.4682 0 0 8.4682 50.7968 419.1306 Tm
(Abbreviations:)Tj
/F4 1 Tf
8.9663 0 0 8.9663 112.5921 419.1306 Tm
[(CD,)-331.6(cluster)-334.6(of)-338.3(differentiation;)-339.5(COPD,)-333.6(chronic)-338.6(obstructive)-335.6(pulmonary)-337(disease)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 50.7968 371.2818 Tm
[(Intro)-10.3(duction)]TJ
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 349.1149 Tm
[(Theophylline)-313.7(has)-309.2(been)-311.6(used)-312.8(in)-310.7(the)-310(treatment)-310.9(of)-309.2(asthma)-311.5(and)]TJ
0 -1.3256 TD
[(chronic)-590.7(obstructive)-593.4(pulmonar)-11.6(y)-592.8(disease)-584.6(\(COPD\))-592.2(since)-589.3(the)]TJ
0 -1.3189 TD
[(1930s)-700.1(although)-697(its)-694.5(popularity)-695.5(has)-690.8(declined)-695.8(due)-698.8(to)-692.3(the)]TJ
0 -1.3256 TD
[(introduction)-549.8(of)-543.5(long)-542.4(acting)]TJ
/F6 1 Tf
14.0657 0 TD
(b)Tj
/F2 1 Tf
6.351 0 0 5.6449 174.5574 314.0787 Tm
(2)Tj
8.4682 0 0 8.4682 178.2425 315.496 Tm
[(-adrenoceptor)-542.4(agonists)-545.8(and)]TJ
-15.0499 -1.3256 TD
[(glucocorticosteroids,)-391.4(either)-385(alone)-388(or)-381(in)-384.3(combination.)-390.9(Theo-)]TJ
0 -1.3189 TD
[(phylline)-260(is)-252.7(often)-251(used)-259.3(with)-249.3(glucocorticosteroids)-267.4(as)-248.9(second-)-255(or)]   TJ
0 -1.3256 TD
[(third-line)-843.7(therapy)-843.1(where)-843.3(it)-839.4(has)-844.8(proven)-840.6(anti-asthmatic)]
TJ
T*
[(activity)-553.1(in)-545(asthma)-552.5(\(Sullivan)]TJ
/F3 1 Tf
14.1729 0 TD
[(et)-545.5(al)]TJ
/F2 1 Tf
2.1423 0 TD
[(.,)-549.4(1994;)-547.4(W)74.6(einberger)-551.8(and)]TJ
-16.3152 -1.3189 TD
[(Hendeles,)-396.3(1996;)-393.4(Lim)]TJ
/F3 1 Tf
10.1627 0 TD
[(et)-391.5(al)]TJ
/F2 1 Tf
1.9817 0 TD
[(.,)-395.4(2000\))-397.3(and)-385.7(in)-391(combination)-400.7(with)]TJ
-12.1443 -1.3256 TD
[(long)-321.4(acting)-323.7(bronchodilator)-324.6(drugs)-322(in)-317.4(COPD)-322.8(\(Rennard,)-322(2004\).)]TJ
T*
[(As)-540.5(an)-541.1(p.o)-540.5(formulation,)-542.6(this)-540.6(drug)-540.5(offers)-543(the)-537.6(advantage)-544.1(of)]TJ
T*
[(improved)-249.4(compliance;)-248.4(however)40.6(,)-244.6(its)-245.9(perce)14.4(ived)-247.9(lack)-245.8(of)-242.3(efficacy)70.2(,)]TJ
0 -1.3189 TD
[(the)-805.4(necessity)-811.5(to)-806.1(monitor)-811.8(plasma)-814.8(levels,)-809(coupled)-809.5(with)]TJ
0 -1.3256 TD
[(numerous)-560.3(side)-554.6(effects,)-555.5(known)-554.5(drug)-560.6(interactions,)-560(and)-553(the)]TJ
T*
[(effect)-335.3(of)-329.3(smoking)-337.7(on)-330.9(plasma)-332.7(clearance)-335.2(\(Boswell-Smith)]TJ
/F3 1 Tf
25.7281 0 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
(.,)Tj
-27.6562 -1.3189 TD
[(2006a\))-724.1(have)-714.2(provided)-719.6(an)-715.2(impetus)-720.6(to)-719.1(discover)-718(a)-715.1(better)]TJ
0 -1.3256 TD
[(theophylline.)-355.4(Moreover)40.9(,)-345(whereas)-349(glucocorticosteroids)-354.4(are)-352.3(of)]TJ
T*
[(clinical)-303.4(utility)-294.4(in)-297.3(asthma)-298.1(\(Barnes,)-299.9(2006a\),)-299.2(they)-293.6(are)-298.7(of)-295.8(limited)]   TJ
0 -1.3189 TD
[(use)-515.2(in)-511.5(COPD)-516.9(\(Rennard,)-509.4(2004\).)-521.4(There)-511.5(is)-513.8(clearly)-514.9(an)-507.7(unmet)]
TJ
0 -1.3256 TD
[(clinical)-243.1(need)-237.1(for)-232.1(the)-236.4(development)-243.5(of)-235.6(disease-modifying)-238.4(drugs)]TJ
30.3542 25.1456 TD
[(in)-645.4(COPD)-650.8(because)-642.3(other)-650.8(than)-641.5(cigarette)-652.3(smoke)-643.8(cessation,)]TJ
0 -1.3256 TD
[(current)-726.5(drug)-728(therapy)-729.3(does)-728.8(not)-725.8(prevent)-732.6(the)-725.1(accelerated)]TJ
0 -1.3189 TD
[(decline)-335.8(in)-337.5(lung)-333.9(function.)]TJ
0.9975 -1.3256 TD
[(The)-305.3(mechanism)-307.5(of)-302.5(action)-305.2(of)-309.2(theophylline,)-301.8(which)-309.4(explains)]TJ
-0.9975 -1.3256 TD
[(its)-252.6(clinical)-256.5(effect)-261.7(is)-252.7(not)-250.5(entirely)-257.4(certain,)-257.7(but)-255.6(several)-255.9(have)-252.3(been)]TJ
0 -1.3189 TD
[(proposed.)-407.4(It)-402.4(was)-401.8(originally)-408.7(shown)-405.9(that)-400.3(theophylline)-405.4(inhib-)]TJ
0 -1.3256 TD
[(ited)-304.4(the)-310(activity)-305.4(of)-309.2(a)-306.8(cyclic)-309.3(3)]TJ
/F7 1 Tf
5.9275 0 0 5.9275 420.4912 284.9385 Tm
()Tj
/F2 1 Tf
8.4682 0 0 8.4682 422.6455 281.8771 Tm
0.3048 Tc
(,5)Tj
/F7 1 Tf
5.9275 0 0 5.9275 432.5101 284.9385 Tm
0 Tc
()Tj
/F2 1 Tf
8.4682 0 0 8.4682 437.2156 281.8771 Tm
[(nucleotide)-313.6(PDE)-304.3(with)-309.5(a)-306.8(K)]TJ
/F3 1 Tf
11.4213 0 TD
(i)Tj
/F2 1 Tf
0.6025 0 TD
(of)Tj
-27.3013 -1.3256 TD
(100)Tj
/F6 1 Tf
1.8879 0 TD
(m)Tj
/F2 1 Tf
6.7745 0 0 6.7745 328.4786 270.6519 Tm
(M)Tj
8.4682 0 0 8.4682 337.833 270.6519 Tm
[(\(Butcher)-343.5(and)-338.8(Sutherland,)-340.9(1962\).)-347.3(This)-341.7(might)-335.5(account)]   TJ
-3.5415 -1.3189 TD
[(for)-613.8(its)-614.1(beneficial)-617.7(effects)-612.2(clinically)65.2(,)-612.8(a)0(s)-610.4(a)0(n)-614.8(increase)-620.2(in)-612(the)]
TJ
0 -1.3256 TD
[(intracellular)-259.3(levels)-249.8(of)-255.6(cyclic)-255.7(AMP)-253.3(can)-253(reduce)-248.6(the)-256.5(activation)-256.6(of)]TJ
T*
[(a)-326.8(wide)-323.5(range)-326.8(of)-329.3(inflammator)-14.5(y)-325(and)-325.4(lung)-327.2(resident)-325.6(cells.)-327.6(There)]TJ
T*
[(are)-573.2(presently)-576.9(11)-576.5(known)-574.6(families)-575.6(of)-577(PDE)-572.1(and)-579.8(at)-567.7(least)-574.8(21)]TJ
0 -1.3189 TD
[(isoforms)-446.8(with)-450.1(numerous)-446.5(splice)-443.1(variants)-451.3(that)-440.5(are)-446(character-)]TJ
0 -1.3256 TD
[(ized)-492.6(by)-485.1(differences)-491.7(in)-491.4(structure,)-493.2(substrate)-492(specificity)68.1(,)-485.6(inhi-)]TJ
T*
[(bitor)-476.7(selectivity)72.5(,)-478.9(tissue)-473.2(and)-472.7(cell)-475.7(distribution,)-481.5(regulation)-477.3(by)]TJ
0 -1.3189 TD
[(kinases,)-269.9(protein–protein)-275(interaction)-266.3(and)-271.9(subcellular)-271.7(distribu-)]TJ
0 -1.3256 TD
0.0001 Tc
[(tion)-795.3(\(Houslay)]TJ
/F3 1 Tf
7.6722 0 TD
0 Tc
[(et)-793.2(al)]TJ
/F2 1 Tf
2.39 0 TD
[(.,)-797.1(2005;)-795.1(Bender)-797.9(and)-794(Beavo,)-802.8(2006\).)]TJ
-10.0623 -1.3256 TD
[(However)39.4(,)-853.8(targeting)-859.4(PDE4,)-860.5(the)-852.3(enzyme)-855.7(responsible)-861.8(for)]TJ
0 -1.3189 TD
[(metabolizing)-833.2(cyclic)-824.8(AMP)-829.1(has)-831.4(been)-827.1(the)-825.5(focus)-828.7(for)-828(the)]TJ
0 -1.3256 TD
[(development)-852.8(of)-851.5(drugs)-850.8(that)-848.9(could)-849.1(prove)-847.2(beneficial)-858.7(in)]TJ
T*
[(the)-256.5(treatment)-264(of)-255.6(respirator)-16.9(y)-258.1(diseases)-258.9(such)-265.1(as)-255.6(asthma)-257.9(\(T)58.3(orphy)72(,)]   TJ
T*
[(1998;)-473.7(Houslay)]TJ
/F3 1 Tf
7.3174 0 TD
[(et)-465.1(al)]
TJ
/F2 1 Tf
2.062 0 TD
[(.,)-469.1(2005\).)-474.5(It)-469.4(is)-467(therefore)-476(of)-469.9(interest)-467.6(that)]TJ
-9.3794 -1.3189 TD
[(plasma)-580.5(levels)-571.1(achieved)-576.6(with)-577.3(a)-574.6(dose)-574.8(of)-577(theophylline)-579.5(that)]TJ
0 -1.3256 TD
[(d)14.9(e)0(m)27.7(o)17.2(n)13.3(s)0(t)31.2(r)0(a)24.7(t)13.5(e)18(d)-346.7(s)17.7(i)0(g)22.9(n)20(if)25.7(i)17.4(c)13.7(a)14.6(n)13.3(t)-348(a)14.6(n)13.3(t)20.2(i-)29.1(in)24(f)15(l)17.4(a)14.6(m)0(m)26.2(a)14.6(t)13.5(o)17.3(ry)-341.7(a)14.6(c)13.7(t)13.5(i)0(v)27.2(i)17.4(t)13.5(y)-345.1(\()12.6(S)18(ul)28.9(li)28.2(v)16.4(a)0(n)]TJ
/F3 1 Tf
T*
[(et)-431.7(al)]TJ
/F2 1 Tf
2.0218 0 TD
[(.,)-435.6(1994\))-430.8(was)-428.6(well)-434.8(below)-427.7(the)-430.5(K)]TJ
/F3 1 Tf
14.4139 0 TD
(i)Tj
/F2 1 Tf
0.7163 0 TD
[(for)-433(PDE)-431.5(inhibition)-434.7(and)]TJ
-17.152 -1.3189 TD
[(suggested)-440.2(that)-440.5(PDE4)-441.9(inhibition)-441.3(alone)-441.6(does)-434.2(not)-444.6(completely)]TJ
0 -1.3256 TD
[(explain)-336.5(this)-326.3(drugs)-335.4(clinical)-330.2(effectiveness)-337.2(\(Barnes)]TJ
/F3 1 Tf
22.461 0 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9214 0 TD
[(.,)-335.2(2005\).)]TJ
/F4 1 Tf
6.9738 0 0 6.9738 50.7968 66.4441 Tm
0.0001 Tc
[(Recei)-10.3(ved)-302(4)-297.7(April)-304.9(2008;)-306.6(revised)-304.4(5)-297.7(J)0.1(une)-308.5(2008;)-306.6(accepted)-309.3(9)-297.7(J)0.1(une)-300.4(20)-10.2(08;)-296.4(publis)-12.6(hed)]TJ
0 -1.2926 TD
[(onlin)-11.2(e)-327.2(2)0(8)-343.5(J)0.1(uly)-337.3(2008)]TJ
ET
q
50.797 124.214 239.131 -48.813 re
W n
0 0 0 RG
1 J 1 j 0.454 w 10 M []0 d
-409.493 124.214 m
546.916 124.214 l
S
Q
BT
6.9738 0 0 6.9738 50.7968 111.2314 Tm   
[(Corres)-13.1(pondence:)-244.4(Dr)-234.8(D)-236.4(Spina)-11.7(,)-229.2(K)0(ing’)-11.3(s)-232.7(Colleg)-13.1(e)-229.7(L)0.1(ondo)-13.5(n)-229.8(S)0(choo)-13.3(l)-232.4(o)0(f)-234.3(B)0(i)-9.9(omedical)-240.5(and)]
TJ
0 -1.2844 TD
0 Tc
[(Health)-319.8(Scienc)-10.7(e)-0.1(,)-312.7(Pha)-9.9(rmaceutical)-322.8(S)-0.1(cienc)-10.7(e)-311.1(Rese)-10.2(arch)-314.2(Division,)-329(Sackler)-319.7(I)0(nstitut)-12.8(e)-311.1(of)]TJ
T*
0.0001 Tc
[(Pulmonar)-14.3(y)-491.7(Pharma)-11.3(cology,)-501.3(S)0.1(t)-494.5(Thoma)-11.2(s)-492.9(S)0(treet,)-505.2(5th)-501.6(Floor,)-495.3(Hodg)-13.2(kin)-495.4(Building,)]TJ
T*
[(London)-340.9(SE1)-342.6(1UL,)-336.4(UK.)]TJ
T*
0 Tc
[(E-mail:)-343.9(domenico.spi)-15.4(n)-0.1(a@kcl.ac.u)-14.6(k)]TJ
ET
q
50.797 767.282 14.91 -14.91 re
W n
0 g
q
15.1199 0 0 14.9039 50.8093 752.3956 cm
/Im1 Do
Q
Q
50.797 749.877 239.131 -0.283 re
f
BT
/F1 1 Tf
5.9275 0 0 8.4682 139.9181 761.8392 Tm
[(British)-323.4(Journal)-334.8(of)-323.7(Pharmacology)-328.2(\(2008\))-324.2(155,)]TJ
/F4 1 Tf
21.2137 0 TD
[(308)-82.2(–)-83.4(315)]TJ
/F8 1 Tf
6.9038 0 0 8.9663 75.1181 753.8455 Tm
()Tj
/F9 1 Tf
5.7532 0 0 7.4718 81.8645 753.8455 Tm
[(2008)-333.3(Macmillan)-324.9(P)32.5(ublishers)-329.9(Limited)-1003.2(All)-334.7(rights)-328.3(reser)-30.4(ved)-1005.3(0007)-116.5(–)-130.7(1188/08)-993.7($)]TJ
5.2302 0 0 7.4718 275.6976 753.8455 Tm
-0.0001 Tc
(32.00)Tj
5.9774 0 0 7.4718 232.5543 742.9038 Tm
[(www)81.1(.brjpharmacol.org)]TJ
ET
  
 Q
q
q 76 0 0 15 519 779 cm /Xi1 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
50 56 240 63 re
f*
0.619608 0.619608 0.619608 rg
n
48 752 242 18 re
f*
0.619608 0.619608 0.619608 rg
n
518 779 75 15 re
f*
0.619608 0.619608 0.619608 rg
n
231 742 59 7 re
f*
0.4 0.4 1 rg
n
50 694 74 20 re
f*
0.4 0.4 1 rg
n
51 656 294 22 re
f*
0.4 0.4 1 rg
n
50 370 59 11 re
f*
0.6 0 0.298039 rg
n
50 627 41 13 re
f*
0.6 0 0.298039 rg
n
51 591 482 22 re
f*
0.6 0 0.298039 rg
n
50 455 497 116 re
f*
0.6 0 0.298039 rg
n
50 434 313 11 re
f*
0.6 0 0.298039 rg
n
50 417 365 11 re
f*
0.6 0 0.298039 rg
n
50 135 239 222 re
f*
0.6 0 0.298039 rg
n
307 325 239 32 re
f*
0.6 0 0.298039 rg
n
307 56 240 267 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 126 704 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 347 668 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 93 630 cm
BT
1 0 0 1 0 0 Tm
(3) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 535 603 cm
BT
1 0 0 1 0 0 Tm
(4) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 561 cm
BT
1 0 0 1 0 0 Tm
(5) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 365 435 cm
BT
1 0 0 1 0 0 Tm
(6) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 417 418 cm
BT
1 0 0 1 0 0 Tm
(7) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 111 371 cm
BT
1 0 0 1 0 0 Tm
(8) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 347 cm
BT
1 0 0 1 0 0 Tm
(9) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 347 cm
BT
1 0 0 1 0 0 Tm
(10) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 313 cm
BT
1 0 0 1 0 0 Tm
(11) Tj
T*
ET
Q
Q


endstream
endobj
25 0 obj
<<
/SA false
/SM 0.02
/TR2 /Default
/Type /ExtGState
>>
endobj
26 0 obj
<<
/BaseFont /DJCIIA+AdvStone-SB
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 27 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 291 291 375 572 572 979 781 208 406 406 427 572 291 333 291 458 572 572 572 572 572 572 572 572 572 572 291 291 572 572 572 458 833 666 625 666 750 541 510 760 739 302 302 645 520 958 781 791 593 791 614 552 593 718 656 1000 687 625 604 354 572 354 572 500 354 541 625 479 625 552 354 625 614 270 270 510 270 916 614 604 625 625 395 427 385 593 520 812 531 520 510 354 260 354 572 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 572 572 0 0 0 0 0 0 0 0 0 0 0 0 0 572 ]
>>
endobj
27 0 obj
<<
/Ascent 735
/CapHeight 700
/CharSet (\057i\057K\057parenleft\057t\057zero\057eight\057parenright\057T\057u\057one\057A\057g\057B\057v\057two\057colon\057m\057b\057C\057w\057o\057d\057R\057c\057D\057comma\057y\057l\057four\057E\057e\057p\057n\057five\057f\057I\057r\057V\057P\057h\057J\057F\057s\057a\057W)
/Descent -249
/Flags 32
/FontBBox [ -177 -239 1395 770 ]
/FontFile3 28 0 R
/FontName /DJCIIA+AdvStone-SB
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 510
>>
endobj
28 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 2344
>>
stream
H‰„UkPWî¦»ÄŞèÒÓdš_¼‚<PAŞàÀÀ‚<u„…Âˆ‰ÏUAƒV¬¸«¤\|ˆÈËA|€"FQbXĞ˜à#‘„ÄÍF\9=9Ce{0»kÕşØª®îº÷~÷|ß9÷;·%„LJH$’ß…†…-q\’Q¢)^ŸŸé¬Yjœv8©À™[â2ÜaCéÿL*J~İ»÷ÍÛœùØNûØÆ,`ºmşönBB˜Jˆ©1MJ°Âš 8‚˜IRÂ• Ü	Â“ Hˆ¥r"JFhH"‰ Ş¥2qmñ!¡#z%f’ù’É T"õ•îvJÇL“¹&&	&ÛLÎ›ü`bÍ‘í”=#g‘«ÈäsÊ‚Ê§*©+T7=ƒ¤7Ò—éåä¹òƒòS+Sa˜ÁPÁ=Yd^ú7( ìGxÜ­L¼H¢«­z F›DG°·UŠğJ½Ìì‡èƒ
sDÿQÊö4\Ç¿wĞ(`3’à„öã"úrŠh3ˆ!ïëÖ4fpé[ŠğH2Ğ¼•‡q˜ÁÍb1Cı1V$Ü0sÀÿ^’>1àÛú¼¯¯Õ}1&}~Ï*}
‹2
5'üáİ¤a&Íè,…ŠWØCÌ$‡Yg»*@n×‹æhê¿bEš²3Œ<ßz­ş&w»qER`²ú£?hA2Âûz5;›B4$‘‘0„ „ˆ'ßxÑø­%$Â'd~B1Õ×Ù„Á¿m¾Ã'˜¿„i?iÀ·5óu0ƒ„5Ôé$S‹ğ>	‹`Ê²¹Qi!óÔ‰Õµ©<-½ìÒôÎÏ¿li¸|†×½?–^î-Ú£YÂ•ù³à¦à¢ÉÍ¸Óü¥ãûúEés¯â;¨T©ÑÄëZÒÍb¥:Ç'ÄNÒq_pUVèUìİ3I)q©kŠøôcÑµ=Škçtİ“E¿Ãjës.4Ö×75gÕgh³²µJøE¦­ÏçÎÿwyMbŞØ8¡&¡¾ 	Q=(~Ü(üT¯&1À°­û®îI5ò
ª‰¯9ÓÅ0ÈŞ§ÜÎòñSkıø@jÄ“ŸŸŸÂÔq‡[ûù
úÊ¡‘6)~ğ¾fJüxBMJø… n·D…Ç%øòéóHo®ŸÃI9µ”Ã=è„QƒZpFwØİ7xì¤ÏxFnX³âƒxßEúïàî¯~†Y×»J6ëê=,&0¡†4|óÄcß~öà‰ügö%ó»âlLğğAOŞ“bÒ„to0ŸPF±J tK!¶PL€f\›"FSAı›…RØL1Ø Å–z5ª&Ô´8˜dTÑÉÛ“·”(·oúpKá¹7Ó~	.¼Şf>ƒbcUU“Æ+(¨Â_aVƒa+Ô£¬÷c/YN1 XcïPÃ—´ÎÚĞİ|néQGÃ¢— ÛÆÆ¡İx,0F¢˜3“èêÆ‚E‰¹‹øX
U3Vd©{LÁLl…y§Ğ:ÈŞ¦[¯0Åõ.*”¸[$L,…1È5ô;C®aŒfú…©–P­Æ©Uá,>˜f]NECZ4GA0:l°‚CÁbo¸	ñb>Õ`H®”—S©°:"R y• ¢`6Õ¾WaáUˆÒ±¸°}å0‹‚"]•Œâ“‚«Eš8X!•3iğb€-Ø—°T)&¹©~×¥f¬¤a>’5.ÁÑ¥‰QJ]$YSß|´‹Óµä§àÑ,‹DyNp¼“Â¥Gı°íbMuƒò,ìbqîÁà°?pëÖ×´vÕ5öTñ¢O¿‚ØÁFOO÷<;/×µOF€nxÌãaCÖİTzC{~73Ÿv º-ÈKÌâË¡­)ÆVc7ædÿ)—sŠ}ğµVV–ï®ä+wWî:¼óì«Ú¤ƒ«9\¦ÛÕvvºBÆÅÎC'/é;EúG-¾s3İü3G_¼¨zÊÃÔIv}Zc[9Õšs*œC…3NGKôxf3v´\¨ã+(&[ØÛY°?Óp>‡v(³Ç÷ĞH8vİ¯lîã3ûÉâœ„Ò$Î;¬t_ñûùs·‡¸ŞÓ	»x?€BK!ÌûĞü+úî/GÿZU¶óˆòx/y$+c·Ø>gğ±C‚h¦I¸&”±h]N]\¿üL4‡6ÿÑe=ôFW…tH¼{Hì¡š$e¡™÷ÙPé ö`9 …<füoÒ¢}SôE,ZM5´S_·ëzîÕ¦.Sâ-q<HÃô¨»hYœœ&Şa÷úD†2°ÊèĞ^öJm‹®imcjÚºŒÌ•gµ—Ä´îAª¥±‚E4ÃbTmeÜ—©'Mº;]µÉbì›F.úYsãİŞªå1JìÇ_Ñå@«ï!¹G½'<oÕjy[^üÉHN^˜–Í—ûì­`ÿGèèc®¯A.à…£($Z8£º¼FÌçdN…¯¿®ùiäûêyŞîT9üÛ–Colé˜xÿŸ¿ÙÒ¢O,ıÄ6‘ç®hÍüÛØ=[°i„hM×åá“Öï$ÍÛ"÷R@\lh;}xçÖcÊ«ß‘Õë×}šÇióW—lâ2Œ7ºÓ…5ìÙµñ‡ã8û õ¢¨¦Ì®şrvGaŠbUö†Ìµ+OœÈS®
&s.µßã@ú` ¿­¤#è¯iI>Ş¬8Wó¯ÍY¹xUcéJ`äÄ~/ı)th.ëoW÷‹¿7°«îúÎ´}÷´ù›äJÎ²6UV5çIÇ­»+ÿ½ë»øùßâìÀHZì»Ä`’ßÊfšë“³ó¢Ü÷Ã@ş5ößB'}¾Ú³t×.9>ÏïûÅ¾çı¨ıÍ¶ ö7{ìo¸ßòÀ#ñ»|üw„ïì¿%‹%¾'ü©¶ Ê~° Ã A!^!ñ·8°XÊø.•ö9X
I|÷øSÉúŒmëwæmßY¶|–J[‹oÿÍ²í73Ç¶ï?š~³ÏNÿÍ”ö›9ã·Ø
ñ„o	ß8ø<{T‰~úÍúÛ2,ªĞO:ÓèÛw±“ßùN,“ÿŞıcÿoVìnãàûqAäÇ=Q úäô×

endstream
endobj
29 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
30 0 obj
<<
/BaseFont /DJCIIC+AdvSTSerif-R
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 31 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 291 291 375 572 572 906 812 208 354 354 427 572 291 333 291 385 572 572 572 572 572 572 572 572 572 572 291 291 572 572 572 458 760 687 614 739 781 572 520 791 802 354 354 666 572 958 791 812 572 812 635 500 614 781 718 1052 760 645 593 333 572 333 572 500 354 510 583 489 604 500 343 541 656 312 312 552 312 947 656 593 604 604 385 406 375 614 552 791 572 552 468 333 260 333 572 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 281 281 0 0 0 500 0 0 0 0 0 0 0 0 0 291 0 572 572 0 0 0 0 0 0 0 0 0 333 0 0 0 572 ]
>>
endobj
31 0 obj
<<
/Ascent 735
/CapHeight 700
/CharSet (\057R\057K\057question\057p\057four\057S\057parenright\057E\057T\057five\057q\057quoteleft\057U\057g\057B\057r\057six\057V\057b\057C\057s\057a\057W\057c\057seven\057D\057l\057comma\057t\057eight\057X\057e\057G\057hyphen\057u\057nine\057H\057f\057I\057Y\057v\057period\057Z\057h\057P\057J\057colon\057F\057w\057slash\057bracketleft\057d\057semicolon\057L\057i\057endash\057y\057N\057zero\057percent\057j\057M\057z\057n\057one\057A\057k\057O\057bracketright\057two\057m\057quoteright\057x\057Q\057three\057o\057parenleft)
/Descent -249
/Flags 34
/FontBBox [ -197 -239 1270 770 ]
/FontFile3 32 0 R
/FontName /DJCIIC+AdvSTSerif-R
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 500
>>
endobj
32 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 5136
>>
stream
H‰¤UiPTgíŞ¢B³>´_Sı»  ,‚Ù5€Ê"0:†}i´hhĞŠeišÍhDBµUhÜW4‹¨Á(‰gƒ:eÄšrnSkæaÆ™LÔ_ó£¿®ºuÎ½çŞï»ç‰E&F"±Xl3oA`HHàtÿÔ¼¨è(…Z™æ9w6ÈÄ;#ƒ©-.Ã";“Á¡­„|‡øŸ¿¦Ô˜ƒŞ²Ön\»•ÈH,nØ¨ÊÒ¨•ËWäòÓRìy—9³=…sÎÌ×§+ïŸªJVğQšœ\EF’™¢Rg©ÔI¹ŠTg÷OOç#G¸9|¤"G¡Î¢!Ñ|T®*SÁ+sø$^­X®¸jE*Ÿ«NJUd$©Wñª4!“ÌLÊUª2“ÒùhM–"-)EÁş;½vşŸîDb)ÑF"3s/M`E>"‘?+R‰DaÂLD&¢u¢ÏEß‹^‰íÄöb?q¤¸Zü‘­Q‰Ñã‰Æ«w˜Œ1‰1)59E°„Š¸JN ÓÉÓ”1¥ .QOi?z?İ7*hÔ™ÑÄè…£O;&L»©™i‚é93{³OÌÚÌ®›=‘˜J6Hşjîh^kŞkácÑkéa©±<kegµÀê¦µ£õJëŸmfØÔÙÜaÆ1jæ ­±mšíyÛ§¶ÃÃø’áó±w¹ğİ[ŞôÅmFcò\]>÷±É³îû0ááR Q‚’?#é²‰Ã	•7İÉÅØønV¾Àêÿ/k©ÀÂ	İîÏ¸áêZæ2iX:A„“l{h˜Ã´]|“°úÌóÅáq:yMÜÎùi	.‡_0ŒÁé0VîÂ‚ï!pö™|c#î¼+ºc‹ë R¹@ØIHŸ Óa=Q®àîƒòØÉ‡Ğ}YÑ¼é8VÀï¹!L[ÇëúûTÖ‡ÇÔßõ[ı8Ë˜;¨›C	ØÛç¥>³µU¿¯µ5C¯Tfd(…Á<õCw‰E$nu—À‘Ba
l oˆÄ òÆHtÀƒ8¸ı&9h]Ïá6XíÚV›ñ6>G«ÍjNÏ‡b¬°ÿLy¢‘øjû…æ vØ›J«(ĞfÉµ¹)å~Åt6´P>u
v']º§b{+1l`fqnNLˆ’ç;º®]ì ¯]Ğ@³@:_Dñ\åü(9Ò-Ô`ı•ã?ÉzN,FÍÑÆÏ—‹‹]I/3„S,ô02§Àg†8,ñ÷IÙr,“‹¹©­-*ß¸Qš«)*®(«*–òıb}ßêkåR]v7„_99uMÚBë¨»z:7ı¢Äó ’Åy¯ÉLà|¨ıDïŞ£úNYÇé˜¦-Š@S-'1xE0‹I¤Ñ½pcÜÜ­ã -\^±N›-×®V”X"ôİÑB}T›¦Ó6ÓÚ–Šú/Ùî?L¤ğºí©;@AàåN»)	D
¹Üğ©k¦"ÍzEy‡+[›5òĞ[Å›‹KJJ¥yù%¥UEU%Ò£^„¦©Sİ+Ì;àQ¦¸¢‰;S	P‘»oƒfäN´k„‹\U†é4”¿œãe }ü$•ØW:^/ó‹ÏHSpåº}àöÆC˜VŠ½ÃLÿw?=:9k¢oŠ“ûŒ°{ÀÖÉ%†à!‚	ÀpôÀ¯\Ğ~LÂxy‚o€}|ØmZ¨o«»JvË$0Ûp™¹rìbOÏ±HÿyŠe	yr·¶ù'~daôğ1Æ#ânÿÖãßäî&qêÖsé¢™òÊ¡¡8pÒüsá}É\¨Ú-IM| È^ö€;ŸÓ.?ÓğËÙ§ì‹™gÑH.y ¼ÛÊz UdÒZÅ÷£µ'OŸˆaçí7½”İ:©oû’Ó•«ĞÍ9ÓI¡×àÉ¸‡ı)À)¾ÿyÏáG=](+‘¿gc"¥>Cˆé¿E{¾G¿×F0IXÄÌoQ0‚IôÃH?rxPA,ÓWw ë’ü›³W:úXyt¡ÙŠ u…ùråÂ²ÒŠÒÚ2©>¯¶¬¦²¦FzöQ¿­©I/ûº5Ô/~MjRì\”X5‹NÄiïØl¢ €9†‘ĞP²r‘,ÖµP‰k\ZÍ)L†ËAGG‘³1Gá_İè•k3×d	¨-TBşÁÃÛ¸“ÀÛÛ½„üö’334“ùš8­˜†tĞÊHÎ—\er•üõçD4›–í2[³û>‡…³©‡…Úgvx	å\]ãR(Ï=S¿ş¥Çã«8u{çµN¡mÒ³ÁC¾ğ!3wU¨/Je˜8xˆgpåCÁ	ÂeàvÎİ«Šk†l(¬W}*oø(®ÑA†Í8Ñw@¨$õßhØÖÎíı´±º™Õƒ¥àé¯5’ıLxU‘Xƒæèê¨®ñˆÒ}Ì[:/QP	SÁb!-ÀK9¼GJØ
I½à/Ù$W—Œ“e.©u÷8Èë£ºv®ˆĞ	Ò”Ùdhy–z‘ÌƒÙİí¿EÏÊ&ÿPFÿZ×êóhÿmïAeCså²µºôI©®æå##Xù¦#)<Ã‚Bæo}M»¯r@=Ò–>Ü*oÁ£Ù½NFyÆ¡%&xA¸VÊÁ·ò:LÅ{'ºm7QÁÕ7@¼bà’oÉ2,ùOÉæ7wşøüß¿«­‘Ïd¡›ù?ÁqæÎOÈÕ|V¿Z®l,üQ«•æç••×KÄŸü‹ñ*ŠêÊÂ£á½ÛŒÚ–ŒO¡»|Ï=’ˆ 8$.qCYei6K£t£â°ˆ¢,6İ@”Uöl6‚— £&#‰Ç‰3c¥fÊhâyät¦æv“*kş¼W¯î»çœûİïœócGŠåy—Œ•Ç$uÅ_]€(™ô1ØÀîE¬“kÄc%³µ«&æ´ü›2öÍK¸ ¶Ì×¨ZØnÛÕÕqº©XbD/5i?zõPx,ÒV£Ù—¡Ê•@È‹G·°'ãöh({
,ìYU8"ˆ;^“Tœ!dså,Ô‹=ŒÎüöKà÷#×:oÑí.»Ì±Y¼È ¯šíí‹
­ÌÁdoNŠ6•ÏVÆ¦‡fÓ.´ÇHB±¥ÙímynEµL´×Ñ®³wlã4ñ*©ÖWèÊyC{kiN«&7²[ÓJ‰.UŸ²WfvÔ´7tOË[‚îjö’)^Ù(˜ãŸ;ŠKßfq¤5·ŸåXyx`ƒ3úH¤pD´¥5[M5ÑjPÂ"´Í˜€Q¸Q…`‹À_hhå³¤!dÓ&i^J{¡,=Ñ›òÓ’HC,X]B+ï»§è„d™0í.Ì•ÁÄe7p9e¯J/Îwãq:w¸B_°³Ğ.®(¬dS3N¹l;jˆNÜ‰‘¸púÃ|\üYváÄ£Ú²«‹ìÌ“Çîs– í1‚şè‹SéÆÉÓ‡a1¬¤#?ı){ëÃh‡Ì»nK…·Yô€û/–£_Xéõˆ &5ã¸+ò'%lLµÿHğ-{°·ıôäµ??‘õüóóy<ÃJİE'±—ƒéÄ§ÏÒñ¥ïú"äH^_¿ÇG]P
ğÆ‚¶@wÙ:ß-ëW­;¯Q?8—¥9£×òÉƒş$‡‰ ½şÛ?kTxı“ïÈnœ¼üY‡ÿ†"6‚g4ü‡ìƒª ·¡MÆ|MD¦½ÑR5ø@şĞÜù"]-åXù²Æ~‚n7fB,p0câyh{ÎÆ–Ò^¨IÏ¯Ùˆ&‚K]qÚG?ƒ™´ƒ8Àiª°²ß¤šyJÂU7qË®•ô³_@ä}ˆ OÉ¹ê–cMr#ªÔä¦Qå©¼ĞÁy C,ô…5Qğ[ÉWqåƒr©˜
M‹”9ç[¶Û7
ğ¦¹™éf!Tì…¹“¡÷î-ş“¬è¬=IM&ªÉçy	û¼Âqv$ÎÃ™-‹!¢‰‰fQaî`è×qs3¹Öxª£ ñÎ˜w²æTUİí«&­-ÉÛbÊ÷u³asyGKe]Ø¯&gªv‡5	4I2Ñ‡Ö¥à:„6ë#‰Úeê¦*Bç„fcODz4])4’€ƒ¥Ÿ
4İÚégà;^û“¬H½®ñX+à"ÓÛĞPÒHİlW“+Í;½cäQ“@ÏhwÜ¡+Ejr¶QãŞb	à2ƒ‹~®Ob…Ç‡NFväh]÷¨ö°f—ïÇ×Ä0b¬W³NyQ‘+äØÆŠKÆ&0–™Äz,‰û3¨Œ®$8ıøya,‡|P|¼—¿c¤UÚX’•úé;~ Lø>‡î?°•wUƒê;gË¸>tï€…8/^–ĞTVøáÙ2-Ÿ}v÷Èı§i Ü‡¶^±A
UGÏ×OêşÖÂÃr,å²™MêÜî~hŒÛ:€Öá±‡ÿ¨à3rÊÚ—h›w8?§@ÛzÈ¶ O$ß i¯«’_­õ]*ào"´Vø',”­ô»aj<^VËß`ŠTe)¼ô­]Ù\ş¥Ò¾µ¸·û‚üöí-8İïµ|GdÁ‰t!µ2·§IFH®üÚ`â—rªa¥0œÀÍq%ª­•Z]xªG†ÖNİE§$
ÒÕ¢×=n¿&>)@s·ì[˜÷eÏ•†ÔÔR¡ßGŸ[pÔo×V“¯;¢ÏÕÛÅ3•q…;ä¸ 'ÍÃ%kÛŞiœGAR\OµşUFzZ\
<âˆRÈŸŞ=CçñW»R"Œ&óÔ_`ÿÎæÃ)¦áàLR¦ÓÅËQÓœp²#8–Õ•UŸ†;&ì)K±£•GM\#›u÷è|¶Êç õšS+OÆòÎŸQR/7±0}(ÕÄd$ÅY6'¬Ú¬ÀæzçğÅ¾pğ]é{¨¤ÖÀ?ÄD˜Ævm9U^•™YË·§h‹´T—×åç
³
ìB;3ŞKÑî×ÚíÊÙ—œ&Qª•JÙòŠğ2YlÈwÉ å§ÖHüJ]Nµ$§îHi‹.ÿ‹tU1Ò$èÎç†|Kàçë8×ïâí®¦ÎZ†Å?pg–„føf¹ëìŠ5*½Rî0ÏoÖŠSÛîDßÉkÔ|e§%³˜´LİŞ4æF‹—İãû_Ô·¾”w<Ál>¾İP'«(+-9Æç•æUÊaÒ­wú“Ïí®Ğ¡‰»®k_ë(S¤¹nÊå]r“ş=,ë«ù(Ÿ—şB(×¼‰ú}b´Ü¹ğù‘òÄ¥ØûPRò¤
ÆÃÔoõÎ<z¾ääiÒ-”.uàá*‘b„ˆïqŠ]›2¨uÒgÒ+<ùâV‘#È‚× n654šL‰ñªDu<o11ÉŸ‹ÈÊÚËŒÑ¤ìÉ‘ì%££½°J;({,¶·Pö^‹í4Èx‰ıb_	·¥'Ã—G:bkjj«ª´è*Wª«®QY%D„».Û$7ıŠ¯ƒŠØƒLa8åÿ‡¡ø‘Š6Tîgq°¾§ûŞ#Ãª5<z¼Ä¾„ÀÊîş¿şï¢ÉÓ·Ñj…÷+/×˜(®(×Â»%B´e*²:·QêT4-õ1â+hÕuY´q›®Œ È"‘İòÖa1Ç®”Z²°(²îúŒòa£ØJM°±hü`L4Ö´gš»<£ÒĞ&úmîœ™3sÎ=÷wşg—1CêÉÉíHÔÏ_¹Ëø-³
o²²QËÊÿf7>*Ä÷ÚÒAúN€”[sÿÆÎKø˜?p&øj*ÿ„3¾ÂçA$kD©5jÃ3ˆ„ø[¿ÂGp4á	+–É"Ü°loA×İèqùõ¿õxüì|>•Ç¤g:ZÍ,%ÔÚİZŞ¥‡% tğuÜMşáœ‰ÙFDlù÷Ï(tÍğó©¡ŠÍ…åÙRyî7öÕš lŠäŸ0j,Õ°®JÇ'h,ZÎépµ“¡Æ·”›ğò^R.¤·ó R.‚¯„»êd±ÖVc¯«q9£êjj‘£_”« ¨²Do-<´/›6‘Ç#*xXF›ºé?4™E9r«Óq¼òğ1üD¢ß!ZÛ»J®è>9ÿ²»¨}f€-õoQz¢İgOy®Ù¶§ZRí&„iÒÂÔ/’Û
î§°éşœUÑ;÷ìX¿ŞğS_¥$co€?5Î€yYÂ¾yùùt“æoàí”O¼š×'î|™BŠ³e{–>Ù>àfĞ!¯ÉæUoÆó±#+d6åq;Œñ‰E}ıÜA{êP¼oì{)mMê:YÕâ‘ùˆ^ZHVçˆ—÷_¯;‡Â ^¦›¶Zê,~FÚ4Š¤ÓÙÔÓƒF“LıWÊ–Yÿ˜ÿHpÈ¨U-â¹óf!E:˜®†Ã”`¸vù)¾ÙÛ|â´æ6M¦keÓ,l·išIRÃHšÀcƒWÉPGeÿ\ÀPmŒø\¼`©:éÃu¡L;\y&…ıÅçò0O¶dÊ9é(‡V)ts‰ğ±{Ïú9!†³69o*4-«¾m?ã1°û)Œ&7¼MÇ=è(	%Wµ5İÌÄŒù2èD>¼¤O¾Tz	íh¯·®;Í`Ap¼P`Ş›“yp|J.)*¯(-¶Ò’êâ£Ò]ÁİpÊídàT˜§×;”—Òeß±ˆiê"Õ&ò|œ"ø*›;zˆøí`Ò‰L¢ÆÂ8Y0~oÍX¨çF®ª	Û«LboĞ¶‰u;Rí_KÓŠ

endstream
endobj
33 0 obj
<<
/BaseFont /DJCIIE+AdvSTSerif-I
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 34 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 291 312 375 572 572 906 760 281 333 333 500 572 291 333 291 333 572 572 572 572 572 572 572 572 572 572 291 291 572 572 572 458 760 687 614 708 770 572 541 739 760 333 333 666 572 885 760 739 572 739 614 479 645 697 718 1072 739 645 645 333 572 333 572 500 354 541 541 416 541 427 333 458 572 291 281 500 291 854 572 500 520 520 354 406 333 552 479 739 520 479 479 333 281 333 572 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 281 0 0 0 0 0 0 0 0 0 0 0 0 0 291 0 572 572 0 0 0 0 0 0 0 0 0 333 0 0 0 572 ]
>>
endobj
34 0 obj
<<
/Ascent 735
/CapHeight 700
/CharSet (\057a\057L\057t\057M\057T\057u\057H\057k\057A\057g\057B\057O\057v\057m\057colon\057b\057x\057C\057w\057o\057d\057c\057R\057l\057comma\057D\057y\057four\057E\057e\057S\057p\057N\057n\057f\057U\057I\057period\057quoteright\057r\057h\057P\057J\057F\057s\057K\057i)
/Descent -224
/Flags 34
/FontBBox [ -208 -250 1291 760 ]
/FontFile3 35 0 R
/FontName /DJCIIE+AdvSTSerif-I
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 512
>>
endobj
35 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 3658
>>
stream
H‰”UkTT×¾ƒœË8j›ËšawT¨hQA%(B	â£((/%Âå1Â 20€ÊC ¼Æ‡ÄFÑ£QÚ€ÔĞøk!…`µËhãÒ‰ûN7©=#&êª]mÜûcï³¿ıíÇùˆ±¶bD"ÑKW.û¹âæğˆp•V½qv Å>G‹„)VÂ{LÄê)ÄÎ¼ƒ8í=­ªûÛÛ@ÍDèœ\;eòõŸ0V"Ñö MF®V”œ­pM˜©ğX´ĞËş¹?ûÏSø'jâUŠğÜ¬lÕ¦,E`z‚F›¡ÑÆe«ç(şiiŠ0Kl–"L•¥Òn¦ÖÀˆ Ex¶&]¥Pg)âZU’šÆjU‰Šlm\¢jSœ6U¡ÙH‘¨1=.[­IKSDäf¨6Æ%¨Ïá©yÎ+Õ1"FÌ0f"Ãp#g˜i„™)fæc–ˆ™ Â„Û0î´9Œ5ãÂ,g¢™.æ–h¡h¯è•—Õ>«ŒË×6îë ë*"&é¤“|Ï&°°!6É6gÄrq¼øÆøéã5ãŸÚ&Ù^²s±SÙ=µO·?4ÁaBü„î	ÿ”dHÎM\:qxRèh½@*xs'/‚8wl)½_]Pé¤‹©Z6ÍY,iÄ@îDL—º#âCµ¹=ò²eÊ‚J^³s¹3=pµ›ËiLé:Ùö~W{¾)yCJFŒ“ä¼`2‡pa,º¢ÎEoœ†îÆt)œaÊ’¶o{7SVš“¨_V^‘)…¶ÆD¢k“û¦ê¦ºæëÒÇlÓU2Åa‡{À|ìÈ·½t9Éñ×äûB`¨QM‡_"K Œ­5‘„-/~ÀbF¶	¥Æø\m”NVI Ÿ&Øùn}ñ-Ùád‹æ¢¶¹‹cÓ¶$¯•ƒÊ8ˆ€ÄÀÅDòŠà	w™½óYäB´@[·‡nïåûÑ…ƒ7ÁµœÿtcÁnŞ`3Ğúğ,X9ş9ô,Jœğ([9T²kg¾ŸlÖhI¾OEã¢âg$®˜=¸«ìı½ë¢ğ§Şëüx_V‘æ`³w´›ä„”Ø)œãğg	ã¶µîâ?…éÙ;‰ÏÚXwt“ãÌu0l!¬a5¤ÁÔ–p$•¼‰bÕ¾æx^@+tFïY¨Á"”é|ÙÂ?Z	ö}O½,üfC:¬ƒUSG0šÇ!ÊwpŒ¯ëhI®Ñ»X&9›gq0…½V·şm=Åÿ ¼Èh8[‘9TNÏú<;»¨¢qq©¥6¡˜½+I&›«&Îk•e³åªêÁ=|7d“¿°—k‹übb» Ê‹%i…[‹WË½XI»p‰.EÖ½Â¢ÂÂ¢‚v­•ÎgWIÙ~ÙqPS´Ïw%òñ&›.ØD¡ò)Ô¶Üâ`
u.—K Ê-ÜãZ…7jMR<ø¼Ò?YF¼ÅvBä˜[F÷M/&÷‚ƒî‡ZÓâ1Ÿ@[l$6X&»pl²¦~	ş:^Éú¿ Ò¨$å€?×Î-·
:éØâ7;ØO&¡C¼#¸r  1ˆ¿éØ¢Y¶ûñd“T˜ïxŠ·²¿…õÿgu§¡¼ÇÂ$!Hné–ß¥Î_U~ä³éRlu
ŸO:kqW*ËÜäóTÕıÍü}!çõ¹fş˜K"ˆo›ßâšÙ¶c9Ëğn£ÚmAyÛ–êŸ‘È¥y–²w_•]æĞKØƒşã’Sè/>ÈÂß…O©Ék4úõM¿)$“¡ÆîÖÃò£!ÀU,Œö®‡Ğ	‡Pz[¶a˜&h‰mãgŒ¦åù¤êbÇÄañ7jd7?`1&¢æ
*dX_‘/[:Œ¿‘[€+i]än[á/
yÿÑ¢gÑ
Béâ
kÄ@³lŞ1+9LÅ•è‹uxRÊïôCgŸ`hw]ùüMtÎ¢NÁÕ~¸#qR8‚¢A4,áéÕ;iÇaG,Z‡ÎÓBœõ¼å"LİşO@áØ§ü®rÂ2Jeø¿­Õ£¿~Ë¹tT‚_òtC&d¿Ã:¢núuÒiy?[½'¥=½{Ã]™7x’ëÍ º“¯‡àT'4¾È¢>®—ıÊ´"Úg=­Á–_ÁJÔBºÙ‡ÛQ£¯+7ˆ›¢Ö7È]oM;:´Œ¿¶ºsE´ã|¿¨UouipÊd5è¬/­ÖUëe[NõõËÁ}øÉ`oéY¯›¼çíÈÎ^Çó{»T:'Ë5–š-
af7¢•¯´¹+;­GÏä½×—ö¬…3ûuÍR­ÿv)Kê-­ÄáÒ¸íªêd™Ë®KÁ0Cãaò¬êà¯Àı½Ã5…Ãc;½uL=êò}iÈ A´5h/GYæİÇïñTÇª„íÜËĞC1:f—ï¹Ï öı¼AŸ†öEJ]±@f(ª+l)Ÿ;Ò’ıÊlu^QCÃIY|Ãa’¾ S•reÕÅc•¼~èw £˜B‹…µÜéšå)˜…sç/ÈÉ1Öçòğ~Õ Éy9‚=\yæ'5¤ÁĞZ©q,Ö—èòPñ=}ßda}H<!ã\Nßªih‹Sã³y½á0ƒHf	‚/×t™4o‰«K‘§*óµ1<Ì¬Ààùâ…‡gŒÈ÷}¸ûĞI~ärÑ’–+÷ÛÜ	lûÀl:ÚÓ4{-•Ïb(û8ÇÂ~Cåû({w£ø4ÔQr=¯’Û„oÜ“Ÿ5ªŞ÷ìªkÔö¼êYuQmáŞrX|GZJ•<Ö(P˜EDâ	OÁKŠ
§„ægƒèñ% ÷ğÁ¿ø¬Ò &¯(êö>ÓÎ˜iÅ`’oš¯q•Ú3hÇ\QAˆ¢hL!	1aIˆ¢D$,"›×ŠNQkup¬c;qŠ¶N¶¾Ø«3} L«Uÿ¾ïÜ{Ï¹çşeq}$Â4†À%‡aô¯î¡]E Á‘œ>û}ìu‡>X)Û¶¼ ØÍóõøî`:eıšÔáêj»L·7ìI³356Û5dßk–Ğ‰œ	»¢?J™ˆRàó"
uQñœ»øûn¬dáÉ”ëbGàĞœ–½·Ã„üÕ‹w„­\Ùüİ‡ßà‹dÖGİÙöİùT&^™L\$¦aÔŒY>¡‰—L™Şj²êY)»#D;øÒªlG¾`YLİ4›ˆÇJná±˜¹ŒY‚{t¡—ßÜSÕ^+8^ÓÓ{—_¡sÊ« €)œŞ†ßî±nÜ²vÛÌĞÍ²ó]$£µxß§·Né §bÁ=º-;<AÁ¬†¢ÿÈñå”•‡…¤U*´j:G_UoanâcèÁaIMí<ğö Âyì	ƒ5™™g^'”dÁ N§™JKL¥tµF,/`Bà›ü÷c43?à'EÕ¦J©‘!Ë‡gsZkÜî"¦¡h¿;‰Ş*íÖ2"­CÔL³s	9™o
]ğbºO®±íh“û`Z-ñ³2‡¸VÔw…ãğlì'VØÖÊ^m™­-£’“}ı¯bI©Ïˆ;‰9Ã}µšFÇ%Ïš§–h¥0şù1îP¦ı¦—{ûJH«iÂÂ°ñàğ˜ûv^ÂsğØ3t£^¸SÉÌ|N¡~ªŠ¼W^ÇFÃïùÌJp)†?å½ëW2şë¸ºdõ‘t `òÜh2~ô´µS~ô\øxóc±¯øw€Ù¼—ÿ·lÙH…UõÅÌ!ş«%5Ñ´?ğ_ñßöNFàBGàJM%ÃpZ†‹£Şsğ˜Ô"› @“ıš|ñ$Æv”³D9x{ß$ùs”£WëK×AP»ø4ş™s»XÏ[Õ)¹9$WfËHè1Â&ÊâB_éJ,:Fc5ÚÍ•Mx!¯P[÷ÃJşQÃï²ZñfÁÂäz<Ño[*xmG8¨‹ãj?íl¤›ª„±°FA€ï¾l£9—¬üçx¢÷	¼¶ò§´µğlåU]Z®RZ™Z»ã>
ÙV0…Tşø=ã]ğ|bêùĞ£ä8„ÆdzÍ¢¸å
FÒšp.–u1º*#‚¿gçÆ5zA„>²Í~ƒ%¦2a’»;ò/ÒO~é»}-şäöf&æTò±ş…³Õµç\ñ	F‹ò$o„cv"bKÇñ<”BI%i™é
étnÀõSáo´*·^ØBã¨Kê£(?#.'•NÙk¿WÁ\Ã=@±[=5ÄÙ(ù"…[a
°"éôlÇ+Y¼Á·7¦"rÔ#`e¸¥-ôx*q®‘Ü0YÀ[OØk¢eïÂë‰Œø³®»Wåä‰{EWP–GË
PN©•ó×Ï2&$…ÀDÑè`¡±>‹†€ğÒL›©Ôd7ğÎ›õIÅÁV`™a¼Æ³H¬ÂëÈ¯"üˆÄÀ6x„š(" ¾#]§¯É„tBA ŒëQ–>&%F ã œÄ4¡ç³Y‰EYÆlC6Ï•›¾Å¾äR©øOäĞÁ«óµ:%‚¨’}å»y¸ÓRóöFxÌe»¯räZe¡^­IâªM‹ ›r:íÎ
†,õ‚nKd‹¤œ.³™L¥öêVWçähsô¼(­ü¸ìê§\bß¹4×å×ğòêH¹k-× ÜárUáª,UVšˆ'ß†ç£:µ¦VI«ä*Šn¼E\Qôª¢âµ§`vànÊ®-Ò%‹½KyƒÆ °éXNª\o3˜+lÜÒc5'ñ)/÷%âîÿI0Åo‹€/ÄïñŒz'	uĞÏMNLOŞ™´{§(Õ(&\tNò”qş ¹Ğnp

endstream
endobj
36 0 obj
<<
/BaseFont /DJCIIG+AdvStone
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 37 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 291 291 375 572 572 927 812 208 354 354 427 572 291 333 291 385 572 572 572 572 572 572 572 572 572 572 291 291 572 572 572 458 791 614 572 687 739 500 479 739 708 260 270 593 479 927 781 791 541 791 552 520 552 687 593 927 645 541 614 333 572 333 572 500 354 500 593 479 593 510 291 593 583 239 239 479 239 895 583 572 593 593 343 385 343 572 489 781 520 500 447 354 260 354 572 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 281 0 0 0 500 0 0 0 0 0 0 0 0 0 291 0 572 572 0 0 0 0 0 0 0 0 0 333 0 0 0 572 ]
>>
endobj
37 0 obj
<<
/Ascent 735
/CapHeight 700
/CharSet (\057R\057K\057p\057four\057E\057parenright\057S\057at\057T\057five\057q\057U\057g\057B\057r\057six\057b\057C\057seven\057s\057a\057c\057W\057l\057D\057comma\057t\057eight\057e\057G\057hyphen\057u\057H\057f\057nine\057I\057v\057period\057colon\057h\057P\057J\057F\057w\057slash\057bracketleft\057d\057endash\057semicolon\057i\057L\057y\057N\057zero\057j\057M\057z\057n\057one\057A\057k\057O\057bracketright\057two\057m\057quoteright\057x\057Q\057three\057o\057parenleft)
/Descent -249
/Flags 32
/FontBBox [ -177 -239 1291 760 ]
/FontFile3 38 0 R
/FontName /DJCIIG+AdvStone
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 510
>>
endobj
38 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 3334
>>
stream
H‰„U	Pgîéƒi¯4Ê´N£x 
ŠƒË%‡À Àp‰   $ (ÜBëV¢¨cL%›*RÆM$Š(‚`#,(ñBtâB†ˆoË7³o¨ì?¦6»UÉÖVWuW½~ïÿŞ÷ÿßû~%·¡d2ÙØğè0­6rvHnibIÑº<kÌİ$Ú˜DG\ŒLÛ›÷Ğê¯d¿ìŞıëÛ½7lÆ}2yÌ¬ñÖl»ßJ)ÅÙPÊ1ÔTò£¨ Š
¢¨P'ªˆ¢¢%§$*ÚJ}AUS­Ô5'›"[.k”õØ6y6›mîÛúÚfÙ~"w‘§Ë«äÃô$z>½”şŒ®§ÏĞıŒŒá™X¦œé`²¡l9{‘íåX.‡+åvqÃv3í2íØ(”Š÷ûŠ‡ö
{GûtûíÛäáëZ('(ı•Ÿ+Ï)‘wâgX¶ñøŞ“N0B}¹n{G˜³y¶DÒá"šG5œ6op¢;ÊÑËU¸ìú€RêÆFÚå†A”
õÂBP<U“ü˜#ÀD#Èa”«`™Ì#”:7—~öƒ1J…‹Ğ®$=Ã€aÈ –<›úÕF1wÛÆ°÷%-†èyĞ©B?ê²$±·MÈ¯)ª«­©©=¾¶¦ `íº|5ïüĞY€ƒæ:šÁªÑš‡“Û˜úfÂŸÁ'0C0çcÙœ	S¥ërMÒSXÚãà`‡;jqU’«FâaÄœ.D1˜\¥ƒ)çèQ¥‘å›M=øÑ ÁôÚKwUo4·Ñ~jDjJº%‹>^ßÖĞ%^kNĞÅo[i¸JB7ô$ÃC¡$ßyal‚olZåşB©(öÈ–úw9¦â'°­x¾\ğ£¹Ÿrz¶ş‹Ç;æ`Ú¿\&ÆÅ”®—èèªÚö­bÓ•27ï,·R<Ë›´fÏ ZÒèLèÁŒÇqÏ°€ÅË°Óz<ÌğL’æc)/˜£
]á‡ò%IÕÕ9ê‚¥tÚù[[/‰à÷h°Hg,?,5ƒqÌ¡š7m$›å0	3vâ^gWŒ¸ÃLÆ¿y{$pÛ3û&²brzyé»R(@ö
<¿á0Á2$D.iÿ¨³m?4Gød†Î“xÓAÒ%0ú|jùçğ&xmæ­‡uNĞ¤tşpûL³¡Nj*:£Â‡‹¨X¡ó+¢_Ş±`ãÚwPjo¸ÕqW5ÒƒãĞIâp&ùJ‘:¾0`‰³ÊyäO ©?6ÏnMMÑ­ÈIY#¥~­ı¶KuõäÉ›jşÑDùAH‚Ì½ çÀKïı§‰¨vqF‡]Úì2 $±ıLeM³¤¯È 2ô,v‚ÓĞ×’=Ç¥¬Z YyıÎƒÖ›CÒÿP£‰’ç×¬#±£ÿ¥PÌ¸Š¡¬ğk¦ná÷Ğfª2})lË¦m)>’&¢"‘ò;•xùÒéTVJeÇâû€2>G8áZÜ„è‰e8\ÕwW_S¡7dÄ”Ì19²¾ $eë/¢·g²KS¶Ÿ¬Ü']‡*ıÓ…ò³wJÈoOËß_¿¿óY÷ÍV2<'ç‡'Fuô#æ6äĞğwæ’œÁJ³F%@h00ÖÃxNÏÔáøãîuîZî2½ƒùnšÈ¬ Éƒy¶X€Ï~;`<ÎÏİ+éÙö¿İoFõ °ÍEkGuŒÑ¬ú™¾¦ü˜E¡ñiÑrŠyªYê3×ÍñcTãRÇd˜€A°wxàè±)¯“.Ê‰Û,âÁ[µ=Bnß.X_Kì$FuËÂp%“¼ÜÀë$œ@ZX:4½0{¦JH1ü§¦+ç'£:Ó$6Ã~ØaÀP
{~ëoÿŒĞòkü€5»MİpSÀ¿°›rW~¨q*ÿÓLô+ë×’NvÒuÙşµ3DÜG˜,!·K¼ƒÁ ¿ïëªk4°<š)àu8uîV˜ç0‚Ï›AëhÖ‘ñÄâVVlîö”JÕÛË7—}ÄéØá¾V˜.™£Yş9X½âí¿è¸háFêñ TAƒ¶	Ï!™õ­ƒošîoŠ4ß#^ŒÆºbœ+¦ú@ª7ÄyC,ç2ªë3uë™Ãsa¶a$×È<†H˜—ªû9½¥›´§Ì1¤ŞßÒQÁ¤ğsø=!š³–¶ë™S±P‰İ0£¹Æªôid2A~ËÑ<1“<®DÌË1Tè…Ä±Qş0&ÀB Ä@,v"N‰AÔJüw„¤Bèf^5%¹èR=>’Öì¢—eÁûùâL“½®¢«„ádşÙÈÀ%ôlîÂÏ@I÷Ö€øÖ©~‡¿…à;C¡úÿá_x‹?Àtµ¯öÕ•ÌÅ±RãrŸ6½d`¶?9‚¡ĞJw7í|©¥Ï÷È¨1á«M™fG¡97öP¨ˆ2¯p×®¬ÎLé|öë„yªÀeïFh3ÉQgÅÓigûJºE¿şl‡¯Ì6HŞ]Y'ÎªÚ¿5œ:]\|\Mºèu4+`£ÁÒ´JFDE)·¬®»ˆÅ¨Şé
F°oµ)ÎËÃÎZéB(ŒKîjS ¹T"MÁ$;ãã1>¸
&
“ 9	’¼Ê&Aöhıã¿ø¬ö ¨ê(lÊ½K	+!«÷:¢b	ÉŠ)5ËLÆ+w•İÍ]vEtYy‰°³d¤‰˜¹4‘2f¾Æğ­«¸,"²±@òÖ&™:ä+ÆÎ¥³8ıÖ¦šiÒ™ß?÷Î½¿ó}ç|ç;‡î ù·ƒty;êÛQŞòÀ›4ÎKØ‘*¾£À‚—*i%ä* œ@2Ç¿'Äã80ì`°§‰tã¬äİB`‡Ú•ƒù8‘xôıÄäWåo+åîÒeuµÖGÀJLÁáûßLÖ¼«Ëàl‹)k}'ë8•-ßÄcğ2*²`jfDLç‚-ÍV›;ëŒİöº45kİİõı<éƒKn²úúi÷<¼İòjll>ã0?V3ŞU´ÎŞ¶¢›…(/iÔèËùˆjeRáü¾.HüŸìeJ²åKX^xw ÆİnëµÛ×®9Â[]ÔáœÌíÄã8|1ÅJ¬iİ‰³»là£n&:óÁïNôÜuÅÅàˆÌIøÓIØA“•tkü`*‹ãc0”ıÌ›€í=İè°ñU´x·²NmÕÀxŒf‘Â)ÎÁ¤ß¢!ÖİUcwóÅªx¹²,“šÔwÿ¾ú+æÜ§õ?ô³Ú¹	şA	á‚
‚Üä]wmÚY³Ã²q'WÓBí2l.f•Fğr©ÚãS‰·RP1’”JÚU”fÏbä´°r¿°¦Ò>oî$™r«MÎ•, Œ=kzX`aäw àÅ¿ÀlRğC&/´Ñıç—®7hc8ìğÂU„ÊÎ¡HhÊXDæeu`a|¯`-`š·?t ô°ÑXZT²r{n3¡T]UŒÇÓR^8&ñÕ‰+rÊÍ\Åª²µæ@:ÿç¯zÂ½pxàJ´İj@#l¿]Oú|9µZ˜KjŒÕNj2d"í³	Œ8é~‡ãÚ•†‚×Eà‹¸®õíNL|òø³è‘EyG°ÊÔÂ,ßX ­•²ªùÅ:ıÒ_òlÒğ%ñÁ©÷ÈÎ<Fğ’İPŠÁY8ı@/d eŸ,‰ÉÇáø>ŸÃïxí!À/±+OÓv¬¿jCë¼ğÍ³N“+êÉ—ÿÖ;zQ@sï nF"{–Dñº—dîe˜EˆÆù‰î¥aD}KË¾½ëÊ÷rTmQŞ.3[š·º´”7.£ÄàW!‡9X¬«Ñ²q	ÒTgî=*×]’¡]b^jÈŞwh—¥¡–Õ3aû~ì¸qqicšƒWœÈÜÓÑÔ¸óØ¡#ëMuœ?ªlc$…%«/âiÑäVÅıãöÏkrf'UQ¶j}«ZÓt‘‡:ãÆ1¤¬Ñá·‹OÒ¯()oœw8h—àU†vÍÑù“š]œØ{Â¡P(—î^ˆ£Õ¦ÆiÄÑ2`šÂ40Zb_Y_›„a„¶Gj1H‡‘Ä3µÄzgs|«©³´BÈi…‰Ä38Ñ…!N	ì¦!Iø0~‡GéQœQ$‚"µ¤…‘d4TX”Á˜	ÙÉGq,YÂ í5ÄbYÖ^Ò©‹(ñ–Ï„÷Ğø2)ÌHÊz_Ææ¦5Ó7»:âa«pUúÅh¨ŸĞ/Ş"ğñq:l¦±Û'¡Vñg±U­Âr«`Óå³ÈHŞ¾Ê™? kœh

endstream
endobj
39 0 obj
<<
/BaseFont /DJCIJI+AdvStone-i
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 40 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 281 291 375 572 572 833 739 208 354 354 427 614 281 333 281 385 572 572 572 572 572 572 572 572 572 572 281 281 614 614 614 458 760 572 520 614 697 458 427 708 666 270 270 541 447 875 739 739 520 739 541 500 541 666 572 885 604 520 593 333 447 333 614 500 354 541 552 427 541 458 281 541 552 229 239 458 229 822 552 520 541 541 333 385 333 541 458 718 458 458 479 333 260 333 614 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 281 0 0 0 0 0 0 0 0 0 0 0 0 0 281 0 572 572 0 0 0 0 0 0 0 0 0 333 0 0 0 614 ]
>>
endobj
40 0 obj
<<
/Ascent 735
/CapHeight 700
/CharSet (\057t\057u\057O\057g\057B\057v\057m\057b\057C\057o\057c\057R\057l\057D\057y\057N\057p\057E\057e\057four\057S\057n\057q\057f\057r\057quoteright\057h\057P\057J\057s\057a\057i)
/Descent -249
/Flags 32
/FontBBox [ -187 -239 1208 760 ]
/FontFile3 41 0 R
/FontName /DJCIJI+AdvStone-i
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 510
>>
endobj
41 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 1778
>>
stream
H‰¬UkPWîæŞ™rÉøX{„iwš‡QAÑD¾x‰ 2¼	>`xŠ„ â ²FBD#â„÷&<"AbĞ$j|€è&Æ¥¶Ü-7Á­ÓSk·ÑİªüIRµµ?º«n÷wê;ç;ß9WÂÈ¤ŒD"™ã­İà«õ]²>>K—‘²o—“~ú«£ÀIÎR…AX4_vÉ|„hª%ÿ*+{ı¶”?,g›¯HŸ3şÍO‚	£`–aì-˜%³\Ê8K/)³QÆÌ`"ÆV¤edÌ"&‚11k‰d¯¤Yò£ÔAš m•NY¬·È±øJ&“%ËZd÷eÄŸ|@nÒ¹t=FÇäóåÛå…òö©%&BŒÌ‚%¬¯®¯¨;rŞºº¼è£\Âşİ¾Éü;èI”£Â9s0A§–NEí ĞA0š<¢ŸB4¡•wˆ;Åzábyi8^ JdÀcöı¦'r*V&{ó.ô‘–…ù`ùTcQ·]NòwœE;ÌQo½…–t¦8ïe0wÍ3ÙÚ}%ËcáÛ»<ùT	J³‹y!{.SÛ´Ã0Üƒ6X‰Y°Ò–İ¸w¦¦‡7ô“œ˜Ğüp•öOÁA6àv§);¯WBìQ¸JÀTá°KxŒ Ä¤¤f?ÖâRôBŠ›0™w J½P)VŒÿIéZq“àiz.HyuØG; @:Ubš˜²şíK·¢øœğ¼,ëüÜÜÜ´’‚`«Ñ±+°à"*³–(¡Ì\.âÜiúã`±‡¢”¦ö£Æ‘?…î5×m„M°éˆV”ÓÆ5ˆ½/Ğ[1 ÊP&dš·³bé³ĞˆŞ(½Š[!€Š –:€WóN/íXœåówp}Úû!íùC7´CÇ LÆH^ìL“(ï5úçÏVÇæñM#ÃfÎ@!Éø7 ‡a¦5ØFy÷½Né;‘ºQŒºIGk#l=tÎ|…)9û¤åp™7İ©zĞ R|KƒÿûºÈU>6/`M»L.J=ŞöhÛÚ±o¾»ÁM½A·İ'(¦Ş”¨IÔ½éÖû„6 ß3ñuàM^{{Ë%õîK×ûêÒòk4JAÿ`QûJ×ra{>Ïï'¸Ú}XÊ®¡…:RJÛ³¢jc9\†³qj‘ğùväAÃy¾¼4Ç‰ŒQåuX5ÉÂÓ$H‡¹á*Ÿ(±ÿ2{¿Èè]ûø7íÙ1z¼•è;|Á×sˆ«çñv®CüâøÒòAxF\©R+¨°Ùúøœ8™<öÀ‚Ï&Z:s
+ù–.R“[%&‘±wØ¯«ÇßÁŠ¾3}¼è/õ6Ï 3Dp‹İ:ÊÃêBpKõ¸C(úˆY£#J»=ÿ98TÙ2¤Áãğû¼ú»ñ[\ËÅ”X#_´Üù
Åôü.Q=tz²— CÏ<%c§;~Ä­0ªàk;IE®áÃt.È5mÓø‚@²†‘»tÕ”(…Í¿ ¨ô• ¿ÿAsWT¥ùø.ãB#O6Gñú`’Ø9˜7Ä8º#°¥…Õn0§³ë(j^¦“QÚ¡Ô5À€å8×u>-!½$©$›÷Ç~±5p›o<VÛ¬şSDÛ|Ãß#$VSZN”XË#ë4eQŒ$s’m­i«;]hJŞ³;%şır}+?²SÆœNÖ¾¦SÂ#ÈãÜètä¨8`Z[›AşM77P…Ù|¶şÒ^h#àÕ°·ÛóXå–*€Ü?–Ù·šsöğNœ>Šş”ã+ĞO„Yt[ˆoáb‡kø,€Å/`¬ +—oòEAìäQœ•ˆs6ã»<˜Ñ–ƒ0dâ’súy;ßlXQ›—…"{/´ÿ¼¯ÉÿcÀ|ñ£3¼/JâJ_7¬–|Ò{ı*wñãƒ‡NğíWIUNöÙTnKŠ>`Û+rÁVHfÏâjB8Ûpß¿î	|OHuî6ut´!6.©Ê”¤I
!)Ÿ]>p…òõí»ı».í¼Ì¿û…¾¶CİôÇšº†¦Üìšiö®ìÁì”¢TnW~ÃW§øk0@`=%ÉjÇ•{3Ñ’øÓ‚02@C°,İ_ğ”«o9YÙÄ+…êá+“­£{Ğ ›a‹‹Ü¸Ã¹öš£Íœã _t˜?Ş&ÅÉÆÌ$uàç1ıü¤mšòR¢ÔÃ>	YZ“¸®wú¢,ÎÇº”æMöÅBñ;yV“SÅ"è‘PÌşe*­0HsÅ;t1£µÖäóÜÑÊíÅ¸ı`ŸV™0O¡>+°ÿ |ö¯

endstream
endobj
42 0 obj
<<
/BaseFont /DJCIJK+AdvPi1
/Encoding /WinAnsiEncoding
/FirstChar 33
/FontDescriptor 43 0 R
/LastChar 126
/Subtype /Type1
/Type /Font
/Widths [ 1000 437 1000 385 1000 1000 0 1000 1000 1000 1000 1000 0 500 1000 1000 1000 0 0 1000 1000 1000 1000 385 1000 1000 1000 666 1000 666 1000 385 0 437 822 666 437 718 666 666 0 0 552 718 0 0 718 822 0 552 666 0 718 1000 552 666 822 666 437 822 437 1000 1000 0 552 552 666 500 437 666 500 885 333 666 552 552 552 500 666 552 500 552 666 437 500 0 552 500 500 437 500 0 385 822 ]
>>
endobj
43 0 obj
<<
/Ascent 712
/CapHeight 0
/CharSet (\057m\057b\057four\057a)
/Descent -207
/Flags 34
/FontBBox [ 13 -323 958 824 ]
/FontFile3 44 0 R
/FontName /DJCIJK+AdvPi1
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 714
>>
endobj
44 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 1091
>>
stream
H‰,“Í«5ÆÏm›ÉÂr¥âqSÁ…](¸é¢UŠ¸‘®¡ŠÒÏÛÓsf&ó™IÒL2Éd&óqîÕRÛZüºq_,¸Å•ÿâ9í­hš²ó<“7¿÷İš:0ÙÚÚÚ>yêÄ»§Ş{ùØ';œ}usòÒúèõÑÃÏtû¿<úğá=ğÜ×[ÿ\»öß~şúäGªgÁûOm>…ÿ»ÜšNONLNO€Kœ¼¾u÷àC>¿ıèÈÃ3«júxÜÿœé«®êå×ïûÓíõ«7Àü{²j)Ô#œ´Şİÿl¯&ëw¦Q‰Ÿ-²Y¾ƒ/“Käû’Ÿ,wÄÜ©fj®µoÖ·ÛÄf]nIç¬×°w¼VZÙê¦n¶k3šÑŞ,Yó™¾¢g2©b«Ôd@cMSOóZh¡e­M«šj1–Cy,<|‘¦EJ²<ÇMˆ¼´L]PbrCdj³>ï‹«'V÷^c'÷O¹Ò‚ïÓo’Ei÷Q7Q4ª” ğÔ/Fy˜õÊÔÖ­j¥–[^1W‹¥–´ØfMfR5¡	Ì\ÏÛ‹œğøñ‹é,½JŠ,LÃ$‰“8pDKXÆsñT¢*Q…Md#›öÀİpÄËbIG:°@Â²+mi«^ª×V7¦qŞ~x|Š#”¸è,ÀAáDS;% †üñïì<;G/‹1DÀo\
'Ş”·Ämş¸ïCÎÀ5oúËd/©hGú¢£=½çTbOîêÁt¦kÚVŠnhw…0ËzWíÊ‘«²-[n…
2wg2â‘©¼Ã]Ö%vSR!ƒ&l°ˆuTEjì‡~›ŞtºÕ mÙ8wd#uŞlHG48MRÇ*rÊK$:w4|/`)sL°ÃÜştjêFµÊ†a†V“¦h3‘¨¤JªæÒßôfÄ#Á²œ†, Èe,r?¾àš€zÌK¨ËÇ<e)ÍhVä˜¦ C—… ‚JZÓ–ZZoäËr”î•Ô^µ‹f^Ïë™HªY5“³rÆ#~\Ò€…ÄÉõP”EIäV‚r„C0zî"”
´oBsî+¶>ËwÑË¡êêN·`ûçcÓbQøÑ"€`K×;"“¹Ä²¨pE•“fš+®D%„TªR¢57Ü¸1–I°Ù¢»tØŒîá-cƒ;lHÍjjOzk¶NvÕh†v0­cŞ¶×o îq@†Òa›¬vMj
´§™âî9ZÑTÆMe]ëFY5T·e¸`‘ˆ ’diVd$g ÷0…‡İãÊvM0Ğk€†#\B¶ºŞòèşƒK3?òãŒ$EŒc9ä!”±ØÍ;wnâ¦õléÊb«À›O{W ¹Lgd¶×wŸşkúï  Œ

endstream
endobj
45 0 obj
<<
/BaseFont /DJCIKL+AdvP4C4E74
/Encoding 46 0 R
/FirstChar 1
/FontDescriptor 47 0 R
/LastChar 2
/Subtype /Type1
/ToUnicode 49 0 R
/Type /Font
/Widths [ 270 770 ]
>>
endobj
46 0 obj
<<
/Differences [ 1 /zero /thorn ]
/Type /Encoding
>>
endobj
47 0 obj
<<
/Ascent 750
/CapHeight 717
/CharSet (\057zero\057thorn)
/Descent -249
/Flags 4
/FontBBox [ -20 -958 1114 770 ]
/FontFile3 48 0 R
/FontName /DJCIKL+AdvP4C4E74
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 705
>>
endobj
48 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 210
>>
stream
H‰bd`ad`ddrñröôöÑvL)0q6q57‰jüfú!Í#Vş/è×»ŸÓXå0şïî†<ìñ¿ìş&RË¤•É Aa3##³^N7ß÷Ekîˆv¶t¶´I5¬léÜ7yJ¿Üw·f¬}û¦M–Ú–4­&¹1³®Cïç´ºß«D¿¯f›9¯{şüŠîZùß«¿¯a›Ù=¯¼¼»¢Vî÷šßkØk+ºËËçuÏ”ÿä±ÕvWÌŸß=o¦@€ ºSo

endstream
endobj
49 0 obj
<<
/Filter /FlateDecode
/Length 228
>>
stream
H‰TAkÄ …ïşŠ9néA“ô„’n!‡m—¦íİÕI•‰)ì¿¯ºéÒ|0¾yãçğ®êÀOäõ€FëáâWÒgœ¬ƒªcuÜª¢zVx
—%âÜ»ÑCÛ2ş–Ì%ÒvæûÔtÍá¡¹wÀ_É Y7Áî½úøLÃÂÎè"ŒwG^ÔŒÀÿÆ‹Wm{ƒKPI¹	¡•LRK@gş{¬¾&ÎãµÜZ‹ˆ½¬Ä6ÏÉÒˆßæ<-ñ¤W¢ÄZöP03”ux[Uğ!3äÃ~ imE

endstream
endobj
50 0 obj
<<
/BaseFont /DJCIMN+AdvTA42
/Encoding 51 0 R
/FirstChar 1
/FontDescriptor 52 0 R
/LastChar 1
/Subtype /Type1
/ToUnicode 54 0 R
/Type /Font
/Widths [ 708 ]
>>
endobj
51 0 obj
<<
/Differences [ 1 /ampersand ]
/Type /Encoding
>>
endobj
52 0 obj
<<
/Ascent 638
/CapHeight 631
/CharSet (\057ampersand)
/Descent -38
/Flags 6
/FontBBox [ -72 -145 875 718 ]
/FontFile3 53 0 R
/FontName /DJCIMN+AdvTA42
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 535
>>
endobj
53 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 240
>>
stream
xœcd`ad`ddäwñröôõÓvL)q41	iüfú!Í#æü[õçÿŸI¬rÿwwCHö;÷ù	vo©å€éc``Tc``g`bddĞÍ÷3âû³3E«Ô[ı¶½ş[äæoÑïa·¾+G,•püÍÿÛs}íwùÚïÒß•¯}g1ß°I"~[äÏV¦‡¢ßmg}Wÿ-2á·ÕÄßn¿u+şvŸûÛqÎo¾ï»¿Û¯ùÎşñáwÎ©kX~‹7üf×Mÿ-ò;ô»Èïèï¡eßK¿[|Wîùßóİï·Õw­ßÕ|\ ÿfÒ
endstream
endobj
54 0 obj
<<
/Filter /FlateDecode
/Length 213
>>
stream
H‰TA‹Â0…ïıstñ´ˆ§R½ôàîbÕ{L¦%`'aš
ş{“ª30yóñŞDlë]M6€øg§ĞZ2ŒƒY#\°³yÆêğš¦®{åAD¸¹ûšZe™‰C‡ÀwXlÌí¸YKùâ²¥ÇütÍèı{¤ ª
¶™Øî•ÿU=‚˜ÙIÈ_–Îàà•FVÔ!”2¯É|koâÒ>ÇÏj)e±®²H¼µ§[fs=2Ç\ÓÁS¤”ÁÎâO–©²‡  wh

endstream
endobj
55 0 obj
<<
/BaseFont /DJCIMP+AdvNewsGothicR
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 56 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 302 312 291 770 604 854 635 145 322 322 500 833 302 333 302 270 604 604 604 604 604 604 604 604 604 604 312 312 833 833 833 437 1000 604 645 604 677 572 541 656 718 281 437 625 520 833 718 666 604 666 656 562 552 708 593 906 552 552 541 322 270 322 1000 500 500 500 541 468 541 479 281 489 552 250 250 489 250 833 531 500 541 541 322 437 302 531 458 729 437 458 437 500 500 500 833 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 0 0 0 302 0 604 604 0 0 0 0 0 0 0 0 0 333 0 0 0 833 ]
>>
endobj
56 0 obj
<<
/Ascent 723
/CapHeight 723
/CharSet (\057seven\057L\057slash\057t\057zero\057eight\057j\057M\057u\057one\057A\057nine\057g\057v\057two\057m\057b\057dollar\057w\057three\057o\057d\057c\057endash\057l\057D\057p\057four\057e\057S\057n\057five\057period\057r\057h\057P\057s\057a\057i)
/Descent -189
/Flags 32
/FontBBox [ -156 -229 1218 812 ]
/FontFile3 57 0 R
/FontName /DJCIMP+AdvNewsGothicR
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 523
>>
endobj
57 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 2262
>>
stream
H‰\”{PWÆ{†éî±ÔV”±{èvUÔ€¢¸€ÔğG‘÷ÓA@äµ¨ ±ÔÄ¤²¾ˆÆhiâ“¨èÈF1Eƒ<‚ˆèQÄGpësföŒ»;˜­Úªıç[uÏ½ßïÖùÎ‘2)!‘H*uà²ĞpwÿôV®Ù\°tİÆÌ¬´Èá7/µğ£8·(eÖzR8-ù÷Ş½¿¯£hópq<¨0n8{Ìÿ=@H’ ÆĞ„³”˜L®1KBx„AÈˆ"TFD‘Ä:‚˜aç dÄ&âSâ ÑNüM2Oò•äºÄ*%Í—¶HÿáàåàïípÄÁ*““u’"™B¾¥””•@¥Q%T;í@/¥³i==$w”»Éåkle\pgşJòğ}8p¿µ¡ëeNĞ-»+³/-o,s^ÕzÅû üNô2>TMâÜoÅ€KŠ€WhÕ¡è«k:"Sœk}»´/wÊšY8E›×Wkƒ9UTÜÜİB4XÙ¹V_iå:ôîz­0ƒÔbğ<\µ°áz×A6QL¼c±ğ)ğy
ã¡
ç‚ú Ï\tÂB¡[)­o€ºy
¦`Jø¤‘{)CÖ|6‚Jßš¸5|›<î8i{€ŒnßÆ‘4S£°dÜ±)©sM†æ-=?«*ÛäºËGÊj8¹°Q1?'æ	÷>&_nixÂÔÇÏÓl\­MSSVdFÄ,UgûÉ™KàÌÎl\ÓÀ„Á¤¶?^;/üğc÷ë¢{è4Ë?ma¸Ğ”Bvèk/ŞåÖjƒæªqì'[öíÛ$Ó_–í=Ìƒ`Œu3m¡ºìA²ÈX¤ğ	‹_Pğ…Å—4¶³S)¬²í!ã¡ÕFPÃÈÖát ËzTŞ×€”×WoÀÜ<^ ó
í–d­ø-l&¡å¢rmÜím¤élı5ÿâv86Äojpäµî4‘—ÏØ‡4[ıÉj[Bˆ…¢H³Œg§¦G«¼93ä0ÿE'Œ2'´M*K+šîs¿y›Ğo¿I‹+#g¯/±(ù>®²•kk©yfnN
Ri×ºf›Õ,LĞ¶¬öå†Ä£|òÒ¦Ÿ:µ ½.0–ø'‹Q>(CÇØÕÇÎf
9¡d^™aûmT0ÜákÈ÷
à$7wäpúÓ90ÑØz¡µ^Üë™ªñç=BÛßš;ŒÏ_uø¡Ó‘9© Ú`	g¨Û¸‰|Da¾u-‰mdAbM~CaM20Ñ¬ 
öÂX``Ioİ+ÃTGÜxô£À#„íoİµÚ ¶®*‡r¥YóÃ4Bj|Èç³ùå–~Š)x­°|p»­“P\7+z¬ä½s$ö`u$ß9öX×¢œF­0Ù$¡³¢ºa6ÓuÊ-ø¡ˆT/°P#hßœãæ“…ãD¦è,cÑéÚàr`ypìƒ‘ ‹¸cõb°.æDîYyî¹m%ßs¦U½š’½Ï
¦Óö–ÈòmEìü%(ŸeH™Vl-hŞ¦Ï‘—n:‘ÌùEÄ{,XÚ8´A`´ğ«‘=¤"ûQ;ŠwëJ8¨¤Q7¢ÔsY†ºp+‹4œ¯,iäo]ÏÔˆkhÌJ‰4çÓ1p«AWW-ìogcÃÖ'ñ±9ô]½Wa^©ÈìéV4R'o‘‰¥›Zìà=C ªEfä"R
49"´èØÂ¨]‘Â}˜ÀÂ1ºîb…®©WáTtœ•¢3dˆÌ‡–HÇ®¼Hç$¬á=Wİ\n™ËN‹¦bòYîÒZO¾3Ğƒº<@ù¬½üy¹Â¢±®eñ(U•—\ÊãÄ%3ÑzİÀ©­ütİUñä2²‘ÚÑ°×`àa‹Çè¸í†8Ş]c‚©à\g|ØX¾!æŠÈ¨-3`:»276[ÍÏ‹hñ$<>CÃâ%/p<õıÀ.üÓlà_uüğ¨LÀ—Ç¾ùªº©‡ïª‰˜ú¥ÈDÛ=Ï†¬Ï‹ç|L«a
Ìé«yş*ä<ŠG…‡ãw–qEÇ‹şò°C§Û­ãAŞy®ı¹ô£ïÄ£_ŸÚ?Ş±ÊÎÛö§,Q—z4‘ÇÑ*”-/Ö”çŠšõ7fpé§òË?Ckªª2õèW}èŸœä·X[Õ'l°Íd«kJ†€4ÄÅDç£ÃÌÄ’Z9Ô¯0Y8ª¾¦N×È·gù‰h3Z&ĞCñu!±ëÃ#ø.fP?¨è²œò§v‚Œ}üÄÛ>®õ8JJï:v¼ğ$ÿ÷“7~--ş¶^:é³ÍiÛ·ïÛ¿]xdİÍ>ñ¢Ş_î´®î¾ßåª+tşfqV€ˆÿºkáèz½^WÏß<“(ÚÓ°~b:n]X”P·5ır¯N°ïÅû!4³ı¿ÄÕ7ì^i=ó?â„:ï1yáQÂp–ög1 ß” ìi·^À‚—¨DåwºàRgüùçZ
è8gvœ	ÙÓ¬	
)miùæf&õ¾7­¯]V¤mĞdˆŸ¶‘Q”É¦|ïÖÒ*;³ù†
ÿ€|| WDÊ¹†t‘Áü~ETØGÌÅÆ&#ØDíÛ¹kïN>X“:/S„‘ş43éÛgìŠòÎÌ~{•·†:Ó*¼JÄè¢ÄƒÿYÆªéMóJí\»òàşE‘›ävïf=é·ÜNZÏ+ĞÌm[Ì“ù9ÇÚ\¥Â’2¼¢–NU¢ß·m¯®i/—ök{@şûcpõğİÖş·­­ïÍ?,ìî›³n­XÒ7i‘_İÈóEÿH±…EGSºoéÚkòßÿ8ÿg×ÛñğÔ¡åÇËÙœeç3ıî)ö’í»ıù¬l¿Uş„üVùdò}÷ın-ö˜X–Ê|gü#Ãú„í»
P‘+Ûoî?^¿yx±ú°ıæ2¹L6`SÏò£cÿŸ6¾D~l ¤[˜

endstream
endobj
58 0 obj
<<
/BitsPerComponent 1
/DecodeParms <<
/Columns 63
/K -1
>>
/Filter /CCITTFaxDecode
/Height 63
/ImageMask true
/Subtype /Image
/Type /XObject
/Width 63
/Length 144
>>
stream
• ¼p@áNtè:ĞtëOu§éú3Î9¸³ø)¨G°D~_»ƒ/’b<&ØAÒfêİÛªÓíÿï§ôıj®—ÿ¯ÿm/ÿkÿØ¯ıKƒÿõşÒ	Ò_§$ÃÅ§4trà Ä~…—¯Ié?]ÿ×jë»º½Šá6	XŠµjÕ¨jÕ…(aH@bQ€ €

endstream
endobj
59 0 obj
<<
/BitsPerComponent 8
/ColorSpace /DeviceGray
/Filter /FlateDecode
/Height 45
/Subtype /Image
/Type /XObject
/Width 228
/Length 32
>>
stream
xœíÁ   Â ş©o         ğ`©î6
endstream
endobj
60 0 obj
<<
/BitsPerComponent 8
/ColorSpace /DeviceRGB
/Filter /FlateDecode
/Height 45
/SMask 59 0 R
/Subtype /Image
/Type /XObject
/Width 228
/Length 4086
>>
stream
xœíš	sTUÇ?ÄLMMÕ|gÔÒ±\FÇ—uF­‰(ˆ,"ˆ ‹(*«+ûª(ƒ€‚¬IÈÒÙÒ	é%İétÒIè$tvBp™E}ªî÷:„«Ş¿n¥î½ïœ{Ï=ïÏ=÷uÂ¹ÙÙ%EEv±Ë[ h8JÔ_lØ¸á!õz[aÃÆĞ {½­°achØ\µñ[ÍU¿W¾Rœ¿p!ræ;wï©¼®ãù]'¨´ùîü…Ÿ®x@6¬ Q‹/gÏÏjï›å?ìğİŸUSÍñ¿á	;Úû¾=÷ÃpG¶aÃ
•òcÒøîÜù­]çVÅS4¾<™Wµ½ñè÷çÏ'?¾V®OÁşS#‹‚É°ÔXF×ÔLr
6¬ Q‹

Î%Œ–³MNü¶fÏ_öÅ²…ë(TFosÄËŒÈö9Úz“™Å†+@TÊÿ†Âî¦®ú=½«xëÌÅ-==xÇC1¥eÄ3[f-E F%=Ò=äD6lXA¸ú}B”tô)÷@VåÆ¹÷ßıX<K¥ïÇÖÎ_ù€Q1»²¬«/ñ\6lXá"Wóó¿µFûÀ ñ&õÏ\iV^b–KqVş#¿ªÿ+¯ªóäéÓ%@ooonnîgŸ}¶víÚ-[¶”––:uÊ(
…ÊËË®lüdĞİİ]Å°´Nœ8áõz1¯‘aW,ËŒñğõD¥|cy°2Öùºû23’ç*Â®¾†O[*LgŠ³gÏîİ»wôèÑ)—cÂ„	ÅÅÅ*öá‡Ò	“‡;~òàõÉÔÉ«tuu½üòË¢õúë¯_3Ó®&>,···'©’———N ¸vVAÔÂ¼¼3¨:ÚsYÂÙÜIçñŒÉsaTö6vÇ©9Öo5£)Ö¯_/®{õÕW·oßOˆ®/¾ø¢t‰Ø|@sÍš5Ã|Xp:2iò*;vì@şùçŸß°aÃîİ»¯mWõõõ²ÌÖÖÖ$U^yåäÓÒÒ®U•rÚAïô=ç<–}‚Í8T/ıÃá*Â¨>=µ¬N¹º¨2l5c<”Ë–-Ğş¶¶6‰WãÇçÌ¢G¸ºzõêä.Ô˜äU°ù>úèÚYuÕQWW'ËliiIRE¸šššzí¬®2CwßÑ<·ıâ½¹ÏõàÜü/|=ÒßŸ6®¦§‰–«ıØ¥¶¾¦“Æƒs'L<¹¿¿?æQFF†¸ôĞ¡C4ßÿ}ájggçW_}EJ°bÅ
’„“'O^¶®îî={ö|ÅÎ;9æb†E}ß¾}è"@b\[[«<(3j‘g1ã477Óÿæ›o"?oŞ¼œœœêêjyÄ¦+(( ]yï½÷V­ZÅ#ãê˜E±<??ŸM
â=sàÀÄ8vã9~ü8ÍÊÊJ1Œ}ÍJ‡³³³ã=6mÚÄ†âoUUyµ,3‰¨Á%%%7nÄ`»yófuã3ËØ±c‘_¾|9kA]GæÕp,òj8VÜnwÌ¼çóÏ?ÇÏxûË/¿4®%µ 7÷¤©UJ·ûqíïKKM««â˜âK¿#EºL'ASS“8WÇ?å¶å‰‚wDS¸:şü—^zÉ˜Öâ¥K‹
ÈrOÉ%\.—
àÛ1cÆÄ$Æ¤òT¹*MÂi	Í9sæ—Æ˜§Â
˜@GG‡ØÆ	‡Ã¢ÈN¡çí·ßæÊSø¿|É‚‡öà
‘?zô(M¦Û„HŠ×^{ËU’Ä#GA n¿ûî»12Ï>û,›…§ØóˆEKnF Ì!(ó²qb9’½iEˆJ9a†JßbåjÀ¿Dû{R‡ÁU„Uq]u³ru}u³é¤1ÀrY÷è!…Ùò"¼`Áäı~?éó@!êâÅ‹yW®\Ió…^à¥ @$¤NÏ;ï¼i	ƒìz¬b4©£"D%fBÔx{ &çÂ[o½EE¿XÅàÂHı’Ì0ZOOôÓ5jgÎœ‰¹fïH¸Šºö¸Ä<šŸ~ú©4'NœÈ¬—“hÜ¸qB`Qa™"CP%û|>¢œ’Gü&ö@$*„¾ššIlX„ÄÕØ Ãº©3Zâ:24®]\Ö²²²$lÛ¶§øV¦`c’.p£ŒÉÁgú~…«ÇÍPç¨\­mØ§ıÇ²2Oİñ`’\íu8T1·©]¹:·¢ŞtÒH„Äœ!……«8‡ÅJu8F“Ä€ú´iÓ „àjqÑ'Ÿ|B“øI}Ò¤I:Xºt)$ÃÔ•«œªÓ§O§BÀ1
[YÅ¦&{DF êªùásÏ=G'/”¦p0u__ŸÕÈÂUQğÆ•«4•«Lª2eeeÒ	3iJeoâ
õ	M‘ill¤‡û,§ç¾¢
d"@’FË¥IfÅu’òòrÕ"= gôèÑ„}ñ$ÁY¦1·EA0]/DÍÏÉé3CÄõåjc‹[û»\eÁ¿ü©÷ö»“ÊW=>Uôµ]úñkJi­é¤1à^)>a/)¬¤Ò’Q/,,¤)´D Â 9‰ˆiÄR¢'µqX‹çy)ÔGœ1c†„‚g2VÁUi~ıõ×èbÄä%ß£N:-³Àá#W333µ‡åˆ"ÓdRŸ={vŒ¢ğŠ“šº4C£€gğÇØOæÀvàè‡ºÆ‰tL,—&Ù¸Ämu5¯h•––â7!3Ô%U (‘ñ¾¬¢RzÍĞå~R¹ÚÔĞşÎ
§÷¦ßUŞôû#·Ş4d€íwWªb]ÇQåêØâ é¤1`Q²:Î‘ø§8jk²La9QF¹J]îª¦`ƒ# ~³²G¹**üåÄL¼„«„?¤1b²eÈQ©ïŞ½;%šH'Y¸Ê±®=z öirŠw`ú¹òP—Uld&2SoÔÏó|ıÖ-á*–KS·›)ÄfNÑR°…‰NVë…¨y99ÇÌĞä©\7Whû¡R¸*eÈ Ûëò¨¢'Òaˆ«5¦“Æ WÈáÈÖ‹J)kÄÕ4—,Y’MF PPçN‘«ùf@@.e+{4à@Ñ]»v·BŒUœ¤)Ñ°#&×E‹Q—‘y‰#\%Êiï@šÂUˆQ”ì…]C]rHNd£€Ş
É$iÊv#“Çx&©¦Æ™ë°\šû÷ï—ífêj¶€ˆ‘>‘ŠpÖ0…ò?Ç‚yQ®v›¡Æ=Y¹ZÚ¥ıíå•«`#·şÙ*ÀöT¸U1«!¢\}³<d:i<$Õgû4ŒıÍrnâ.Mô(+ŒbJ'êò–Ò(Àm"==ÚS—€ÃÍË( ÃâLêÊURë<‡ËÊş«$g#y OSım2Ğ”<·ŸØ3ÂURDíÑx‘H„æ†¨sXUSeûs|Ğ|ã7¨s2,y{J4	AWbojjª
èù"á*–KS3gÎzÕb¨ô(ĞŠ:}Š$7…”èA`º^áj—\Ş%ÊÕªÊ…Úßê,6rUJı÷<5*«İå.U\UÙ \]í;l:i<B¡ì}ö5»µµµ•Nò(®œâr ‘„c)Ñ«¨Q]d¸S'‘ÚãjyÊ8S¦L¡“kM‰=D€,KŞ,4 É82 <…ç°.~R#b¬"I¦A•µ@{!órøÒ³sçÎ”è/±g¸$¦D¿B°UiBBùæ ¡Gï“oÎôÀ	à˜MÌÔ¹ğ­ÛíÖ%kˆ«­­Å`©ïØ±C— —/"¤t
Wá¼4™N2.înÆe²µ1–¦Ds	ò7vêÔ©)ÑoŒ¦ë…¨¹G§\5û”«ÇÜÿĞşgÑeqõ–?6,_ÔÙÖFé[±~ğ®G.ãjY…*.(W³ë˜Nj
N(õN&ÈN—7. ¬0êê±Bw*ÇYJô[ù.„Ÿ‰r0”ÜŸ˜IV)T¤‚.%®
4rM·
Iáÿøñã94‹fÓ‰€r5±[¸2‹"öÃXÜ"ÜR¢ßš®J'4 Âk~ÈıQa¿è=‘eÎ;—µë8\i‘Ñ›Ô¬Y³,X ¿n¼$2èÊ ì ¶<=Ü¤d™dVX25ƒË»PfÊ¼_¶0oÄï÷›®¢RÚÍ4ï¹SéeHÿ‘ƒ…JÔÀS”•µºœåÏS®Ò”ş‚†KWqøšZÛL'µ9;Tn<°}ûv\­2œ¼_v¥QqRRiâ"ö¾~ÇQKèVy'9}Ì¸jÕ*˜,OG4ÊsŒÒÃ[£o9‰ç‘ÍØét:‘×Ç[ãdÔ§d}¨U&ö	kaXÙM šeffŠybğºuëd£q|ëÿÏ°ëÙ_F¿É!¥¾…ººLâ*D`vœXË_ÖË	¥¿x<dÈĞ`2ƒ €ı22ù³_$gÏMØÑyq;ù˜Ú›‚äÁj½ÂÕ6ø\Ó•«-n.}­t))¸HÔ›ÿPÿñÂ¶HÄD-é]¶vğÎ‡ájgiY[TmrIµru~y­ÕŒ‰A¸à¨bÃrøâí+ğ–Ù¼^¯—­ØÌÂÁzÅ³‰p8Ì¡~Í 0÷ã	WauÜÅŠÈILÇa¥C‚j5üg£Ç˜4ãQA‘ÅZÍ‹ŸyCº¢ædg·XÀ*şÙ{‹ÒµÒ¿†Î¦¢¼ª'ïá¯•– £¨dà™1%Nê_ø/eª”Ò†¦Äº6®
ä;\½Ş†\@TJÄ~×4åêŞÛüÁÔ#õu‘¦Æ*Š–pcKCCE0çß§u3˜Œ®_5kÖW¯·!W¹š•Õlªzÿ û^¥ë9Ï_½	äcà	ì@å¤û¾…› ê9>ßáÆäÕmü7.\¸ôûzru Q)M	á¬Ú{Á{«Òõ'ï->Ï¼ÃášÄZ‡k|î¹Æ¢¢l\Zu(±–V®†‡B‘gÓOÖQN»ïõx–V‡Êâ…!§Ç½äÏ=FyÊ!ïÚ!'²aÃ
Õ‘™y8	”x7ŸóÜC¿‹ÿ‰í~¸Ş5>àšQåšYï×ï/C¢[æİ”Ì,6lX¢Rê“ƒÓŸİáz"Š‰Ë1×£UÉNaÃ†„«uI£:TSâZ6è¾/–qÿÍéú0ªN~|6¬ Q³32j‡‰Ê` ÈıYõ¡	ßzîŠ§è÷;k+Æ•¸?­ª©îÈ6lX¢Rj®UÁ Ó_XìÙYèş/¥Ä³Ãé/ƒW< V€¨YÕ6lÜğÈŠr5`ÃÆáªß†5óÀŸ7< jÚşı^6nx@ÔúPˆ¿Ö.v¹a‹õÿrwg
endstream
endobj
61 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 360
>>
stream
H‰ìW	Ã äÿä;F£¢hÔÉ!ÓLÓ$®ìºBŠø€xÆDçÙt'’H;l1NÜ½J¶ğ"¹-‚T-8?6$¿íÈñèáòx¯ÓKC©™lå÷ê®¸¶èP¼¢é8¤Ç°³ã['i¨ˆÄ¿ÍñC{r2¥»Lq«xãÖn
µ‹9A—Ÿf1ic·ÛÎİãİ«¢m’Ü¤¡Èo•’­Q/UÆœ
¤õ:q}&>Qéû6vá/ŒôÀ\vìœ3¨¹ ³ƒÇhéæXı¡$5V§úÌÔœAbQñ›°«' å„ĞèqLÆIì$Û)9eHstb’Té„Z,5‘]æŞbnœ­ª ·ys1!¥xzß
v˜~Yk‹”_[á‚–œÈıÉıŒÎWNÂ¢³JH 'à1‘‚Rˆm’N¢Ï)Yƒ„Jy*ª$„8ä» .a¤yŸS\&§Á]!±ãUñ ræ¤k
endstream
endobj
62 0 obj
[ /Indexed /DeviceRGB 255 63 0 R ]
endobj
63 0 obj
<<
/Filter /FlateDecode
/Length 337
>>
stream
H‰´R[•BA«,`¡°€…X¸°XÀB,`Ùd<lÿz¦Mó˜™ÔÎ`†3šq»İYÌrV³î#v€¸³Ü!†jè®jGq¤‘ƒ4Ş1Ækì:XYÎ´{§…]îj×=›Xp¡…Ë"Ä’K-]R™V\iåpÌêk®µv)WCH‡eh¹
z)ĞÁÊ²+¨}Š€ W_Î¦#A®Ü°È£	rÔ‡TfaÂ‚]3jV¶cGô»ŞTRÀB:,]«z8Ø–ë\ŸÓ§DºFF_Î¦“(Ç×È‹<Ò¢]››
:[£]×ëºZ;ÜªE*i7“ò@íFÔiôNËI,FF_Î¦“íó|òöIÔ'3ŸT||÷qÖÇ;w|ôû(ôÑàÃÒ‡‡Ï%,ŸiŸşv»İï÷Çãñ|>¯ëz½^ï÷ûóù|¿ßßïç«? q«c
endstream
endobj
64 0 obj
<<
/Annots [ 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R 81 0 R 82 0 R 83 0 R 84 0 R 85 0 R 86 0 R 87 0 R 88 0 R 89 0 R 90 0 R 91 0 R 92 0 R 93 0 R 94 0 R 95 0 R 96 0 R 97 0 R 98 0 R 99 0 R 100 0 R 101 0 R 102 0 R 103 0 R 104 0 R 105 0 R 106 0 R 107 0 R 108 0 R 109 0 R 110 0 R 111 0 R 112 0 R 113 0 R 114 0 R 115 0 R 116 0 R ]
/Contents 117 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 118 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F5 39 0 R
/F6 42 0 R
/F7 45 0 R
/F9 55 0 R
>>
/XObject <<
/Xi2 119 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 121 0 R
/Type /Page
/Parent 2 0 R
>>
endobj
65 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib9)
/Rect [ 262 672 290 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
66 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib9)
/Rect [ 51 661 94 669 ]
/Subtype /Link
/Type /Annot
>>
endobj
67 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib38)
/Rect [ 229 581 290 590 ]
/Subtype /Link
/Type /Annot
>>
endobj
68 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib38)
/Rect [ 51 570 70 579 ]
/Subtype /Link
/Type /Annot
>>
endobj
69 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib38)
/Rect [ 118 514 196 523 ]
/Subtype /Link
/Type /Annot
>>
endobj
70 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib88)
/Rect [ 417 672 474 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
71 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib16)
/Rect [ 479 672 544 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
72 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib85)
/Rect [ 308 661 377 669 ]
/Subtype /Link
/Type /Annot
>>
endobj
73 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib88)
/Rect [ 438 616 497 624 ]
/Subtype /Link
/Type /Annot
>>
endobj
74 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib16)
/Rect [ 503 616 547 624 ]
/Subtype /Link
/Type /Annot
>>
endobj
75 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib16)
/Rect [ 308 605 327 613 ]
/Subtype /Link
/Type /Annot
>>
endobj
76 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib85)
/Rect [ 332 605 400 613 ]
/Subtype /Link
/Type /Annot
>>
endobj
77 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib16)
/Rect [ 311 537 376 546 ]
/Subtype /Link
/Type /Annot
>>
endobj
78 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib85)
/Rect [ 381 537 450 546 ]
/Subtype /Link
/Type /Annot
>>
endobj
79 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib6)
/Rect [ 311 470 369 478 ]
/Subtype /Link
/Type /Annot
>>
endobj
80 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib37)
/Rect [ 376 470 434 478 ]
/Subtype /Link
/Type /Annot
>>
endobj
81 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137tbl1)
/Rect [ 338 392 366 400 ]
/Subtype /Link
/Type /Annot
>>
endobj
82 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib27)
/Rect [ 382 297 454 305 ]
/Subtype /Link
/Type /Annot
>>
endobj
83 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 459 297 542 305 ]
/Subtype /Link
/Type /Annot
>>
endobj
84 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 380 288 397 296 ]
/Subtype /Link
/Type /Annot
>>
endobj
85 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 401 288 461 296 ]
/Subtype /Link
/Type /Annot
>>
endobj
86 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib62)
/Rect [ 466 288 524 296 ]
/Subtype /Link
/Type /Annot
>>
endobj
87 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib25)
/Rect [ 382 279 450 287 ]
/Subtype /Link
/Type /Annot
>>
endobj
88 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 455 279 514 287 ]
/Subtype /Link
/Type /Annot
>>
endobj
89 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 382 270 483 278 ]
/Subtype /Link
/Type /Annot
>>
endobj
90 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 487 270 545 278 ]
/Subtype /Link
/Type /Annot
>>
endobj
91 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib60)
/Rect [ 380 261 455 269 ]
/Subtype /Link
/Type /Annot
>>
endobj
92 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 382 252 483 260 ]
/Subtype /Link
/Type /Annot
>>
endobj
93 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 487 252 545 260 ]
/Subtype /Link
/Type /Annot
>>
endobj
94 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib41)
/Rect [ 380 243 438 251 ]
/Subtype /Link
/Type /Annot
>>
endobj
95 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 382 235 483 242 ]
/Subtype /Link
/Type /Annot
>>
endobj
96 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 487 235 545 242 ]
/Subtype /Link
/Type /Annot
>>
endobj
97 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib36)
/Rect [ 380 226 446 233 ]
/Subtype /Link
/Type /Annot
>>
endobj
98 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib41)
/Rect [ 451 226 509 233 ]
/Subtype /Link
/Type /Annot
>>
endobj
99 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib26)
/Rect [ 382 217 454 224 ]
/Subtype /Link
/Type /Annot
>>
endobj
100 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 458 217 516 224 ]
/Subtype /Link
/Type /Annot
>>
endobj
101 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 380 208 425 215 ]
/Subtype /Link
/Type /Annot
>>
endobj
102 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 429 208 489 215 ]
/Subtype /Link
/Type /Annot
>>
endobj
103 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib4)
/Rect [ 380 199 442 206 ]
/Subtype /Link
/Type /Annot
>>
endobj
104 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 382 190 484 197 ]
/Subtype /Link
/Type /Annot
>>
endobj
105 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib36)
/Rect [ 380 181 446 188 ]
/Subtype /Link
/Type /Annot
>>
endobj
106 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib87)
/Rect [ 382 172 448 179 ]
/Subtype /Link
/Type /Annot
>>
endobj
107 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib73)
/Rect [ 452 172 519 179 ]
/Subtype /Link
/Type /Annot
>>
endobj
108 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib22)
/Rect [ 382 163 457 170 ]
/Subtype /Link
/Type /Annot
>>
endobj
109 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib32)
/Rect [ 462 163 528 170 ]
/Subtype /Link
/Type /Annot
>>
endobj
110 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib41)
/Rect [ 382 145 440 152 ]
/Subtype /Link
/Type /Annot
>>
endobj
111 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib72)
/Rect [ 445 145 501 152 ]
/Subtype /Link
/Type /Annot
>>
endobj
112 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib44)
/Rect [ 382 127 454 134 ]
/Subtype /Link
/Type /Annot
>>
endobj
113 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib74)
/Rect [ 459 127 519 134 ]
/Subtype /Link
/Type /Annot
>>
endobj
114 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib54)
/Rect [ 380 118 468 125 ]
/Subtype /Link
/Type /Annot
>>
endobj
115 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib21)
/Rect [ 473 118 542 125 ]
/Subtype /Link
/Type /Annot
>>
endobj
116 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib78)
/Rect [ 382 109 441 116 ]
/Subtype /Link
/Type /Annot
>>
endobj
117 0 obj
<<
/Length 19670
>>
stream
q
q

BT
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(Nevertheless,)-520.5(highly)-525.8(potent)-518.7(and)-519.6(selective)-519.3(PDE4)-515.6(inhibitors)]TJ
0 -1.3256 TD
[(have)-325.9(been)-331.7(developed)-325.5(to)-330.8(target)-326.5(inflammator)-14.5(y)-325(air)-11.4(way)-329.4(disease.)]TJ
T*
[(This)-589.4(strategy)-587(is)-594.2(not)-585.2(unique)-589.5(and)-586.5(is)-587.5(exemplified)-592.7(with)-590.7(the)]TJ
0 -1.3189 TD
[(development)-752.3(and)-747.2(clinical)-745.2(success)-753.6(of)-744.4(a)-748.6(PDE5)-749.9(inhibitor)40.1(,)]TJ
0 -1.3256 TD
[(sildenafil,)-389.2(for)-386.1(the)-383.7(treatment)-384.5(of)-382.8(erectile)-382.6(dysfunction)-391.6(\(Boolell)]TJ
/F3 1 Tf
T*
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(1996\).)]TJ
/F3 1 Tf
-1.9281 -4.0437 TD
(PDE4)Tj
/F2 1 Tf
0 -1.3189 TD
[(PDE4)-455.3(catalyses)-458.8(the)-457.3(hydrolysis)-457.1(of)-449.8(cyclic)-456.6(AMP)121.6(,)-452.1(which)-456.7(termi-)]TJ
0 -1.3256 TD
[(nates)-418.3(the)-417.1(downstream)-425.4(signalling)-422.7(of)-416.3(this)-420(second)-413.9(messenger)67.8(.)]TJ
T*
[(There)-357.5(are)-359(four)-361.2(gene)-360.3(families)-354.6(\(A–D\),)-360.2(although)-362.2(there)-355.5(is)-359.8(added)]TJ
0 -1.3189 TD
[(complexity)-628.5(with)-630.9(over)-627.8(20)-623.4(splice)-630.6(variants)-625.4(\(Houslay)]TJ
/F3 1 Tf
25.4335 0 TD
[(et)-625.8(al)]TJ
/F2 1 Tf
2.2227 0 TD
(.,)Tj
-27.6562 -1.3256 TD
[(2007\).)-327.2(Hydrolysis)-317.8(of)-322.6(cyclic)-322.7(AMP)-320.2(is)-319.7(a)-320.2(common)-327.3(feature)-321.1(of)-315.9(this)]TJ
T*
[(family)70.6(,)-351.7(and)-345.5(it)-350.7(is)-346.5(clear)-347.9(that)-346.8(these)-347.9(isoforms)-353(can)-346.7(be)-349.7(targeted)-347.2(to)]TJ
0 -1.3189 TD
[(different)-273.2(domains)-276.6(within)-272.1(the)-269.8(extracellular)-262.4(compartment)-273.3(and)]TJ
0 -1.3256 TD
[(their)-416.4(activity)-419.2(differentially)-424.1(regulated)-418.8(by)-411.5(kinases,)-417.2(suggesting)]TJ
T*
[(that)-326.7(these)-327.9(isoforms)-326.3(have)-325.9(specific)-327.4(functions)-329.2(in)-324.1(the)-323.4(control)-332.5(of)]TJ
0 -1.3189 TD
[(cellular)-335(activity)-332.2(\(Houslay)]TJ
/F3 1 Tf
12.0573 0 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-328.5(2007\).)-333.9(X-ray)-332(cr)-16.4(ystallography)]TJ
-13.9854 -1.3256 TD
[(has)-389.5(resolved)-392.3(the)-390.4(catalytic)-394(domain)-394.7(of)-389.5(these)-394.8(enzymes,)-392.9(which)]TJ
T*
[(are)-419.2(comprised)-428.6(of)-416.3(three)-422.5(important)-424.5(domains,)-420.7(consisting)-428.9(of)-416.3(a)]TJ
T*
[(bivalent)-290.3(metal-binding)-294.5(pocket)-294.5(\(Zn)]TJ
6.351 0 0 5.6449 186.5763 486.5385 Tm
(2)Tj
/F7 1 Tf
0.7409 0 TD
()Tj
/F2 1 Tf
8.4682 0 0 8.4682 197.2346 482.7401 Tm
0.2914 Tc
[(,M)291.4(g)]TJ
6.351 0 0 5.6449 214.8661 486.5385 Tm
0 Tc
(2)Tj
/F7 1 Tf
0.7409 0 TD
()Tj
/F2 1 Tf
8.4682 0 0 8.4682 225.5244 482.7401 Tm
[(\),)-285.6(which)-296(forms)-291.7(a)]TJ
-20.6333 -1.3189 TD
[(complex)-314.4(with)-309.5(the)-303.3(phosphate)-311(moiety)-309.3(of)-309.2(cyclic)-309.3(AMP)121.6(,)-304.8(a)-306.8(pocket)]TJ
0 -1.3256 TD
[(containing)-563.6(glutamine)-568.5(\(Q)-554.5(pocket\),)-566.7(which)-563.8(forms)-559.5(hydrogen)]TJ
T*
[(bonds)-471.8(with)-463.5(the)-470.7(nucleotide)-467.6(\(purine\))-472(moiety)-469.9(of)-463.2(cyclic)-470(AMP)121.6(,)]TJ
0 -1.3189 TD
[(and)-291.9(a)-293.4(solvent)-294.7(pocket.)-298.1(PDE4)-294.6(inhibitors)-297(occupy)-294.1(this)-292.8(active)-294.6(site)]TJ
0 -1.3256 TD
[(through)-518.1(a)-514.3(number)-519.2(of)-510(important)-518.3(interactions)-523(and)-512.9(prevent)]TJ
T*
[(cyclic)-456.6(AMP)-447.4(metabolism.)-456.6(These)-450.4(include)-456.1(indirect)-450.7(binding)-453.1(to)]TJ
0 -1.3189 TD
[(the)-484.1(metal)-489(ions)-483.2(by)-485.1(the)-484.1(formation)-494.3(of)-483.3(hydrogen)-487(bonding)-486.8(to)]TJ
0 -1.3256 TD
[(water)37.2(,)-271.4(whereas)-282.1(hydrophobic)-279.2(interactions)-275.3(between)-279.1(the)-276.5(planar)]TJ
T*
[(ring)-442.4(structure)-442.8(of)-436.4(these)-441.7(inhibitors)-437.6(and)-439.2(hydrophobic)-446.6(amino-)]TJ
0 -1.3189 TD
[(acid)-374.6(residues)-376.7(such)-372.2(as)-369.4(phenylalanine)-373.6(and)-379(isoleucine)-373.7(ser)-7.7(ve)-374(to)]TJ
30.3542 41.0993 TD
[(‘clamp’)-472.2(the)-484.1(inhibitor)-495.5(within)-486.3(the)-484.1(active)-482.1(site)-482.3(and)-486.1(hydrogen)]TJ
0 -1.3256 TD
[(bond)-583.3(interaction)-587.6(between)-587(the)-584.5(aromatic)-592(ring)-583(structure)-590(of)]TJ
T*
[(these)-247.5(inhibitors)-250.1(and)-251.8(the)-243.1(invariant)-250.8(glutamine)-253.9(residue)-247.2(in)-250.4(the)-243.1(Q)]TJ
0 -1.3189 TD
[(pocket,)-385.1(the)-383.7(site)-381.9(which)-383(is)-379.9(normally)-385.7(occupied)-380.7(by)-384.7(the)-383.7(nucleo-)]TJ
0 -1.3256 TD
[(tide)-324.5(moiety)-322.7(of)-322.6(cyclic)-329.4(AMP)-320.2(\(Xu)]TJ
/F3 1 Tf
14.5411 0 TD
[(et)-324.5(al)]TJ
/F2 1 Tf
1.9147 0 TD
[(.,)-321.8(2000;)-326.4(Card)]TJ
/F3 1 Tf
6.3734 0 TD
[(et)-324.5(al)]TJ
/F2 1 Tf
1.9147 0 TD
[(.,)-328.5(2004;)]TJ
-24.7439 -1.3256 TD
[(W)74.6(ang)]TJ
/F3 1 Tf
3.0193 0 TD
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2007\).)]TJ
-3.9499 -1.3256 TD
[(There)-678.9(are)-680.3(considerable)-677.2(challenges)-681.2(to)-678.9(the)-671.5(synthesis)-678.3(of)]TJ
-0.9975 -1.3189 TD
[(subtype)-717.5(selective)-713.4(inhibitors)-718.8(due)-712.1(to)-712.4(the)-711.7(high)-713.7(degree)-712.3(of)]TJ
0 -1.3256 TD
[(sequence)-731.8(and)-727.1(structural)-729.9(homology)-736(within)-727.3(the)-731.8(catalytic)]TJ
T*
[(domains)-390.4(of)-396.2(the)-390.4(PDE4)-388.4(subtypes)-391.8(\(Xu)]TJ
/F3 1 Tf
17.1119 0 TD
[(et)-384.8(al)]TJ
/F2 1 Tf
1.9817 0 TD
[(.,)-388.7(2000;)-393.4(Card)]TJ
/F3 1 Tf
6.5743 0 TD
[(et)-391.5(al)]TJ
/F2 1 Tf
1.9817 0 TD
(.,)Tj
-27.6495 -1.3189 TD
[(2004;)-299.6(W)74.6(ang)]TJ
/F3 1 Tf
5.8646 0 TD
[(et)-291.1(al)]TJ
/F2 1 Tf
1.8879 0 TD
[(.,)-295(2007\).)-300.5(One)-294.8(possibility)-300.7(might)-295.3(be)-296.1(to)-297.3(exploit)]TJ
-7.7526 -1.3256 TD
[(subtle)-262.7(differences)-264(between)-265.7(the)-256.5(interaction)-266.3(of)-262.3(these)-260.9(inhibitors)]TJ
T*
[(to)-270.5(the)-269.9(catalytic)-273.5(active)-267.9(site,)-271.6(or)-267.2(alternatively)67(,)-271.4(b)0(y)-264.2(non-active)-272.5(site)]TJ
0 -1.3189 TD
[(inhibition)-267.3(by)-264.2(targeting)-263.5(the)-263.1(N-terminal)-268.1(region)-259.9(of)-269(the)-256.5(enzyme,)]TJ
0 -1.3256 TD
[(which)-269.2(contain)-278.4(phosphory)-12(lation)-267.9(sites)-270.5(and/or)-274.5(protein-binding)]TJ
T*
[(sequences)-607(and)-599.9(so)-601(indirectly)-604.2(interfere)-609.7(with)-597.4(PDE4)-609.3(activity)]TJ
0 -1.3189 TD
0.0002 Tc
(\(Card)Tj
/F3 1 Tf
2.9256 0 TD
0 Tc
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2004;)-339.8(W)74.6(ang)]TJ
/F3 1 Tf
6.8555 0 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2007\).)]TJ
-12.6398 -1.3256 TD
[(W)21(ith)-484.6(well)-481.7(over)-487.2(100)-479.8(mediators)-489.3(including)-484.7(prostaglandins,)]TJ
-0.9975 -1.3256 TD
[(leukotrienes,)-444.1(chemokines,)-444.4(cytokines,)-442.2(proteases)-447.3(and)-439.2(growth)]TJ
T*
[(factors)-795.2(and)-787.3(numerous)-801.3(cell)-790.4(types)-789.8(including)-792.7(mast)-794.7(cells,)]TJ
0 -1.3189 TD
[(neutrophils,)-555.4(eosinophils,)-551.4(macrophages,)-557.1(DCs)-551(and)-546.3(lympho-)]TJ
0 -1.3256 TD
[(cytes)-422.8(implicated)-424.1(in)-417.8(the)-423.8(pathogenesis)-421.3(of)-423(asthma)-418.6(and)-419.1(COPD)]TJ
T*
[(\(Barnes,)-581.1(2006b;)-580.2(Holgate,)-581.4(2007\),)-581.6(suggests)-582.5(that)-581.1(a)-574.6(chemical)]TJ
0 -1.3189 TD
[(strategy)-399.5(designed)-409.2(to)-397.7(target)-400.2(a)-400.5(single)-406(mediator)-399.9(or)-394.4(cell)-402.1(type)-399.1(is)]TJ
0 -1.3256 TD
[(unlikely)-688.7(to)-678.9(be)-684.4(successful)-689.6(particularly)-685.2(as)-684(many)-682.3(of)-684.1(these)]TJ
T*
[(mediators)-335.3(and)-332.1(cell)-335.1(types)-334.5(have)-332.6(overlapping)-335.6(and)-332.1(complemen-)]TJ
0 -1.3189 TD
[(tar)-8.7(y)-653.1(roles)-655.9(in)-652.1(disease)-651.5(pathology)69.9(.)-653(PDE4)-649.5(is)-654.4(expressed)-651(in)-652.1(a)]TJ
0 -1.3256 TD
[(number)-264.8(of)-262.3(cell)-254.8(types)-260.9(that)-259.7(are)-265.3(considered)-259.7(suitable)-264.1(drug)-259.3(targets)]TJ
T*
[(for)-325.9(the)-316.7(treatment)-324.2(of)-322.6(respirator)-16.9(y)-318.3(diseases)-325.9(such)-318.7(as)-322.5(asthma)-324.9(and)]TJ
T*
[(COPD)-269.2(\()5.9(T)58.3(able)-264(1\).)-262.5(It)-268.5(might)-261.9(reasonably)-268.3(be)-262.6(argued)-266.9(that)-259.7(targeting)]TJ
0 -1.3189 TD
[(PDE4)-408.4(could)-413.9(potentially)-415.3(suppress)-406.4(the)-410.4(function)-413.9(of)-409.6(numerous)]TJ
0 -1.3256 TD
[(cell)-274.9(types;)-271.1(however)40.6(,)-271.4(i)0(t)-270.3(i)0(s)-272.8(well)-267.4(known)-273.3(that)-273.1(other)-269.2(PDE)-270.8(enzymes)]TJ
ET
1 i 
50.797 329.783 496.176 -0.737 re
f
50.797 97.625 496.176 -0.737 re
f
50.797 310.11 61.285 -0.283 re
f
112.082 310.11 61.285 -0.283 re
f
173.367 310.11 61.228 -0.283 re
f
234.595 310.11 144.964 -0.283 re
f
379.559 310.11 167.414 -0.283 re
f
BT
/F1 1 Tf
7.4718 0 0 7.4718 50.7968 335.5653 Tm
0.0001 Tc
[(Table)-339.9(1)]TJ
/F4 1 Tf
4.4918 0 TD
0 Tc
[(PD)-9.8(E)-327(d)-0.1(ist)-10.5(ribution)-339.9(w)-0.1(ithin)-335.1(human)-341.9(cells)-333.1(of)-335.8(interest)-347.8(for)-334.2(t)0(he)-331.8(treatment)-349.1(o)-0.1(f)-335.8(respiratory)-344(diseases)-339.6(such)-333(as)-336.5(asthma)-337.1(and)-334.6(COPD)]TJ
/F5 1 Tf
-4.4918 -2.3066 TD
[(Cell)-336.4(type)-4568.2(PDE4)-340.2(Subtype)]TJ
/F4 1 Tf
5.6038 0 0 4.9805 156.9259 321.6188 Tm
(a)Tj
/F5 1 Tf
7.4718 0 0 7.4718 178.1858 318.3306 Tm
[(Other)-339.1(PDE’s)-2454.1(Biologi)-11.6(cal)-312.8(consequence)-318.1(of)-306.7(PDE4)-317.4(inhibition)-1804.4(Reference)]TJ
/F4 1 Tf
-17.0492 -2.5646 TD
[(T)-237.1(lymphocyt)-15(es)]TJ
0 -1.2064 TD
0.0001 Tc
[(CD4)-338.7(CD8)]TJ
8.2021 1.2064 TD
0 Tc
(B)Tj
/F6 1 Tf
0.5766 0 TD
(4)Tj
/F4 1 Tf
0.994 0 TD
[(A)-8331.7(3)-0.1(,)-335.8(7)-4109.5(Inhib)-10.5(ition)-338.1(o)-0.1(f)-335.8(p)-0.1(roliferation)-346(a)0(nd)-334.6(cytokine)]TJ
14.8261 -1.2064 TD
(release)Tj
19.4013 1.2064 TD
0.0004 Tc
(\(Gantner)Tj
/F5 1 Tf
4.2946 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.9045 0 TD
[(.,)-328.4(1997b;)-340.7(Hatze)-10.8(lmann)-333.3(a)0.1(nd)-334.5(Schudt)-12.9(,)]TJ
-6.199 -1.2064 TD
[(2001;)-341.9(Smith)]TJ
/F5 1 Tf
5.8424 0 TD
0 Tc
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336.1(2003;)-334.4(Pet)-9.6(er)]TJ
/F5 1 Tf
6.4191 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2007\))]TJ
-60.0554 -1.1988 TD
0 Tc
[(B)-338.5(cells)-5439.5(B,)-335.8(D)]TJ
/F6 1 Tf
10.1445 0 TD
(4)Tj
/F4 1 Tf
0.994 0 TD
[(A)-7565.4(7)-4708.9(Incre)-10.1(ased)-333.7(proliferation)-9526.9(\()-2.6(Gantner)]TJ
/F5 1 Tf
37.1562 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.9045 0 TD
0 Tc
[(.,)-328.5(1998;)-342(Smith)]TJ
/F5 1 Tf
6.7529 0 TD
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2003\))]TJ
-58.849 -1.1988 TD
[(Eosinophi)-12.9(ls)-3298.6(A,)-331.6(D)]TJ
/F6 1 Tf
10.1825 0 TD
0 Tc
(4)Tj
/F4 1 Tf
1.0016 0 TD
0.0001 Tc
[(B)-7561.7(7)-4708.8(Inhib)-10.4(ition)-338(o)0(f)-335.7(s)0.1(uperoxide)-344.8(a)0.1(nion)]TJ
13.4148 -1.1988 TD
0 Tc
[(gener)-10.2(ation;)-339.9(delayed)-333.3(apop)-10.5(tosis)]TJ
19.4013 1.1988 TD
0.0001 Tc
[(\(Hatzelmann)-260.7(and)-251(Schudt,)-260.6(2001;)-258.4(Smith)]TJ
/F5 1 Tf
17.1706 0 TD
[(et)-248.3(al)]TJ
/F4 1 Tf
1.8134 0 TD
[(.,)-252.5(2003;)]TJ
-18.984 -1.1988 TD
0 Tc
(Parkkonen)Tj
/F5 1 Tf
4.9319 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2007\))]TJ
-50.8289 -1.1988 TD
[(Neutroph)-12.3(ils)-3029.3(A,)-331.6(D)]TJ
/F6 1 Tf
10.1825 0 TD
0 Tc
(4)Tj
/F4 1 Tf
1.0016 0 TD
0.0001 Tc
[(B)-7561.7(7)-4708.8(Inhib)-10.4(ition)-338(o)0(f)-335.7(s)0.1(uperoxide)-344.8(a)0.1(nion)-337.7(and)]TJ
13.4148 -1.1988 TD
0 Tc
[(neut)-10.1(rophil)-336.8(elastase)-338(release)]TJ
19.4013 1.1988 TD
0.0001 Tc
[(\(Hatzelmann)-260.7(and)-251(Schudt,)-260.6(2001;)-258.4(Smith)]TJ
/F5 1 Tf
17.1706 0 TD
[(et)-248.3(al)]TJ
/F4 1 Tf
1.8134 0 TD
[(.,)-252.5(2003;)]TJ
-18.984 -1.1988 TD
(Jones)Tj
/F5 1 Tf
2.6632 0 TD
0 Tc
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2005\))]TJ
-48.5603 -1.2064 TD
[(Monocyte)-3715.7(B)]TJ
/F6 1 Tf
9.1051 0 TD
0 Tc
(4)Tj
/F4 1 Tf
1.0016 0 TD
0.0001 Tc
[(A,)-339.2(D)-7227.8(7)-4708.8(Inhib)-10.4(ition)-338(o)0(f)-335.7(TNF-)]TJ
/F6 1 Tf
22.4212 0 TD
0 Tc
(a)Tj
/F4 1 Tf
0.8877 0 TD
0.0001 Tc
[(release)-7587.3(\(Hatzelmann)-260.7(and)-251(Schudt,)-260.6(2001;)-258.4(Smith)]TJ
/F5 1 Tf
27.7552 0 TD
[(et)-248.3(al)]TJ
/F4 1 Tf
1.8134 0 TD
[(.,)-252.5(2003;)]TJ
-18.984 -1.1988 TD
0 Tc
[(Heyste)-10.5(k)]TJ
/F5 1 Tf
3.7786 0 TD
0.0001 Tc
[(et)-331.8(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2003;)-334.3(Jones)]TJ
/F5 1 Tf
6.4949 0 TD
0 Tc
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2005\))]TJ
-58.0675 -1.1988 TD
[(Macrophage)-14.2(s)-2202.3(A)0(,)-331.6(B)0.1(,)-335.7(D)-6742.2(1,)-335.7(3,)-335.7(7)-3510(I)0.1(nhib)-10.4(ition)-338(o)0(f)-335.7(TNF-)]TJ
/F6 1 Tf
32.5278 0 TD
0 Tc
(a)Tj
/F4 1 Tf
0.8877 0 TD
(release)Tj
5.6038 0 0 4.9805 322.866 221.7826 Tm
(b)Tj
7.4718 0 0 7.4718 379.559 218.4377 Tm
0.0004 Tc
(\(Gantner)Tj
/F5 1 Tf
4.2946 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.9045 0 TD
0 Tc
[(.,)-328.5(1997a)-11.6(;)-331.2(H)-0.1(atzelmann)-344.3(a)0(nd)]TJ
-6.199 -1.1988 TD
0.0001 Tc
[(Schudt,)-344.1(2001;)-341.9(Smith)]TJ
/F5 1 Tf
9.5603 0 TD
0 Tc
[(et)-339.5(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2003;)]TJ
-11.4572 -1.1988 TD
0 Tc
[(Barb)-10.2(er)]TJ
/F5 1 Tf
3.2019 0 TD
[(et)-339.5(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2004\))]TJ
-49.099 -1.1988 TD
[(DCs)-6390.9(A)]TJ
/F6 1 Tf
8.8167 0 TD
0 Tc
(4)Tj
/F4 1 Tf
1.0016 0 TD
0.0001 Tc
[(B,)-335.7(D)-6962.3(1)0(,)-335.7(3)-4109.4(Inhib)-10.4(ition)-338(o)0(f)-335.7(TNF-)]TJ
/F6 1 Tf
22.7095 0 TD
0 Tc
(a)Tj
/F4 1 Tf
0.8877 0 TD
0.0001 Tc
[(release)-7587.3(\(Hatzelmann)-344.2(a)0.1(nd)-334.5(Schudt,)-344.1(2)0(001;)]TJ
10.5846 -1.1988 TD
0 Tc
[(Heyste)-10.5(k)]TJ
/F5 1 Tf
3.7786 0 TD
0.0001 Tc
[(et)-331.8(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2003\))]TJ
-49.6756 -1.2064 TD
0 Tc
[(Mast)-341.1(cells)-20250.4(Littl)-11(e)-332.2(i)0(f)-335(a)0(ny)-336.5(mast)-335.2(cell)-338.7(stabilization)-4633.8(\()-2.6(Weston)]TJ
/F5 1 Tf
48.014 0 TD
[(et)-339.5(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336.1(1997;)-342(Shichijo)]TJ
/F5 1 Tf
7.6331 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(1998\))]TJ
-59.4408 -1.1988 TD
0 Tc
(Airway)Tj
T*
[(epithelial)-344.7(cells)]TJ
16.4043 1.1988 TD
[(1–3,)-325.9(4,)-320.6(5,)-328.2(7,)-328.2(8)-1795.3(I)0(ncre)-10.1(ased)-235(production)-247.4(of)-237.1(PGE)]TJ
5.6038 0 0 4.9805 327.4582 163.389 Tm
(2)Tj
7.4718 0 0 7.4718 330.633 164.6362 Tm
0.0001 Tc
[(;)-232.4(i)0.1(nhi)-9.9(bition)]TJ
-12.8533 -1.1988 TD
0 Tc
[(of)-335.8(IL-6)-336.3(produ)-12.8(ction)]TJ
19.4013 1.1988 TD
0.0003 Tc
(\(Fuhrmann)Tj
/F5 1 Tf
5.2354 0 TD
0 Tc
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(1999;)-341.9(Haddad)]TJ
/F5 1 Tf
7.6634 0 TD
[(et)-331.8(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2002\))]TJ
-60.6927 -2.3977 TD
0 Tc
[(Endothe)-10.8(lial)]TJ
0 -1.1988 TD
(cells)Tj
17.5196 1.1988 TD
0.0001 Tc
[(2,)-335.7(3,)-335.7(4,)-335.7(5)-2910.6(I)0.1(nhib)-10.4(ition)-338(o)0(f)-335.7(a)0.1(dhesion)-336.7(molecule)]TJ
7.0792 -1.1988 TD
0 Tc
[(expre)-12.5(ssion)]TJ
19.4013 1.1988 TD
0.0006 Tc
(\(Jones)Tj
/F5 1 Tf
3.0123 0 TD
0 Tc
[(et)-339.5(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2005;)-341.9(Sanz)]TJ
/F5 1 Tf
6.2294 0 TD
[(et)-331.8(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2007\))]TJ
-57.0355 -2.3977 TD
0 Tc
[(Fibroblasts)-3530.7(A,)-331.7(B)]TJ
/F6 1 Tf
10.3494 0 TD
(4)Tj
/F4 1 Tf
1.0016 0 TD
[(D)-5429.7(1)-0.1(,)-335.8(4)-0.1(,)-335.8(5)-0.1(,)-335.8(7)-2910.7(Inhib)-10.5(ition)-338.1(o)-0.1(f)-335.8(fibroblast)-340.4(chemotaxis;)]TJ
13.2478 -1.2064 TD
[(inhi)-10(bition)-336.8(o)-0.1(f)-335.8(p)-0.1(ro-MMP1,)-340.8(2)-338.5(release)]TJ
19.4013 1.2064 TD
0.0004 Tc
(\(Kohyama)Tj
/F5 1 Tf
4.8408 0 TD
0 Tc
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2002;)-341.9(Smith)]TJ
/F5 1 Tf
6.7529 0 TD
0 Tc
[(et)-339.5(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-336(2003;)]TJ
-15.3875 -1.2064 TD
0 Tc
[(Martin-C)-13(houly)]TJ
/F5 1 Tf
6.7681 0 TD
0.0001 Tc
[(et)-339.4(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2004;)-341.9(Dunkern)]TJ
/F5 1 Tf
7.9897 0 TD
[(et)-331.8(al)]TJ
/F4 1 Tf
1.8969 0 TD
[(.,)-336(2007\))]TJ
-62.5517 -1.1988 TD
0 Tc
(Sensory)Tj
T*
(nerves)Tj
5.6038 0 0 4.9805 71.9433 105.222 Tm
(c)Tj
7.4718 0 0 7.4718 112.0819 110.8347 Tm
0.0001 Tc
[(D)-9777.2(1)0(,)-335.7(3)-4109.4(Inhib)-10.4(ition)-338(o)0(f)-335.7(n)0(europeptide)-343.6(release)-4317.1(\(Spina)]TJ
/F5 1 Tf
38.9317 0 TD
0 Tc
[(et)-331.9(al)]TJ
/F4 1 Tf
1.8969 0 TD
0.0001 Tc
[(.,)-328.4(1995\))]TJ
6.9738 0 0 6.9738 50.7968 84.189 Tm
0 Tc
[(Abbr)-11.1(eviations:)-344.2(CD,)-331.5(clu)-10.6(ster)-337.4(o)-0.1(f)-332(d)-0.1(ifferen)-13.4(tiation;)-336.6(CO)-9.6(PD,)-331.2(chr)-9.4(onic)-338.1(obstructive)-342.5(pulmona)-12.8(ry)-335.7(disease;)-342.5(IL,)-335.7(interleukin;)-344.5(TNF,)-335.6(t)0(um)-10.9(our)-333.9(necrosis)-340.8(factor.)]TJ
5.2302 0 0 4.6485 50.7968 78.3496 Tm
(a)Tj
6.9738 0 0 6.9738 53.4047 75.2315 Tm
[(PDE4)-338.7(s)0(ub)-10.8(type)-338.2(mRNA)-336.4(expression)-342.9(illustr)-13.6(ating)-335.1(relative)-338.6(abun)-11.8(dance)-334.5(i)0(n)-340.5(cells.)]TJ
5.2302 0 0 4.6485 50.7968 69.3921 Tm
(b)Tj
6.9738 0 0 6.9738 53.9149 66.274 Tm
0.0001 Tc
[(In)-335.6(the)-336(p)0(resence)-346.4(o)0(f)-331.9(a)-337.2(PDE3)-338.6(inhibitor.)]TJ
5.2302 0 0 4.6485 50.7968 60.3779 Tm
0 Tc
(c)Tj
6.9738 0 0 6.9738 53.2913 57.3165 Tm
[(Gui)-10.7(nea-pig)-339.5(sensory)-339.3(nerves.)]TJ
ET
307.842 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 307.8424 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-335.3(and)-325.8(respiratory)-335.9(disease)]TJ
/F9 1 Tf
0 -1.2519 TD
[(D)-328.5(Spina)]TJ
7.0982 0 0 9.4646 534.1038 751.8612 Tm
0.0001 Tc
(309)Tj
ET
307.842 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 405.2408 31.2378 Tm
[(British)-322.5(J)0.1(ournal)-334(of)-334.4(Pharmacolog)18.7(y)-339.1(\(2008\))]TJ
/F1 1 Tf
17.5955 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi2 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
405 29 141 10 re
f*
0.619608 0.619608 0.619608 rg
n
533 752 14 8 re
f*
0.619608 0.619608 0.619608 rg
n
307 751 111 18 re
f*
0.619608 0.619608 0.619608 rg
n
573 2 14 445 re
f*
0.8 0.8 0 rg
n
48 97 502 236 re
f*
1 1 0.4 rg
n
49 333 415 14 re
f*
0.898039 1 0.8 rg
n
49 55 424 37 re
f*
0.4 0.4 1 rg
n
50 628 22 8 re
f*
0.6 0 0.298039 rg
n
50 661 239 67 re
f*
0.6 0 0.298039 rg
n
50 370 239 256 re
f*
0.6 0 0.298039 rg
n
307 661 240 67 re
f*
0.6 0 0.298039 rg
n
307 538 240 121 re
f*
0.6 0 0.298039 rg
n
307 370 240 167 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 718 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 74 626 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 616 cm
BT
1 0 0 1 0 0 Tm
(3) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 718 cm
BT
1 0 0 1 0 0 Tm
(4) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 649 cm
BT
1 0 0 1 0 0 Tm
(5) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 527 cm
BT
1 0 0 1 0 0 Tm
(6) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 466 337 cm
BT
1 0 0 1 0 0 Tm
(7) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 552 323 cm
BT
1 0 0 1 0 0 Tm
(8) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 475 82 cm
BT
1 0 0 1 0 0 Tm
(9) Tj
T*
ET
Q
Q


endstream
endobj
118 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
119 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
120 0 obj
<<
/BaseFont /Times-Roman
/Encoding /WinAnsiEncoding
/Subtype /Type1
/Type /Font
>>
endobj
121 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 498
>>
stream
H‰ì—’Ã †¹ÿ¹ÎÎtå¡şˆQ›´3eºMWüx†ù'TË¦¦Áä:S+ŒwHFŸÌ<Àôšgcènï5õY>ÉRï³2Áñ)£Oæ SÈÌà¡ÇehóºƒUf¸fÎÄˆT}<¯£İš±0øu‡Ÿæ˜‚ùVáŞ×_hİšØ]|9~ÎOM@—4ñ¸-<hİÓŒ¦AÙ\eµàƒ=rÃªí5eµ3ºëó¢uÑé ¦î4…Æ°%\a!½5 Ø_íœ\§˜÷­K‚
˜²;ÏYwŠé„ŸÎ[÷İâœ!ïµ¯]@åòêxüÿÍRn`Úg*îe,ÇŠâpââwrµ˜åäÑ1!V¯oè1Ql+|ûU=ô6É_£Im¨˜úw«)¹i¾F÷‡˜4kLÇDS@ÿ/‡˜øToO™sÖ¹dÂ'CËA*)˜š_á)š­lÃÇ-ñÈdß@ª<şf©7¼{[dD†Å¨Ë
fé7Zéì|	3
ÚnMkÚºVy3¬ÛY¯_~…BÔkêTL®471»Bm‡åi»¯İÒ\ë.ÅUËï–OÚ“J“‹H‰ŠÔl=6‰³íåji¦ÍS›qùª¨–ù,øI& ¨¯y–
endstream
endobj
122 0 obj
<<
/Annots [ 123 0 R 124 0 R 125 0 R 126 0 R 127 0 R 128 0 R 129 0 R 130 0 R 131 0 R 132 0 R 133 0 R 134 0 R 135 0 R 136 0 R 137 0 R 138 0 R 139 0 R 140 0 R 141 0 R 142 0 R 143 0 R 144 0 R 145 0 R 146 0 R 147 0 R 148 0 R 149 0 R 150 0 R 151 0 R 152 0 R 153 0 R 154 0 R ]
/Contents 155 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 156 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F6 42 0 R
/F9 55 0 R
>>
/XObject <<
/Xi3 157 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 158 0 R
/Type /Page
/Parent 2 0 R
>>
endobj
123 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib75)
/Rect [ 54 683 128 691 ]
/Subtype /Link
/Type /Annot
>>
endobj
124 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib11)
/Rect [ 134 683 245 691 ]
/Subtype /Link
/Type /Annot
>>
endobj
125 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib71)
/Rect [ 113 571 178 579 ]
/Subtype /Link
/Type /Annot
>>
endobj
126 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib18)
/Rect [ 100 436 179 445 ]
/Subtype /Link
/Type /Annot
>>
endobj
127 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib27)
/Rect [ 86 403 168 411 ]
/Subtype /Link
/Type /Annot
>>
endobj
128 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib49)
/Rect [ 54 358 135 366 ]
/Subtype /Link
/Type /Annot
>>
endobj
129 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib42)
/Rect [ 54 324 128 333 ]
/Subtype /Link
/Type /Annot
>>
endobj
130 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib82)
/Rect [ 73 235 125 243 ]
/Subtype /Link
/Type /Annot
>>
endobj
131 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib76)
/Rect [ 131 235 177 243 ]
/Subtype /Link
/Type /Annot
>>
endobj
132 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib33)
/Rect [ 129 156 206 165 ]
/Subtype /Link
/Type /Annot
>>
endobj
133 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib46)
/Rect [ 122 111 192 120 ]
/Subtype /Link
/Type /Annot
>>
endobj
134 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib43)
/Rect [ 199 111 284 120 ]
/Subtype /Link
/Type /Annot
>>
endobj
135 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib33)
/Rect [ 390 705 464 714 ]
/Subtype /Link
/Type /Annot
>>
endobj
136 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib57)
/Rect [ 469 705 541 714 ]
/Subtype /Link
/Type /Annot
>>
endobj
137 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib33)
/Rect [ 489 672 547 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
138 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib33)
/Rect [ 308 661 327 669 ]
/Subtype /Link
/Type /Annot
>>
endobj
139 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib46)
/Rect [ 441 593 506 602 ]
/Subtype /Link
/Type /Annot
>>
endobj
140 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib43)
/Rect [ 511 593 547 602 ]
/Subtype /Link
/Type /Annot
>>
endobj
141 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib43)
/Rect [ 308 582 351 591 ]
/Subtype /Link
/Type /Annot
>>
endobj
142 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib45)
/Rect [ 357 582 429 591 ]
/Subtype /Link
/Type /Annot
>>
endobj
143 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib34)
/Rect [ 505 504 547 512 ]
/Subtype /Link
/Type /Annot
>>
endobj
144 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib34)
/Rect [ 308 492 351 501 ]
/Subtype /Link
/Type /Annot
>>
endobj
145 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib83)
/Rect [ 418 470 522 478 ]
/Subtype /Link
/Type /Annot
>>
endobj
146 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137tbl1)
/Rect [ 442 403 471 411 ]
/Subtype /Link
/Type /Annot
>>
endobj
147 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib11)
/Rect [ 460 380 547 389 ]
/Subtype /Link
/Type /Annot
>>
endobj
148 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib11)
/Rect [ 308 369 332 378 ]
/Subtype /Link
/Type /Annot
>>
endobj
149 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib53)
/Rect [ 372 336 438 344 ]
/Subtype /Link
/Type /Annot
>>
endobj
150 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib20)
/Rect [ 500 235 547 243 ]
/Subtype /Link
/Type /Annot
>>
endobj
151 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib20)
/Rect [ 308 223 327 232 ]
/Subtype /Link
/Type /Annot
>>
endobj
152 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib81)
/Rect [ 423 145 499 153 ]
/Subtype /Link
/Type /Annot
>>
endobj
153 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib34)
/Rect [ 311 78 404 86 ]
/Subtype /Link
/Type /Annot
>>
endobj
154 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib83)
/Rect [ 411 78 524 86 ]
/Subtype /Link
/Type /Annot
>>
endobj
155 0 obj
<<
/Length 18500
>>
stream
q
q

BT
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(are)-245.2(also)-240.9(expressed)-242.6(in)-243.7(these)-240.8(cells)-243.8(and)-238.4(the)-243.1(contribution)-249.4(of)-242.3(other)]TJ
0 -1.3256 TD
[(PDEs)-581.1(to)-578.5(cell)-582.8(function)-581.2(\(for)-581.1(example,)-584.1(PDE3,)-586.1(PDE7\))-583.3(in)-578.5(the)]TJ
T*
[(context)-383.1(of)-382.8(benefits)-381.9(in)-377.6(respirator)-16.9(y)-378.6(diseases)-379.4(is)-379.9(being)-380.4(explored)]TJ
0 -1.3189 TD
0.0001 Tc
(\(Smith)Tj
/F3 1 Tf
3.6286 0 TD
0 Tc
[(et)-478.5(al)]TJ
/F2 1 Tf
2.0754 0 TD
[(.,)-482.5(2004;)-480.4(Boswell-S)-10.5(mith)]TJ
/F3 1 Tf
11.2673 0 TD
[(et)-478.5(al)]TJ
/F2 1 Tf
2.0754 0 TD
[(.,)-482.5(2006b\).)-480.6(It)-482.7(would)]TJ
-19.0467 -1.3256 TD
[(seem)-405.2(prudent)-405.9(to)-404.4(develop)-405.3(subtype)-409.5(selective)-405.4(PDE4)-401.7(inhibitors)]TJ
T*
[(in)-364.2(attempts)-359.9(to)-357.5(maximize)-365.9(therapeutic)-363.6(benefit)-366.1(at)-360.2(the)-356.9(expense)]TJ
T*
[(of)-409.6(adverse)-405.7(effects,)-414.9(whereas)-409.3(there)-402.4(is)-406.7(also)-408.3(the)-410.4(possibility)-407.9(that)]TJ
0 -1.3189 TD
[(nonselective)-294.6(PDE)-290.9(inhibitors)-290.3(might)-288.6(offer)-292.9(a)-286.7(better)-287.8(appro)-8.6(ach)-286.4(in)]TJ
0 -1.3256 TD
[(targeting)-310.4(multiple)-301.8(target)-306.5(cells)-304(in)-304(the)-303.3(disease)-303.4(process.)-302.5(Indeed,)]TJ
T*
[(it)-250.3(has)-255.6(been)-251.4(suggested)-252.7(that)-253(clozapine)-255.5(is)-252.7(a)-253.2(better)-254.4(anti-psychotic)]TJ
0 -1.3189 TD
[(than)-346.9(newer)-347.9(generation)-347.7(atypical)-352.7(anti-psychotics)-349.5(because)-347.8(this)]TJ
0 -1.3256 TD
[(drug)-600.8(targets)-603.4(numerous)-600.5(receptors,)-600(and)-599.9(as)-597(such,)-603.4(has)-597.1(been)]TJ
T*
[(described)-818.7(as)-811.2(a)-815.6(‘magic)-816.2(shotgun’,)-815.4(for)-814.6(the)-812.1(treatment)-819.7(of)]TJ
0 -1.3189 TD
[(Schizophrenia)-341.4(\(Roth)]TJ
/F3 1 Tf
9.9284 0 TD
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2004\).)]TJ
/F3 1 Tf
-11.8565 -3.9767 TD
[(Asthma)-335.9(and)-341(PDE4)]TJ
/F2 1 Tf
0 -1.3189 TD
[(Increased)-583.4(PDE4)-589.2(function)-587.9(due)-578.2(to)-585.2(either)-585.8(increased)-585.3(protein)]TJ
0 -1.3256 TD
[(expression)-341.3(or)-340.8(activity)-338.9(might)-335.5(provide)-339.5(a)-340.2(plausible)-339(mechanism)]TJ
T*
[(to)-263.8(account)-263.9(for)-258.9(the)-256.5(pathogenesi)-10.5(s)-256.8(o)0(f)-262.3(asthma.)-261.5(The)-258.5(expression)-267.6(of)]TJ
T*
[(a)-634.8(novel)-640.6(and)-633.4(distinct)-641.7(cyclic)-637.3(AMP-PDE)-639.6(was)-636.1(isola)-9.3(ted)-629.8(from)]TJ
0 -1.3189 TD
[(monocytes)-251.3(obtained)-245.2(from)-249.2(individuals)-248.6(with)-249.3(atopic)-250(dermatitis.)]TJ
0 -1.3256 TD
[(This)-549.2(enzyme)-547.7(had)-539.6(increased)-551.8(PDE)-545.3(activity)-546.4(and)-546.3(as)-543.4(a)-547.8(conse-)]TJ
T*
[(quence)-305.6(monocyte)-302.5(function)-306.7(was)-301.4(increased)-304.1(and)-305.3(thought)-300.4(to)-304(be)]TJ
0 -1.3189 TD
[(the)-256.5(underlying)-257.1(basis)-253.3(for)-252.2(the)-256.5(pathology)-258.1(associated)-255.6(with)-256(atopic)]TJ
0 -1.3256 TD
0.0001 Tc
[(dermatitis)-756.7(\(Chan)]TJ
/F3 1 Tf
9.1518 0 TD
0 Tc
[(et)-759.7(al)]TJ
/F2 1 Tf
2.3499 0 TD
[(.,)-756.9(1993\).)-755.7(However)39.4(,)-753.4(soluble)-757(PDE4)]TJ
-11.5016 -1.3256 TD
[(activity)-513(was)-508.9(not)-511.6(increased)-511.6(in)-511.5(a)-514.3(range)-507.6(of)-510(peripheral)-514(blood)]TJ
0 -1.3189 TD
[(leukocytes)-603.2(from)-597.3(atopic)-598.2(patients)-600.1(of)-597.1(either)-599.2(mild)-596.6(or)-601.9(severe)]TJ
0 -1.3256 TD
0.0001 Tc
[(severity)-240.5(\(Gantner)]TJ
/F3 1 Tf
8.2881 0 TD
0 Tc
[(et)-237.5(al)]TJ
/F2 1 Tf
1.8344 0 TD
[(.,)-234.8(1997b\).)-246.3(Similarly)71.7(,)-237.9(increased)-243.8(total)-238.3(PDE)]TJ
-10.1225 -1.3256 TD
[(catalytic)-494.4(activity)-492.9(was)-488.8(obser)-16.7(ved)-486.3(in)-491.5(peripheral)-493.9(blood)-494.9(mono-)]TJ
0 -1.3189 TD
[(cytes)-704(from)-711.1(individuals)-710.6(with)-704.5(mild)-703.7(asthma,)-710(whereas)-703.9(this)]TJ
0 -1.3256 TD
[(was)-542.4(associated,)-540.4(paradoxically)65.9(,)-532.5(with)-543.8(reduced)-535(PDE4)-542.3(activity)]TJ
T*
0.0001 Tc
(\(Landells)Tj
/F3 1 Tf
4.6596 0 TD
0 Tc
[(et)-425(al)]TJ
/F2 1 Tf
2.0151 0 TD
[(.,)-428.9(2000\))-424.1(and)-432.5(the)-423.8(expression)-428.3(of)-423(PDE4A–D)-435.4(was)]TJ
-6.6747 -1.3256 TD
[(not)-431.2(increased)-438(in)-431.2(peripheral)-433.6(blood)-428(cluster)-433.6(of)-436.4(differentiation)]TJ
0 -1.3189 TD
[(\(CD\)4)-346.4(positive)-342.6(T)-343.4(lymphocyte)-9.9(s)-337.1(i)0(n)-344.2(patients)-345.7(with)-343(mild)-348.9(asthma)]TJ
0 -1.3256 TD
0.0001 Tc
(\(Jones)Tj
/F3 1 Tf
3.4679 0 TD
0 Tc
[(et)-605.7(al)]TJ
/F2 1 Tf
2.1959 0 TD
[(.,)-603(2007\).)-608.4(T)65(ogether)-607.3(these)-602.3(studies)-605.6(indicate)-600.1(that)]TJ
-5.6638 -1.3256 TD
[(the)-658.1(underlying)-665.5(pathogenesis)-662.3(of)-664(mild)-663.5(asthma)-659.6(cannot)-664.1(be)]TJ
0 -1.3189 TD
[(attributed)-341(to)-330.8(enhanced)-336.1(PDE4)-334.8(expression)-341.3(or)-334.1(activity)69.5(.)]TJ
1.0042 -1.3256 TD
[(Numerous)-539.1(preclinical)-548.2(studies)-538.6(in)-538.3(models)-540.9(of)-543.5(allergic)-541.9(pul-)]TJ
-1.0042 -1.3256 TD
[(monar)-15.3(y)-720(inflammation)-730.3(have)-727.6(repeatedly)-727.9(documented)-725.5(the)]TJ
0 -1.3189 TD
[(ability)-525.2(of)-523.4(PDE4)-522.3(inhibitors)-524.6(to)-524.9(inhibit)-522.9(two)-523.9(important)-525(char-)]TJ
0 -1.3256 TD
[(acteristic)-593.4(features)-584.6(of)-590.4(asthma,)-582.8(namely)69.5(,)-586(the)-584.5(recruitment)-594.2(of)]TJ
T*
[(eosinophils)-454.1(to)-444.6(the)-450.6(air)-11.4(ways)-445.6(and)-445.9(bronchial)-451.2(hyperresponsive-)]TJ
0 -1.3189 TD
[(ness)-314.8(\(T)58.3(orphy)72(,)-318.2(1998;)-319.7(Spina,)-313.6(2003\).)-320.5(One)-314.8(disadvantag)-9.9(e)-310.1(o)0(f)-322.6(these)]TJ
0 -1.3256 TD
[(studies)-297.6(is)-299.6(the)-296.6(inability)-300.2(to)-304(ascertain)-295.5(the)-296.6(role)-298.7(of)-302.5(PDE4)-301.3(isoforms)]TJ
T*
[(because)-468.3(of)-463.2(the)-464(nonselective)-461.9(nature)-467.9(of)-463.2(the)-464(PDE4)-462(inhibitors)]TJ
T*
[(currently)-431.6(under)-427.6(development.)-434.6(The)-425.8(use)-428.1(of)-429.7(genetically)-430.5(mod-)]TJ
0 -1.3189 TD
[(ified)-519.8(mice)-523.6(has)-516.7(revealed)-521.9(some)-519.7(interesting)-525.1(findings.)-518.3(Air)-15.2(way)]TJ
0 -1.3256 TD
[(inflammation)-281.8(characterized)-277.2(by)-270.9(recruitment)-272.8(of)-275.7(eosinophils)-273.4(to)]TJ
T*
[(the)-377(air)-11.4(ways)-378.7(of)-369.5(mice)-376.3(deficient)-380.9(in)-377.6(PDE4D)-377.2(was)-375(no)-371.1(different)-380.3(to)]TJ
0 -1.3189 TD
[(wild-type)-350(controls)-348.3(\(Hansen)]TJ
/F3 1 Tf
13.1218 0 TD
[(et)-344.6(al)]TJ
/F2 1 Tf
1.9415 0 TD
[(.,)-348.6(2000\).)-347.3(This)-348.4(indicated)-344.3(that)]TJ
-15.0633 -1.3256 TD
[(other)-684.3(PDE4)-682.9(subtypes)-679.6(contributed)-686.4(in)-678.9(the)-684.9(metabolism)-687.4(of)]TJ
T*
[(intracellular)-433.4(cyclic)-436.5(AMP)121.6(,)-432(a)0(s)-436.3(cell)-442.2(recruitment)-433.5(to)-437.9(the)-437.2(air)-11.4(ways)]TJ
0 -1.3189 TD
[(was)-361.6(inhibited)-369.5(when)-362.7(animals)-363.7(were)-361.2(treated)-366.1(with)-363.1(nonselective)]TJ
0 -1.3256 TD
[(PDE4)-468.7(inhibitors)-464.4(\(Kung)]TJ
/F3 1 Tf
11.3142 0 TD
[(et)-458.4(al)]TJ
/F2 1 Tf
2.0553 0 TD
[(.,)-462.4(2000;)-460.3(Kanehiro)]TJ
/F3 1 Tf
8.8304 0 TD
[(et)-458.4(al)]TJ
/F2 1 Tf
2.0553 0 TD
[(.,)-462.4(2001\).)]TJ
-24.2552 -1.3256 TD
[(However)39.4(,)-485.6(air)-18.1(way)-483.4(obstruction)-490.1(caused)-492.1(by)-485.1(methacholine)-496.5(was)]TJ
T*
[(enhanced)-496.8(in)-498.1(wild-type)-497.3(allergic)-501.7(mice)-496.8(but)-496.6(was)-495.5(abolished)-498(in)]TJ
0 -1.3189 TD
[(PDE4D)-471(gene-deficient)-468.5(mice.)-473.5(These)-463.7(mice)-470(were)-461.7(hypor)-8.3(espon-)]TJ
0 -1.3256 TD
[(sive)-760.6(to)-752.5(this)-761.5(stimulus,)-757.3(even)-757.7(in)-759.2(the)-751.9(absence)-761(of)-757.8(allergic)]TJ
T*
[(sensitization)-478.8(and)-472.7(appeared)-475.9(to)-471.4(be)-476.9(related)-469.2(to)-478.1(an)-474.2(increase)-472.9(in)]TJ
30.3542 78.0947 TD
[(dilator)-584.3(prostaglandin)-592(production)-585.9(in)-585.2(the)-584.5(air)-11.4(ways)-586.2(of)-583.7(these)]TJ
0 -1.3256 TD
[(gene-deficient)-247.5(mice)-249.1(\(Hansen)]TJ
/F3 1 Tf
13.49 0 TD
[(et)-244.2(al)]TJ
/F2 1 Tf
1.8411 0 TD
[(.,)-241.4(2000;)-252.8(Mehats)]TJ
/F3 1 Tf
7.304 0 TD
[(et)-244.2(al)]TJ
/F2 1 Tf
1.8344 0 TD
[(.,)-248.1(2003\).)]TJ
-24.4694 -1.3256 TD
[(However)39.4(,)-425.3(this)-420(effect)-422.4(was)-421.9(specific)-427.8(for)-426.3(methacholine)-422.8(because)]TJ
0 -1.3189 TD
[(the)-457.3(enhanced)-463.3(air)-11.4(way)-456.6(obstruction)-463.3(in)-458(response)-455.4(to)-458(serotonin)]TJ
0 -1.3256 TD
[(was)-542.4(unaffected)-535.4(by)-538.7(the)-537.6(removal)-545.7(of)-536.8(PDE4D)-537.9(\(Hansen)]TJ
/F3 1 Tf
25.5205 0 TD
[(et)-538.8(al)]TJ
/F2 1 Tf
2.1289 0 TD
(.,)Tj
-27.6495 -1.3256 TD
[(2000\).)-394.2(This)-381.9(study)-387.9(highlighted)-392.7(the)-383.7(potential)-388.9(complimentar)-17.6(y)]TJ
T*
[(role)-432.6(of)-429.7(PDE4)-435.2(isoforms)-433.4(in)-431.2(regulating)-435.6(allergic)-434.8(air)-11.4(way)-429.9(inflam-)]TJ
0 -1.3189 TD
[(mation,)-292.5(and)-285.2(the)-289.9(need)-283.9(to)-290.6(target)-286.4(more)-293(than)-286.7(one)-286.2(PDE4)-287.9(isoform)]TJ
0 -1.3256 TD
[(because)-448.2(inhibition)-448(of)-449.8(the)-443.9(inflammator)-14.5(y)-445.5(response,)-445.6(hyperre-)]TJ
T*
[(sponsiveness)-503.4(and)-499.5(air)-18.1(way)-496.8(remodelling)-510.3(in)-498.1(allergic)-501.8(wild-type)]TJ
0 -1.3189 TD
[(mice)-496.8(was)-488.8(obser)-16.7(ved)-486.3(following)-501(exposure)-492.1(to)-491.4(PDE4)-495.5(inhibitors)]TJ
0 -1.3256 TD
[(such)-258.4(as)-262.3(rolipram)-263.3(and)-265.2(roflumilast)-260(\(Kung)]TJ
/F3 1 Tf
18.4174 0 TD
[(et)-257.6(al)]TJ
/F2 1 Tf
1.8478 0 TD
[(.,)-261.5(2000;)-266.2(Kanehiro)]TJ
/F3 1 Tf
-20.2651 -1.3256 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2001;)-339.8(Kumar)]TJ
/F3 1 Tf
7.2906 0 TD
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2003\).)]TJ
-10.1493 -1.3189 TD
[(The)-767.3(numerous)-761.1(preclinical)-769.2(studies)-759.6(reporting)-763.6(the)-765.2(anti-)]TJ
-0.9975 -1.3256 TD
[(inflammator)-14.5(y)-606.2(potential)-609.8(of)-603.8(PDE4)-609.3(inhibitors)-611.6(in)-605.3(models)-601.2(of)]TJ
T*
[(allergic)-300.9(inflammation)-301.8(and)-298.6(in)-297.3(human)-299(cells)]TJ
/F3 1 Tf
19.7697 0 TD
[(in)-301.9(vitro)]TJ
/F2 1 Tf
3.421 0 TD
[(have)-292.5(been,)]TJ
-23.1907 -1.3189 TD
[(to)-411.1(some)-412.6(degree,)-407.8(corroborated)-418.3(in)-411.1(clinical)-410.5(trials)-411.3(in)-411.1(asthmatic)]TJ
0 -1.3256 TD
[(patients.)-402.8(T)31.6(wice)-405.1(daily)-401.2(treatment)-404.6(for)-399.5(9.5)-406(days)-405(with)-396.6(the)-403.7(PDE4)]TJ
T*
[(inhibitor)-589.2(CDP840)-583.6(inhibited)-583.7(the)-584.5(development)-585(of)-583.7(the)-584.5(late)]TJ
T*
[(phase)-537.4(response)-542.5(in)-538.3(asthmatic)-541.3(patients)-539.8(by)-538.7(30%)-540.8(\(Harbinson)]TJ
/F3 1 Tf
0 -1.3189 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(1997\).)-333.9(A)-337.3(similar)-330.6(degree)-337.4(of)-336(inhibition)-334.2(of)-336(the)-330.1(late)-338.2(phase)]TJ
-1.9281 -1.3256 TD
[(response)-488.9(was)-488.8(obser)-10(ved)-486.3(following)-487.6(once)-493.4(daily)-481.6(treatment)-491.6(for)]TJ
T*
[(7–10)-294.5(days)-284.5(with)-289.4(roflumilas)-12.4(t)-287.8(\()-0.8(van)-283.7(Schalkwyk)]TJ
/F3 1 Tf
20.2651 0 TD
[(et)-291.1(al)]TJ
/F2 1 Tf
1.8812 0 TD
[(.,)-288.3(2005\).)-293.8(This)]TJ
-22.1463 -1.3189 TD
[(late)-659.5(phase)-657.9(response)-656.3(is)-661.1(used)-654.3(by)-659.2(clinicians)-660.6(to)-658.8(model)-659.1(the)]TJ
0 -1.3256 TD
[(inflammator)-14.5(y)-318.3(component)-317.5(following)-313.5(an)-313.5(allergic)-321(insult)-310.8(to)-317.4(the)]TJ
T*
[(air)-11.4(ways.)-275.1(In)-282.1(both)-276.7(studies,)-274.4(the)-276.5(effects)-277.5(of)-275.7(drug)-279.4(treatment)-277.4(on)-277.4(the)]TJ
0 -1.3189 TD
[(acute)-799(allergen)-802.8(bronchoconstriction)-807.3(was)-803.5(modest)-799.3(and)-800.7(is)]TJ
0 -1.3256 TD
[(consistent)-534.1(with)-530.5(the)-530.9(lack)-533.7(of)-530.1(demonstrable)-537.7(action)-532.8(of)-530.1(PDE4)]TJ
T*
[(inhibition)-327.5(on)-324.2(mast)-326(cell)-321.7(function)-326.8(\(T)58.3(able)-324.3(1\))-325.9(and)-325.4(highlight)-325.2(the)]TJ
T*
[(role)-379(of)-376.2(other)-376.4(PDE)-384.6(enzymes,)-379.5(namely)-372.4(PDE3)-381.7(in)-377.6(the)-377(context)-376.4(of)]TJ
0 -1.3189 TD
[(air)-11.4(way)-737.8(smooth)-734.6(muscle)-735.3(relaxation)-737.8(\(Boswell-Smith)]TJ
/F3 1 Tf
25.3264 0 TD
[(et)-732.9(al)]TJ
/F2 1 Tf
2.3231 0 TD
(.,)Tj
-27.6495 -1.3256 TD
[(2006b\).)-413.7(Bronchial)-406.9(hyperresponsiveness)-409.2(was)-408.5(not)-404.5(reduced)-407.7(by)]TJ
T*
[(these)-682.7(drugs,)-687(although)-683.6(a)-688.4(later)-682.9(study)-682.5(purported)-684.9(to)-685.6(show)]TJ
0 -1.3189 TD
[(modest)-250.3(protection)-252.7(against)-251.5(allergen-induced)-252.3(bronchial)-257.1(hyper-)]TJ
0 -1.3256 TD
[(responsiveness)-287.8(\(Louw)]TJ
/F3 1 Tf
10.3769 0 TD
[(et)-284.4(al)]TJ
/F2 1 Tf
1.8812 0 TD
[(.,)-281.6(2007\),)-287.1(which)-289.3(might)-282(suggest)-285.6(that)]TJ
-12.2582 -1.3256 TD
[(PDE4)-743.2(may)-735.8(not)-739.2(be)-731.3(a)-741.9(suitable)-739.5(target)-734.9(for)-741(this)-734.7(particular)]TJ
0 -1.3189 TD
[(phenomenon,)-417.4(or)-414.5(that)-413.7(higher)-411.1(doses)-416.5(are)-412.5(required)-414(to)-411.1(provide)]TJ
0 -1.3256 TD
[(complementar)-17.1(y)-271.5(and)-278.5(persistent)-274.3(inhibition)-280.7(of)-275.7(the)-276.5(enzyme)-273.2(and)]TJ
T*
[(hence)-325.4(attenuation)-321.4(of)-322.6(bronchial)-330.7(hyperresponsiveness.)-325.7(It)-322.1(is)-326.4(of)]TJ
0 -1.3189 TD
[(interest)-722(that)-728.4(roflumilast)-728.6(has)-724.3(a)-721.8(plasma)-727.7(half-life)-723.8(of)-724.3(16)-168.2(h)]TJ
0 -1.3256 TD
[(following)-521(a)-514.3(single)-513.2(p.o)-520.4(administration,)-514.9(and)-519.6(is)-513.8(metabolized)]TJ
T*
[(by)-572.1(CYP3A4)-577.9(to)-571.8(the)-571.1(active)-575.8(N-oxide)-572.8(metabolite,)-579.8(which)-577.2(has)]TJ
T*
[(considerably)-477.9(greater)-472.6(bioavailability)-483(with)-470.2(a)-474.1(half-life)-476.1(of)-469.9(20)-174.8(h)]TJ
0 -1.3189 TD
[(that)-313.3(would)-319.5(favour)-316.8(prolonged)-319.9(enzyme)-313.4(exposure)-318(\(David)]TJ
/F3 1 Tf
25.7414 0 TD
[(et)-317.8(al)]TJ
/F2 1 Tf
1.908 0 TD
(.,)Tj
-27.6495 -1.3256 TD
[(2004\).)-581.6(This)-576(favourable)-580.8(pharmacokinetic)-578.5(profile)-579.4(would)-580.6(be)]TJ
T*
[(anticipated)-604(to)-605.3(produce)-602.6(long)-602.6(periods)-606(of)-603.8(PDE4)-602.6(inhibition.)]TJ
0 -1.3189 TD
[(There)-357.6(was)-354.9(a)-353.6(significant)-356.6(reduction)-359(in)-350.9(the)-356.9(activity)-352.3(of)-356.1(circulat-)]TJ
0 -1.3256 TD
[(ing)-405.7(monocytes)-412(in)-411.1(patients)-405.9(maintained)-408.8(on)-411.3(roflumilast)-414(for)-406.2(4)]TJ
T*
[(weeks,)-541.6(whereas)-543.2(the)-537.6(magnitude)-544.3(of)-543.5(this)-540.6(change)-537.5(was)-542.4(small,)]TJ
0 -1.3189 TD
[(resulting)-625.3(in)-618.7(approximately)-628.1(1.3-fold)-624.4(reduction)-626.8(in)-618.7(tumour)]TJ
0 -1.3256 TD
[(necrosis)-490.6(factor)-9.6(-)]TJ
/F6 1 Tf
7.2705 0 TD
(a)Tj
/F2 1 Tf
1.0444 0 TD
[(production)-492.1(by)-491.8(monocytes)-492.3(in)-491.5(response)-495.6(to)]TJ
-8.3149 -1.3256 TD
[(endotoxin)-273.7(challenge)]TJ
/F3 1 Tf
9.8748 0 TD
[(in)-268.4(vitro)]TJ
/F2 1 Tf
3.3608 0 TD
[(\()5.9(Timmer)]TJ
/F3 1 Tf
4.3181 0 TD
[(et)-264.3(al)]TJ
/F2 1 Tf
1.8545 0 TD
[(.,)-268.2(2002\).)-273.7(Therefore,)]TJ
-19.4082 -1.3256 TD
[(it)-605.1(is)-600.9(questionable)-609(whether)-602.3(total)-599.9(PDE4)-609.3(inhibition)-602(can)-607.8(be)]TJ
0 -1.3189 TD
[(achieved)-442.7(in)-444.6(cells)-437.9(within)-446.1(the)-437.2(air)-11.4(way)-443.2(tissue)-446.4(compartment)-440.7(at)]TJ
0 -1.3256 TD
[(the)-336.8(dose)-333.8(used)-332.9(in)-330.8(clinical)-343.5(studies.)]TJ
0.9975 -1.3256 TD
[(Side)-688.2(effects)-685.8(most)-684.9(commonly)-688.4(reported)-679.9(were)-682.6(headache,)]TJ
-0.9975 -1.3189 TD
[(nausea)-927.9(and)-921.2(diarrhoea)-927.4(of)-925.1(a)-929.4(mild-to-moderate)-928.4(severity)]TJ
0 -1.3256 TD
0.0001 Tc
(\(Harbinson)Tj
/F3 1 Tf
5.8178 0 TD
0 Tc
[(et)-552.2(al)]TJ
/F2 1 Tf
2.1423 0 TD
[(.,)-556.1(1997;)-560.7(van)-551.5(Schalkwyk)]TJ
/F3 1 Tf
12.0171 0 TD
[(et)-558.9(al)]TJ
/F2 1 Tf
2.149 0 TD
[(.,)-556.1(2005\))-558(and)]TJ
-22.1263 -1.3256 TD
[(suggest)-439.6(that)-433.8(unless)-439.9(the)-437.2(risk/benefit)-434.9(ratio)-435.9(can)-440.4(be)-436.7(improved,)]TJ
0 -1.3189 TD
[(then)-383.7(this)-386.6(may)-381(well)-387.9(hamper)-381.2(the)-383.7(use)-388(of)-382.8(this)-379.9(drug)-386.5(in)-384.3(asthma.)]TJ
ET
1 i 
50.797 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 179.1496 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-325.8(and)-335.3(respiratory)-326.4(disease)]TJ
/F9 1 Tf
15.1373 -1.2519 TD
[(D)-337.9(Spina)]TJ
7.0982 0 0 9.4646 50.7968 751.8612 Tm
0.0001 Tc
(310)Tj
ET
50.797 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 50.7968 31.2378 Tm
[(British)-331.9(J)0.1(ournal)-324.5(of)-334.4(Pharmacology)-320.4(\(2008\))]TJ
/F1 1 Tf
17.6049 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi3 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
50 29 142 10 re
f*
0.619608 0.619608 0.619608 rg
n
50 752 14 8 re
f*
0.619608 0.619608 0.619608 rg
n
178 751 112 19 re
f*
0.619608 0.619608 0.619608 rg
n
574 11 13 513 re
f*
0.4 0.4 1 rg
n
50 538 70 10 re
f*
0.6 0 0.298039 rg
n
50 572 239 155 re
f*
0.6 0 0.298039 rg
n
50 303 239 234 re
f*
0.6 0 0.298039 rg
n
50 56 239 245 re
f*
0.6 0 0.298039 rg
n
307 582 240 145 re
f*
0.6 0 0.298039 rg
n
307 109 239 474 re
f*
0.6 0 0.298039 rg
n
307 56 239 54 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 717 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 122 538 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 527 cm
BT
1 0 0 1 0 0 Tm
(3) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 291 cm
BT
1 0 0 1 0 0 Tm
(4) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 717 cm
BT
1 0 0 1 0 0 Tm
(5) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 573 cm
BT
1 0 0 1 0 0 Tm
(6) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 100 cm
BT
1 0 0 1 0 0 Tm
(7) Tj
T*
ET
Q
Q


endstream
endobj
156 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
157 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
158 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 380
>>
stream
H‰äW[„0óşä:û±3;…	µåKm	R@‘ÿ³K[éÍuœƒµÒ©Ïvq’æ¢_×Oªêâ]+ÕÎ–”¥.t"î³ƒœ¦Ç‰ãÔí®"mN‚„Ó·<ÊwãÔäÛ’x+ÛâÔ|°êi‘P…SUÖöéª2Lq&öÃĞˆÏ*§.NZu·õ•ÎËu‰ˆŞ"ºü|™ŠË\_éD@P÷ûD'‰Q§Ş’ËæÒ±, íÓÊlY3qòrS@Eë,’]Ï¨Ë»U=5?ÅqşíÁÿ$ëê §yêx$]ºkçè,Qs,ª7ñHSå¥>ÇÔ‰ùHy%Aò\¢ÛÂäe·1ŸŸLxàÔƒ²`
’?EC¤p ;§|ŠQ—¸Ú®în¥ãjf­Äç®ÿÛX'5¨néœ6N+Õ±œ€:tŸèÁ>YNëâä»â¦ÅX¿‡éeê¤UşTgVİ™J7ÏŞÍş]ö õ€cõ
endstream
endobj
159 0 obj
<<
/Annots [ 160 0 R 161 0 R 162 0 R 163 0 R 164 0 R 165 0 R 166 0 R 167 0 R 168 0 R 169 0 R 170 0 R 171 0 R 172 0 R 173 0 R 174 0 R 175 0 R 176 0 R 177 0 R 178 0 R 179 0 R 180 0 R 181 0 R 182 0 R 183 0 R ]
/Contents 184 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 185 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F6 42 0 R
/F7 45 0 R
/F9 55 0 R
>>
/XObject <<
/Xi4 186 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 187 0 R
/Type /Page
/Parent 2 0 R
>>
endobj
160 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib12)
/Rect [ 54 683 137 691 ]
/Subtype /Link
/Type /Annot
>>
endobj
161 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib6)
/Rect [ 145 492 204 501 ]
/Subtype /Link
/Type /Annot
>>
endobj
162 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137tbl1)
/Rect [ 54 448 82 456 ]
/Subtype /Link
/Type /Annot
>>
endobj
163 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib42)
/Rect [ 84 414 161 422 ]
/Subtype /Link
/Type /Annot
>>
endobj
164 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib4)
/Rect [ 138 358 214 366 ]
/Subtype /Link
/Type /Annot
>>
endobj
165 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib4)
/Rect [ 54 313 123 322 ]
/Subtype /Link
/Type /Annot
>>
endobj
166 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib26)
/Rect [ 180 246 262 254 ]
/Subtype /Link
/Type /Annot
>>
endobj
167 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib75)
/Rect [ 266 246 290 254 ]
/Subtype /Link
/Type /Annot
>>
endobj
168 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib75)
/Rect [ 51 235 94 243 ]
/Subtype /Link
/Type /Annot
>>
endobj
169 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib3)
/Rect [ 54 123 133 131 ]
/Subtype /Link
/Type /Annot
>>
endobj
170 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib55)
/Rect [ 190 67 287 75 ]
/Subtype /Link
/Type /Annot
>>
endobj
171 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib50)
/Rect [ 51 55 129 64 ]
/Subtype /Link
/Type /Annot
>>
endobj
172 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib64)
/Rect [ 311 672 374 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
173 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib66)
/Rect [ 378 672 456 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
174 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib15)
/Rect [ 460 672 541 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
175 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137tbl1)
/Rect [ 513 582 541 591 ]
/Subtype /Link
/Type /Annot
>>
endobj
176 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib30)
/Rect [ 381 537 483 546 ]
/Subtype /Link
/Type /Annot
>>
endobj
177 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib24)
/Rect [ 311 526 389 535 ]
/Subtype /Link
/Type /Annot
>>
endobj
178 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137tbl1)
/Rect [ 360 403 389 411 ]
/Subtype /Link
/Type /Annot
>>
endobj
179 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib64)
/Rect [ 311 347 378 355 ]
/Subtype /Link
/Type /Annot
>>
endobj
180 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib15)
/Rect [ 383 347 468 355 ]
/Subtype /Link
/Type /Annot
>>
endobj
181 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib66)
/Rect [ 370 313 457 322 ]
/Subtype /Link
/Type /Annot
>>
endobj
182 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib17)
/Rect [ 311 111 400 120 ]
/Subtype /Link
/Type /Annot
>>
endobj
183 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib17)
/Rect [ 445 67 541 75 ]
/Subtype /Link
/Type /Annot
>>
endobj
184 0 obj
<<
/Length 18072
>>
stream
q
q

BT
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(This)-288.1(is)-286.2(a)-286.7(worthy)-283.1(aim)-286.3(to)-290.6(pursue)-284.5(in)-283.9(the)-283.2(light)-287.7(of)-289.1(a)-286.7(clinical)-283.3(study)]TJ
0 -1.3256 TD
[(reporting)-502.5(comparable)-498.3(clinical)-504.2(efficacy)-498.8(between)-500(roflumilast)]TJ
T*
[(and)-700.3(beclomethasone)-708(diproprionate)-703.4(in)-705.7(persistent)-702.7(asthma)]TJ
0 -1.3189 TD
0.0001 Tc
(\(Bousquet)Tj
/F3 1 Tf
5.0144 0 TD
0 Tc
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2006\).)]TJ
/F3 1 Tf
-6.9425 -5.2956 TD
[(COPD)-337.4(and)-334.3(PDE4)]TJ
/F2 1 Tf
0 -1.3256 TD
[(Chronic)-621.9(obstructive)-626.8(pulmonar)-11.6(y)-619.6(disease)-618.1(unlike)-622.2(asthma)-619.4(is)]TJ
T*
[(caused)-880.4(by)-880.1(cigarette)-879.9(smoking,)-883.6(although)-884.4(in)-879.7(developing)]TJ
T*
[(countries)-369.6(smoke)-376(derived)-365.6(from)-369.7(burning)-370.1(biomass)-373.5(fuels)-368.9(is)-366.5(also)]TJ
0 -1.3189 TD
[(a)-735.2(predisposing)-738.1(factor)70.8(.)-733.3(The)-740.5(nature)-735.7(of)-731(the)-738.5(inflammator)-14.5(y)]TJ
0 -1.3256 TD
[(response)-555.8(is)-560.7(distinct)-554.7(from)-557.1(asthma)-559.2(and)-559.7(is)-554(characterized)-558.4(by)]TJ
T*
[(the)-283.2(activation)-276.6(of)-282.4(macrophages,)-282.6(air)-18.1(way)-275.9(epithelial)-286.5(cells,)-280.8(which)]TJ
0 -1.3189 TD
[(in)-397.7(turn,)-403.7(secrete)-399.8(a)-393.8(range)-400.5(of)-396.2(chemokines)-400.7(and)-399.1(lipid)-399.9(mediators)]TJ
0 -1.3256 TD
[(resulting)-725.8(in)-719.1(the)-718.4(recruitment)-728.1(of)-717.6(neutrophils)-725.9(and)-720.4(CD8)]TJ
/F7 1 Tf
6.351 0 0 5.6449 283.9747 554.3432 Tm
()Tj
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 539.3763 Tm
[(T)-423.7(lymphocytes.)-430.9(The)-425.8(secretion)-423.3(of)-429.7(a)-420.6(range)-427.2(of)-429.7(proteases)-420.6(from)]TJ
0 -1.3189 TD
[(neutrophils)-424.6(\(elastase,)-428.4(MMP9,)-424.7(cathepsins\))-422.3(and)-425.8(macrophages)]TJ
0 -1.3256 TD
[(\(MMP12\))-312.7(is)-313(thought)-313.8(to)-310.7(contribute)-312.9(towards)-312.5(air)-11.4(way)-316(fibrosis)-315.2(of)]TJ
T*
[(the)-243.1(small)-244.4(air)-18.1(ways,)-241.6(increased)-243.8(mucus)-250.5(secretion)-242.6(and)-245.1(destruction)]TJ
T*
[(of)-677.4(the)-671.5(alveolar)-684.1(wall)-679.2(\(Barnes,)-674.8(2006b\))-677.9(These)-671.3(pathological)]TJ
0 -1.3189 TD
[(changes)-807.7(give)-806.3(rise)-807.1(to)-799.4(the)-805.4(symptoms)-806.8(of)-804.6(cough,)-812.6(mucus)]TJ
0 -1.3256 TD
[(secretion,)-386.7(difficult)-379.7(breathing)-389.1(and)-379(emphysema.)-386.5(Many)-376.7(of)-382.8(the)]TJ
T*
[(cell)-502.5(types)-501.9(implicated)-497.7(in)-504.8(this)-500.4(disease)-497.6(process)-499.8(express)-503.1(PDE4)]TJ
0 -1.3189 TD
0.0002 Tc
[(\(T)58.5(able)-330.8(1\).)]TJ
1.0042 -1.3256 TD
0 Tc
[(The)-459.3(expression)-468.5(of)-463.2(PDE4A–D)-462.2(in)-464.7(peripheral)-467.1(blood)-461.4(neutro-)]TJ
-1.0042 -1.3256 TD
[(phils)-501.6(and)-492.8(CD8T)-433.8(cells)-498.2(is)-493.7(not)-498.2(altered)-496(in)-498.1(patients)-499.6(with)-490.3(mild)]TJ
0 -1.3189 TD
0.0001 Tc
[(COPD)-697.6(\(Jones)]TJ
/F3 1 Tf
7.1634 0 TD
0 Tc
[(et)-699.4(al)]TJ
/F2 1 Tf
2.2896 0 TD
[(.,)-696.7(2007\).)-702.1(However)39.4(,)-693.1(the)-698.3(expression)-702.8(of)]TJ
-9.453 -1.3256 TD
[(PDE4A4)-354.4(and)-345.5(total)-352.1(cyclic)-349.5(AMP)-347(PDE)-351.2(activity)-345.6(was)-348.2(significantly)]TJ
T*
[(increased)-638.8(in)-632(macrophages)-640.5(purified)-637.3(from)-637.5(bronchoalveolar)]TJ
0 -1.3189 TD
[(lavage)-643.2(fluid)-640.1(from)-644.2(patients)-640.2(with)-644.3(mild-to-moderate)-647.2(COPD)]TJ
0 -1.3256 TD
[(compared)-529.5(with)-530.5(healthy)-522.7(patients)-526.4(or)-528.3(smokers)-529(who)-524(did)-528.6(not)]TJ
T*
[(present)-503.7(with)-497(COPD)-503.5(\(Barber)]TJ
/F3 1 Tf
13.798 0 TD
[(et)-498.6(al)]TJ
/F2 1 Tf
2.0955 0 TD
[(.,)-495.8(2004\).)-501.3(Of)-498.6(the)-504.2(12)-496.2(PDE4)]TJ
-15.8934 -1.3256 TD
[(variants)-290.6(analysed,)-284.9(only)-290.4(the)-283.2(activity)-292(of)-282.4(PDE4A4)-294.2(was)-288(increased)]TJ
0 -1.3189 TD
[(and)-312(suggested)-313(that)-306.6(local)-314.5(events/processes)-310.1(within)-312.2(the)-310(lung)-313.8(of)]TJ
0 -1.3256 TD
[(patients)-620.1(with)-617.5(COPD)-617.4(specifically)-616.3(upregulated)-620(this)-614.2(variant)]TJ
T*
0.0001 Tc
(\(Barber)Tj
/F3 1 Tf
3.5951 0 TD
0 Tc
[(et)-257.6(al)]TJ
/F2 1 Tf
1.8478 0 TD
[(.,)-261.5(2004\).)-260.3(However)32.7(,)-258(the)-256.5(functional)-261.3(consequence)-265.8(of)]TJ
-5.4429 -1.3189 TD
[(this)-473.6(change)-477.3(remains)-474.8(to)-471.4(be)-476.9(established)-472.8(in)-471.4(light)-475.1(of)-476.6(findings)]TJ
0 -1.3256 TD
[(showing)-342.9(that)-340.1(PDE4)-341.5(inhibition)-347.6(has)-336(modest)-344(effect)-342(in)-337.5(suppres-)]TJ
T*
[(sing)-762.8(tumour)-763.2(necrosis)-765.1(factor-)]TJ
/F6 1 Tf
14.5143 0 TD
(a)Tj
/F2 1 Tf
1.3122 0 TD
[(production)-766.6(from)-764.7(human)]TJ
-15.8265 -1.3189 TD
[(macrophages)-633.8(derived)-626.7(from)-624.1(cultur)-9.3(ed)-623.2(monocytes,)-629.8(and)-626.7(the)]TJ
0 -1.3256 TD
[(contribution)-490.4(of)-476.6(PDE3)-488.8(and)-479.4(PDE7)-482.1(in)-484.8(regulating)-482.4(function)-487.5(in)]TJ
T*
[(this)-259.4(cell)-261.5(type)-258.5(cannot)-262.4(be)-255.9(ignored)-265.1(\(Gantner)]TJ
/F3 1 Tf
19.3948 0 TD
[(et)-264.3(al)]TJ
/F2 1 Tf
1.8545 0 TD
[(.,)-261.5(1997a;)-264.9(Smith)]TJ
/F3 1 Tf
-21.2492 -1.3189 TD
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2004\).)]TJ
-0.9239 -1.3256 TD
[(There)-283.9(are)-292(a)-286.7(limited)-293.2(number)-291.5(of)-289.1(preclinical)]TJ
/F3 1 Tf
19.455 0 TD
[(in)-288.5(vivo)]TJ
/F2 1 Tf
3.1867 0 TD
[(models)-293.2(of)]TJ
-23.646 -1.3256 TD
[(COPD.)-681.1(However)39.4(,)-673(the)-678.2(recruitment)-681.2(of)-677.4(neutrophils)-679(to)-678.9(the)]TJ
T*
[(air)-11.4(ways)-639.8(can)-634.6(be)-637.5(readily)-640.9(induced)-639.4(using)-637.5(the)-631.4(bacterial)-643.2(wall)]TJ
0 -1.3189 TD
[(component,)-542(endotoxin,)-545(although)-543(it)-538.1(is)-540.6(widely)-544.1(appreciated)]TJ
0 -1.3256 TD
[(that)-293.2(this)-292.8(stimulus)-291.8(can)-293.1(only)-290.3(model)-297.5(neutrophil)-295(recruitment)-292.9(to)]TJ
T*
[(the)-330.1(air)-11.4(ways.)-335.3(The)-332.1(recruitment)-333.1(of)-336(these)-327.9(cells)-330.8(to)-330.8(the)-336.8(air)-11.4(ways)-331.8(of)]TJ
0 -1.3189 TD
[(wild-type)-356.7(mice)-356.2(was)-348.2(inhibited)-356.1(by)-357.9(around)-353.5(50%)-353.4(in)-350.9(PDE4B)-356.8(and)]TJ
0 -1.3256 TD
[(PDE4D-deficient)-264.4(mice,)-259.3(and)-258.5(a)-259.9(greater)-258.4(degree)-257(of)-255.6(inhibition)-267.3(was)]TJ
T*
[(obser)-16.7(ved)-459.5(when)-463.1(wild-type)-470.5(mice)-463.3(were)-461.7(treated)-466.5(with)-463.5(rolipram)]TJ
0 -1.3189 TD
0.0001 Tc
(\(Ariga)Tj
/F3 1 Tf
3.6152 0 TD
0 Tc
[(et)-819.9(al)]TJ
/F2 1 Tf
2.4101 0 TD
[(.,)-823.9(2004\).)-829.3(This)-817(once)-821.4(again)-825(highlighted)-827.9(the)]TJ
-6.0253 -1.3256 TD
[(complimentar)-17.6(y)-947.6(roles)-950.5(of)-951.9(PDE4)-950.7(isoforms)-955.6(in)-946.7(regulating)]TJ
T*
[(neutrophil)-509.3(recruitment)-513.8(to)-504.8(the)-504.2(air)-11.4(ways.)-509.4(Similarly)71.7(,)-512.4(smoking)]TJ
T*
[(induced)-512.2(neutrophil)-516(recruitment)-513.8(to)-511.5(the)-510.9(air)-18.1(ways,)-509.4(release)-515.4(of)]TJ
0 -1.3189 TD
[(chemokines)-387.3(and)-379(emphysem)-9.3(atous)-380.7(changes)-385.9(to)-377.6(the)-383.7(lung)-380.8(were)]TJ
0 -1.3256 TD
[(attenuated)-718.2(by)-706(PDE4)-716.4(inhibitors)-718.8(\(Martorana)]TJ
/F3 1 Tf
22.0526 0 TD
[(et)-712.8(al)]TJ
/F2 1 Tf
2.303 0 TD
[(.,)-716.8(2005;)]TJ
-24.3556 -1.3256 TD
(Leclerc)Tj
/F3 1 Tf
3.7357 0 TD
[(et)-498.6(al)]TJ
/F2 1 Tf
2.0955 0 TD
[(.,)-495.8(2006\).)-501.3(T)65(ogether)35.4(,)-492.3(these)-501.9(studies)-498.5(highlight)-499.2(the)]TJ
24.523 78.0947 TD
[(utility)-502(of)-503.3(inhibiting)-506.7(PDE4)-508.9(in)-498.1(cell)-502.5(types)-501.9(implicated)-511.1(in)-498.1(this)]TJ
0 -1.3256 TD
(disease.)Tj
0.9975 -1.3256 TD
[(A)-558.2(number)-559.3(of)-556.9(phase)-550.8(III)-558.1(clinical)-557.8(trials)-558.6(have)-553.6(assessed)-559.9(the)]TJ
-0.9975 -1.3189 TD
[(potential)-241.6(utility)-240.9(of)-235.6(PDE4)-241.1(inhibitors)-243.4(in)-237(the)-236.4(treatment)-243.9(of)-235.6(COPD)]TJ
0 -1.3256 TD
0.0002 Tc
(\(Rabe)Tj
/F3 1 Tf
2.8319 0 TD
0 Tc
[(et)-244.2(al)]TJ
/F2 1 Tf
1.8344 0 TD
[(.,)-248.1(2005;)-252.8(Rennard)]TJ
/F3 1 Tf
7.853 0 TD
[(et)-250.9(al)]TJ
/F2 1 Tf
1.8411 0 TD
[(.,)-248.1(2006;)-246.1(Calverley)]TJ
/F3 1 Tf
8.2681 0 TD
[(et)-244.2(al)]TJ
/F2 1 Tf
1.8411 0 TD
[(.,)-248.1(2007\).)]TJ
-24.4694 -1.3256 TD
[(All)-248.8(three)-248.4(studies)-257.5(report)-250.9(modest)-250.3(but)-248.9(significant)-249.5(improvements)]TJ
T*
[(in)-752.5(spirometr)-18.5(y)-753.5(over)-755(placebo,)-757.3(quality)-757.8(of)-757.8(life)-755.6(scores)-755.7(and)]TJ
0 -1.3189 TD
[(reduction)-513(in)-504.8(the)-510.9(number)-505.8(of)-510(exacerbations)-511(in)-511.5(the)-504.2(severest)]TJ
0 -1.3256 TD
[(group)-469.7(of)-463.2(COPD)-470.1(patients.)-469.7(The)-466(mechanism)-468.2(of)-463.2(the)-470.7(improve-)]TJ
T*
[(ment)-481(in)-478.1(spirometr)-11.8(y)-479(i)0(s)-480.4(unlikely)-474.5(to)-478.1(be)-483.6(due)-477.8(to)-478.1(relaxation)-476.7(of)]TJ
0 -1.3189 TD
[(air)-11.4(way)-597.2(smooth)-600.7(muscle)-594.8(because)-602.2(this)-594.1(drug)-600.8(class)-595(has)-597.1(weak)]TJ
0 -1.3256 TD
[(bronchodilator)-331.3(activity)69.5(.)-324.9(I)0(t)-322.1(i)0(s)-326.4(possible)-327.5(that)-326.7(this)-326.3(improvement)]TJ
T*
[(is)-306.3(due)-297.1(to)-304(an)-306.8(anti-inflammator)-17.6(y)-304.9(action)-305.2(of)-302.5(the)-303.3(drugs)-301.9(\(T)58.3(able)-297.5(1\),)]TJ
0 -1.3189 TD
[(although)-489.4(no)-484.9(biomarker)-488.2(of)-483.3(inflammation)-489.3(was)-488.8(measured)-488(in)]TJ
0 -1.3256 TD
[(these)-696.1(studies.)-696.2(However)39.4(,)-693.1(separate)-695.3(studies)-692.6(have)-694.1(addressed)]TJ
T*
[(whether)-515.2(PDE4)-508.9(inhibitors)-517.9(are)-513(anti-inflammator)-17.6(y)-512.5(i)0(n)-511.5(COPD.)]TJ
0 -1.3189 TD
[(Both)-446.5(roflumilast)-447.4(\(Grootendorst)]TJ
/F3 1 Tf
15.2976 0 TD
[(et)-445(al)]TJ
/F2 1 Tf
2.0352 0 TD
[(.,)-442.3(2007\))-450.9(and)-439.2(cilomilast)]TJ
-17.3328 -1.3256 TD
0.0001 Tc
(\(Gamble)Tj
/F3 1 Tf
4.3851 0 TD
0 Tc
[(et)-391.5(al)]TJ
/F2 1 Tf
1.9817 0 TD
[(.,)-388.7(2003\))-390.6(reduced)-394.4(the)-383.7(number)-392(of)-389.5(inflammator)-14.5(y)]TJ
-6.3667 -1.3256 TD
[(cells)-411.1(such)-412.4(as)-409.5(neutrophils)-417.9(and)-412.4(lymphocytes)-413.9(recruited)-415.1(to)-411.1(the)]TJ
T*
[(air)-11.4(ways)-459(and)-452.6(the)-457.3(levels)-450.6(of)-456.5(two)-456.9(biochemical)-462.6(markers)-452.2(of)-456.5(this)]TJ
0 -1.3189 TD
[(disease,)-467.6(namely)-459.4(interleukin-8)-468.2(and)-466(neutrophil)-462.4(elastase.)-467.8(The)]TJ
0 -1.3256 TD
[(magnitude)-330.1(of)-322.6(the)-323.4(change)-323.3(in)-324.1(the)-323.4(number)-331.7(of)-322.6(these)-321.2(inflamma-)]TJ
T*
[(tor)-12.7(y)-452.2(cells)-451.3(and)-445.9(concentration)-453.6(of)-456.5(mediators)-449.1(was)-455.3(between)-446.5(30)]TJ
0 -1.3189 TD
[(and)-419.1(50%)-413.6(and)-419.1(might)-415.9(underlie)-414.9(their)-416.4(beneficial)-416.9(action)-419(in)-417.8(the)]TJ
0 -1.3256 TD
[(phase)-430.3(III)-437.6(clinical)-430.6(trials.)-434.9(However)39.4(,)-432(the)-430.5(biomarker)-441.3(study)-428.1(also)]TJ
T*
[(highlights)-274(a)-273.3(recurring)-278.6(theme)-268.8(that)-273.1(complementar)-17.1(y)-271.5(inhibition)]TJ
0 -1.3189 TD
[(of)-496.7(PDE4)-495.5(was)-502.2(not)-491.5(achievable)-498.6(because)-501.8(of)-496.7(dose-limiting)-498.2(side)]TJ
0 -1.3256 TD
[(effects;)-515.3(or)-514.9(alternatively)67(,)-512.4(other)-510.3(PDE)-518.5(isoforms)-513.7(\(for)-514.1(example,)]TJ
T*
[(PDE3,)-365.1(7,)-368.8(see)-361.4(T)65(able)-364.5(1\))-366.1(in)-364.3(these)-361.3(same)-361.7(inflammator)-21.2(y)-358.5(processes)]TJ
T*
[(may)-240.4(also)-240.9(require)-234.7(targeting)-243.5(for)-238.8(a)-239.8(full)-239.9(anti-inflammator)-17.6(y)-238(action)]TJ
0 -1.3189 TD
[(to)-337.5(be)-329.6(revealed)-334.5(in)-337.5(this)-333(disease.)]TJ
0.9975 -1.3256 TD
[(The)-479.4(most)-477.3(common)-481.3(side)-480.9(effect)-475.9(reported)-479.1(with)-476.9(roflumilas)-12.4(t)]TJ
-0.9975 -1.3256 TD
[(included)-494.8(diarrhoea)-492.3(\(9%\),)-495.4(headache)-488.8(\(6%\))-491.8(and)-492.8(nausea)-492.7(\(5%\))]TJ
0 -1.3189 TD
0.0002 Tc
(\(Rabe)Tj
/F3 1 Tf
2.9792 0 TD
0 Tc
[(et)-391.5(al)]TJ
/F2 1 Tf
1.9883 0 TD
[(.,)-388.7(2005;)-400.1(Calverley)]TJ
/F3 1 Tf
8.7099 0 TD
[(et)-391.5(al)]TJ
/F2 1 Tf
1.9884 0 TD
[(.,)-395.4(2007\),)-394.2(which)-396.4(was)-395.1(of)-396.2(the)]TJ
-15.6658 -1.3256 TD
[(same)-455.4(order)-451.8(of)-456.5(magnitude)-457.3(as)-449.7(that)-453.9(reported)-452.3(with)-456.8(cilomilast,)]TJ
T*
[(although)-409.1(abdominal)-415.6(pain)-408.4(and)-405.8(vomiting)-411.6(were)-408.1(also)-408.3(reported)]TJ
0 -1.3189 TD
[(for)-600.4(this)-607.5(drug)-600.8(\(Rennard)]TJ
/F3 1 Tf
11.9234 0 TD
[(et)-605.7(al)]TJ
/F2 1 Tf
2.1959 0 TD
[(.,)-603(2006\).)-608.4(The)-599.9(adverse)-606.6(effects)]TJ
-14.1193 -1.3256 TD
[(appeared)-348.7(to)-350.9(disappear)-358.3(with)-349.7(continued)-349.1(use)-354.5(but)-342.6(were)-354.5(a)-346.9(m)-0.1(ajor)]TJ
T*
[(reason)-310.7(why)-303.9(patients)-312.2(discontinued)-305.7(with)-309.5(the)-310(study)-307.6(during)-308.9(the)]TJ
0 -1.3189 TD
[(first)-548.9(3–4)-551.8(weeks)-551.4(of)-550.2(treatment.)-555.4(No)-550.8(cardiovascular)-559.1(liabilities)]TJ
0 -1.3256 TD
[(were)-334.5(noted.)]TJ
/F3 1 Tf
0 -3.97 TD
[(PDE4)-339.1(inhibitors:)-337.9(unwanted)-335.5(effects)]TJ
/F2 1 Tf
0 -1.3256 TD
[(Nausea)-431.3(is)-426.8(a)-427.3(commonly)-427.3(reported)-432.2(side)-427.4(effect)-422.4(associated)-436.4(with)]TJ
T*
[(theophylline)-298.3(and)-291.9(therefore)-301.9(not)-290.6(surprisingly)69.2(,)-298.1(PDE4)-294.6(inhibitors)]TJ
T*
[(also)-254.3(produce)-261.2(a)-253.2(similar)-243.6(constellation)-264.1(of)-255.6(adverse)-251.8(events)-257.9(and)-251.8(are)]TJ
0 -1.3189 TD
[(a)-286.7(major)-285.6(drawback)-295.6(for)-285.7(the)-283.2(therapeutic)-290(use)-287.5(of)-289.1(these)-287.7(drugs.)-285.3(The)]TJ
0 -1.3256 TD
[(mechanism)-361.1(responsible)-359.7(for)-352.7(this)-359.8(side)-353.7(effect)-355.4(has)-356(been)-351.8(investi-)]TJ
T*
[(gated)-288.4(in)-290.6(an)-293.4(attempt)-290.5(to)-290.6(discover)-289.5(non-emetic)-295.9(PDE4)-294.6(inhibitors.)]TJ
0.9975 -1.3189 TD
[(The)-399(direct)-394.4(recording)-395.2(of)-389.5(neuronal)-399.9(activity)-392.4(within)-392.6(the)-397(area)]TJ
-0.9975 -1.3256 TD
[(postrema)-312.6(conclusively)-311.7(demonstrated)-313.1(that)-313.3(substances)-310.2(known)]TJ
T*
[(to)-612(cause)-607.4(nausea)-606.5(\(for)-614.6(example,)-610.8(apomorphine\))-609.8(caused)-612.6(the)]TJ
0 -1.3189 TD
[(excitation)-547.8(of)-543.5(neurones)-543.5(within)-546.5(the)-537.6(area)-545.2(postrema)-546.9(of)-543.5(dogs)]TJ
0 -1.3256 TD
0.0001 Tc
(\(Carpenter)Tj
/F3 1 Tf
5.4763 0 TD
0 Tc
[(et)-465.1(al)]TJ
/F2 1 Tf
2.062 0 TD
[(.,)-462.4(1988\).)-474.5(Neuronal)-465.7(activity)-466.1(within)-472.9(the)-464(area)]TJ
-7.5383 -1.3256 TD
[(postrema)-386.2(was)-381.7(also)-381.5(increased)-384.4(following)-387.1(the)-383.7(systemic)-384.5(admin-)]TJ
T*
[(istration)-481(of)-476.6(8-bromo)-479.3(cyclic)-476.7(AMP)-480.9(or)-474.7(following)-480.9(elevation)-476.6(of)]TJ
0 -1.3189 TD
[(endogenous)-810.6(levels)-805.5(of)-804.6(cyclic)-804.7(AMP)-809(within)-807.6(neurones)-804.6(by)]TJ
0 -1.3256 TD
[(forskolin,)-758.6(an)-755.4(activator)-752.5(of)-757.8(AC)-749.8(\(Carpenter)]TJ
/F3 1 Tf
21.6108 0 TD
[(et)-753(al)]TJ
/F2 1 Tf
2.3499 0 TD
[(.,)-750.2(1988\).)]TJ
-23.9606 -1.3256 TD
[(Elevated)-634(levels)-631.4(of)-637.2(cyclic)-630.6(AMP)-634.9(within)-633.6(the)-638.1(area)-632.3(postrema)]TJ
ET
1 i 
307.842 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 307.8424 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-335.3(and)-325.8(respiratory)-335.9(disease)]TJ
/F9 1 Tf
0 -1.2519 TD
[(D)-328.5(Spina)]TJ
7.0982 0 0 9.4646 534.1038 751.8612 Tm
0.0001 Tc
(311)Tj
ET
307.842 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 405.2408 31.2378 Tm
[(British)-322.5(J)0.1(ournal)-334(of)-334.4(Pharmacolog)18.7(y)-339.1(\(2008\))]TJ
/F1 1 Tf
17.5955 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi4 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
405 29 141 10 re
f*
0.619608 0.619608 0.619608 rg
n
533 752 13 8 re
f*
0.619608 0.619608 0.619608 rg
n
307 751 111 18 re
f*
0.619608 0.619608 0.619608 rg
n
574 5 13 453 re
f*
0.619608 0.619608 0.619608 rg
n
574 404 12 367 re
f*
0.4 0.4 1 rg
n
50 639 65 9 re
f*
0.4 0.4 1 rg
n
307 235 127 10 re
f*
0.6 0 0.298039 rg
n
50 684 239 44 re
f*
0.6 0 0.298039 rg
n
50 448 239 189 re
f*
0.6 0 0.298039 rg
n
50 235 239 212 re
f*
0.6 0 0.298039 rg
n
50 56 240 177 re
f*
0.6 0 0.298039 rg
n
307 706 239 22 re
f*
0.6 0 0.298039 rg
n
307 382 239 322 re
f*
0.6 0 0.298039 rg
n
307 269 240 110 re
f*
0.6 0 0.298039 rg
n
307 168 240 66 re
f*
0.6 0 0.298039 rg
n
307 56 240 111 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 718 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 117 638 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 627 cm
BT
1 0 0 1 0 0 Tm
(3) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 437 cm
BT
1 0 0 1 0 0 Tm
(4) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 292 223 cm
BT
1 0 0 1 0 0 Tm
(5) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 718 cm
BT
1 0 0 1 0 0 Tm
(6) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 694 cm
BT
1 0 0 1 0 0 Tm
(7) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 369 cm
BT
1 0 0 1 0 0 Tm
(8) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 436 235 cm
BT
1 0 0 1 0 0 Tm
(9) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 224 cm
BT
1 0 0 1 0 0 Tm
(10) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 157 cm
BT
1 0 0 1 0 0 Tm
(11) Tj
T*
ET
Q
Q


endstream
endobj
185 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
186 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
187 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 374
>>
stream
H‰ì—QÂ0D½ÿ¹êH	»„&Ğ#µéfßšÒDä_c-*‘›ç=ÙZğØQÊ¨ë¢ÑE‰ÎÇ‹ğ™*éLÑçg:0oQêÈéŒ'ùRG
ó‰J-µîá_5ú2Jòvªğ,–¢Ô50W““ÂpP^pº1/'ı[/Î\º¨İù\’7ïg``¹4'râ	Ó±ñÍxû<Õ*Ù·…­·ÚœÜÖ”X™®–o¦[õyd§L½v/ójsŠ¶±¾'‹ƒE¯¢‹¶p!íœd¯(A;OeùœÀgÛs=Kwä¼Á*p}1ki¥ºá©`Š•:s¢&Krê¢Ët_‹bÚ@^I¯@ı.‡¯†šwß§´¯¢¹.:x1èÒap=Ÿ)ÏÙïİØöîØ.ÿ"€‘³Jİ9­ÓñûRKç®lï½³}~¤©hŸ¸-ñ’˜òışÀVÓyg˜ğt;(1E†\B×W0¡Ÿ ë­ç º[ş}
endstream
endobj
188 0 obj
<<
/Annots [ 189 0 R 190 0 R 191 0 R 192 0 R 193 0 R 194 0 R 195 0 R 196 0 R 197 0 R 198 0 R 199 0 R 200 0 R 201 0 R 202 0 R 203 0 R 204 0 R 205 0 R 206 0 R 207 0 R 208 0 R 209 0 R 210 0 R 211 0 R 212 0 R 213 0 R 214 0 R 215 0 R 216 0 R 217 0 R 218 0 R 219 0 R 220 0 R ]
/Contents 221 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 222 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F5 39 0 R
/F6 42 0 R
/F7 45 0 R
/F9 55 0 R
>>
/XObject <<
/Im2 223 0 R
/Xi5 224 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 225 0 R
/Type /Page
/Parent 2 0 R
>>
endobj
189 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib17)
/Rect [ 80 672 168 680 ]
/Subtype /Link
/Type /Annot
>>
endobj
190 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib70)
/Rect [ 114 649 212 658 ]
/Subtype /Link
/Type /Annot
>>
endobj
191 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib70)
/Rect [ 101 593 214 602 ]
/Subtype /Link
/Type /Annot
>>
endobj
192 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib19)
/Rect [ 54 537 147 546 ]
/Subtype /Link
/Type /Annot
>>
endobj
193 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib80)
/Rect [ 153 537 238 546 ]
/Subtype /Link
/Type /Annot
>>
endobj
194 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib61)
/Rect [ 243 537 290 546 ]
/Subtype /Link
/Type /Annot
>>
endobj
195 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib61)
/Rect [ 51 526 93 535 ]
/Subtype /Link
/Type /Annot
>>
endobj
196 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib48)
/Rect [ 97 526 191 535 ]
/Subtype /Link
/Type /Annot
>>
endobj
197 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib61)
/Rect [ 147 481 240 490 ]
/Subtype /Link
/Type /Annot
>>
endobj
198 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib68)
/Rect [ 54 414 169 422 ]
/Subtype /Link
/Type /Annot
>>
endobj
199 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib68)
/Rect [ 54 380 147 389 ]
/Subtype /Link
/Type /Annot
>>
endobj
200 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib68)
/Rect [ 120 324 209 333 ]
/Subtype /Link
/Type /Annot
>>
endobj
201 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib69)
/Rect [ 54 257 149 266 ]
/Subtype /Link
/Type /Annot
>>
endobj
202 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib23)
/Rect [ 157 190 226 198 ]
/Subtype /Link
/Type /Annot
>>
endobj
203 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib2)
/Rect [ 84 156 172 165 ]
/Subtype /Link
/Type /Annot
>>
endobj
204 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137fig1)
/Rect [ 125 123 157 131 ]
/Subtype /Link
/Type /Annot
>>
endobj
205 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib1)
/Rect [ 179 78 243 86 ]
/Subtype /Link
/Type /Annot
>>
endobj
206 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib67)
/Rect [ 248 78 290 86 ]
/Subtype /Link
/Type /Annot
>>
endobj
207 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib67)
/Rect [ 51 67 97 75 ]
/Subtype /Link
/Type /Annot
>>
endobj
208 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137fig1)
/Rect [ 349 448 385 456 ]
/Subtype /Link
/Type /Annot
>>
endobj
209 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib31)
/Rect [ 496 436 547 445 ]
/Subtype /Link
/Type /Annot
>>
endobj
210 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib31)
/Rect [ 308 425 327 434 ]
/Subtype /Link
/Type /Annot
>>
endobj
211 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib77)
/Rect [ 494 324 541 333 ]
/Subtype /Link
/Type /Annot
>>
endobj
212 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib51)
/Rect [ 426 313 502 322 ]
/Subtype /Link
/Type /Annot
>>
endobj
213 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib59)
/Rect [ 371 246 436 254 ]
/Subtype /Link
/Type /Annot
>>
endobj
214 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib56)
/Rect [ 311 223 400 232 ]
/Subtype /Link
/Type /Annot
>>
endobj
215 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib13)
/Rect [ 479 134 547 142 ]
/Subtype /Link
/Type /Annot
>>
endobj
216 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib13)
/Rect [ 308 123 327 131 ]
/Subtype /Link
/Type /Annot
>>
endobj
217 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 333 123 454 131 ]
/Subtype /Link
/Type /Annot
>>
endobj
218 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib70)
/Rect [ 308 582 391 590 ]
/Subtype /Link
/Type /Annot
>>
endobj
219 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib69)
/Rect [ 510 519 547 527 ]
/Subtype /Link
/Type /Annot
>>
endobj
220 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib69)
/Rect [ 308 511 355 519 ]
/Subtype /Link
/Type /Annot
>>
endobj
221 0 obj
<<
/Length 19101
>>
stream
q
q

BT
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(enhanced)-777.9(the)-778.7(emetogenic)-779.4(response.)-780.3(Dogs)-778.6(treated)-781.1(with)]TJ
0 -1.3256 TD
[(theophylline)-378.6(and)-365.6(the)-370.3(PDE4)-375(selective)-372(inhibitor)33.4(,)-365.1(4-\(3-butoxy-)]TJ
T*
[(4-methoxyphenyl\)methyl-2-imi)-16.9(dazolidone)-1154.3(\(Ro)-1149.4(20–1724\))]TJ
0 -1.3189 TD
[(reduced)-494.8(the)-484.1(emetic)-492.1(threshold)-493.7(of)-490(the)-490.8(D2)-488(agonist,)-493.4(apomor-)]TJ
0 -1.3256 TD
0.0001 Tc
[(phine)-405(\(Carpenter)]TJ
/F3 1 Tf
8.5559 0 TD
0 Tc
[(et)-404.9(al)]TJ
/F2 1 Tf
1.995 0 TD
[(.,)-408.8(1988\).)-407.6(Similarly)65.1(,)-405.3(the)-403.7(i.c.v)67.2(.)-405.3(adminis-)]TJ
-10.551 -1.3256 TD
[(tration)-275.2(of)-275.7(highly)-271.4(potent)-277.7(PDE4)-274.5(inhibitors)-276.9(also)-274.4(induced)-277.9(emesis)]TJ
T*
[(in)-705.7(the)-705(ferret)-712(\()5.9(Robichaud)]TJ
/F3 1 Tf
13.1686 0 TD
[(et)-706.1(al)]TJ
/F2 1 Tf
2.2963 0 TD
[(.,)-710.1(1999\),)-708.8(and)-707(the)-705(emetic)]TJ
-15.465 -1.3189 TD
[(response)-602.7(to)-605.3(systemically)-606.5(administered)-603.6(PDE4)-602.6(inhibitors)-604.9(is)]TJ
0 -1.3256 TD
[(reduced)-447.9(by)-438.2(anti-emetic)-448.3(agents)-439.6(including)-444.6(the)-443.9(5HT3-antago-)]TJ
T*
[(nist,)-497.2(ondansetron,)-503(and)-499.5(the)-490.8(neurokinin)-501.2(1)-499.2(antagonist,)-498.8(\()]TJ
/F7 1 Tf
26.6118 0 TD
()Tj
/F2 1 Tf
0.9373 0 TD
(\)-)Tj
-27.549 -1.3189 TD
(\(2)Tj
/F3 1 Tf
0.9306 0 TD
(S)Tj
/F2 1 Tf
0.4753 0 TD
(,3)Tj
/F3 1 Tf
0.8636 0 TD
(S)Tj
/F2 1 Tf
0.482 0 TD
(\)-3-\(2-[)Tj
6.351 0 0 5.6449 101.0834 610.4125 Tm
0.0001 Tc
(11)Tj
8.4682 0 0 8.4682 108.3968 606.6707 Tm
0 Tc
(C]methoxybenzylamino\)-2-phenylpiperidine)Tj
-6.8019 -1.3256 TD
[(\(CP-99994\))-344.4(\(Robichaud)]TJ
/F3 1 Tf
11.2405 0 TD
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(1999,)-339.8(2001\).)]TJ
-12.1644 -1.3256 TD
[(Many)-363.3(studies)-364.6(have)-366.1(documented)-364(the)-363.6(expression)-368.1(of)-369.5(PDE4D)]TJ
-1.0042 -1.3189 TD
[(within)-707.2(the)-711.7(area)-705.9(postrema,)-704.5(nucleus)-713.6(tractus)-708.8(solitaris)-707(and)]TJ
0 -1.3256 TD
[(nodose)-731.7(ganglion)-732.6(neurones)-737.7(in)-725.8(various)-731.8(species)-732.8(including)]TJ
T*
[(man)-477.8(and)-479.4(implicated)-484.3(this)-473.6(isoform)-484.6(in)-478.1(nausea)-479.3(and)-479.4(vomiting)]TJ
0 -1.3189 TD
[(\(Cherr)-12.8(y)-304.9(and)-305.3(Davis,)-307.8(1999;)-306.3(T)65(akahashi)]TJ
/F3 1 Tf
16.978 0 TD
[(et)-304.4(al)]TJ
/F2 1 Tf
1.9013 0 TD
[(.,)-301.7(1999;)-313(Perez-T)64.9(orres)]TJ
/F3 1 Tf
-18.8793 -1.3256 TD
[(et)-244.2(al)]TJ
/F2 1 Tf
1.8344 0 TD
[(.,)-248.1(2000;)-246.1(Lamontagne)]TJ
/F3 1 Tf
9.761 0 TD
[(et)-244.2(al)]TJ
/F2 1 Tf
1.8344 0 TD
[(.,)-248.1(2001\).)-246.9(However)39.4(,)-237.9(i)0(t)-243.6(should)-242.6(also)]TJ
-13.4297 -1.3256 TD
[(be)-369.7(recognized)-374.6(that)-373.5(detectable)-373.3(transcript)-369.9(for)-372.7(PDE4B)-376.9(was)-368.3(also)]TJ
T*
[(found)-309.7(within)-298.8(the)-303.3(nucleus)-305.2(tractus)-307.1(solitaris)-305.3(and)-305.3(area)-304.2(postrema)]TJ
0 -1.3189 TD
[(in)-330.8(humans)-328.1(and)-332.1(rodents,)-333.9(respectively)71.2(,)-331.6(and)-325.4(could)-333.6(be)-329.6(involved)]TJ
0 -1.3256 TD
[(in)-324.1(the)-323.4(emetic)-318(response)-328.2(\(Perez-T)64.9(orres)]TJ
/F3 1 Tf
17.2257 0 TD
[(et)-317.8(al)]TJ
/F2 1 Tf
1.9147 0 TD
[(.,)-321.8(2000\).)-320.5(As)-326.3(rodents)]TJ
-19.1404 -1.3256 TD
[(do)-336.1(not)-330.8(possess)-334.2(an)-326.9(emetic)-338.1(reflex,)-330.5(it)-330.6(is)-333.1(not)-330.8(possible)-334.2(to)-330.8(directly)]TJ
0 -1.3189 TD
[(investigate)-356.8(the)-350.2(role)-352.3(of)-349.4(different)-353.5(isoforms)-353(of)-349.4(PDE4)-354.9(in)-350.9(emesis.)]TJ
0 -1.3256 TD
[(However)39.4(,)-385.2(a)-387.1(surrogate)-390.6(biological)-390.2(response)-388.5(that)-386.9(measures)-391.4(the)]TJ
T*
[(reversal)-339.5(of)-342.7(anaesthesia)-335.9(induced)-344.8(by)]TJ
/F6 1 Tf
16.4424 0 TD
(a)Tj
/F2 1 Tf
0.549 0 TD
[(2-adrenoceptor)-345.3(agonists)]TJ
-16.9914 -1.3189 TD
[(has)-362.7(been)-351.8(used)-359.7(to)-357.6(study)-361.1(the)-356.9(role)-359(of)-362.8(PDE4)-354.9(subtypes)-365(in)-357.6(emesis)]TJ
0 -1.3256 TD
0.0001 Tc
(\(Robichaud)Tj
/F3 1 Tf
5.6236 0 TD
0 Tc
[(et)-264.3(al)]TJ
/F2 1 Tf
1.8545 0 TD
[(.,)-268.2(2001,)-266.2(2002a\).)-272.5(It)-261.8(was)-267.9(previously)-264.5(shown)-265.4(that)]TJ
-7.4781 -1.3256 TD
[(the)-664.8(ability)-672.5(of)-664(PDE4)-669.5(inhibitors)-671.9(to)-665.5(induce)-667.7(emesis)-671.3(in)-665.5(the)]TJ
T*
[(ferret)-504.5(was)-508.9(inhibited)-503.4(by)-505.2(the)]TJ
/F6 1 Tf
13.6975 0 TD
(a)Tj
/F2 1 Tf
0.549 0 TD
[(2-selective)-511.3(agonist,)-506.8(clonidine)]TJ
-14.2465 -1.3189 TD
0.0001 Tc
(\(Robichaud)Tj
/F3 1 Tf
5.8713 0 TD
0 Tc
[(et)-512(al)]TJ
/F2 1 Tf
2.1089 0 TD
[(.,)-509.2(2001\))-517.8(and)-519.6(suggested)-513.8(that)-514.1(raising)-513.1(cyclic)]TJ
-7.9802 -1.3256 TD
[(AMP)-855.8(within)-854.5(central)-856.7(noradrenergic)-861.4(terminals)-852.2(by)-853.3(PDE4)]TJ
T*
[(inhibitors)-497.8(promoted)-493.5(emesis,)-487.4(and)-492.8(this)-493.7(could)-494.3(be)-490.2(attenuated)]TJ
0 -1.3189 TD
(by)Tj
/F6 1 Tf
1.4996 0 TD
(a)Tj
/F2 1 Tf
0.549 0 TD
[(2-adrenoceptor-mediated)-366.5(inhibition)-367.7(of)-362.8(AC.)-358.3(The)-358.9(hypno-)]TJ
-2.0486 -1.3256 TD
[(tic)-430.7(action)-439.1(of)-429.7(xylazine)-436(was)-428.6(reversed)-432.4(in)-431.2(rodents)-437.5(treated)-433(with)]TJ
T*
[(PDE4)-354.9(inhibitors)-357.2(\(Robichaud)]TJ
/F3 1 Tf
13.5101 0 TD
[(et)-351.3(al)]TJ
/F2 1 Tf
1.9482 0 TD
[(.,)-355.3(2001\))-357.2(and)-352.2(therefore)-355.4(used)]TJ
-15.4583 -1.3189 TD
[(as)-309.1(a)-300.1(surrogate)-310.2(for)-305.8(emesis.)-306.6(Deletion)-309.1(of)-309.2(PDE4D)-303.6(and)-305.3(not)-304(PDE4B)]TJ
0 -1.3256 TD
[(reduced)-514.9(the)-510.9(duration)-516.7(of)-510(anaesthesia)-516.7(induced)-512.2(by)-511.9(xylazine,)]TJ
T*
[(compared)-482.6(with)-470.2(wild-type)-477.2(mice,)-480.2(and)-472.7(second,)-477.7(the)-477.4(ability)-478.3(of)]TJ
0 -1.3189 TD
[(PDE4)-656.2(inhibitors)-651.8(to)-652.1(shorten)-653.3(xylazine-induced)-655.3(anaesthesia)]TJ
0 -1.3256 TD
[(was)-642.8(impaired)-639.4(in)-638.7(PDE4D)-645(but)-637.2(not)-638.8(PDE4B)-644.7(knockout)-643.8(mice)]TJ
T*
0.0001 Tc
(\(Robichaud)Tj
/F3 1 Tf
5.7374 0 TD
0 Tc
[(et)-384.8(al)]TJ
/F2 1 Tf
1.9817 0 TD
[(.,)-382(2002b\).)-386.9(T)65(ogether)35.4(,)-385.2(these)-381.4(studies)-384.7(suggested)]TJ
-7.7191 -1.3256 TD
[(that)-527.5(PDE4)-522.3(inhibito)-10.2(rs)-521.2(with)-523.8(low)-526.6(affinity)-526.7(for)-526.7(PDE4D)-531.2(should)]TJ
0 -1.3189 TD
[(have)-332.6(reduced)-340.8(emetic)-331.4(potential.)]TJ
1.0042 -1.3256 TD
[(However)39.4(,)-264.7(i)0(t)-263.6(i)0(s)-259.4(not)-263.9(entirely)-270.7(clear)-274.3(whether)-260.8(PDE4D)-270.1(inhibition)]TJ
-1.0042 -1.3256 TD
[(alone)-240.7(is)-239.3(the)-236.4(sole)-237.5(basis)-239.9(of)-242.3(emesis)-236.1(as)-235.5(there)-241.7(are)-238.5(examples)-241.4(of)-235.6(PDE4)]TJ
0 -1.3189 TD
[(inhibitors)-370.6(that)-366.8(document)]TJ
/F3 1 Tf
12.392 0 TD
[(in)-368.8(vivo)]TJ
/F2 1 Tf
3.3541 0 TD
[(anti-inflammator)-17.6(y)-365.2(activity)]TJ
-15.7461 -1.3256 TD
[(but)-536.8(are)-533.1(not)-538.4(emetogenic)-538.4(\(Gale)]TJ
/F3 1 Tf
15.157 0 TD
[(et)-532.1(al)]TJ
/F2 1 Tf
2.1289 0 TD
[(.,)-536(2002\))-537.9(and)-532.9(there)-536.3(are)]TJ
-17.2859 -1.3256 TD
[(examples)-589.6(of)-590.4(PDE4)-589.2(inhibitors)-591.6(that)-587.8(have)-587(little)-592.3(emetogenic)]TJ
0 -1.3189 TD
[(activity)-352.3(but)-349.3(potent)-351.4(anti-inflammator)-17.6(y)-351.8(activity)-352.3(in)-350.9(preclinical)]TJ
0 -1.3256 TD
[(studies)-311(\()5.9(Aoki)]TJ
/F3 1 Tf
6.3333 0 TD
[(et)-304.5(al)]TJ
/F2 1 Tf
1.8946 0 TD
[(.,)-308.4(2000,)-306.3(2001\).)-313.8(Similarly)71.7(,)-304.8(the)-303.3(emetic)-311.3(profile)]TJ
-8.2279 -1.3256 TD
[(of)-322.6(various)-330.1(PDE4)-321.4(inhibitors)-330.5(in)-317.4(the)-323.4(ferret)-323.7(cannot)-329.3(be)-322.9(explained)]TJ
T*
[(by)-485.1(their)-483.3(selectivity)-483.2(for)-486.5(PDE4D)-484.3(or)-481.4(to)-484.7(differences)-485(in)-484.8(PDE4D)]TJ
0 -1.3189 TD
[(inhibitor)-247.8(potency)-247.7(\(Figure)-241(1\).)-249.1(One)-241.2(possible)-247.2(explanation)-244.3(might)]TJ
0 -1.3256 TD
[(be)-316.2(that)-320(some)-318.9(PDE4)-314.7(inhibitors)-323.8(preferentially)-321.3(partition)-316.5(within)]TJ
T*
[(the)-370.3(CNS)-366.7(and)-365.6(hence)-372.2(the)-363.6(degree)-370.8(of)-369.5(PDE4D)-370.5(inhibition)-367.7(in)-370.9(area)]TJ
0 -1.3189 TD
[(postrema)-607.2(neurones)-603.8(might)-610(explain)-604.3(the)-604.6(differences)-605.5(in)-605.3(the)]TJ
0 -1.3256 TD
[(emetic)-304.6(potential)-295.2(of)-302.5(these)-301.1(drugs)-295.2(\(Aoki)]TJ
/F3 1 Tf
17.5805 0 TD
[(et)-297.8(al)]TJ
/F2 1 Tf
1.8946 0 TD
[(.,)-295(2001;)-306.3(Robichaud)]TJ
/F3 1 Tf
-19.4751 -1.3256 TD
[(et)-250.9(al)]TJ
/F2 1 Tf
1.8478 0 TD
[(.,)-248.1(2002a\).)-259.1(However)39.4(,)-251.3(the)-249.8(concentration)-252.8(of)-255.6(the)-249.8(‘low)-252.3(emetic’)]TJ
-1.8478 -1.3189 TD
[(PDE4)-328.1(inhibitor)33.4(,)-324.9(C)0(T)60.9(-2450)-324.6(within)-325.6(the)-330.1(CNS)-326.5(was)-321.5(comparable)-331(to)]TJ
30.3542 47.6468 TD
[(that)-507.4(achieved)-502.9(by)-505.2(the)-504.2(most)-510.8(potent)-505.4(emetic)-505.4(PDE4)-508.9(inhibitor)40.1(,)]TJ
0 -1.3256 TD
[(PMNPQ)-793.8(\(Figure)-796.6(1\).)-791.4(Second,)-798.8(the)-792(area)-792.9(postrema)-794.6(is)-795(not)]TJ
T*
[(completely)-633.5(behind)-625.4(the)-631.4(blood–brain)-628.4(barrier)-628.7(\(Gross)]TJ
/F3 1 Tf
25.4335 0 TD
[(et)-625.8(al)]TJ
/F2 1 Tf
2.216 0 TD
(.,)Tj
-27.6495 -1.3189 TD
[(1990\),)-668.7(and)-660.1(therefore)-663.4(accessible)-667.9(to)-665.5(free)-662(drug)-661(within)-667(the)]TJ
0 -1.3256 TD
[(circulation.)-492.9(It)-502.8(would)-500.2(seem)-498.9(unlikely)-501.3(that)-500.7(differential)-504.9(parti-)]TJ
T*
[(tioning)-712.3(of)-710.9(these)-709.5(inhibitors)-712.1(within)-713.9(the)-705(CNS)-708.1(is)-714.7(a)-708.5(likely)]TJ
T*
[(explanation)-445.2(for)-446.4(their)-443.1(ability)-451.5(to)-437.9(induce)-446.7(emesis.)-447.2(However)39.4(,)-445.4(i)0(t)]TJ
0 -1.3189 TD
[(remains)-427.9(to)-424.5(be)-430(established)-425.9(whether)-428.2(the)-423.8(magnitude)-430.5(of)-423(PDE4)]TJ
0 -1.3256 TD
[(inhibition)-615.4(within)-606.8(the)-611.3(area)-612.2(postrema)-613.9(differs)-608.3(between)-613.8(the)]TJ
T*
[(various)-336.8(PDE4)-334.8(inhibitors.)]TJ
0.9975 -1.3189 TD
[(A)-243.6(number)-244.7(of)-242.3(preclinical)-247(studies)-244.1(have)-238.9(highlighted)-245.4(a)-246.5(number)]TJ
-0.9975 -1.3256 TD
[(of)-242.3(disadvantages)-242(to)-243.7(targeting)-243.5(PDE4,)-244.6(include)-241.9(the)-236.4(developmen)-9.3(t)]TJ
T*
[(of)-382.8(mesenteric)-386(vasculitis,)-388.3(immunosuppression)-386.3(\(Spina,)-387.2(2004\),)]TJ
0 -1.3189 TD
[(heart)-285.3(failure)-284.2(and)-285.2(arrhythmia)-288.5(\(Lehnart)]TJ
/F3 1 Tf
17.8952 0 TD
[(et)-284.4(al)]TJ
/F2 1 Tf
1.8812 0 TD
[(.,)-281.6(2005\).)-287.1(However)39.4(,)]TJ
-19.7764 -1.3256 TD
[(none)-420.1(of)-416.3(these)-414.9(events)-418.5(appear)-415(to)-417.8(be)-416.6(realized)-419(in)-417.8(phase)-416.9(II)-416.7(and)]TJ
T*
[(phase)-711.5(III)-705.4(clinical)-711.8(trials)-712.6(undertaken)-713.2(with)-711.2(cilomilast)-714(and)]TJ
0 -1.3189 TD
[(roflumilast.)-571.5(Similarly)65(,)-565.9(slow)-569.2(release)-569(theophylline)-566.1(has)-570.3(been)]TJ
0 -1.3256 TD
[(used)-326.2(for)-325.9(decades)-330.1(in)-324.1(the)-330.1(treatment)-324.2(of)-329.3(asthma)-324.9(and)-325.4(COPD)-329.5(and)]TJ
T*
[(has)-362.7(not)-364.3(been)-365.2(associated)-369.5(with)-363.1(a)-367(number)-365.2(of)-369.5(these)-361.3(potentially)]TJ
T*
[(adverse)-305.3(events)-298(\(Ohta)]TJ
/F3 1 Tf
10.0623 0 TD
[(et)-304.5(al)]TJ
/F2 1 Tf
1.8946 0 TD
[(.,)-301.7(2004\).)-307.1(It)-302(has)-302.5(been)-304.9(suggested)-299.6(that)]TJ
-11.9569 -1.3189 TD
[(PDE4)-843.6(inhibitors)-846(may)-836.2(have)-841.4(proinflammator)-19.1(y)-840.5(properties)]TJ
0 -1.3256 TD
0.0001 Tc
(\(McCluskie)Tj
/F3 1 Tf
5.6504 0 TD
0 Tc
[(et)-404.9(al)]TJ
/F2 1 Tf
2.0017 0 TD
[(.,)-408.8(2006\).)-407.6(This)-415.4(conclusion)-409.7(was)-408.5(based)-409.6(on)-411.3(the)]TJ
-7.6521 -1.3256 TD
[(finding)-666.4(that)-668.1(roflumilast)-668.4(at)-661.5(ver)-15.7(y)-659.8(high)-666.8(doses)-670.9(\(100)-166(mg/kg\))]TJ
0 -1.3189 TD
[(promoted)-312.8(the)-303.3(recruitment)-313(of)-309.2(neutrophils)-310.8(to)-304(the)-310(air)-11.4(ways)-305(and)]TJ
0 -1.3256 TD
[(this)-821.7(correlated)-829.8(with)-818.3(the)-825.5(release)-823.4(of)-824.7(interleukin-8)-823.1(from)]TJ
T*
[(cultured)-445.1(endothelial)-447.4(cells)]TJ
/F3 1 Tf
12.5728 0 TD
[(in)-442.5(vitro)]TJ
/F2 1 Tf
3.2671 0 TD
[(,)-438.7(although)-449.3(the)-437.2(concentra-)]TJ
-15.8399 -1.3189 TD
[(tions)-516.6(required)-521.1(to)-511.5(achieve)-517.8(these)-515.3(effects)-518.5(were)-521.9(at)-514.2(least)-514.6(1000)]TJ
0 -1.3256 TD
[(times)-492.6(greater)-499.4(than)-494.2(the)-490.8(ED)]TJ
6.351 0 0 5.6449 416.2393 156.926 Tm
0.0001 Tc
(50)Tj
8.4682 0 0 8.4682 427.6912 158.3433 Tm
0 Tc
[(and)-492.8(EC)]TJ
6.351 0 0 5.6449 457.9652 156.926 Tm
0.0001 Tc
(50)Tj
8.4682 0 0 8.4682 469.4172 158.3433 Tm
0 Tc
[(values)-493.4(reported)-499.2(for)]TJ
-19.0801 -1.3256 TD
[(roflumilast)-440.8(against)-432.2(several)]TJ
/F3 1 Tf
12.8942 0 TD
[(in)-435.8(vivo)]TJ
/F2 1 Tf
3.4813 0 TD
[(biomarkers)-437(of)-436.4(inflamma-)]TJ
-16.3754 -1.3189 TD
[(tion)-273.2(and)-265.2(cell)-274.9(function)]TJ
/F3 1 Tf
10.4439 0 TD
[(in)-268.4(vitro)]TJ
/F2 1 Tf
3.093 0 TD
[(,)-264.7(respectively)-270.3(\(Bundschuh)]TJ
/F3 1 Tf
12.2515 0 TD
[(et)-271(al)]TJ
/F2 1 Tf
1.8612 0 TD
(.,)Tj
-27.6495 -1.3256 TD
[(2001;)-333.1(Hatzelmann)-335.9(and)-325.4(Schudt,)-333.7(2001\).)-333.9(It)-328.8(is)-333.1(unlikely)-327.2(that)-333.4(the)]TJ
T*
[(plasma)-480(concentrations)-482.8(required)-474.2(to)-478.1(produce)-482.1(this)-473.6(purported)]TJ
T*
[(proinflammator)-19.1(y)-271.5(effect)-268.4(could)-273.4(be)-269.3(achieved)-275.3(even)-269(with)-269.4(chronic)]TJ
0 -1.3189 TD
[(dosing.)-740.9(Similarly)71.7(,)-733.3(another)-736.7(study)-736(has)-737.6(shown)-734(that)-735.1(PDE4)]TJ
0 -1.3256 TD
[(inhibitors,)-708.9(at)-701.6(concentrations)-710.4(that)-701.6(are)-700.4(pharmacologically)]TJ
T*
[(relevant,)-585.1(delay)-581.4(apoptosis)-591.1(of)-577(neutrophils)-592(and)-579.8(eosinophils,)]TJ
0 -1.3189 TD
[(an)-313.5(effect)-308.6(that)-313.3(increased)-310.8(when)-309.1(combined)-316.8(with)]TJ
/F6 1 Tf
21.5974 0 TD
(b)Tj
/F2 1 Tf
0.5557 0 TD
(2-adrenocep-)Tj
ET
q
1 i 
309.43 725.953 235.899 -119.792 re
W n
0 g
q
236.1588 0 0 119.8074 309.4412 606.1475 cm
/Im2 Do
Q
Q
BT
/F1 1 Tf
7.9702 0 0 7.9702 307.8424 593.2345 Tm
[(Figure)-519(1)]TJ
/F4 1 Tf
5.0361 0 TD
[(Line)-514.9(graph)-524.8(drawn)-514.6(from)-523.7(data)-518(presented)-516.5(in)-529.5(Table)-515.2(2)-523.4(o)0(f)]TJ
-5.0361 -1.1239 TD
(Robichaud)Tj
/F5 1 Tf
4.9934 0 TD
[(et)-311.5(al)]TJ
/F4 1 Tf
1.8708 0 TD
[(.)-313.6(\(1999\))-311.5(showing)-311.2(the)-313.8(number)-309.4(of)-310.6(retches)-310.9(\()]TJ
/F1 1 Tf
18.5084 0 TD
(a)Tj
/F4 1 Tf
0.5406 0 TD
[(\))-314.6(and)-308.5(the)]TJ
-25.9132 -1.1239 TD
[(percentage)-370.6(of)-381.8(animals)-379(who)-375.7(retch)-380.9(\()]TJ
/F1 1 Tf
15.5991 0 TD
(b)Tj
/F4 1 Tf
0.626 0 TD
[(\))-385.8(i)0(n)-380.1(response)-372.5(to)-379.6(increasing)-375.6(p.o)]TJ
-16.2251 -1.131 TD
[(doses)-336.1(of)-339.1(PDE4)-336.7(inhibitors,)-334.2(PMNPQ)-331.1(\(open)-339.8(circles\),)-329.9(R-rolipram)-334.4(\(closed)]TJ
0 -1.1239 TD
[(circles\))-336.4(and)-344.1(CT-2450.)]TJ
5.9774 0 0 5.3127 386.5322 560.9196 Tm
(1)Tj
7.9702 0 0 7.9702 389.9338 557.3479 Tm
[(Inhibitory)-339.9(potency)-339.2(\(IC)]TJ
5.9774 0 0 5.3127 468.1133 556.0439 Tm
-0.0001 Tc
(50)Tj
7.9702 0 0 7.9702 474.9731 557.3479 Tm
0 Tc
[(\))-343.1(for)-344.6(these)-336.3(inhibitors)]TJ
-20.9695 -1.1239 TD
[(against)-605.5(human)-608.4(cloned)-608.9(PDE4)-607(subtype)10.7(s.)]TJ
5.9774 0 0 5.3127 457.7385 551.9621 Tm
(2)Tj
7.9702 0 0 7.9702 461.1967 548.3904 Tm
[(Concentra)12.2(tion)-610.3(of)-616.5(PDE4)]TJ
-19.241 -1.1239 TD
[(inhibitors)-362.1(measured)-365.1(in)-373(homoge)12.1(nates)-367.7(of)-367.5(whole)-366.4(brain)-366.7(and)-365.4(in)-373(plasma)]TJ
T*
[(1)-167.8(h)-398.6(following)-386.3(systemic)-396.6(administra)10.9(tion)-396.9(of)-396(drug.)]TJ
5.9774 0 0 5.3127 476.3337 533.9904 Tm
(3)Tj
7.9702 0 0 7.9702 479.792 530.4755 Tm
(IC)Tj
5.9774 0 0 5.3127 487.3322 529.1149 Tm
-0.0001 Tc
(50)Tj
7.9702 0 0 7.9702 497.3101 530.4755 Tm
0 Tc
[(values)-399.1(against)]TJ
-23.7721 -1.1239 TD
[(whole)-259.7(blood)-254.8(tumour)-259.4(necrosis)-259.6(factor-)]TJ
/F6 1 Tf
15.9334 0 TD
(a)Tj
/F4 1 Tf
0.818 0 TD
[(\(referenc)11(es)-264.4(cited)-254.4(in)-259.2(Robichaud)]TJ
/F5 1 Tf
-16.7514 -1.131 TD
[(et)-581.8(al)]TJ
/F4 1 Tf
2.1411 0 TD
[(.)-583.9(2002b\).)-578.1(CT-2450)12(,)-583.9(\(R\)-)]TJ
/F5 1 Tf
11.2957 0 TD
(N)Tj
/F4 1 Tf
0.7327 0 TD
[(-\(4-[1-3-cycl)12.1(opentyloxy-)8.6(4-methoxy-)]TJ
-14.1694 -1.1239 TD
[(phenyl\)-2-)12.2(\(4-pyridyl\)eth)10.1(yl]phenyl\)-)]TJ
/F5 1 Tf
15.3928 0 TD
(N)Tj
/F7 1 Tf
5.5789 0 0 5.5789 436.4219 506.4377 Tm
()Tj
/F4 1 Tf
7.9702 0 0 7.9702 438.4062 503.5463 Tm
[(-ethylurea;)-546.6(PMNPQ;)-552.2(6-\(4-pyr-)]TJ
-16.3815 -1.1239 TD
[(idylmethyl)10.6(\)-8-\(3-nitro)8.9(phenyl\)quino)10.3(line.)]TJ
ET
1 i 
50.797 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 179.1496 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-325.8(and)-335.3(respiratory)-326.4(disease)]TJ
/F9 1 Tf
15.1373 -1.2519 TD
[(D)-337.9(Spina)]TJ
7.0982 0 0 9.4646 50.7968 751.8612 Tm
0.0001 Tc
(312)Tj
ET
50.797 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 50.7968 31.2378 Tm
[(British)-331.9(J)0.1(ournal)-324.5(of)-334.4(Pharmacology)-320.4(\(2008\))]TJ
/F1 1 Tf
17.6049 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi5 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
50 29 142 10 re
f*
0.619608 0.619608 0.619608 rg
n
50 752 14 8 re
f*
0.619608 0.619608 0.619608 rg
n
178 761 112 8 re
f*
0.619608 0.619608 0.619608 rg
n
269 751 21 7 re
f*
0.619608 0.619608 0.619608 rg
n
574 7 13 454 re
f*
0.6 1 0.2 rg
n
309 605 236 124 re
f*
0.4 0.698039 1 rg
n
306 493 241 109 re
f*
0.6 0 0.298039 rg
n
50 594 239 133 re
f*
0.6 0 0.298039 rg
n
50 235 239 359 re
f*
0.6 0 0.298039 rg
n
50 56 239 177 re
f*
0.6 0 0.298039 rg
n
307 359 240 110 re
f*
0.6 0 0.298039 rg
n
307 56 239 300 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 717 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 584 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 223 cm
BT
1 0 0 1 0 0 Tm
(3) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 547 719 cm
BT
1 0 0 1 0 0 Tm
(4) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 592 cm
BT
1 0 0 1 0 0 Tm
(5) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 459 cm
BT
1 0 0 1 0 0 Tm
(6) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 346 cm
BT
1 0 0 1 0 0 Tm
(7) Tj
T*
ET
Q
Q


endstream
endobj
222 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
223 0 obj
<<
/BitsPerComponent 1
/DecodeParms <<
/Columns 984
/K -1
>>
/Filter /CCITTFaxDecode
/Height 500
/ImageMask true
/Subtype /Image
/Type /XObject
/Width 984
/Length 4993
>>
stream
š2ÈHPƒ ˆùôÓOé#[è)$ß­Mú×øèˆü |œ%ıæŒÏ™À“‰ÿşjë¯šœ_>9ÍÒ/ÿn-ôE¾Ç÷ùĞ[hK‘sñzí&Òé¿—ĞO†)ŠëÒÛ¾´şø%[íDÂCıûÿA}£ÿèŸ^'şû®#úÈHòÜ b×i¯ıŞÂü·0â¹	•ÍAëáıtc¿äœ.A¾±/L<¯oMoñÿ"Q»ÿ§ÿ¤xÿô³¨†Ëÿ~©ÿÃYÎ|ú­&ÿâ9ïÿˆÿ"™Å.>Húk·ëı/¶Óÿÿ·ÿşëjÿ‚#ÿı†ÛR¶—ıˆĞ¦+ó Ff|4kó!]4ó#A‘X•ÑıQ¡£CÂaô›I¾ÓNLÿºMÓèœ4Óÿÿú:iÈœnüÊ‘»ÿêï¤ÿ­ÿæ‚n‡§ÿOÿ_¿ÿ	?ûëõşÒÿó£½q¥µı¿ÿı*ìWìR_şZj×î¸m&ÒĞªj?´ÒqLVI©=ìG5¢V‘paSÕ1ĞB˜A™Yá$©7 Óô’ï§p°‚K®‰ÃZĞI[KA9ÜÆJÅ{`·¤¶ºp¨‚-Â	(ë¢>¾‚Jv>p¿@±ÂIH”nTöÕ'ÒK¦¨Öÿª2ÈâÂ	-#½PMí¤“I§¤—IàˆşúA„ÃxA%¿ÿ×j¯ÒJilj—åK%«oĞUI6’Kı&á$´Œñ¿ÒuØmøA%nµ<Ôé}¸ô’·çA#õëŠĞIb”ÓLˆdÒüÂICP©¦›KK\t’ˆˆí‘ô¿¯$»Z_™@¤”6…­/×$©Ù¨‡2	ë¾’Ğ"<Úzi~eHõ„ZoFÇéu¤ú	.ı7™?ÿÂI[ÿÚK^²)4ŠŸGjJÃoßÒşıp‚R ‹LE0Óÿ­´ˆ×0ŠIpÒ ÀWKö)/$¸ş—á¯#ÚK7cş¸¬^‚Oy8OKô¥Ã4%ıN‘¿ë®¶Õ/èÀÃ¿_Ì{p‚ÿS½ı/Õ!rCAöÿÿFøIõ·ÿ¥ÿøJ£··úıµ]—07®»Ñœ–‚K¸1__¶“•˜I,ĞZõë‡Wk4’¥úˆèBK“ç?¯ÇDİ%ÖÉIŸ/_ôƒ	%¤è4ş¿é¤½hùF·ë®dAtÚU¼t›ô¿	ë¥ßéÿzÑ¹ş—o3Fÿı%ô›İR[¿åt¡Ù[¯½.Õä™ªykÚIqoÿÒé[KcJ¬†üÔş½Šé%š'ÿÒ4ÒK¦àô±®Xá%TCé*i~wÔt….š†Òô“ô’á˜,SÿFEBô—¦šô½=R[’f#é‘h¾zIqOõêô’ª>?Kéı.OI7õ«~’^ï^¯ÒK Dy½}/!V’KI½´¿õô¾ûé MGH%Vı¯«ı$»¼xşŒ”ÿIq@És"¦™PÙi„—¼5®"=§¤UG¥úŞsŸ’_¯­é7érŸÿÛü÷ÒUú^¬kÿK©òHëiı4”¸ùñO¦’zöš¦ı£ğ¨-=ÔEÿt¾µéëCù!¥­ÿ¿Ìc‹ÿkôÃ!ñkêúé=QÃ!tişé EöÈM[KJ»óãGçúõ|S¤×JõĞimá¦¼0ÖÁ;ïøC¿ÒdN7ÿ¥Ó¿KéÚù@ˆ±Ö“ë7ë_t¿Úğk¯^Şı&:Òÿø%á”ôƒJ@µ/ğÛtQëõn4ºæAo¯àÅSiiRéYMu! WË*&$«I‡ÇkJ©ÎÈ…éÔGKM„›zH>EKKAµŞ’/WÓ×M¦¤:Ş‚L>±çe!„´ó±uH6º¯èt’aıı-?ÒIˆ}s²Ö—ÿIûî—¹z¤ö×ÒéI ÉæLş»ïé?ôºÉ[ı'ãõ¿YØ³ÒKş–Âü'¤—È˜OKkùíé%õô¶¾ÿÒüæ}-ü‰ÿ¤”Ò×óºßéo×ÿ`Ø¯KÈBHA×üÔ°mi$5ĞiîDÈàM$³™ÓKÿV&–’_DìWúd{;IOa/ šÿ<ì»¿¤•²/küŒøA°}ÏID(Š}‘`zç¸?h"¥ôl~—éÈ0.ĞJ/MúùÙNEú[n’_ûş4Ç$.Hi%"A(+ùt¾A/Òÿ«øıb‚ô’’¿ş¿öXá —IÿÁ/üeÈtP’Ò	Î¬ÿêB@¯Jÿá,ÿíi%_ğ@¿ÿÒJD‚v–/ÿúKI±X@¿ÿÕ(íaş?ÒJ#‚÷¯¤R&¼‹ƒåÒ®/ßô’Îgó½é%ğ@¼jh-÷¤•¼ ¿ë.é[Âšë¤–ğ@ˆĞ`¤úH(D)$_ëI_Wş¡(áµ¯I.#/ÁOÒJRF«/Ò¶–&=$†–"¸«5†4’¶–zA(1X ­¯KX@Šå æ»I(á_I.'ô’à‚ÒœğzH*y20ô‚Thx@—ô¨&ô™KÁ$»è›åÓ§‚—úœè×Ò2¡oÕ&ôÒù8‹ùØ¨=7ËÇ_­ÿı'—ÿ×ÿçÄ§ÿ°µö½%ÿâİxÿÿı_ñö“Uû_±Lqı¬pÓ´›	q'm&)â,SUh0†#ÿó³ 3ÚtÌ“˜(ªy`Ë ¿.Ë³9c–9‡,dfÂàĞXä8C_—dàĞg0æ°e_—eÁnXôûÕ?µÓıu3˜~ô×ı=S»³–\´åÙp[–9c˜s-ùv\åCƒ-ùv\åCƒ-ùvMËrÇó±ÙxìDv^­İÿıİß™Ì=ß~¤Qîû_,ÿß÷i¯úö·Ùİ[Ó]ÿñÅ¬Zi¦‡ki­¦‡|E¢%iéßÎÆGc!â"#ÿÄDGÎÅŒfy32;ÕÖ™İçÌùÓMSTÕ5M:5´{jmUQñèöÑñ©ŒœäÈŠ#²3°óÃ;<GŠ“&İ&İİ&ô›JÓ	ªjªš¦´é½ÿt7=›ú67ÜÑùÿÿÿÿ¾·I½Şéºoÿÿÿÿÿÿ¿ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ¯ÿÿÿÿİ	µí#ÿÛ[_ÿÿÿşÚVÚJÚWkl0–ÚM¥ÿëÿö•ö+b­ŠÓM6)6)Šm @›Km#Ú[­¥jšÚªjšÚiŠ¶4Ø®ÓMŠMŠb¥ !Ó[ZöÒ´Ôµÿü·>m<‘®3UşšZ[xi~ŞqÃ¯òn"1“<‘ıvÉ±Š´¶ølÎ>g,ã>fƒ#Ç, Ûƒ	}´Õ?M8´üæƒç_¿l#CFŒñôxh÷í5¤ÿún…IÒúªÒÒ¯Û3ŒÙÆ–r3dè¼^<id†ßıƒI/ÿÿ×	†ÓT¦ši¥œA6ÿíĞKÿÿú‹ÿmÚ;ç EôhlÎghÑôç‡ÿÃlWÿÿéAÿİ&Òı&ĞZUIih$Ÿë«ÂûÿÿJzÿ¼:_¯ëë\%ÿA6‘Hßí¥¯úÿ¯şH ¿ÿÿâÿ±±Q±ûÇ÷÷_á½/ÿÿÒ‚#ßØM4×´ÁúÚ`kv¥¯·¿ÿÿJëÄD[DGÄGô­#£¶ºÿ­mÿaøéE1Qà¾Ä(şØÿ+j©$Ği Å{A‚#ÿLKmÒ¹ ‰4*ĞKa4i±i¬DZñgñB¤(DDlGm4ÓkŠIDD6’IT³KŒ«"¬«UCÿù bxÿ–uS;9hUdåC:™Ó*nT3»Ê•2qœ‰Âe3ŒĞ!¤pŠr8ÉÂf„Fó4id.²å‹yqé`#b)C3.ó½ÁÚkpínáÚ…¸v°áÁYIƒğWƒşœ4¬.æ}Ï¯™óæ×3¹áÃŸ\Ï™İÍ¦áó;ÿ™ûçëyùQı3ĞßA¹à?\7†´Ãs8~“Xyà:”>xwÃc¥á½A^üRëªnÿ·£¿Ãzÿá½#éíëá¼7şÿÁÖÿÔd[¿ı¼ÜºGÿo1N?]wÌ5ÿß7/·¹æxÏ©¼Î¼¼G< ¿ÎÃ/‘Â?ÿ#‘ÏÒ‡ïÂïZ^»Å¯®»qu¥®‹ıöÂ(OÕO‹ázé…BÓşw|a__—¼Vßô±]éqQ[ëñ]õíî[´hñRcÂ.<›ù˜­(·É[Â.9}·óÀı*¿õòSZ­|”ÿ_%5Õ|”×ÿ½5¯×__õıu]{]7Í4×Õëç@¸ºø$.ëç@¾¾tÿ­ƒ®5_^=uÁ××ß_ö?ùÏõDŸıÏnzWO‚ı=uö.kãÿüì?ÿö?ÿõş–ğ_¥Öÿï^–Ö—ùúµÿÿşzÿÿ¯£Ù¿úæ½o×5ZøK5öŸ¥šít­Kª¥õÿÿûÈûÿïÿ¶¶­¤ş*BQÓñR˜®9	KÇ!)ŠŠBØ®+bÿÿ?âÿ}´Ë§68¦4½~şım}tÿT×Ó¿ÿí‘Çûïn±MRÜ0ƒM5M	Úaa„ÖMM0ƒL ÖÂ¦ÓM{[-ÓÓMg^ÓM…t&k–…\­ùßÇf1°Á`Â°Òß«¥-E¿&Ê3(RºÎv_TÎÄó"ÈĞ¥Ä>EÂ2£=Û©ËĞÒ5ç“zµ Ÿmé.é*mÒi™óĞí[ê¶ëıi=ÚMûé.é{Qˆ{ŸË¿÷9˜Ë³ÏÍ£ÆFEÿúºîÖúèiÖš…AùäqZ—Í×o¨µ]$ÁUµ»@ˆúİı*oäß÷ß&9oF‡ZH¸Ëz4ãıU}]p¡ik^ô?ö¿ü­ÆŞ=¥ÖÁ¯ú3Šÿı¯ÿÿëŞ ßÿ[óÙ^¿¯ÿô¦ïÿÿıµ´­}_ÿí}‡jCÜÂ³êµöÁ8Ø¯İ´¯ö:İ4ØÒ}Uî¾&}/¿ì±ÒîÌóXkâ÷]æÖ¶"#Ğˆøˆ­Ê¥õ¸ˆ¥ãÒN¢#VL5	*L5Jôé/Nõ,b•c
¢?ÎÂ€ÌŒ’€ÌÿÿÿÍfh#ù:0dæUY8©GHğ„²:e‚GHĞÌ‡ÎÊY«3Íc¦fÂGXàJkw¦i„ì&Pš¨L&TÔ&TÂa?w}Úi§I§¦ªši¨MSMU4ë4=oš7´h£\FŒöæ
4=Q£=¹¯Í{hÖÕQ­Ím‹mıû¤Ú··JW¢9¤Øm^œ:M D~½ÁÃî“Ñÿ÷ıték]\CßIÒí}×¿«[ˆ}S‚#ó¿Õ[­ô¿ú_ÿØ¯ëJ¿ö¿¥GşïÖ¿ÿş]¿ÒÿßõÂÿÿË·ŠooŠÿô¿ëÿÿ×úëÿşŸPDröúÿÿüÒ¿ôhª ¿ÿÇÍE¾ß7³Ÿë×ÿüCÿ§ıiÿÿşÿ¾Õµõ´»_Ö×ıt­~Òµ^µxcÛm&ëÕ¿Ëéu“Íïß¶‘Ó®¿ú/×ßßaÅZ˜ÛI&Ò7¶”5mLKV‘½´µíL^ÚFôöÒ7¶•…û¾ûÅq\lS ö+Š6+äD¡á0ƒŠÕwO‡kjšÃL&«ÚÃL-§é­è5†˜QÚ¢U˜á¸ˆİíG”¥5» óİ™˜‡f¡Ä+,Í”¬É^vÍYó&lèÊ3º™ÑæwØMuÂj¡5	¦Biöö­÷´ÕS[M5´ûyŸ=çß›S™hú.;+5´kèÑF·Ü£/yGe9|]”åY:‘ÎE¡Î.ğôÚGÇİ­#í;_âÓîã	ÄZ±pá¥¯î–©Xë?X"<æwG‘ŸGÁ)q“ŒœAR¯¥ğKÖ•RëZÿOZO3…¤“tİ6T¿×KÂ¥„‚âª¿Ş«Zğm®ºÁĞ_ı`ş‚İ$ÿãÿ¶8ã¶’şë·é*¤–Çÿş¿ßöÒBj„6ı$!¤–gÿ×·ÿÿKÿÛJ´’á½´¿K×ó\§%&’GäŠ­Tvkí¤tÍÕéº®üÅÿi;´¬(#»[[îÔÅ¶­¤oüŸôí0ºª`ˆÿ[Å1\S"-BlWÅ1\„D¼„Ø¹ŞdÌöaí5°šÚk–a¿ÿ Ì¸!”fÄ>È»$3¾dáI&uÊË'eÆ}3¡Ÿ3±ó®pC½Y8¸MS	„Ó	¨U	á0˜L&i…PÕ’&­&˜@ˆò,vÉ°’,vÌ:´Ñc»Õ&“¬Ñ?Œ÷çA¯5à› ãK
ƒ¤e]5á9¯FÎ‚FØÃ^}…¤8ºGò9¥jÚºMĞ:I\‰$Rm[ıR‘v_"ì­-W‹Ş·ıUií~µmgPûúUÉ»ú×¯ÑWÉÄ%ş	Fº"Ù7¬·t°«Â÷ı.Ói«UÃ ØJƒAW_ı…ÿšßÖÿƒ¢ÇkÍšÒ¯ç†’ãÿ±^—Oãßûtéu‚úHCõµ`ˆı­k¿ŞôèCı/ã_÷ÿ®Úÿí^©UÎ}³¶“¤a$ÚFÒ¹ÅjÚFÑ‰#(¾›HÚ7*äÒSµ/%“¢òãäSØ¨ã´£º
¬U­ÇØ[TØ¦ucc‘-¶	Zïi¦³Ö¨>˜¬4ÓÄ.˜¯¦½Š†VÂh5I5M5†š¦M;A¦a¦ì)Œ´œ7  

endstream
endobj
224 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
225 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 426
>>
stream
H‰ìWQr… ôşÌu:ÓÖ÷’°›ÚN›d³»B@‘¿‡ÒÈµÏÁGé'Sõ¤ºªágÛØEÅÉ uhˆ¾î|dè÷1bpD@|ú|¦P±ãjØaïÍ¯/âà˜Gâ9åğ¥ˆTÈèôø,³†OåòâF¨ï¯uãä+¬Bµ™?C¾I&”E¤Û”MÎéE5©
sHZ‚Ğ7ËìáúAô¤ŸÉÍ=”úõO#‘ÖÆ~˜r®r¢{õEu-¤qR¬iF¢éRµ¬‹’áè…I$í˜Zoê®ŠÄ¶ '|B¡÷¥­•èMêDå¡’«ëÃŒ:ÑêH·ìÙ¥Vúd´k¾|¢ûİ.-H]$ ²&,®.GâcŸšaÎê\%KlU—%·mˆt	+:–©ggÁ’S4J~n¨™…šA…bÇÖY Ê‰uŸOT]Ê‰vÕôıhR÷©3Ç¶Iq7ş#€G=è>Ÿ¸ºààŸ L]@ªdëüN‹}"Ó¹h‚-ÿ7¨›àÄÎ«Ôm·02uÿ±.> ·¯.k
endstream
endobj
226 0 obj
<<
/Annots [ 227 0 R 228 0 R 229 0 R 230 0 R 231 0 R 232 0 R 233 0 R 234 0 R 235 0 R 236 0 R 237 0 R 238 0 R 239 0 R 240 0 R 241 0 R 242 0 R 243 0 R ]
/Contents 244 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 245 0 R
/F10 246 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F7 45 0 R
/F9 55 0 R
>>
/XObject <<
/Xi6 249 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 250 0 R
/Type /Page
/Parent 2 0 R
>>
endobj
227 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib60)
/Rect [ 108 717 204 725 ]
/Subtype /Link
/Type /Annot
>>
endobj
228 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib24)
/Rect [ 54 661 131 669 ]
/Subtype /Link
/Type /Annot
>>
endobj
229 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib30)
/Rect [ 136 661 236 669 ]
/Subtype /Link
/Type /Annot
>>
endobj
230 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib29)
/Rect [ 147 492 287 501 ]
/Subtype /Link
/Type /Annot
>>
endobj
231 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib40)
/Rect [ 115 481 246 490 ]
/Subtype /Link
/Type /Annot
>>
endobj
232 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib47)
/Rect [ 54 392 117 400 ]
/Subtype /Link
/Type /Annot
>>
endobj
233 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib63)
/Rect [ 183 392 258 400 ]
/Subtype /Link
/Type /Annot
>>
endobj
234 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib84)
/Rect [ 263 392 290 400 ]
/Subtype /Link
/Type /Annot
>>
endobj
235 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib84)
/Rect [ 51 380 97 389 ]
/Subtype /Link
/Type /Annot
>>
endobj
236 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib58)
/Rect [ 270 291 290 299 ]
/Subtype /Link
/Type /Annot
>>
endobj
237 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib58)
/Rect [ 51 279 123 288 ]
/Subtype /Link
/Type /Annot
>>
endobj
238 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137tbl1)
/Rect [ 54 235 84 243 ]
/Subtype /Link
/Type /Annot
>>
endobj
239 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib6)
/Rect [ 169 201 226 209 ]
/Subtype /Link
/Type /Annot
>>
endobj
240 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib35)
/Rect [ 123 179 250 187 ]
/Subtype /Link
/Type /Annot
>>
endobj
241 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib75)
/Rect [ 240 123 290 131 ]
/Subtype /Link
/Type /Annot
>>
endobj
242 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib75)
/Rect [ 51 111 70 120 ]
/Subtype /Link
/Type /Annot
>>
endobj
243 0 obj
<<
/Border [ 0 0 0 ]
/Dest (bm\137bib11)
/Rect [ 86 55 194 64 ]
/Subtype /Link
/Type /Annot
>>
endobj
244 0 obj
<<
/Length 20361
>>
stream
q
q

BT
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(tor)-621.9(agonists)-619.4(\(Parkkonen)]TJ
/F3 1 Tf
12.3519 0 TD
[(et)-619.1(al)]TJ
/F2 1 Tf
2.2093 0 TD
[(.,)-623(2007\).)-621.8(However)39.4(,)-619.5(t)0(o)-618.6(what)]TJ
-14.5612 -1.3256 TD
[(extent)-302.3(these)-294.4(findings)-300.5(translate)-302.4(into)-300(the)-296.6(clinic,)-298.8(particularly)64.7(,)-298.1(i)0(f)]TJ
T*
[(combined)-437.3(with)-436.7(bronchodilator)-438.4(drugs,)-439.3(remains)-434.6(to)-437.9(be)-430(estab-)]TJ
0 -1.3189 TD
[(lished.)-440.3(The)-439.2(clinical)-444(evidence)-439.3(suggests)-441.9(that)-440.5(PDE4)-435.2(inhibitors)]TJ
0 -1.3256 TD
[(suppress)-506.8(and)-506.2(not)-504.9(exacerbate)-505.3(inflammation)-509.4(in)-504.8(the)-504.2(air)-11.4(ways)]TJ
T*
0.0001 Tc
(\(Gamble)Tj
/F3 1 Tf
4.3382 0 TD
0 Tc
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9214 0 TD
[(.,)-335.2(2003;)-339.8(Grootendorst)]TJ
/F3 1 Tf
10.4305 0 TD
[(et)-337.9(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2007\).)]TJ
/F3 1 Tf
-18.6182 -3.97 TD
[(PDE4)-339.1(inhibitors)-341(and)-334.3(the)-335(future)]TJ
/F2 1 Tf
0 -1.3256 TD
[(Although)-794.4(there)-784(is)-788.3(cause)-788.1(for)-787.8(optimism)-786(concernin)-10.4(g)-784.6(the)]TJ
T*
[(potential)-710.3(therapeutic)-705.1(utility)-709.5(of)-704.2(PDE4)-703(inhibito)-10.2(rs)-701.9(for)-707.5(the)]TJ
0 -1.3189 TD
[(treatment)-324.2(of)-315.9(respirator)-16.9(y)-318.3(diseases)-319.2(such)-318.7(as)-322.5(asthma)-318.2(and)-318.7(COPD,)]TJ
0 -1.3256 TD
[(it)-337.3(is)-333.1(clear)-334.5(that)-333.4(further)-337(improvements)-339.2(are)-332.2(requi)-8.4(red.)-328.8(Strategies)]TJ
T*
[(at)-433.8(improving)-433.5(the)-437.2(risk)-427(to)-437.9(benefit)-433.1(ratio)-429.2(will)-435.3(be)-430(important,)-441.5(if)]TJ
0 -1.3189 TD
[(this)-312.9(drug)-312.9(class)-313.8(is)-313(to)-310.7(be)-309.5(widely)-316.4(used.)-309.7(The)-312(therapeutic)-316.8(window)]TJ
0 -1.3256 TD
[(for)-359.3(anti-inflammator)-17.6(y)-358.5(action)-358.7(of)-356.1(these)-354.6(drugs)-362.1(and)-352.2(side)-360.4(effects)]TJ
T*
[(such)-358.9(as)-356(nausea)-352.1(and)-358.9(emesis)-356.6(is)-353.1(probably)-356.6(not)-357.6(wide)-357(enough)-356.3(for)]TJ
0 -1.3189 TD
[(cilomilast,)-402.9(and)-392.4(may)-401.1(limit)-399.7(the)-390.4(use)-394.7(of)-396.2(roflumilas)-12.4(t)-394.9(i)0(n)-391(asthma.)]TJ
0 -1.3256 TD
[(There)-906.5(are)-901.3(PDE4)-903.9(inhibitors)-906.2(currently)-900.2(in)-906.5(development,)]TJ
T*
[(which)-965.5(appear)-957.3(to)-966.8(lack)-962.1(significant)-959.1(emet)-7.7(ic)-959.7(action)-961.3(\(for)]TJ
T*
[(example,)-825.1(oglemilast\))-829.6(\(Glenmark)-823.1(Pharmaceuticals,)-824.9(2005\))]TJ
0 -1.3189 TD
[(and)-285.2(IPL512602)-291.7(\()5.9(Inflazyme)-291.9(pharmaceuticals,)-284(2005\),)-287.1(although)]TJ
0 -1.3256 TD
[(the)-336.8(molecular)-338.8(basis)-333.6(for)-332.6(this)-339.7(has)-329.3(not)-337.5(been)-331.7(published.)]TJ
1.0042 -1.3256 TD
[(Most)-292.3(PDE4)-294.6(inhibitors)-297(under)-300.4(development)-297.1(are)-292(designed)-295.4(for)]TJ
-1.0042 -1.3189 TD
[(p.o)-801.6(administration,)-809.5(however)40.6(,)-800.2(the)-798.7(inhaled)-801.5(route)-800(would)]TJ
0 -1.3256 TD
[(deliver)-570.6(PDE4)-569.1(inhibitor)-569.1(directly)-568.1(to)-571.8(target)-567.6(cells)-571.8(within)-566.6(the)]TJ
T*
[(lung)-782.5(and)-774(thereby)-773.7(minimize)-781.1(systemic)-779.5(absorption)-780.5(as)-777.8(in)]TJ
0 -1.3189 TD
[(the)-584.5(case)-585.4(of)-583.7(A)77.8(W)-0.1(D)-583.8(12-281)-589.4(\(N-\(3,5-dichloropyrid-4-yl\)-[1-\(4-)]TJ
0 -1.3256 TD
[(fluorobenzyl\)-5-hydroxy-indol)-18.8(e-3-yl]-glyoxylic)-851.7(acid)-843.2(amide)]TJ
T*
0.0002 Tc
(\(Kuss)Tj
/F3 1 Tf
2.7516 0 TD
0 Tc
[(et)-304.4(al)]TJ
/F2 1 Tf
1.9013 0 TD
[(.,)-301.7(2003\))-310.3(or)-300.7(UK-500001)-311(\(Phillips)]TJ
/F3 1 Tf
14.7888 0 TD
[(et)-304.5(al)]TJ
/F2 1 Tf
1.8946 0 TD
[(.,)-308.4(2007;)-306.3(V)55.2(estbo)]TJ
/F3 1 Tf
-21.3363 -1.3189 TD
[(et)-491.9(al)]TJ
/F2 1 Tf
2.0888 0 TD
[(.,)-489.2(2007\),)-494.6(although)-496.1(clinical)-497.5(trials)-491.6(in)-491.4(respirator)-16.9(y)-492.4(disease)]TJ
-2.0888 -1.3256 TD
[(have)-312.5(thus)-312.2(far)-315.1(been)-311.6(disappointing.)-320.2(Nonetheless,)-313.5(the)-310(develop-)]TJ
T*
[(ment)-434.1(of)-429.7(a)-434(potent,)-435.3(long)-428.6(acting)-437.5(PDE4)-435.2(inhibitor)-428.5(through)-437.7(the)]TJ
T*
[(inhaled)-366.3(route)-358.1(would)-366.3(offer)-359.8(a)-360.3(solution)-363.3(to)-357.5(the)-363.6(issues)-361.9(of)-362.8(emesis)]TJ
0 -1.3189 TD
[(and)-285.2(nausea.)-282(Another)-285.2(approach)-288.3(might)-282(be)-282.7(the)-283.2(use)-280.8(of)-282.4(antisense)]TJ
0 -1.3256 TD
[(oligodeoxynucleotides)-827.6(targeting)-825.9(PDE4,)-820.4(which)-824.9(could)-822.3(be)]TJ
T*
[(delivered)-397.1(by)-398.1(the)-397(inhaled)-399.8(route,)-395.1(and)-399.1(in)-397.7(view)-395.6(of)-402.9(the)-390.4(positi)-8.9(ve)]TJ
0 -1.3189 TD
[(results)-329.2(obtained)-332.2(in)-324.1(the)-323.4(successful)-334.8(targeting)-330.5(of)-322.6(the)-330.1(adenosine)]TJ
0 -1.3256 TD
[(A1)-280.8(receptor)-279.4(in)-270.5(a)-280(rabbit)-277.9(model)-277.5(of)-275.7(allergic)-280.8(inflammation)-281.8(\(Nyce)]TJ
T*
[(and)-245.1(Metzger)38.3(,)-237.9(1997\),)-246.9(illustrates)-246.1(the)-243.1(potential)-241.6(of)-242.3(this)-246(approach.)]TJ
1.0042 -1.3189 TD
[(Another)-412.4(reason)-411.1(why)-411.1(targeting)-417.5(PDE4)-408.4(alone)-414.8(may)-414.4(not)-411.2(fully)]TJ
-1.0042 -1.3256 TD
[(resolve)-300.1(air)-11.4(way)-296(inflammation)-308.5(is)-292.9(the)-296.6(fact)-298.1(that)-299.9(other)-296(PDE)-304.3(types)]TJ
T*
[(exist)-720.4(in)-719.1(structural)-723.3(and)-720.4(inflammator)-21.2(y)-720(cells)-719.1(in)-719.1(the)-718.4(lung)]TJ
0 -1.3189 TD
[(\(T)58.3(able)-578.7(1\))-580.3(and)-579.8(therefore,)-579.9(targeting)-584.9(multiple)-583(PDE)-578.8(enzymes)]TJ
0 -1.3256 TD
[(may)-414.4(be)-409.9(required)-414(for)-412.9(optimal)-417.3(anti-inflammator)-17.6(y)-412(action.)-415.8(For)]TJ
T*
[(example,)-356.4(the)-350.2(macrophage)-357(is)-353.2(viewed)-356.1(as)-349.3(a)-353.6(critical)-350.7(cell)-355.2(type)-352.3(in)]TJ
T*
[(the)-544.3(pathogenesis)-548.5(of)-543.5(COPD)-543.7(\(Barnes,)-540.9(2006b\);)-547.6(however)40.6(,)-545.8(the)]TJ
0 -1.3189 TD
[(activity)-372.4(of)-376.1(these)-368(cells)-371(is)-373.2(only)-370.7(inhibited)-376.2(to)-370.9(a)-373.7(small)-371.6(degree)-370.8(by)]TJ
0 -1.3256 TD
[(PDE4)-549(inhibitors)-544.7(\(Hatzelmann)-543.5(and)-546.3(Schudt,)-541.3(2001\))-544.6(and)-546.3(the)]TJ
T*
[(potential)-261.7(functional)-261.3(involvement)-264.2(of)-255.6(PDE3)-261.2(and)-258.5(PDE7)-261.2(in)-257.1(these)]TJ
0 -1.3189 TD
[(cells)-478.1(cannot)-476.6(be)-470.2(completely)-479.6(ignored.)-476.1(The)-479.4(inhibitor)-13.4(y)-472.3(action)]TJ
0 -1.3256 TD
[(of)-831.4(PDE4)-836.9(inhibitors)-832.6(on)-833(the)-832.2(cellular)-830.4(activity)-834.3(of)-831.4(CD8)]TJ
/F7 1 Tf
6.351 0 0 5.6449 283.918 150.8598 Tm
()Tj
/F2 1 Tf
8.4682 0 0 8.4682 50.7968 135.8929 Tm
[(T)-309.9(lymphocytes)-313.5(and)-312(macrophages)-312.5(was)-314.8(significantly)-316(increased)]TJ
0 -1.3189 TD
[(in)-491.4(the)-484.1(presence)-492.2(of)-490(PDE7)-488.8(selective)-492.5(inhibitors)-491.1(\(Smith)]TJ
/F3 1 Tf
25.5741 0 TD
[(et)-485.2(al)]TJ
/F2 1 Tf
2.0821 0 TD
(.,)Tj
-27.6562 -1.3256 TD
[(2004\).)-481.2(Similarly)65(,)-472.2(combined)-477.5(PDE3)-482.1(and)-479.4(PDE4)-475.4(inhibitor)-482.1(in)-471.4(a)]TJ
T*
[(single)-245.4(molecule)-251.8(offers)-248.4(the)-243.1(advantage)-242.8(of)-248.9(delivering)-246.5(a)-246.5(broncho-)]TJ
T*
[(dilator)-631.2(and)-626.7(anti-inflammator)-17.6(y)-633(substance.)-626(Moreover)34.3(,)-626.2(i)0(t)-625.2(i)0(s)]TJ
0 -1.3189 TD
[(likely)-291.8(that)-293.2(retention)-294(of)-289.1(the)-289.9(inhibitor)-301.3(within)-292.1(the)-296.6(lung)-287(may)-293.9(be)]TJ
0 -1.3256 TD
[(required)-387.2(to)-391(maintain)-388.1(anti-inflammator)-17.6(y)-385.3(activity)-392.4(within)-385.9(the)]TJ
T*
[(air)-11.4(ways)-338.5(\(Boswell-Smith)]TJ
/F3 1 Tf
11.1602 0 TD
[(et)-331.2(al)]TJ
/F2 1 Tf
1.9281 0 TD
[(.,)-335.2(2006b\).)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 307.8424 718.7526 Tm
[(Conclu)-11.9(sion)]TJ
/F2 1 Tf
8.4682 0 0 8.4682 307.8424 696.5857 Tm
[(A)-511.4(number)-505.8(of)-510(clinical)-510.9(trials)-511.7(assessing)-509.7(the)-504.2(efficacy)-512.2(of)-510(PDE4)]TJ
0 -1.3256 TD
[(inhibitors)-437.6(for)-439.7(the)-430.5(treatment)-438.1(of)-436.4(respirator)-10.2(y)-438.8(diseases)-433(such)-439.2(as)]TJ
T*
[(asthma)-539.1(and)-539.6(COPD)-543.7(have)-533.5(been)-539.3(moderately)-539.5(successful.)-545.9(The)]TJ
0 -1.3189 TD
[(dose)-487.8(limiting)-490.7(side)-480.9(effects)-491.7(of)-483.3(nausea,)-489.5(emesis)-483.8(and)-486.1(headache)]TJ
0 -1.3256 TD
[(potentially)-435.4(limit)-439.9(the)-430.5(utility)-441.7(of)-436.4(these)-428.3(drugs.)-439.3(However)39.4(,)-438.7(there)]TJ
T*
[(are)-399.2(examples)-408.8(of)-396.2(PDE4)-408.4(inhibitors)-404.1(that)-400.3(have)-399.6(low)-399.4(emetogenic)]TJ
T*
[(potential,)-285.3(although)-288.6(the)-276.5(molecular)-291.9(basis)-280.1(of)-282.4(this)-286.2(phenomenon)]TJ
0 -1.3189 TD
[(remains)-253.8(to)-243.7(be)-249.2(established.)-248.7(Other)-251.1(strategies)-249(including)-250.4(deliver)-14.9(y)]TJ
0 -1.3256 TD
[(through)-277.1(the)-269.8(inhaled)-272.6(route,)-274.6(development)-277(of)-269(subtype)-275.6(selective)]TJ
T*
[(PDE4)-435.2(inhibitors,)-441.1(use)-434.8(of)-436.4(mixed)-432.4(PDE)-438.2(inhibitors,)-434.4(interference)]TJ
0 -1.3189 TD
[(with)-282.7(PDE4)-274.5(activation,)-286.9(targeting)-276.9(proteins)-286.1(that)-273.1(are)-278.7(involved)-283.8(in)]TJ
0 -1.3256 TD
[(locating)-369.3(PDE4)-368.3(to)-364.2(specific)-360.9(microcellular)-373.8(domains)-370.3(and)-358.9(finally)]TJ
T*
[(the)-885.8(potential)-884.3(of)-885(antisense)-887.4(oligonucleotides)-890.4(may)-889.8(offer)]TJ
0 -1.3189 TD
[(another)-462.2(solution)-463.7(to)-458(the)-457.3(problem)-460.9(of)-463.2(targeting)-464.4(PDE4)-462(in)-458(the)]TJ
0 -1.3256 TD
[(context)-336.2(of)-336(respirator)-16.9(y)-331.7(diseases,)-336.1(is)-333.1(a)-333.5(cause)-332.9(for)-339.3(optimism.)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 307.8424 502.2424 Tm
[(Confli)-10.3(ct)-336.7(of)-333.7(intere)-9(st)]TJ
/F2 1 Tf
8.4682 0 0 8.4682 307.8424 480.0755 Tm
[(The)-332.1(author)-341.5(is)-333.1(a)-333.5(consultant)-336.1(for)-332.6(V)48.5(eronapharma)-338.1(plc.)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 307.8424 444.9826 Tm
[(Refer)-8.4(ences)]TJ
/F2 1 Tf
7.4718 0 0 7.4718 307.8424 425.0834 Tm
0.0001 Tc
[(Aoki)-321.7(M,)-321.4(Fukun)-10.4(aga)-320.5(M,)-321.4(Sugimoto)-327.5(T)75.4(,)-315.9(H)0(irano)-330.6(Y)98.8(,)-323.5(Kobayashi)-325.5(M)0(,)-329(Honda)-324.9(K)]TJ
/F3 1 Tf
1.1988 -1.1988 TD
0 Tc
[(et)-552.6(al.)]TJ
/F2 1 Tf
2.9971 0 TD
0.0001 Tc
[(\(2001\).)-559.5(Studies)-550.7(on)-556.7(mechani)-11.6(s)0.1(ms)-555(of)-551(low)-557.3(e)0.1(metogenic)-11.5(ity)-551.5(of)]TJ
-2.9971 -1.2064 TD
[(YM976)-11.6(,)-429.7(a)-423.2(novel)-436.9(phosphodie)-10.3(sterase)-430.7(type)-427.1(4)-429.5(inhibit)-10.8(o)0(r)75.2(.)]TJ
/F3 1 Tf
25.3879 0 TD
0 Tc
[(J)-433.3(Pharmacol)]TJ
-25.3879 -1.1988 TD
0.0001 Tc
[(Exp)-337.8(Ther)]TJ
/F10 1 Tf
4.287 0 TD
(298)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(1142–)-11.5(1149.)]TJ
-7.2689 -1.1988 TD
0 Tc
[(Aoki)-344.5(M,)-344.3(Kobayashi)-348.3(M)-0.1(,)-344.3(Ishika)-9.6(w)-0.1(a)-337.8(J)0(,)-348.9(S)0(aita)-342.3(Y)91.1(,)-338.8(T)60.1(erai)-349.1(Y)98.7(,)-346.4(T)60.1(akayama)-347.4(K)]TJ
/F3 1 Tf
29.7735 0 TD
[(et)-340.2(al.)]TJ
/F2 1 Tf
-28.5747 -1.1988 TD
0.0001 Tc
[(\(2000\).)-498.8(A)-496.6(novel)-497.6(phosphodie)-10.3(sterase)-491.4(type)-495.4(4)-497.7(inhibitor)34.1(,)-490.4(YM976)-497.2(\()0.1(4-)]TJ
T*
0 Tc
[(\(3-chloroph)-14.2(enyl\)-1,7-dieth)-12.4(ylpyrido[2,3-d]pyrimi)-18.9(d)-0.1(in-2\(1H\)-one\),)]TJ
T*
[(with)-278.7(little)-272.2(emetogenic)-277.2(activity)62.9(.)]TJ
/F3 1 Tf
14.5377 0 TD
[(J)-274(Pharmacol)-275.3(Exp)-277.2(Ther)]TJ
/F10 1 Tf
9.6817 0 TD
0.0001 Tc
(295)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-278(255–260.)]TJ
-27.2013 -1.1988 TD
0 Tc
[(Ariga)-440.5(M,)-442.9(Neitzert)-444.1(B,)-445.5(Nakae)-437.4(S,)-445.7(Mottin)-441.1(G,)-443(Bertrand)-439.7(C,)-441.9(Pruni)-10.2(aux)-443.6(M)-0.1(P)]TJ
/F3 1 Tf
1.1988 -1.2064 TD
[(et)-476.7(al.)]TJ
/F2 1 Tf
2.8302 0 TD
0.0001 Tc
[(\(2004\).)-476(Nonredun)-11(dant)-472.4(function)-476.2(o)0(f)-475.1(phosphodie)-10.3(sterases)-472.3(4)0(D)]TJ
-2.8302 -1.1988 TD
0 Tc
[(and)-506.2(4)-0.1(B)-498.4(i)0(n)-504(n)-0.1(eutrophil)-501.1(recruit)-12.7(ment)-496.1(to)-503.9(the)-502.4(site)-501.1(of)-498(inflammat)-11.9(i)0(on.)]TJ
/F3 1 Tf
T*
0.0001 Tc
[(J)-334.6(I)0.1(mmunol)]TJ
/F10 1 Tf
4.9622 0 TD
(173)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(7531–7538.)]TJ
-7.9442 -1.1988 TD
[(Barber)-368.8(R,)-371.3(Baillie)-367.6(GS,)-367.8(B)-8.1(ergmann)-372.3(R)0(,)-363.7(S)0.1(hepherd)-374.7(MC,)-363.9(Seppe)-8(r)-366.1(R)0(,)-363.7(Hou)-9.1(slay)]TJ
1.1988 -1.1988 TD
(MD)Tj
/F3 1 Tf
2.079 0 TD
0 Tc
[(et)-332.6(al.)]TJ
/F2 1 Tf
2.5494 0 TD
[(\(2004\).)-339.6(D)-0.1(ifferential)-338.4(express)-10.8(ion)-335.8(o)-0.1(f)-331.1(PDE4)-340.6(cAMP)-336.4(phospho-)]TJ
-4.6284 -1.1988 TD
[(diesterase)-357.7(isoforms)-354.7(i)0(n)-344.6(i)0(nflammat)-11.9(ory)-359.2(cells)-348.2(of)-346.2(smokers)-353.5(with)-354.6(COPD,)]TJ
0 -1.2064 TD
0.0001 Tc
[(smokers)-391.3(without)-388.4(COPD,)-386(and)-384.7(nonsmo)-10.7(kers.)]TJ
/F3 1 Tf
20.4029 0 TD
0 Tc
[(Am)-378.6(J)-387.8(Physiol)-386.6(Lung)-387.7(Cell)]TJ
-20.4029 -1.1988 TD
[(Mol)-334.6(P)0(hysiol)]TJ
/F10 1 Tf
5.463 0 TD
0.0001 Tc
(287)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(L332–L343.)]TJ
-8.4449 -1.1988 TD
0 Tc
[(Barnes)-836.3(PJ)-834.3(\(2006a\).)-838.7(How)-833.7(corticosteroids)-838.2(c)0(ontrol)-838.2(i)0(nflammat)-11.9(i)0(on:)]TJ
1.1988 -1.1988 TD
[(Quintiles)-344.2(Prize)-335(Lecture)-343.3(2005.)]TJ
/F3 1 Tf
13.908 0 TD
0.0001 Tc
[(Br)-336.9(J)-334.6(Pharmacol)]TJ
/F10 1 Tf
6.9578 0 TD
(148)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(245–254)-13.1(.)]TJ
-23.8476 -1.1988 TD
0 Tc
[(Barnes)-555.6(PJ)-561.1(\(2006b\).)-560.8(Novel)-559.9(signal)-555.8(transduction)-565(modulato)-11.7(r)0(s)-552(for)-560.6(the)]TJ
1.1988 -1.1988 TD
[(treatment)-338.9(o)-0.1(f)-338.7(air)-14.5(way)-332.1(d)-0.1(isease)-9.2(s.)]TJ
/F3 1 Tf
13.9231 0 TD
[(Pharmacol)-343.6(Ther)]TJ
/F10 1 Tf
7.3144 0 TD
0.0001 Tc
(109)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(238–245.)]TJ
-24.2194 -1.2064 TD
0 Tc
[(Barnes)-760.5(PJ,)-755.7(Adcock)-758.9(I)0(M,)-756.6(Ito)-749.3(K)-752.9(\()0(2005)-13.4(\).)-751.1(Histone)-756.5(acetylati)-10.2(on)-754(and)]TJ
1.1988 -1.1988 TD
[(deacetyla)-10.5(tion:)-640.9(impo)-9.8(rtance)-643.3(in)-640.5(inflammat)-11.9(ory)-655.1(l)0(ung)-638.7(disease)-9.2(s.)]TJ
/F3 1 Tf
29.3183 0 TD
0.0001 Tc
(Eur)Tj
-29.3183 -1.1988 TD
0 Tc
[(Respir)-339.3(J)]TJ
/F10 1 Tf
3.6193 0 TD
0.0001 Tc
(25)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(552–563)-13.1(.)]TJ
-6.0093 -1.1988 TD
0 Tc
[(Bender)-428.3(A)26.9(T)82.9(,)-422.2(Beavo)-425.2(JA)-423.4(\(2006\).)-430.6(Cyclic)-430.1(nucleoti)-10.7(de)-421(phosphodie)-10.4(sterases:)]TJ
1.1988 -1.1988 TD
[(molecul)-11.3(a)0(r)-334.1(regulation)-338.4(t)0(o)-337(clinical)-340.8(use.)]TJ
/F3 1 Tf
17.3299 0 TD
[(Pharmacol)-343.6(Rev)]TJ
/F10 1 Tf
6.8364 0 TD
0.0001 Tc
(58)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(4)0(88–5)-11.5(20.)]TJ
-26.5564 -1.1988 TD
0 Tc
[(Boolell)-474(M,)-465.7(Gepi-)-9.2(A)-0.1(ttee)-468.8(S,)-460.9(Gingell)-475.7(JC,)-467.3(A)-0.1(llen)-469.2(MJ)-471(\(1996\).)-468.6(Sild)-9.5(enafil,)-467.4(a)]TJ
1.1988 -1.1988 TD
[(novel)-292.8(effective)-289.2(o)-0.1(ral)-286.4(therapy)-287.4(f)0(or)-287.5(male)-287.8(erecti)-11(le)-280.6(dysfuncti)-11.5(on.)]TJ
/F3 1 Tf
27.0875 0 TD
0.0001 Tc
[(Br)-283.8(J)-281.5(U)0(rol)]TJ
/F10 1 Tf
-27.0875 -1.2064 TD
(78)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(257–2)-11.5(6)0(1.)]TJ
-2.3901 -1.1988 TD
0 Tc
[(Boswell-Smit)-13.8(h)-269.7(V)133.8(,)-270.5(C)-0.1(azzola)-276.9(M,)-268.4(Page)-274.5(CP)-274.7(\(2006a\).)-277.2(A)-0.1(re)-271.7(phosphod)-10.7(iesterase)]TJ
1.1988 -1.1988 TD
[(4)-422(i)0(nhibitors)-425(just)-425(more)-420.1(t)0(heophyllin)-10.5(e?)]TJ
/F3 1 Tf
17.899 0 TD
[(J)-418.2(A)-0.1(llergy)-427.2(Clin)-421.7(Immunol)]TJ
/F10 1 Tf
10.8274 0 TD
0.0001 Tc
(117)Tj
/F2 1 Tf
1.7831 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(1237–)-11.5(1243.)]TJ
-1.1988 -1.1988 TD
[(Boswell-Smit)-13.7(h)-724.8(V)133.9(,)-725.6(S)0.1(pina)-725.9(D,)-726.1(Oxf)-10.3(ord)-724.4(A)80.1(W)96.1(,)-725.6(Comer)-728.1(MB,)-731.7(Seeds)-729.6(EA,)]TJ
1.1988 -1.1988 TD
[(Page)-911.8(CP)-904.4(\(2006b\).)-917.3(The)-908.2(pharmacolog)-12.9(y)-904.7(of)-907.6(two)-911.6(n)0(ovel)-907.3(long-)]TJ
0 -1.2064 TD
0 Tc
[(acting)-1092.7(phosphod)-10.7(iesterase)-1090.7(3/4)-1088.6(i)0(nhibitors,)-1090(RPL55)-13.2(4)-1082.1([)0(9,10)-12(-di-)]TJ
0 -1.1988 TD
[(metho)21(xy-2\()15.9(2,4)16.2(,6-t)15.7(rimet)15.3(hyl)17.8(pheny)16.7(lim)15.6(ino\)-)17.4(3)-0.1(-\()14.7(n-ca)15.4(rbamo)21.1(y)-0.1(l-2)16.4(-ami)15.6(no-)]TJ
T*
[(ethyl\))-1249.4(-)0(3,4,)-12.2(6,7-tetrahydro-2H-p)-15.2(y)-0.1(rimido[6,1-a]is)-15(oquinolin-4-one])]TJ
T*
0.0001 Tc
[(and)-1317.9(RPL565)-1322.7([6,7-dihydro-2-\(2,6-diisop)-19.5(r)0.1(opylphenox)-12.1(y\)-9,10-di-)]TJ
T*
0 Tc
[(metho)-9.3(xy-4H-pyrimido[6,1-a]i)-438.9(soquinolin-4)-15.5(-one].)]TJ
/F3 1 Tf
23.3544 0 TD
0.0001 Tc
[(J)-425.7(Pharmac)-11.6(o)0.1(l)-422.9(Exp)]TJ
-23.3544 -1.1988 TD
(Ther)Tj
/F10 1 Tf
2.337 0 TD
(318)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(840–8)-11.5(48.)]TJ
-5.3189 -1.1988 TD
[(Bo)23.5(us)33.8(qu)26.9(et)-240.2(J)20.2(,)-255.2(Au)26.5(bi)30.2(er)-237.8(M,)-238(Sa)23.8(s)19.1(t)0.1(r)24.1(e)-251.1(J,)-235(Iz)25.4(qu)26.9(i)16.2(e)0.1(r)27.8(d)0(o)-236.9(J)0.1(L)23.2(,)-247.6(Ad)24(l)16.2(e)0.1(r)-237.8(L)0(M)27.8(,)-255.2(Ho)29.4(f)16.8(b)0(a)23.3(u)0(e)29.1(r)-252.2(P)]TJ
/F3 1 Tf
29.9101 0 TD
-0.0173 Tc
[(et)-268.5(a)-17.4(l)10.5(.)]TJ
/F2 1 Tf
-28.7113 -1.2064 TD
0 Tc
[(\(2)23.1(0)18.1(0)-0.1(6)28.7(\))0(.)-295.8(C)18.2(om)22.5(pa)29(ri)29.3(so)27.8(n)-307.6(o)16.3(f)-309.5(r)0(o)29.6(f)16.7(lu)23.1(mi)29.9(l)16.1(a)-0.1(s)28.3(t)0(,)-297.6(a)16.8(n)-307.6(o)16.3(ra)30.1(l)-310.2(a)16.8(nt)29.5(i)16.1(-)0(i)22.9(n)18.6(fl)25.3(a)16.8(m)-0.1(m)27.6(a)0(t)27.7(o)-0.1(r)14.4(y)89.2(,)-308.4(w)-0.1(ith)]TJ
ET
1 i 
307.842 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 307.8424 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-335.3(and)-325.8(respiratory)-335.9(disease)]TJ
/F9 1 Tf
0 -1.2519 TD
[(D)-328.5(Spina)]TJ
7.0982 0 0 9.4646 534.1038 751.8612 Tm
0.0001 Tc
(313)Tj
ET
307.842 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 405.2408 31.2378 Tm
[(British)-322.5(J)0.1(ournal)-334(of)-334.4(Pharmacolog)18.7(y)-339.1(\(2008\))]TJ
/F1 1 Tf
17.5955 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi6 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
405 29 141 10 re
f*
0.619608 0.619608 0.619608 rg
n
307 751 111 19 re
f*
0.619608 0.619608 0.619608 rg
n
533 752 14 8 re
f*
0.619608 0.619608 0.619608 rg
n
573 9 15 464 re
f*
0.4 0.4 1 rg
n
50 627 115 10 re
f*
0.4 0.4 1 rg
n
307 717 51 11 re
f*
0.4 0.4 1 rg
n
307 500 89 12 re
f*
0.4 0.4 1 rg
n
307 443 51 11 re
f*
0.6 0 0.298039 rg
n
50 661 240 67 re
f*
0.6 0 0.298039 rg
n
50 471 239 155 re
f*
0.6 0 0.298039 rg
n
50 279 239 190 re
f*
0.6 0 0.298039 rg
n
50 56 239 223 re
f*
0.6 0 0.298039 rg
n
307 538 239 166 re
f*
0.6 0 0.298039 rg
n
308 478 197 10 re
f*
0.156863 0.662745 0.360784 rg
n
306 56 241 378 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 292 718 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 167 627 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 616 cm
BT
1 0 0 1 0 0 Tm
(3) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 459 cm
BT
1 0 0 1 0 0 Tm
(4) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 291 269 cm
BT
1 0 0 1 0 0 Tm
(5) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 360 718 cm
BT
1 0 0 1 0 0 Tm
(6) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 548 694 cm
BT
1 0 0 1 0 0 Tm
(7) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 398 502 cm
BT
1 0 0 1 0 0 Tm
(8) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 507 478 cm
BT
1 0 0 1 0 0 Tm
(9) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 360 444 cm
BT
1 0 0 1 0 0 Tm
(10) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 424 cm
BT
1 0 0 1 0 0 Tm
(11) Tj
T*
ET
Q
Q


endstream
endobj
245 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
246 0 obj
<<
/BaseFont /DJCOIN+AdvStoneS-SB
/Encoding /WinAnsiEncoding
/FirstChar 32
/FontDescriptor 247 0 R
/LastChar 177
/Subtype /Type1
/Type /Font
/Widths [ 291 312 406 593 593 947 791 218 375 375 427 593 291 333 291 458 593 593 593 593 593 593 593 593 593 593 291 291 593 593 593 479 791 718 677 739 812 625 541 791 833 395 385 697 625 979 791 812 625 812 687 541 645 791 739 1072 781 697 625 354 572 354 593 500 385 552 625 520 645 520 385 572 687 343 312 625 343 1000 687 614 645 625 427 427 395 645 593 864 625 593 510 354 333 354 593 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 593 593 0 0 0 0 0 0 0 0 0 0 0 0 0 593 ]
>>
endobj
247 0 obj
<<
/Ascent 735
/CapHeight 700
/CharSet (\057eight\057zero\057one\057nine\057two\057three\057four\057five\057six\057seven)
/Descent -249
/Flags 34
/FontBBox [ -187 -250 1312 770 ]
/FontFile3 248 0 R
/FontName /DJCOIN+AdvStoneS-SB
/ItalicAngle 0
/StemV 0
/Type /FontDescriptor
/XHeight 500
>>
endobj
248 0 obj
<<
/Filter /FlateDecode
/Subtype /Type1C
/Length 1036
>>
stream
H‰T’oLSÅû
å½	Ö<²ö‘¾gDÇ‘LhAüQ
(…JûŠÄÒÖ¶Ca˜@©¥$[H˜™‰â„	›‚˜HÜ˜l!®nS§“¸)Æ9™·ì’l·/ûr>œäœÜ_î!DşbA¡™9Û³ócÒô5Ev³‰/Š+J_òã|áûÂƒÂp;¶†K¸…‰¢‹øÛíşWƒHh[ıëbˆHLÇº3Ì–ZkUå^;©‹âÖ«”É±‚ª^i"—¦7Wğ\Q­ÍÎWÛ¸l“Îlµ˜­Z;¯ç¸4£‘+\ÊÚ¸BŞÆ[k7[“Á½º‰«²qZÎÊWV	Y+¯çìV­¯ÖZ÷qfƒĞ$˜&­½ÊlÒ9M­…7hu<—ñ_½`ÇÿNDˆ‚_
ô"?Ñf‘]4N¼E¼O|#æÄo‹Gü–sRù€†$ a-4@´
q'+±£±H\Øóşºø6˜…ë¿¶şæÄë8çÔ±RŸt¡ŒÆQú‹Ç%ƒãÇóå‹*Òà®wZN»ÎµÅA}¯÷›ÛyóÕ|Æıñ€\êë5]`7X2ôŒ=>u•òNAÈ<Pr'Ü@:!U—U¢@ÿAòÅ±ÉşIæÊÃ” ‰”2…-Û³«ÜPNeùJÈIPK¤ÏéHéBu¤&k[iåÙ^û·¹½ÑÕĞ 3×46¹·6Êú’NúÁrË%ƒHÿë"aWtPòÏ.ïDË3
ükz1ˆÉİú©”U’Ÿ×Iîõ\8}™¹4VúfîNt
Ôš…4$£wã©òoÀÙ•îCÎı
ç»¼+½™2Â“r÷Ñ*óÊyÚİÙ/Ÿzüs,‰/ÃÆ>ƒ˜é)
¯‘R(ª"pN%à·—­/Ò¨3­½g²E¿4Ôäp8dÕûš=M­M²XIıÉïên3Á@òÕŠÙ‘À€ş§©¯eé'ê° µN4R˜. ¢Ä1ıøa!êHìÍUÌ–=ÕÕl7$Ì=êÃ~¿¨¢ï^¹<uoP•¾7qcJñO°²]!õeùÑkp†a=‡)¬€t˜»9× „º´˜‡ëÎc_¹zaH©ôÌPIf–¡T{€M>¯–OÌ(pÕb3}»oèê9ÅºùŠxyJq¡jS¾÷®8_7Ë10Eiã;îT°yöØ2”È‘z¾	!$^X‘£IŸ)<äpÇÜèïò£¨>v{¢
ÀÜ
&
òZqÙdLŒYÒ£ZdÍ3·¾üô\ëqíÇu‚êx}*Z©)ÉMÖİy:Ó÷ğşÍ‰Tu°³¡/é Â!á¹

endstream
endobj
249 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
250 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 575
>>
stream
H‰ìV	nÄ0äÿä;­n;ìm¢JKÕUÎ	3àÁˆß ‡H‹›û9Å8Èñ‰Ò¥ø,‹µŸ«Íïıä[³ƒ$#—S‚á<B÷qòØ£Q×i	ÛHÛß,ç4>«ak'ı„áä§Ë>¹Í.òÄáÊÛì2w*zÁõà”óÒ$'åy’Îì ıIòEv©	—‘¨u’JkæX×®“íä½HØu€dÛf…ÙØËÊ¢=zyw8UŒ\id~×ß=ŞècH9ñéÊuÔÛ‡R
ÈS®]èŒİ4©¢{ÔÉ}…ÄŠ_=Aš2µfw ¿ætâBUÙIÖ®ƒù5_º%B!ÕOaú:¢ú2‚2CéÖ;“*e$‘–³…;¤±i¡xn3q¬B}Y"ÓÉt1Uıê] ¢7ï´­@<½æÜ£YNvõ›¦dc‚Û.Xsµ,I>Ç´=€BLÖrS'ıcÓ×ìlN¤†jşs ¦œ©ì±Gam³’º€ô²cªûÓ±f€±ô¦'¢CÁ<;^eÖßdø·çß¸…h;”8ÚV¨İ½‰w§ù’ğc$^kàÒ—9ÕŠ+%õWtrÕ°§âte'e×ZìĞ$‹ìRˆ±²IJˆf“¡ÃÜ#ÀŒÄ÷ntñ<'·3ØÅ‹5&¥×y­‰Vev¢SdÜô­¬'^Ta7Ev9ÓÒÉD˜|‹d ÈıßQ¨í7Šñ3 ‚kh”
endstream
endobj
251 0 obj
<<
/Contents 252 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 253 0 R
/F10 246 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F7 45 0 R
/F9 55 0 R
>>
/XObject <<
/Xi7 254 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 255 0 R
/Type /Page
/Annots [ ]
/Parent 2 0 R
>>
endobj
252 0 obj
<<
/Length 27596
>>
stream
q
q

BT
/F2 1 Tf
7.4718 0 0 7.4718 59.7543 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(beclom)-12.9(ethasone)-750.7(dipropio)-14.1(n)-0.1(ate)-751.1(in)-754.3(the)-752.8(treatment)-756.2(o)-0.1(f)-756(p)-0.1(ersiste)-9.6(nt)]TJ
0 -1.2064 TD
0.0001 Tc
[(asthma)-10(.)]TJ
/F3 1 Tf
4.0366 0 TD
0 Tc
(Allergy)Tj
/F10 1 Tf
3.3309 0 TD
0.0001 Tc
(61)Tj
/F2 1 Tf
1.1837 0 TD
0 Tc
[(:)-338.8(7)-0.1(2–78.)]TJ
-9.75 -1.1988 TD
[(Bundschu)-13(h)-330.4(DS,)-332.4(E)-0.1(ltze)-329.8(M,)-336.7(Barsig)-335.1(J,)-326.2(W)73.2(o)-0.1(llin)-333.9(L,)-335.8(Hatzelmann)-341.2(A)-0.1(,)-327(B)-0.1(eume)-337.8(R)]TJ
1.1988 -1.1988 TD
0.0001 Tc
(\(2001\).)Tj
/F3 1 Tf
3.7786 0 TD
0 Tc
[(In)-475.9(vivo)]TJ
/F2 1 Tf
3.6117 0 TD
[(efficacy)-483.1(in)-481.2(airw)-12.6(ay)-478.2(disease)-479.6(models)-484.6(of)-475.2(roflumi)-14.3(last,)]TJ
-7.3903 -1.1988 TD
[(a)-468.8(novel)-474.9(o)-0.1(rally)-469.5(active)-471.3(PDE4)-469.5(inhibit)-10.9(o)-0.1(r)75.1(.)]TJ
/F3 1 Tf
18.2556 0 TD
[(J)-471.3(Pharmacol)-472.6(Exp)-474.5(Ther)]TJ
/F10 1 Tf
10.4708 0 TD
0.0001 Tc
(297)Tj
/F2 1 Tf
1.7831 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(280–2)-11.5(90.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Butcher)-486.7(R)20.4(W)96(,)-482.9(S)0(utherl)-11.4(and)-483.4(E)0(W)-477.7(\()0(1962\).)-491.3(Adenosine)-487.9(3)]TJ
/F7 1 Tf
5.2302 0 0 5.2302 229.6062 667.6723 Tm
()Tj
/F2 1 Tf
7.4718 0 0 7.4718 231.4771 664.951 Tm
(,5)Tj
/F7 1 Tf
5.2302 0 0 5.2302 237.9401 667.6723 Tm
()Tj
/F2 1 Tf
7.4718 0 0 7.4718 239.8676 664.951 Tm
[(-phosph)-9.8(ate)-481.4(in)]TJ
-24.1056 -1.1988 TD
[(biologic)-12.9(a)0(l)-551.3(m)-0.1(aterials.)-558(I.)-546.2(Purification)-558.6(a)0(nd)-551.7(proper)-9.3(ties)-546.6(of)-551.1(cycl)-9.2(ic)-549.6(3)]TJ
/F7 1 Tf
5.2302 0 0 5.2302 285.7889 658.6581 Tm
()Tj
/F2 1 Tf
7.4718 0 0 7.4718 287.7165 655.9935 Tm
(,)Tj
-30.5095 -1.2064 TD
(5)Tj
/F7 1 Tf
5.2302 0 0 5.2302 64.063 649.7007 Tm
()Tj
/F2 1 Tf
7.4718 0 0 7.4718 65.9905 646.9794 Tm
[(-nucleotide)-789.2(phosphodie)-10.4(sterase)-779.8(and)-786.9(u)-0.1(se)-778.9(of)-786.3(this)-785.1(enzyme)-785.1(t)0(o)]TJ
-0.8346 -1.1988 TD
[(charac)-11(terize)-585.9(ad)-8.9(enosine)-587.8(3)]TJ
/F7 1 Tf
5.2302 0 0 5.2302 150.0661 640.7432 Tm
()Tj
/F2 1 Tf
7.4718 0 0 7.4718 151.9937 638.0219 Tm
(,5)Tj
/F7 1 Tf
5.2302 0 0 5.2302 158.4566 640.7432 Tm
()Tj
/F2 1 Tf
7.4718 0 0 7.4718 160.3275 638.0219 Tm
[(-phos)-10.3(phate)-587.1(in)-595(human)-592.6(u)-0.1(rine.)]TJ
/F3 1 Tf
14.7198 0 TD
[(J)-592.7(B)-0.1(iol)]TJ
-28.1801 -1.1988 TD
0.0001 Tc
(Chem)Tj
/F10 1 Tf
2.8984 0 TD
(237)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(1244–1250.)]TJ
-5.8803 -1.1988 TD
0 Tc
[(Calverley)-1222.1(PM,)-1213.9(Sanchez-T)60(oril)-1220.4(F)102.7(,)-1211.3(McIvor)-1213.7(A,)-1214.7(T)60.1(eichmann)-1214.7(P)124.3(,)]TJ
1.1988 -1.1988 TD
[(Breden)-11(broeker)-523.1(D,)-528.9(Fabbri)-521.2(L)-0.1(M)-526.2(\()0(2007\).)-529.3(E)-0.1(ffect)-534.2(of)-520.8(1-year)-531.8(treatment)]TJ
T*
[(wit)-9.1(h)-315.2(roflumilast)-323.2(in)-321.9(severe)-320.8(chronic)-327.3(obstructive)-324.1(pulmonar)-14.6(y)-320.6(disease.)]TJ
/F3 1 Tf
0 -1.2064 TD
[(Am)-340.6(J)-334.7(R)-0.1(espir)-331.8(Crit)-339.7(Care)-337.2(Med)]TJ
/F10 1 Tf
12.0718 0 TD
0.0001 Tc
(176)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(154–161.)]TJ
-15.0537 -1.1988 TD
[(Card)-303.6(GL,)-310.9(England)-306.6(B)0(P)123.9(,)-300.7(Suzuki)-308.5(Y)91.2(,)-300.7(Fong)-307.4(D,)-301.2(Powe)-9.7(ll)-301.6(B,)-301.3(Lee)-301.9(B)]TJ
/F3 1 Tf
26.215 0 TD
0 Tc
[(et)-302.2(al.)]TJ
/F2 1 Tf
2.4963 0 TD
0.0001 Tc
(\(2004\).)Tj
-27.5124 -1.1988 TD
0 Tc
[(Structur)-10.9(a)0(l)-513.4(b)-0.1(asis)-514.3(for)-507.5(t)0(h)-8.5(e)-509.1(activity)-513.8(of)-513.2(drugs)-515.2(t)0(hat)-511.9(i)0(nhibit)-519.2(phospho-)]TJ
T*
[(diestera)-11.8(ses.)]TJ
/F3 1 Tf
5.5389 0 TD
(Structure)Tj
/F10 1 Tf
4.1428 0 TD
0.0001 Tc
(12)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(2233–2247.)]TJ
-12.0642 -1.1988 TD
[(Carpent)-9.2(e)0.1(r)-328.9(DO,)-331.3(Briggs)-334.3(D)-8(B)0(,)-331.6(Knox)-335.3(AP)128.6(,)-331.1(Stromin)-10.2(ger)-334.1(N)-331.9(\()0.1(1988\).)-331.9(E)0.1(xcitat)-11.8(ion)]TJ
1.1988 -1.1988 TD
0 Tc
[(of)-490.4(are)-8.6(a)-484(postrema)-497.7(n)-0.1(eurones)-492.5(b)-0.1(y)-496.3(transmitters,)-495.5(peptides)-495.4(and)-491(c)0(yclic)]TJ
T*
[(nucleot)-11.7(i)0(des.)]TJ
/F3 1 Tf
6.0017 0 TD
[(J)-327.1(N)-0.1(eur)-8.6(ophysiol)]TJ
/F10 1 Tf
6.6619 0 TD
0.0001 Tc
(59)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(358–369.)]TJ
-15.0461 -1.2064 TD
[(Chan)-580(S)0.1(C,)-571.5(Reifsny)-10(d)0(er)-574.6(D,)-574.3(Beavo)-576.8(JA,)-579.9(H)0(anifin)-574.2(JM)-577.2(\(1993\).)-582.3(I)0.1(mmuno-)]TJ
1.1988 -1.1988 TD
0 Tc
[(che)-9(m)-0.1(ical)-449.6(characterization)-456.5(o)-0.1(f)-444.9(t)0(he)-449.3(distinct)-446.6(m)-9(onocyte)-445.2(cycl)-9.2(ic)-443.3(AMP-)]TJ
T*
[(phos)-9.5(phodiesterase)-401.4(from)-402.7(p)-0.1(atien)-9.5(ts)-395(with)-400.1(atopic)-402.2(d)-0.1(ermat)-9.7(itis.)]TJ
/F3 1 Tf
27.0799 0 TD
[(J)-395.4(A)-0.1(llergy)]TJ
-27.0799 -1.1988 TD
0.0001 Tc
[(Clin)-338.2(Immunol)]TJ
/F10 1 Tf
6.4949 0 TD
(91)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-338.7(1179–1188.)]TJ
-8.885 -1.1988 TD
0 Tc
[(Cherr)-13.2(y)-608.9(J)0(A,)-602.7(Davis)-602.8(R)-0.1(L)-606.4(\()0(1999\).)-612.7(Cyclic)-604.6(AMP)-605.4(phosphod)-10.7(iesterases)-608.8(are)]TJ
1.1988 -1.1988 TD
[(loc)-9.6(alized)-336.4(in)-329.4(regions)-339.8(of)-338.7(the)-327.9(mouse)-339(b)-0.1(rain)-338.5(associated)-340.3(with)-331.8(reinfo)-10.6(rce-)]TJ
0 -1.2064 TD
[(ment,)-341.7(movement)-339.5(and)-339.2(affect.)]TJ
/F3 1 Tf
13.8169 0 TD
[(J)-334.7(C)-0.1(omp)-339(N)-0.1(eurol)]TJ
/F10 1 Tf
6.806 0 TD
0.0001 Tc
(407)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(287–301.)]TJ
-23.6048 -1.1988 TD
0 Tc
[(David)-640(M)-0.1(,)-640.2(Z)-0.1(ech)-637.5(K,)-643.9(Seiberling)-641.6(M)-0.1(,)-640.2(W)80.8(eimar)-646.4(C,)-639.2(Bethke)-634.5(TD)-638.4(\(2004\).)]TJ
1.1988 -1.1988 TD
[(Ro)-8.7(flumilast,)-471.6(a)-461.2(novel,)-464.6(oral,)-465.8(selective)-469.6(PDE4)-469.6(inhibitor)34(,)-460.2(shows)-471.1(high)]TJ
T*
[(abso)-9.6(lute)-331(bioavai)-11.8(lability)73.9(.)]TJ
/F3 1 Tf
11.442 0 TD
[(J)-334.7(A)-0.1(llergy)-336.1(Clin)-338.3(Immunol)]TJ
/F10 1 Tf
10.486 0 TD
0.0001 Tc
(113)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(S)0.1(220–S221.)]TJ
-24.9099 -1.1988 TD
0 Tc
[(Dunker)-9.6(n)-262.1(TR,)-265.7(Feurstein)-269(D,)-263.3(Rossi)-265.5(GA,)-271.9(Sabatini)-263.1(F)102.7(,)-262.9(H)-0.1(atzelman)-10.8(n)-262.1(A)-261.4(\(2007)-13.4(\).)]TJ
1.1988 -1.1988 TD
[(Inhibi)-10(tion)-431.2(o)-0.1(f)-429.7(TGF)-9.7(-beta)-430.3(induced)-439.4(lung)-433.9(fibroblast)-438.5(to)-428.1(myofibrobla)-15.1(st)]TJ
T*
[(conve)-9.6(rsion)-386.9(b)-0.1(y)-390(phosphod)-10.7(iesterase)-392.6(inhibiting)-391(d)-0.1(rugs)-393.8(and)-392.3(activators)]TJ
0 -1.2064 TD
[(of)-338.7(soluble)-336.9(g)0(uany)-10.1(lyl)-333.8(cyclase.)]TJ
/F3 1 Tf
13.2099 0 TD
0.0001 Tc
[(Eur)-335.2(J)-334.6(Pharmac)-11.6(o)0.1(l)]TJ
/F10 1 Tf
7.4661 0 TD
(572)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(12–22.)]TJ
-23.658 -1.1988 TD
[(Fuhrm)-11.4(a)0.1(nn)-241.6(M,)-253.1(Jahn)-244.2(H)0(-U,)-251.1(Seybold)-255.6(J)0.1(,)-242.6(N)0(eurohr)-256.3(C,)-244.5(Barnes)-252(PJ,)-247.2(H)0(ippensti)-11.4(el)]TJ
1.1988 -1.1988 TD
0 Tc
(S)Tj
/F3 1 Tf
0.9864 0 TD
[(et)-484.3(al.)]TJ
/F2 1 Tf
2.8529 0 TD
[(\(1999\).)-491.3(I)0(dentification)-490.4(a)0(nd)-491(function)-491.4(o)-0.1(f)-482.8(c)0(yclic)-490.5(nucleotide)]TJ
-3.8393 -1.1988 TD
[(phos)-9.5(phodiesterase)-606.2(isoenzymes)-608.2(in)-595(air)-14.5(way)-605.2(e)0(pithelial)-599.2(cell)-10.6(s.)]TJ
/F3 1 Tf
28.3243 0 TD
0.0001 Tc
[(Am)-606.1(J)]TJ
-28.3243 -1.1988 TD
0 Tc
[(Respi)-10.5(r)-328.9(C)-0.1(ell)-339.1(Mol)-334.6(B)-0.1(iol)]TJ
/F10 1 Tf
9.0519 0 TD
0.0001 Tc
(20)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(292–302)-13.1(.)]TJ
-11.442 -1.1988 TD
0 Tc
[(Gale)-421.1(DD,)-415.5(Landel)-9.7(l)0(s)-412.5(L)-0.1(J,)-414.2(Spina)-422.5(D)-0.1(,)-415.1(M)-0.1(iller)-422.7(AJ,)-413(S)0(mith)-419.3(K,)-416.3(Nichol)-10.7(s)-413.5(T)]TJ
/F3 1 Tf
29.6976 0 TD
[(et)-416(al.)]TJ
/F2 1 Tf
-28.4988 -1.2064 TD
[(\(2002\).)-324.4(Pharmacoki)-12.4(netic)-315.9(and)-308.9(pharmac)-11.1(odynamic)-321.6(p)-0.1(rofile)-319.6(following)]TJ
0 -1.1988 TD
[(oral)-597.5(administration)-596(o)-0.1(f)-596.6(t)0(he)-585.8(phosphod)-10.7(iesterase)-589.9(\(PDE\)4)-596.1(i)0(nhibit)-10.9(o)-0.1(r)]TJ
T*
0.0001 Tc
[(V1129)-13.5(4A)-334.2(in)-329.3(heal)-9.7(thy)-328.9(voluntee)-10(rs.)]TJ
/F3 1 Tf
15.342 0 TD
0 Tc
[(Br)-329.4(J)-334.7(C)-0.1(lin)-338.3(Pharmac)-11.7(ol)]TJ
/F10 1 Tf
9.1506 0 TD
0.0001 Tc
(54)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(478–4)-11.5(84.)]TJ
-26.8827 -1.1988 TD
[(Gamble)-279.4(E)0(,)-267.4(G)0(roote)-10.1(ndorst)-273.6(DC,)-267.7(Bri)-9(g)0.1(htling)-271.4(CE,)-271.9(T)52.6(r)0.1(oy)-275.6(S,)-271.1(Qiu)-272.5(Y)91.2(,)-270.4(Zhu)-268.9(J)]TJ
/F3 1 Tf
29.8494 0 TD
0 Tc
[(et)-264.3(al.)]TJ
/F2 1 Tf
-28.6506 -1.1988 TD
[(\(2003\).)-817.6(Antiinfl)-11.5(ammator)-12(y)-813.8(effects)-814.8(of)-809.1(the)-813.5(phosphodiestera)-11.9(se-4)]TJ
T*
[(inhibit)-10.9(o)-0.1(r)-615.3(cilomilast)-636.7(\(Ariflo\))-628(i)0(n)-625.4(c)0(hroni)-12(c)-626.4(obstructive)-627.6(pulmo)-10.3(nar)-11.9(y)]TJ
T*
[(disease)-9.2(.)]TJ
/F3 1 Tf
3.8696 0 TD
[(Am)-333.1(J)-334.7(R)-0.1(espi)-10.5(r)-328.9(C)-0.1(rit)-339.8(Care)-337.2(Med)]TJ
/F10 1 Tf
12.0718 0 TD
0.0001 Tc
(168)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(976–982.)]TJ
-18.9233 -1.2064 TD
0 Tc
[(Gantne)-9.6(r)-404.1(F)102.7(,)-407.1(Gotz)-413.3(C)-0.1(,)-411.6(G)-0.1(ekeler)-412.8(V)133.8(,)-407.1(Schudt)-411.3(C,)-411.6(W)73.2(e)0(ndel)-409.7(A)-0.1(,)-410.5(H)-0.1(atzelman)-10.8(n)-406.3(A)]TJ
1.1988 -1.1988 TD
[(\(1998\).)-385.1(P)-0.1(h)-8.7(o)-0.1(sphodiesterase)-388.7(profile)-380.3(of)-384.2(human)-380.2(B)-380(lymphocyt)-10.8(es)-376.3(from)]TJ
T*
0.0001 Tc
[(norma)-12(l)-332.8(a)0.1(nd)-339.1(atopic)-341.4(donors)-344(a)0.1(nd)-339.1(the)-342.9(effects)-344.2(of)-338.6(PDE)-335.9(inhibit)-10.8(i)0.1(on)-335.7(on)-344.2(B)]TJ
T*
0 Tc
[(cell)-336.9(proliferat)-13.1(ion.)]TJ
/F3 1 Tf
8.4677 0 TD
0.0001 Tc
[(Br)-336.9(J)-334.6(P)0.1(harmacol)]TJ
/F10 1 Tf
6.9578 0 TD
(123)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(1)0.1(031–10)-13.1(38.)]TJ
-18.4074 -1.1988 TD
[(Gantne)-9.5(r)-479.9(F)102.8(,)-482.8(Kupferschmidt)-488.6(R,)-485.1(Schudt)-487.1(C,)-479.8(W)73.3(e)0.1(ndel)-485.5(A)0(,)-478.6(H)0(a)-8.1(tzelmann)-484.7(A)]TJ
1.1988 -1.1988 TD
[(\(1997a)-11.7(\).)]TJ
/F3 1 Tf
4.2642 0 TD
0 Tc
[(In)-460.7(vitro)]TJ
/F2 1 Tf
3.7862 0 TD
[(differentiation)-469.5(o)-0.1(f)-460.1(human)-456(m)-9(onocytes)-456.5(to)-466(macro-)]TJ
-8.0504 -1.2064 TD
[(phages:)-346.2(change)-342.9(of)-338.6(PDE)-343.5(profile)-342.4(and)-346.8(its)-333.4(relati)-11.1(onship)-338.9(t)0(o)-337(s)0(upp)-10.2(ression)]TJ
0 -1.1988 TD
[(of)-513.2(tumour)-515.9(necrosis)-509.3(factor-al)-11.7(pha)-506.1(release)-513.6(by)-511.4(PDE)-510.5(inhibitors.)]TJ
/F3 1 Tf
28.992 0 TD
0.0001 Tc
[(Br)-511.4(J)]TJ
-28.992 -1.1988 TD
[(Pharmac)-11.6(o)0.1(l)]TJ
/F10 1 Tf
4.985 0 TD
(121)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(221–231.)]TJ
-7.9669 -1.1988 TD
[(Gantne)-9.5(r)-358.5(F)102.8(,)-361.4(T)60.2(enor)-362(H,)-363.6(Gekeler)-367.2(V)141.4(,)-361.4(Sch)-8.9(udt)-356.8(C,)-365.9(W)73.3(e)0.1(ndel)-364.1(A)0(,)-357.2(H)0(atzelman)-10.7(n)-360.6(A)]TJ
1.1988 -1.1988 TD
0 Tc
[(\(1997b\).)-651.8(Phosphodiesterase)-647.7(profiles)-642(of)-642.2(highly)-643.1(purified)-643(human)]TJ
T*
0.0001 Tc
[(periphera)-12.6(l)-416.3(b)0(lood)-418(leukocyte)-421.7(populations)-422.2(from)-425.4(normal)-420.7(a)0.1(nd)-415(atopic)]TJ
0 -1.2064 TD
[(individual)-14.4(s)0.1(:)-623.1(a)-628(comparative)-633.9(study)70.2(.)]TJ
/F3 1 Tf
17.072 0 TD
0 Tc
[(J)-623(A)-0.1(llerg)-10.9(y)-621.2(C)-0.1(lin)-634.2(Immunol)]TJ
/F10 1 Tf
11.6545 0 TD
0.0001 Tc
(100)Tj
/F2 1 Tf
1.7831 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(527–5)-11.5(35.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Glenmar)-11.1(k)-1041.4(Pharm)-10.3(aceuticals)-1051.9(\(2005\).)-1052.8(GRC3886.)-1052.5(Report.)-1047.8(http://)]TJ
1.1988 -1.1988 TD
[(www)66.5(.glenmarkp)-12.8(h)-0.1(arma.com/research/clinical.html.)]TJ
-1.1988 -1.1988 TD
[(Groote)-10.2(ndorst)-554.5(DC,)-556.2(Gauw)-564.1(SA,)-555.4(V)50.3(erhoosel)-554.1(RM,)-559(Sterk)-555.9(PJ,)-558.4(Hospers)-560.3(JJ,)]TJ
1.1988 -1.1988 TD
[(Breden)-11(broker)-272(D)]TJ
/F3 1 Tf
7.5951 0 TD
[(et)-279.5(al.)]TJ
/F2 1 Tf
2.4356 0 TD
0.0001 Tc
[(\(2007\).)-278.8(R)0(educ)-10.6(tion)-271.8(i)0.1(n)-276.2(s)0.1(putum)-279(neutroph)-9.7(il)-271.2(and)]TJ
-10.0307 -1.1988 TD
0 Tc
[(eosinoph)-12.1(il)-316.8(number)-9.8(s)-314.8(by)-321.8(the)-320.3(PDE)-9.7(4)-315.7(i)0(nhibitor)-330.2(r)0(oflumilast)-330.8(in)-314.3(patien)-9.5(ts)]TJ
0 -1.2064 TD
0.0001 Tc
[(wit)-9(h)-330.3(COPD.)]TJ
/F3 1 Tf
6.0093 0 TD
0 Tc
(Thorax)Tj
/F10 1 Tf
3.4675 0 TD
0.0001 Tc
(62)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-338.7(1081–1087.)]TJ
-11.8669 -1.1988 TD
0 Tc
[(Gross)-635.9(PM,)-629.6(W)80.8(all)-633.8(KM,)-626.7(Pang)-634.5(JJ,)-624.7(Shaver)-629.8(SW)95.2(,)-627.1(W)73.2(ainman)-635(D)-0.1(S)-623.4(\()0(1990)-13.4(\).)]TJ
1.1988 -1.1988 TD
[(Microv)-11.3(ascular)-1311.1(specializations)-1315.1(promotin)-11.3(g)-1302.8(rapid)-1310.3(interstitial)]TJ
T*
[(sol)-9.1(u)-0.1(te)-430.6(dispersion)-441.8(i)0(n)-428.1(nucleus)-437.7(tractus)-442.2(s)0(olitarius.)]TJ
/F3 1 Tf
22.4364 0 TD
[(Am)-431.7(J)-433.3(P)-0.1(hysiol)]TJ
/F10 1 Tf
6.2901 0 TD
0.0001 Tc
(259)Tj
/F2 1 Tf
1.7831 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(R1131)-13.1(–R1138.)]TJ
-1.1988 -1.1988 TD
[(Haddad)-387(JJ,)-381.8(Land)-381.7(SC,)-381.8(T)60.2(arnow-Mordi)-389.5(WO,)-379(Zembala)-384.7(M,)-382.1(Kowalczyk)-385.4(D,)]TJ
1.1988 -1.2064 TD
0 Tc
[(Lauter)-10.5(bach)-341.6(R)-343.8(\()0(2002\).)-347.2(I)0(mmunopharmacol)-17.6(ogical)-346.1(potential)-345.5(of)-338.7(selec-)]TJ
0 -1.1988 TD
[(tive)-613(phosphodie)-10.4(sterase)-605.3(inhibition)-12.8(.)-604.3(I.)-606.9(Differential)-619.2(regulation)-611.5(o)-0.1(f)]TJ
34.4019 87.6058 TD
[(lipopolysa)-12.1(ccharide-medi)-12.7(a)-0.1(ted)-780.3(proinflamm)-12.9(a)-0.1(tor)-11(y)-783.4(cytokine)-788.8(\(inter-)]TJ
0 -1.2064 TD
[(leukin-6)-306.7(a)0(nd)-301.3(tumor)-302.9(nec)-9(r)0(osis)-303.1(factor-alpha\))-308(b)-0.1(iosynthesis)-304.9(in)-299.1(alveola)-11.3(r)]TJ
0 -1.1988 TD
[(epitheli)-10(al)-331.3(cells.)]TJ
/F3 1 Tf
7.3827 0 TD
[(J)-334.7(Pharmacol)-343.6(Exp)-337.9(T)-0.1(her)]TJ
/F10 1 Tf
9.9397 0 TD
0.0001 Tc
(300)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(559–566.)]TJ
-20.3043 -1.1988 TD
0 Tc
[(Hansen)-293.9(G,)-298.9(Jin)-286.5(S,)-294(Umetsu)-299.5(DT)82.4(,)-293.2(Conti)-291.5(M)-293.9(\(2000\).)-301.6(Absence)-291.1(of)-293.1(m)-9(u)-0.1(scarinic)]TJ
1.1988 -1.1988 TD
[(choliner)-11.8(gic)-691.4(air)-14.5(way)-696.3(responses)-695.6(in)-693.6(mice)-695.8(deficient)-696.4(i)0(n)-693.6(t)0(he)-692.1(cycl)-9.2(i)0(c)]TJ
T*
0.0001 Tc
[(nucleoti)-10.6(de)-390.6(phosphod)-10.6(iesterase)-392.5(PDE4D.)]TJ
/F3 1 Tf
18.3391 0 TD
0 Tc
[(Proc)-396.2(Natl)-396.6(A)-0.1(cad)-394.6(Sci)-399.7(USA)]TJ
/F10 1 Tf
10.9792 0 TD
(97)Tj
/F2 1 Tf
1.1912 0 TD
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(6751–)-11.5(6756.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Harbinson)-461(P)-0.1(L,)-461.8(MacLeo)-12.1(d)-450.7(D)-0.1(,)-460.6(H)-0.1(awksw)-9.8(orth)-456.8(R,)-454.9(O’T)53(oole)-460.2(S)0(,)-453.3(Sullivan)-465.6(PJ,)]TJ
1.1988 -1.2064 TD
[(Heath)-373.9(P)]TJ
/F3 1 Tf
4.158 0 TD
[(et)-378.1(al.)]TJ
/F2 1 Tf
2.6329 0 TD
[(\(1997\).)-377.5(The)-369.6(effect)-378.6(of)-369(a)-370.2(novel)-376.3(orally)-378.4(active)-372.7(selective)]TJ
-6.7908 -1.1988 TD
0.0001 Tc
[(PDE4)-727.4(isoenzyme)-725.8(i)0.1(nhibit)-10.8(o)0(r)-721.5(\()0.1(CDP840\))-726.5(on)-723.6(allergen-in)-13(duced)-724.5(re-)]TJ
T*
0 Tc
[(sponses)-343.9(in)-329.4(asthma)-10.1(tic)-333.9(subjects.)]TJ
/F3 1 Tf
14.4543 0 TD
0.0001 Tc
[(Eur)-335.2(Respir)-339.2(J)]TJ
/F10 1 Tf
5.4327 0 TD
(10)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(1008–1014.)]TJ
-22.2694 -1.1988 TD
[(Hatzelman)-10.7(n)-421.3(A)0(,)-433.1(Schudt)-426.4(C)-429.4(\()0.1(2001\).)-430.5(Anti-i)-10.7(nflammator)-21(y)-419.1(and)-430.2(i)0.1(mmuno)-12.7(-)]TJ
1.1988 -1.1988 TD
[(modul)-10.2(ator)-10.9(y)-593.6(potential)-595.8(of)-596.5(the)-593.3(novel)-596.2(PDE)-9.6(4)-588.8(i)0.1(nhibitor)-603.3(r)0.1(oflumilast)]TJ
/F3 1 Tf
T*
0 Tc
[(in)-335.8(vitro)]TJ
/F2 1 Tf
3.164 0 TD
(.)Tj
/F3 1 Tf
0.6222 0 TD
0.0001 Tc
[(J)-334.6(Pharmacol)-343.5(Exp)-337.8(Ther)]TJ
/F10 1 Tf
9.9321 0 TD
(297)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(267–279.)]TJ
-16.7002 -1.2064 TD
[(Heystek)-546.5(HC,)-542.7(Thierr)-15.8(y)-548.1(AC,)-543.9(Soulard)-548.6(P)124.4(,)-543.5(Moulon)-545.4(C)-543.2(\()0.1(2003\).)-551.9(Phospho-)]TJ
1.1988 -1.1988 TD
0 Tc
[(diesterase)-334.9(4)-338.5(i)0(nhibitors)-333.9(reduce)-337.3(human)-334.6(dendritic)-337.9(cell)-336.9(inflammator)-20.2(y)]TJ
T*
0.0001 Tc
[(cytoki)-9.9(ne)-300.6(production)-313.4(a)0.1(nd)-308.8(Th1-polarizing)-316.7(capacity)70.4(.)]TJ
/F3 1 Tf
23.5138 0 TD
[(Int)-302.1(I)0.1(mmunol)]TJ
/F10 1 Tf
5.8045 0 TD
0 Tc
(15)Tj
/F2 1 Tf
1.1912 0 TD
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(827–8)-11.5(35.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Holgate)-365.3(ST)-365.5(\(2007\).)-369.9(E)0(pithelium)-372.5(d)-0.1(ysfuncti)-11.5(on)-359.5(in)-367.4(asthma.)]TJ
/F3 1 Tf
26.086 0 TD
[(J)-357.5(A)-0.1(llerg)-10.9(y)-363.2(C)-0.1(lin)]TJ
-24.8871 -1.1988 TD
0.0001 Tc
(Immunol)Tj
/F10 1 Tf
4.2945 0 TD
(120)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(1233–1244.)]TJ
-7.2765 -1.1988 TD
0 Tc
[(Houslay)-490.1(MD,)-481.3(Baillie)-489.1(GS,)-489.3(M)-0.1(aurice)-488.3(DH)-480.7(\(2007\).)-491.3(c)0(AMP-Specific)-490.6(phos)-9.5(-)]TJ
1.1988 -1.2064 TD
[(phod)-8.8(iesterase-4)-238.7(enzymes)-242.5(i)0(n)-238.4(t)0(he)-236.8(cardiovascular)-248.3(system:)-240.6(a)-233.6(molecular)]TJ
0 -1.1988 TD
[(toolb)-9.8(o)-0.1(x)-458.7(f)0(or)-454.4(genera)-11.1(ting)-452.8(c)0(ompa)-13.2(rtmentalized)-459.4(cAMP)-465.4(signaling.)]TJ
/F3 1 Tf
29.0375 0 TD
(Circ)Tj
-29.0375 -1.1988 TD
0.0001 Tc
(Res)Tj
/F10 1 Tf
1.7831 0 TD
(100)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(950–966.)]TJ
-4.765 -1.1988 TD
0 Tc
[(Houslay)-915(MD,)-913.8(Schafer)-918.9(P)124.3(,)-915.4(Zhang)-913.4(KY)-912.1(\(2005\).)-923.8(K)-0.1(eynote)-915.1(review:)]TJ
1.1988 -1.1988 TD
[(phosphod)-10.7(iesterase-4)-557.4(as)-555.9(a)-559.8(t)0(herapeutic)-559.9(target.)]TJ
/F3 1 Tf
22.0418 0 TD
0.0001 Tc
[(Drug)-559.3(Discov)-552.1(T)60.9(o)0.1(day)]TJ
/F10 1 Tf
-22.0418 -1.1988 TD
(10)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(1503–)-11.5(1519.)]TJ
-2.3901 -1.2064 TD
0 Tc
[(Inflazyme)-1313.8(pharmac)-11.1(euticals)-1307.4(\(2005\).)-1310.8(I)0(PL512,)-15.3(602.)-1308.6(http://www)64.9(.)]TJ
1.1988 -1.1988 TD
0.0001 Tc
[(inflazy)-10.7(me.com/IPL512)-15.9(602.php.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Jones)-434.8(NA,)-431.2(Boswell-Smit)-13.8(h)-429(V)133.8(,)-429.8(L)-0.1(ever)-434.8(R,)-432.1(Page)-433.8(CP)-434.1(\(2005\).)-438.2(The)-430.3(effec)-10(t)-429.3(o)-0.1(f)]TJ
1.1988 -1.1988 TD
[(selective)-454.5(phosphod)-10.7(iesterase)-453.3(isoenzyme)-452.7(i)0(nhibition)-460.4(o)-0.1(n)-450.6(n)-0.1(eutrophil)]TJ
T*
0.0001 Tc
[(functi)-10.5(on)]TJ
/F3 1 Tf
4.378 0 TD
0 Tc
[(in)-335.8(vitro)]TJ
/F2 1 Tf
3.164 0 TD
(.)Tj
/F3 1 Tf
0.6222 0 TD
0.0001 Tc
[(Pulm)-340.9(Pharmacol)-335.9(The)-9.9(r)]TJ
/F10 1 Tf
9.9245 0 TD
(18)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(93–10)-11.5(1.)]TJ
-20.4788 -1.1988 TD
[(Jones)-260.2(NA,)-256.6(Leport)-256.1(M)0(,)-253.1(Holand)-263.3(T)83(,)-247.6(V)50.4(os)-260.4(T)83(,)-255.2(Morgan)-256.6(M,)-253.1(Fink)-258.8(M)]TJ
/F3 1 Tf
26.3136 0 TD
0 Tc
[(et)-256.7(al.)]TJ
/F2 1 Tf
2.3901 0 TD
0.0001 Tc
(\(2007\).)Tj
-27.5048 -1.1988 TD
0 Tc
[(Phosph)-10.6(odiesterase)-508.2(\(PDE\))-508(7)-505.4(i)0(n)-504(i)0(nflammat)-11.9(ory)-511(c)0(ells)-507.5(from)-508.9(p)-0.1(atients)]TJ
0 -1.2064 TD
0.0001 Tc
[(with)-339.3(asthma)-336.3(and)-339.1(COPD.)]TJ
/F3 1 Tf
11.8593 0 TD
[(Pulm)-333.3(Pharmac)-11.6(ol)-331.8(Ther)]TJ
/F10 1 Tf
9.9245 0 TD
(20)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(60–68.)]TJ
-24.1663 -1.1988 TD
[(Kanehir)-9.7(o)-302.2(A,)-311.7(Ikemura)-310.7(T)83(,)-300.7(M)0(akela)-314.8(MJ,)-308.8(L)0(ahn)-306.9(M)0(,)-306.3(J)0.1(oetham)-313.7(A,)-304.1(Dakhama)-313.7(A)]TJ
/F3 1 Tf
1.1988 -1.1988 TD
0 Tc
[(et)-347.7(al.)]TJ
/F2 1 Tf
2.5798 0 TD
[(\(2001\).)-354.7(I)0(nhibition)-350.1(o)-0.1(f)-346.2(phosphod)-10.7(iesterase)-347.1(4)-346.1(attenua)-10.7(tes)-342.7(air)-14.5(way)]TJ
-2.5798 -1.1988 TD
[(hyperres)-10.3(ponsiveness)-645.5(and)-642.7(air)-14.5(way)-643.2(i)0(nflammat)-11.9(i)0(on)-646.9(in)-640.5(a)-643.3(model)-647.9(o)-0.1(f)]TJ
T*
[(secondar)-22.2(y)-601.3(allergen)-608.6(challenge.)]TJ
/F3 1 Tf
15.0233 0 TD
[(Am)-613.8(J)-600.3(R)-0.1(espir)-612.5(Crit)-605.3(Care)-610.3(M)-0.1(ed)]TJ
/F10 1 Tf
13.7031 0 TD
0.0001 Tc
(163)Tj
/F2 1 Tf
1.7831 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(173–1)-11.5(84.)]TJ
-1.1988 -1.2064 TD
[(Kohyama)-338.1(T)83(,)-323.5(Liu)-330.4(X)0(,)-329.8(Zhu)-329.6(YK)-9.1(,)-323.5(W)73.3(en)-331(FQ,)-326.8(W)73.3(ang)-333.8(HJ,)-328.3(F)0(ang)-329.7(Q)]TJ
/F3 1 Tf
26.1618 0 TD
0 Tc
[(et)-332.6(al.)]TJ
/F2 1 Tf
2.5418 0 TD
0.0001 Tc
(\(2002\).)Tj
-27.5048 -1.1988 TD
0 Tc
[(Phosph)-10.6(odiesterase)-910.3(4)-900(i)0(nhibitor)-899.3(cilomilast)-909.8(inhibit)-10.8(s)-899.1(fibroblast-)]TJ
T*
[(media)-10(ted)-562(col)-9.6(lagen)-569(gel)-566.6(degra)-9.2(d)-0.1(ation)-569(i)0(nduced)-576(by)-564.6(tumor)-576(necrosis)]TJ
T*
[(factor-al)-11.7(pha)-346.8(and)-354.4(n)-0.1(eutroph)-9.8(il)-347.2(elastase.)]TJ
/F3 1 Tf
17.6334 0 TD
[(Am)-348.2(J)-349.9(R)-0.1(espi)-10.5(r)-344.1(Cell)-354.3(Mol)-349.8(B)-0.1(iol)]TJ
/F10 1 Tf
11.6848 0 TD
(27)Tj
/F2 1 Tf
1.1912 0 TD
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(487–4)-11.5(94.)]TJ
-1.1988 -1.1988 TD
[(Kumar)-337.6(RK,)-342.6(Herbert)-339.3(C,)-335.6(Thomas)-340.5(PS,)-336.4(W)73.3(ollin)-341.4(L,)-335.7(Beume)-337.7(R,)-333.4(Y)76(a)0.1(ng)-333.8(M)]TJ
/F3 1 Tf
29.7811 0 TD
0 Tc
[(et)-332.6(al.)]TJ
/F2 1 Tf
-28.5823 -1.1988 TD
[(\(2003\).)-278.9(I)0(nhibition)-274.3(o)-0.1(f)-270.4(i)0(nflammat)-11.9(ion)-267.5(and)-270.9(remodeling)-279.5(b)-0.1(y)-268.6(r)0(oflumilast)]TJ
0 -1.2064 TD
0.0001 Tc
[(and)-430.2(d)0(examethas)-11.4(one)-428.4(in)-428(murine)-424.9(c)0.1(hroni)-12(c)-421.4(a)0(sthma)-10(.)]TJ
/F3 1 Tf
23.3469 0 TD
[(J)-425.7(Pharm)-12.7(acol)-429.4(Exp)]TJ
-23.3469 -1.1988 TD
(Ther)Tj
/F10 1 Tf
2.337 0 TD
(307)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(349–3)-11.5(55.)]TJ
-5.3189 -1.1988 TD
[(Kung)-489.4(TT)82.4(,)-490.4(C)0(rawley)-490(Y)91.2(,)-490.4(Luo)-489.5(B,)-491(Y)83.6(oung)-494.2(S,)-483.6(Kreut)-9.1(n)0(er)-484.7(W)96.1(,)-490.4(Chapman)-491.5(R)20.5(W)]TJ
1.1988 -1.1988 TD
[(\(2000\).)-293.9(I)0.1(nhibi)-9.9(tion)-286.9(o)0(f)-293(pulmonar)-14.5(y)-290.1(eosinophilia)-295.9(and)-293.6(airw)-12.5(ay)-288.4(hyperre-)]TJ
T*
0 Tc
[(sponsiven)-11.3(ess)-827.6(in)-837.8(allergic)-834.6(mice)-832.4(by)-837.7(rolipram:)-835.3(i)0(nvolvemen)-11.6(t)-831.4(o)-0.1(f)]TJ
T*
[(endogenous)-12(ly)-539.7(released)-546.9(corticosterone)-549(and)-544.1(c)0(atecholam)-13.3(ines.)]TJ
/F3 1 Tf
28.9616 0 TD
0.0001 Tc
[(Br)-541.8(J)]TJ
-28.9616 -1.2064 TD
0 Tc
[(Pharmac)-11.7(ol)]TJ
/F10 1 Tf
4.985 0 TD
0.0001 Tc
(130)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(457–4)-11.5(63.)]TJ
-7.9669 -1.1988 TD
0 Tc
[(Kuss)-426.9(H)-0.1(,)-416.8(Hoefgen)-427.5(N,)-420.3(Johanssen)-422.2(S,)-423(Kronbach)-431.5(T)82.9(,)-414.6(Rund)-9.9(feldt)-415.3(C)-421.9(\(2003\).)]TJ
/F3 1 Tf
1.1988 -1.1988 TD
[(In)-377.3(vivo)]TJ
/F2 1 Tf
3.4144 0 TD
[(efficacy)-376.9(in)-375(air)-14.5(way)-377.6(d)-0.1(isease)-381(models)-378.4(of)-384.2(N-\(3,5-dichloropyr)-16.7(i)0(d-)]TJ
-3.4144 -1.1988 TD
[(4-yl\)-)-9.8([1-\(4-fluorobenzyl\))-16(-)0(5-hydroxy-indole-3)-18(-yl]-glyo)-1078.2(xylic)-1078.6(acid)]TJ
T*
[(amide)-472.9(\()0(A)85(W)-0.1(D)-465.9(12–28)-11.6(1\),)-467.3(a)-468.8(selective)-469.6(phosphod)-10.7(iesterase)-468.5(4)-467.5(i)0(nhibitor)]TJ
T*
[(for)-340.6(i)0(nhaled)-334.5(administra)-13.1(tion.)]TJ
/F3 1 Tf
13.1416 0 TD
[(J)-334.7(Pharmacol)-336(Exp)-337.9(Ther)]TJ
/F10 1 Tf
9.9321 0 TD
0.0001 Tc
(307)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(373–385.)]TJ
-26.0556 -1.2064 TD
[(Lamontagne)-361.2(S)0.1(,)-347(M)0(eadows)-357(E,)-350.9(Luk)-348.4(P)124.4(,)-353.8(Normandin)-357.5(D)0(,)-354.3(Muise)-350.9(E,)-350.8(Boulet)-352.9(L)]TJ
/F3 1 Tf
1.1988 -1.1988 TD
0 Tc
[(et)-370.5(al.)]TJ
/F2 1 Tf
2.6253 0 TD
[(\(2001\).)-369.9(Local)-12.5(ization)-370.3(o)-0.1(f)-369(phosphod)-10.7(iesterase-4)-375.3(isoforms)-369.9(i)0(n)-375(t)0(he)]TJ
-2.6253 -1.1988 TD
[(medulla)-442.1(and)-430.3(nodose)-441.5(ganglion)-438.8(o)-0.1(f)-429.7(t)0(h)-8.5(e)-425.7(squirr)-10.1(el)-432.3(monkey)67.2(.)]TJ
/F3 1 Tf
26.5412 0 TD
[(Brain)-442.8(Res)]TJ
/F10 1 Tf
-26.5412 -1.1988 TD
0.0001 Tc
(920)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(84–96.)]TJ
-2.9819 -1.1988 TD
0 Tc
[(Landells)-1127.9(LJ,)-1119.9(Szilagyi)-1121.1(C,)-1124.8(Orr)-1119.1(LM,)-1122.8(Petersen)-1121.1(B)-0.1(,)-1120.8(A)-0.1(llen)-1121.7(J)0(M,)]TJ
1.1988 -1.1988 TD
0.0001 Tc
[(O’Conn)-10.9(or)-516.6(BJ)]TJ
/F3 1 Tf
6.7301 0 TD
0 Tc
[(et)-514.7(al.)]TJ
/F2 1 Tf
2.9212 0 TD
[(\(2000\).)-521.7(I)0(dentifi)-11.2(cation)-517.1(and)-521.3(quanti)-9.3(fication)-522.2(of)]TJ
-9.6513 -1.1988 TD
0.0001 Tc
[(phosphod)-10.6(iesterase)-286.3(\(PDE\)4)-292.5(s)0.1(ubtypes)-292(i)0.1(n)-283.8(CD4)-290.3(and)-286(CD8)-282.7(lym)-9.8(phocytes)]TJ
0 -1.2064 TD
0 Tc
[(from)-463.4(h)-0.1(ealthy)-460.1(and)-453(asthmatic)-465.3(subjects.)]TJ
/F3 1 Tf
18.4605 0 TD
[(Am)-454.5(J)-456.1(R)-0.1(espir)-460.7(Crit)-453.6(Care)-458.6(M)-0.1(ed)]TJ
/F10 1 Tf
-18.4605 -1.1988 TD
0.0001 Tc
(161)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(A200.)]TJ
-2.9819 -1.1988 TD
0 Tc
[(Leclerc)-273.4(O,)-277.9(Lagent)-9.8(e)-281.5(V)141.3(,)-285.7(Planquois)-284.2(J)0(M,)-278.6(Bertheli)-10.5(er)-275.8(C,)-282.6(Artola)-286.6(M,)-276(Eichholtz)]TJ
1.1988 -1.1988 TD
(T)Tj
/F3 1 Tf
1.0243 0 TD
[(et)-469.1(al.)]TJ
/F2 1 Tf
2.8226 0 TD
0.0001 Tc
[(\(2006\).)-476(I)0.1(nvolvem)-10.2(ent)-471.9(o)0(f)-467.5(MMP-12)-480.9(a)0.1(nd)-468.1(phosphod)-10.6(iesterase)]TJ
-3.8469 -1.1988 TD
0 Tc
[(type)-579(4)-581.3(in)-579.8(cigarett)-10.6(e)-577.4(s)0(moke-induced)-590.8(inflammation)-590.5(i)0(n)-579.8(m)-0.1(ice.)]TJ
/F3 1 Tf
29.3183 0 TD
0.0001 Tc
(Eur)Tj
-29.3183 -1.1988 TD
0 Tc
[(Respir)-339.3(J)]TJ
/F10 1 Tf
3.6193 0 TD
0.0001 Tc
(27)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(1102–11)-13.1(09.)]TJ
-6.0093 -1.2064 TD
0 Tc
[(Lehnart)-382.3(SE,)-382(W)73.2(ehrens)-379.4(XH,)-385.2(Reiken)-380.6(S,)-377.4(W)73.2(arrier)-383.3(S,)-377.4(Belevych)-384.8(AE,)-384.7(H)-0.1(ar)-10.1(vey)]TJ
1.1988 -1.1988 TD
0.0001 Tc
(RD)Tj
/F3 1 Tf
2.2914 0 TD
0 Tc
[(et)-878.9(al.)]TJ
/F2 1 Tf
3.6344 0 TD
[(\(2005\).)-878.3(Phosph)-10.6(odiesterase)-880(4D)-870.1(deficienc)-13.3(y)-874.5(in)-868.2(the)]TJ
ET
1 i 
50.797 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 179.1496 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-325.8(and)-335.3(respiratory)-326.4(disease)]TJ
/F9 1 Tf
15.1373 -1.2519 TD
[(D)-337.9(Spina)]TJ
7.0982 0 0 9.4646 50.7968 751.8612 Tm
0.0001 Tc
(314)Tj
ET
50.797 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 50.7968 31.2378 Tm
[(British)-331.9(J)0.1(ournal)-324.5(of)-334.4(Pharmacology)-320.4(\(2008\))]TJ
/F1 1 Tf
17.6049 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi7 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
50 29 142 10 re
f*
0.619608 0.619608 0.619608 rg
n
50 752 14 9 re
f*
0.619608 0.619608 0.619608 rg
n
178 751 113 19 re
f*
0.619608 0.619608 0.619608 rg
n
573 24 15 468 re
f*
0.156863 0.662745 0.360784 rg
n
49 64 241 676 re
f*
0.156863 0.662745 0.360784 rg
n
306 63 241 666 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 292 730 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 719 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
Q


endstream
endobj
253 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
254 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
255 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 906
>>
stream
H‰ä•rã0ùÿê;7M`)É®ÓIænzjë¤L €Œñÿ­êë¥'/«şÃ¼^¨ôO®züŒÇß×å«¥ã>(íªz«—5_õü=ã·„zÉUî¢¹G•/Şªåã ç ÇéPu¿\z¬
jCoû§j‚D>y=¿!LÕ¾ ç–ÉêÊÑ9xW3÷j'4•ß	hŸ¯+©ÓpŒ	°Z]Aùù’†Õ9öÃÕ9½sE$WGH_“¨ÚóêQG’±íÀy;-a³/Ò'Ê•fKÇÄœc³C	»ÍpÏÀìé©)Fö…'q ½C–~¢®R!Yió¥9Í×ÎîÚî}KSéQÜ,}o­<I‚Ç{)À_-²ÿ&M;¦0€ÀÅ$Y¦ªVîùPáwƒ%ÒšãTi°U‘´æDK%}ï)!‘ºİQÃÊ»0`cvI“/1WÚŞ¤ïÛü•(ióº§¥‘‡óÍÃg«'WØ(„ÆÎTµ‚ó;dN9>e:„Â¶\Ò·¹vIOùÓ´xYIbl¡šrÃV~=k“5§Ir²øLøª‚Ã“*±c	h?±4ºğ:1D†¥´ê4Ğá¦z‚5Ut†d¾ñpÒ7ãªp¶fAíHË”³ÍãZÙµÃtgJ[;ÉTLÊ„„„?œÓúë”r‚EÏ›¼f¦GãÃ®OØkÊÌ±é.>a¹¦)›$µ>§na·¼v!"j[WÄä=›û³¿çNI21±9ü°›×ÌÄ”Şe&Â2¯†E“åKfuKñ®ç-™²·LùØSW¬;ƒ
üm¦Ûxb·g”è±Q•mçqÅ›½ïºD°ß4šæÓ<Î–WÂ-??Á*o¦H±2-1°õİÈ|öL¢åì]¾<şì˜4”NµšÆÁuÉü1'
;ˆ+ÙcTwô“•™Ë-ğ›õ3}˜ÿ:O—(i;&ñX·KQUõ-DroîÏÅDlñ¬{ÔN­R´¡"_ÇØabü¦¡Ğl=ç1‘
l¶1œ‹“Ë%3i‘•J³3üxs½Êxx6=¯Ú¡p©v§y»åÀ‰ñšéÙšxƒƒ_ÈÔBÃUÆqT¦?' JO¨Û‚Æ}rK‘¶(jayßˆ–¬¹¸jîîw¯º^Ş¯Z Ï‚“Õ
endstream
endobj
256 0 obj
<<
/Contents 257 0 R
/CropBox [ 0 0 595 794 ]
/MediaBox [ 0 0 595 794 ]
/Resources <<
/ExtGState <<
/GS1 25 0 R
/gRLs0 <<
/ca 0.3
>>
/gRLs1 <<
/ca 1
>>
>>
/Font <<
/F1 26 0 R
/F1-0 258 0 R
/F10 246 0 R
/F2 30 0 R
/F3 33 0 R
/F4 36 0 R
/F7 45 0 R
/F9 55 0 R
>>
/XObject <<
/Xi8 259 0 R
>>
/ProcSet [ /ImageB /ImageC /ImageI /PDF /Text ]
>>
/Rotate 0
/Thumb 260 0 R
/Type /Page
/Annots [ ]
/Parent 2 0 R
>>
endobj
257 0 obj
<<
/Length 25425
>>
stream
q
q

BT
/F2 1 Tf
7.4718 0 0 7.4718 59.7543 718.7526 Tm
0 0 0 rg
/GS1 gs
0 Tc
0 Tw
[(r)-17.1(y)-0.1(anodine-receptor)-1247.8(c)0(omplex)-1256(promotes)-1249.3(heart)-1253.8(failure)-1250(and)]TJ
0 -1.2064 TD
[(arrhythm)-10.3(ias.)]TJ
/F3 1 Tf
6.3356 0 TD
(Cell)Tj
/F10 1 Tf
2.0486 0 TD
0.0001 Tc
(123)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(25–35.)]TJ
-11.3661 -1.1988 TD
[(Lim)-376.8(S)0.1(,)-377.3(Jatakanon)-374.8(A,)-380(Gordon)-376.3(D,)-377(Macdonald)-378.2(C,)-373.5(Chung)-375(KF)101.1(,)-376.6(B)0(arnes)-373.4(PJ)]TJ
1.1988 -1.1988 TD
0 Tc
[(\(2000\).)-673.4(Comparison)-673.6(o)-0.1(f)-664.9(h)-0.1(igh)-665(dose)-666.3(i)0(nhaled)-660.8(stero)-9.5(ids,)-663.1(low)-663.6(dose)]TJ
T*
[(inhaled)-281.4(steroids)-273.2(p)-0.1(lus)-279.4(l)0(ow)-276.7(dose)-271.8(t)0(heophy)-9.2(lline,)-272.4(and)-278.5(l)0(ow)-276.7(dose)-271.8(i)0(nhaled)]TJ
T*
[(stero)-9.5(ids)-407.9(alone)-418.3(in)-412.9(chroni)-12(c)-406.3(asthma)-419.9(in)-412.9(general)-419.8(practice.)]TJ
/F3 1 Tf
25.7749 0 TD
(Thorax)Tj
/F10 1 Tf
3.551 0 TD
0.0001 Tc
(55)Tj
/F2 1 Tf
1.1837 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(837–8)-11.5(41.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Louw)-700.1(C,)-692.3(W)20.1(illiams)-697.7(Z)-0.1(,)-694.2(V)50.3(enter)-694.7(L,)-692.4(Leichtl)-698.9(S,)-696.1(Schmid-W)14.6(irlitsch)-698.3(C,)]TJ
1.1988 -1.2064 TD
[(Breden)-11(broker)-401(D)]TJ
/F3 1 Tf
7.8531 0 TD
[(et)-400.9(al.)]TJ
/F2 1 Tf
2.686 0 TD
[(\(2007\).)-407.9(Roflumilast,)-411.9(a)-400.5(phosphodie)-10.4(sterase)-400.4(4)]TJ
-10.5391 -1.1988 TD
[(inhibit)-10.9(o)-0.1(r)44.8(,)-869.9(reduc)-10.3(es)-869.4(airw)-12.6(ay)-872.8(hyperresponsivene)-11(s)0(s)-864.8(aft)-8.7(er)-867.7(allergen)]TJ
T*
(challenge.)Tj
/F3 1 Tf
5.114 0 TD
(Respiration)Tj
/F10 1 Tf
5.1899 0 TD
0.0001 Tc
(74)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(411–417)-13.1(.)]TJ
-12.694 -1.1988 TD
0 Tc
[(Marti)-9.2(n-Chouly)-567.6(CA,)-559.1(Astier)-567.1(A,)-562.2(Jacob)-566.5(C)-0.1(,)-563.3(P)-0.1(runiaux)-567.6(M)-0.1(P)118.8(,)-558.8(Bertrand)-568.7(C)-0.1(,)]TJ
1.1988 -1.1988 TD
[(Lagent)-9.7(e)-858.2(V)-852.6(\(2004\).)-863.1(Modulation)-868.8(o)-0.1(f)-854.6(m)-0.1(atrix)-867.1(metalloprotein)-13.5(ase)]TJ
T*
0.0001 Tc
[(produc)-11.2(tion)-598(from)-599.9(human)-600.1(l)0.1(ung)-600.7(fibroblasts)-601.4(by)-594.8(type)-601.6(4)-596.4(phospho-)]TJ
0 -1.2064 TD
0 Tc
[(diestera)-11.8(se)-330.7(inhibitors.)]TJ
/F3 1 Tf
10.0611 0 TD
[(Li)-9.5(fe)-332.6(Sci)]TJ
/F10 1 Tf
3.4827 0 TD
0.0001 Tc
(75)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(823–8)-11.5(40.)]TJ
-15.9338 -1.1988 TD
[(Martor)-10.8(a)0.1(na)-281.4(P)48.6(A)0(,)-281.4(B)0(eume)-292.2(R,)-280.3(Lucattelli)-294.9(M,)-283.5(W)73.3(o)0(llin)-288.3(L,)-282.6(Lungarella)-292.5(G)-286.3(\()0.1(2005\).)]TJ
1.1988 -1.1988 TD
0 Tc
[(Ro)-8.7(flumilast)-868.8(fully)-863.9(preve)-8.2(nts)-861.9(e)0(mph)-9.1(ysema)-863.4(i)0(n)-868.2(m)-0.1(ice)-862.7(chronical)-13.6(ly)]TJ
T*
[(expos)-10.8(ed)-656.3(to)-663.3(cigarett)-10.6(e)-660.9(s)0(moke.)]TJ
/F3 1 Tf
14.6895 0 TD
[(Am)-666.9(J)-661(R)-0.1(espir)-665.6(Crit)-658.4(Care)-663.4(Me)-8.1(d)]TJ
/F10 1 Tf
14.0369 0 TD
0.0001 Tc
(172)Tj
/F2 1 Tf
1.7831 0 TD
0 Tc
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(848–8)-11.5(53.)]TJ
-1.1988 -1.1988 TD
[(McClusk)-11.7(i)0.1(e)-394.3(K)0(,)-401(K)0(lein)-399.1(U,)-399.8(Linnevers)-407.6(C,)-396.3(Ji)-403.7(YH,)-401.5(Y)83.6(a)0.1(ng)-402.1(A,)-395.2(Husfeld)-409.7(C)]TJ
/F3 1 Tf
29.7204 0 TD
0 Tc
[(et)-393.3(al.)]TJ
/F2 1 Tf
-28.5216 -1.1988 TD
[(\(2006\).)-461(P)-0.1(h)-8.7(o)-0.1(sphodiesterase)-464.5(type)-450(4)-459.9(i)0(nhibitors)-455.3(cause)-462.7(proinflamma-)]TJ
0 -1.2064 TD
[(tor)-12.7(y)-335.7(effects)]TJ
/F3 1 Tf
5.5465 0 TD
[(in)-335.8(vivo)]TJ
/F2 1 Tf
2.9516 0 TD
(.)Tj
/F3 1 Tf
0.6298 0 TD
[(J)-334.7(Pharmacol)-336(Exp)-337.9(Ther)]TJ
/F10 1 Tf
9.9321 0 TD
0.0001 Tc
(319)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(4)0.1(68–476.)]TJ
-22.0418 -1.1988 TD
[(Meha)-8.6(ts)-341.8(C,)-350.8(Jin)-347.1(SL,)-344(W)73.3(ahlstrom)-352.9(J)0.1(,)-348.8(L)0(aw)-342.4(E,)-350.9(Umetsu)-352.5(DT)82.5(,)-346.3(Conti)-344.5(M)-347(\(2003\).)]TJ
1.1988 -1.1988 TD
0 Tc
[(PDE)-9.7(4D)-255.5(play)-9.8(s)-254.1(a)-263.9(critical)-268.1(role)-258.5(in)-261.2(the)-267.2(c)0(ontrol)-261.5(o)-0.1(f)-262.8(air)-14.5(way)-263.8(s)0(mooth)-261.4(musc)-9.8(l)0(e)]TJ
T*
[(contra)-11.6(ction.)]TJ
/F3 1 Tf
6.07 0 TD
-0.063 Tc
[(FA)-63.1(S)-63(E)-63.1(B)-404.4(J)]TJ
/F10 1 Tf
3.8393 0 TD
0.0001 Tc
(17)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(1831–1841.)]TJ
-12.2918 -1.1988 TD
0 Tc
[(Nyce)-240(J)0(W)93.4(,)-232.5(Metzger)-241(WJ)-232.8(\(1997\).)-240.9(DNA)-237.2(antis)-9.5(ense)-236.9(therapy)-234.2(f)0(or)-242(asthma)-237.8(in)-238.4(an)]TJ
1.1988 -1.1988 TD
[(ani)-9(m)-0.1(al)-332.6(model.)]TJ
/F3 1 Tf
7.1778 0 TD
0.0001 Tc
(Nature)Tj
/F10 1 Tf
3.3006 0 TD
(385)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(7)0.1(21–725.)]TJ
-13.4603 -1.2064 TD
[(Ohta)-347.9(K)0(,)-347.9(F)0.1(ukuchi)-347.4(Y)91.2(,)-346.3(Grouse)-352.7(L)0(,)-343.3(M)0(izutani)-354.7(R)0(,)-341(R)0(abe)-351.5(K)0(F)101.1(,)-338.7(Renna)-9.4(rd)-346.3(SI)]TJ
/F3 1 Tf
29.7735 0 TD
0 Tc
[(et)-340.2(al.)]TJ
/F2 1 Tf
-28.5747 -1.1988 TD
[(\(2004\).)-301.6(A)-291.8(prospective)-294.3(clinical)-295.3(study)-294.1(of)-293.1(theophyllin)-10.5(e)-289.1(safety)-288.1(in)-291.5(3810)]TJ
T*
[(elderly)-340.2(with)-339.4(asthma)-336.4(or)-334.6(COPD.)]TJ
/F3 1 Tf
14.5681 0 TD
[(Respir)-339.3(Med)]TJ
/F10 1 Tf
5.1368 0 TD
0.0001 Tc
(98)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(1016–)-11.5(1024.)]TJ
-22.0949 -1.1988 TD
0 Tc
[(Parkkon)-11.4(en)-323.5(J,)-333.8(Hasala)-333.8(H,)-325.8(Moilanen)-335.9(E,)-328.2(Giemby)-9.8(cz)-325.2(MA)-9(,)-323.6(K)-0.1(ankaa)-10.1(n)-0.1(ranta)-329.7(H)]TJ
1.1988 -1.1988 TD
[(\(2007\).)-498.9(Phosphodiestera)-13.5(se)-482.5(4)-490.3(i)0(nhibitors)-493.3(delay)-488.5(human)-494(e)0(osinophil)]TJ
T*
[(and)-840(n)-0.1(eutro)-10.4(phil)-832.2(a)0(p)-8.9(optosis)-838.4(in)-837.8(the)-836.2(a)0(bsence)-847.5(and)-832.4(p)-0.1(res)-9.3(ence)-836.8(of)]TJ
T*
[(sal)-8.7(butamol.)]TJ
/F3 1 Tf
5.7969 0 TD
[(Pulm)-341(Pharmacol)-343.6(Ther)]TJ
/F10 1 Tf
9.9321 0 TD
0.0001 Tc
(21)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(499–506.)]TJ
-18.1115 -1.2064 TD
0 Tc
[(Perez-T)56.5(orres)-598.9(S,)-589.9(Miro)-597.2(X,)-595.4(Palacios)-597.8(J)0(M,)-597.3(Cortes)-598.3(R,)-591.5(Puigdomenec)-14.6(h)-588.4(P)124.3(,)]TJ
1.1988 -1.1988 TD
[(Mengod)-366.4(G)-362.3(\()0(2000\).)-369.9(Phosphodi)-11.3(esterase)-363.2(type)-358.9(4)-361.3(iso)-9.2(zymes)-359.1(express)-10.8(ion)]TJ
T*
[(in)-314.3(human)-319.5(b)-0.1(rain)-308.1(exami)-11.7(n)-0.1(ed)-311.3(by)]TJ
/F3 1 Tf
14.1052 0 TD
[(in)-313(situ)]TJ
/F2 1 Tf
3.073 0 TD
[(hybridiza)-10.8(tion)-309.8(h)-0.1(istochemi)-11.7(str)-10(y)]TJ
-17.1782 -1.1988 TD
[(and[3)-10.8(H)-0.1(]rolipram)-856.3(binding)-850.3(autoradiography)58.5(.)-847.1(Comparison)-855.7(w)-0.1(ith)]TJ
T*
0.0001 Tc
[(monkey)-342.4(a)0.1(nd)-331.5(rat)-338.4(brain.)]TJ
/F3 1 Tf
10.9261 0 TD
[(J)-334.6(Chem)-337.2(N)0(eur)-8.5(oanat)]TJ
/F10 1 Tf
8.4905 0 TD
(20)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(349–374.)]TJ
-21.8066 -1.1988 TD
0 Tc
[(Peter)-391.7(D,)-384.7(Jin)-385.1(SL,)-382(Conti)-390.1(M)-0.1(,)-382.2(H)-0.1(atzelman)-10.8(n)-383.5(A)-0.1(,)-380.1(Z)-0.1(itt)-385.9(C)-384(\()0(2007\).)-392.7(D)-0.1(ifferential)]TJ
1.1988 -1.2064 TD
0.0001 Tc
[(express)-10.7(ion)-381.2(a)0.1(nd)-377.1(function)-385.1(o)0(f)-384.1(phosphodiestera)-11.8(se)-376.2(4)-376.3(\()0.1(PDE4\))-383.5(subt)-9.7(ypes)]TJ
0 -1.1988 TD
[(in)-473.5(human)-471.1(p)0(rimar)-13.1(y)-472.2(CD4)]TJ
/F7 1 Tf
11.7379 0 TD
0 Tc
()Tj
/F2 1 Tf
1.4037 0 TD
0.0001 Tc
[(T)-402.6(cells:)-474.3(predominant)-473.7(role)-470.9(of)-467.5(PDE)-9.6(4D.)]TJ
/F3 1 Tf
-13.1416 -1.1988 TD
[(J)-334.6(I)0.1(mmunol)]TJ
/F10 1 Tf
4.9623 0 TD
(178)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(4820–4831.)]TJ
-7.9442 -1.1988 TD
0 Tc
[(Phillips)-368.2(P)124.3(,)-361.5(B)-0.1(ennetts)-364(M,)-367.1(Banner)-366.3(K)-0.1(,)-355.6(W)73.2(ard)-367.5(J,)-356.5(W)73.2(essels)-360.7(D,)-362(Fuhr)-366.7(R)-359(\()0(2007)-13.4(\).)]TJ
1.1988 -1.1988 TD
0.0001 Tc
[(The)-604.7(PDE)-9.6(4)-596.4(i)0.1(nhibit)-10.8(o)0(r)-600.1(UK-500)-176(001)-605.6(does)-605.5(not)-598.9(signi)-11(ficantly)-601(inhibit)]TJ
T*
0 Tc
[(air)-14.5(way)-339.7(responses)-338.9(to)-337(allergen)-335.5(and)-339.2(h)-0.1(istamine.)]TJ
/F3 1 Tf
20.9796 0 TD
0.0001 Tc
[(Eur)-335.2(Resp)-339.4(J)]TJ
/F2 1 Tf
4.7877 0 TD
(490s.)Tj
-26.9661 -1.1988 TD
[(Rabe)-662.6(KF)101.1(,)-657.3(B)0(ateman)-660.1(ED,)-662.4(O’Donnell)-665.7(D,)-657.8(W)20.2(itte)-660.9(S,)-658.1(Bredenbroker)-662.2(D,)]TJ
1.1988 -1.2064 TD
0 Tc
[(Bethke)-497.9(TD)-486.7(\(2005\).)-498.9(Roflumilast–an)-501.2(oral)-491.3(anti-inflammator)-19.2(y)-495.1(treat-)]TJ
0 -1.1988 TD
[(ment)-503.7(for)-484.7(c)0(hronic)-501.8(obstructive)-498.6(pulmo)-10.3(nar)-11.9(y)-495.1(disease:)-499.7(a)-491.6(randomise)-10.9(d)]TJ
T*
[(contro)-12.1(lled)-335.7(trial.)]TJ
/F3 1 Tf
7.6862 0 TD
(Lancet)Tj
/F10 1 Tf
3.2019 0 TD
0.0001 Tc
(366)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(563–5)-11.5(71.)]TJ
-13.87 -1.1988 TD
0 Tc
[(Ren)23.2(n)-0.1(ar)18.4(d)-238.2(S)0(I)-231(\()0(2)15.5(0)-0.1(0)13.5(4)-0.1(\))15.5(.)-240.1(T)60.1(r)0(e)20.1(atm)18.7(ent)-221.6(o)-0.1(f)-232.4(sta)24(bl)14.9(e)-236(c)0(h)14.5(r)0(o)14.4(n)-0.1(ic)-227.3(ob)15.2(str)20.4(uc)18(tiv)17.5(e)-236(p)-0.1(u)19.2(l)0(mo)15.9(nary)]TJ
1.1988 -1.1988 TD
[(disease)-9.2(.)]TJ
/F3 1 Tf
3.8696 0 TD
(Lancet)Tj
/F10 1 Tf
3.2019 0 TD
0.0001 Tc
(364)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(7)0.1(91–8)-11.5(02.)]TJ
-10.0535 -1.1988 TD
0 Tc
[(Renna)-9.5(rd)-680.2(SI,)-675.9(Schachter)-690.2(N,)-678.2(Strek)-684.9(M,)-678.1(Ri)-9(ckard)-676.9(K,)-681.8(Amit)-683.5(O)-682.7(\(2006\).)]TJ
1.1988 -1.2064 TD
[(Cilomila)-14.4(st)-539.2(for)-545.4(COPD:)-553(results)-545.1(of)-551.1(a)-544.7(6)-0.1(-month,)-546.5(placebo-con)-13(trolled)]TJ
0 -1.1988 TD
[(stu)-8.6(dy)-262.8(of)-262.8(a)-263.9(poten)-10.9(t,)-259.6(selective)-272.4(i)0(nhibitor)-269.5(o)-0.1(f)-270.4(phosphodiestera)-11.9(se)-262.4(4.)]TJ
/F3 1 Tf
28.3546 0 TD
(Chest)Tj
/F10 1 Tf
-28.3546 -1.1988 TD
0.0001 Tc
(129)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(56–66.)]TJ
-2.9819 -1.1988 TD
0 Tc
[(Robichaud)-269.3(A)-0.1(,)-258.7(Savoie)-257.5(C,)-259.8(Stamatiou)-263.8(PB,)-260.4(Lachance)-261.2(N,)-260.9(Jolicoeu)-11.3(r)-252.4(P)124.3(,)-262.9(Rasori)]TJ
1.1988 -1.1988 TD
(R)Tj
/F3 1 Tf
0.956 0 TD
[(et)-325(al.)]TJ
/F2 1 Tf
2.5266 0 TD
[(\(2002)-13.4(a\).)-316.9(Assessing)-330.8(t)0(he)-320.3(emetic)-321.5(potential)-330.3(of)-323.5(PDE4)-325.4(inhibitors)]TJ
-3.4827 -1.1988 TD
[(in)-337(rats.)]TJ
/F3 1 Tf
3.6117 0 TD
0.0001 Tc
[(Br)-336.9(J)-327(Pharmac)-11.6(o)0.1(l)]TJ
/F10 1 Tf
6.9502 0 TD
(135)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(113–118.)]TJ
-13.5438 -1.2064 TD
0 Tc
[(Robichaud)-269.3(A)-0.1(,)-266.3(Savoie)-265.1(C)-0.1(,)-259.8(Stamatiou)-271.4(PB,)-260.4(T)60.1(attersall)-267.8(FD,)-266.8(Chan)-261.4(C)-0.1(C)-259.5(\()0(2001)-13.4(\).)]TJ
1.1988 -1.1988 TD
[(PDE)-9.7(4)-642(i)0(nhibitor)-11.6(s)-641.1(induce)-648.9(e)0(mesis)-654.2(in)-648.1(ferrets)-649.2(via)-644.2(a)-643.3(noradren)-12.8(ergic)]TJ
T*
0.0001 Tc
[(pathway)68.1(.)]TJ
/F3 1 Tf
4.5601 0 TD
0 Tc
[(Neuropharmac)-12.3(ology)]TJ
/F10 1 Tf
8.9685 0 TD
0.0001 Tc
(40)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(262–269.)]TJ
-15.9111 -1.1988 TD
0 Tc
[(Robichaud)-603.2(A)-0.1(,)-585(Stama)-10.7(tiou)-587(PB,)-594.3(Jin)-597.6(SL,)-586.9(L)-0.1(achance)-602.7(N,)-587.2(Macdo)-9.8(n)-0.1(ald)-588.7(D,)]TJ
1.1988 -1.1988 TD
[(Lal)-9.6(i)0(berte)-501.2(F)]TJ
/F3 1 Tf
5.5844 0 TD
[(et)-507.1(al.)]TJ
/F2 1 Tf
2.8984 0 TD
[(\(2002b\).)-515.3(D)-0.1(eletion)-508(o)-0.1(f)-505.6(phosphodie)-10.4(sterase)-506.7(4D)-505.9(in)]TJ
-8.4829 -1.1988 TD
[(mice)-961.4(shortens)-954.6(alpha)-10.3(\(2\)-adrenoceptor-media)-18.3(ted)-948.9(anesthesi)-11.1(a,)-951.7(a)]TJ
T*
[(behavio)-11.6(ral)-333.2(correlate)-336.3(of)-338.6(emesis)-9.3(.)]TJ
/F3 1 Tf
14.6212 0 TD
[(J)-334.7(C)-0.1(lin)-338.3(Invest)]TJ
/F10 1 Tf
5.7514 0 TD
0.0001 Tc
(110)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(1045–1052.)]TJ
11.0475 77.9999 TD
[(Robichaud)-337.5(A,)-334.5(T)60.2(attersall)-336(FD,)-335(Choud)-10.8(hury)-342.2(I)0.1(,)-333.7(Rodger)-338.1(I)0.1(W)-331.4(\()0.1(1999\).)-339.5(Emesis)]TJ
1.1988 -1.2064 TD
0 Tc
[(induced)-651.8(by)-648(inhibitor)-11.6(s)-641.1(of)-649.7(type)-647.3(IV)-650.3(cyclic)-649.8(nucleot)-11.7(i)0(de)-647.7(phospho-)]TJ
0 -1.1988 TD
[(diesterase)-342.5(\(PDE)-338.5(IV\))-334.2(i)0(n)-337(t)0(he)-335.4(ferret.)]TJ
/F3 1 Tf
15.5013 0 TD
[(Neur)-8.6(opharmacology)]TJ
/F10 1 Tf
8.9685 0 TD
0.0001 Tc
(38)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(289–2)-11.5(97.)]TJ
-26.8599 -1.1988 TD
0 Tc
[(Roth)-244.7(BL,)-245.3(Sheffler)-246.9(DJ,)-243.1(K)-0.1(roeze)-249(WK)-239.5(\(2004\).)-248.5(M)-0.1(agic)-247.6(shotguns)-244.5(versu)-8.8(s)-238.9(m)-0.1(agic)]TJ
1.1988 -1.1988 TD
[(bullets:)-552.2(selectively)-546.4(non-selective)-553.2(drugs)-545.5(for)-545.4(m)-0.1(ood)-548.2(d)-0.1(isorders)-546.9(and)]TJ
T*
[(schizoph)-11.6(renia.)]TJ
/F3 1 Tf
7.1854 0 TD
[(Nat)-338.6(R)-0.1(ev)-331.3(Drug)-339.4(Discov)]TJ
/F10 1 Tf
9.4996 0 TD
(3)Tj
/F2 1 Tf
0.5918 0 TD
0.0001 Tc
[(:)-338.7(353–359.)]TJ
-18.4757 -1.1988 TD
0 Tc
[(Sanz)-817.4(M)-0.1(J)-8.1(,)-816.8(Cortijo)-818.4(J,)-819.4(T)60.1(a)0(ha)-820.2(MA,)-818.1(Cerda-Nicola)-14.3(s)-815.6(M)-0.1(,)-814.7(S)0(chatton)-823.1(E,)]TJ
1.1988 -1.1988 TD
[(Burgbac)-11.9(her)-628.9(B)]TJ
/F3 1 Tf
7.1626 0 TD
[(et)-628.5(al.)]TJ
/F2 1 Tf
3.1488 0 TD
[(\(2007\).)-635.5(Roflumilast)-642.3(inhibits)-636.7(leukocyte-en-)]TJ
-10.3115 -1.2064 TD
[(dothelial)-370.6(cell)-367.2(inte)-8.2(ractions,)-368.2(e)0(xpressi)-9.8(on)-367.1(of)-361.4(adhes)-9.8(i)0(on)-366.1(molecules)-372.3(and)]TJ
0 -1.1988 TD
[(microvasc)-13.3(ular)-333.7(permeabili)-12(ty)77.2(.)]TJ
/F3 1 Tf
13.3085 0 TD
0.0001 Tc
[(Br)-329.3(J)-334.6(Pharmac)-11.6(ol)]TJ
/F10 1 Tf
6.9502 0 TD
(152)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(481–492.)]TJ
-23.2406 -1.1988 TD
0 Tc
[(Shichijo)-411.1(M,)-412.6(Inagaki)-411.6(N,)-405.1(Nakai)-412.9(N)-0.1(,)-405.1(K)-0.1(imata)-412.8(M,)-405(Nakahat)-10.8(a)-400.5(T)82.9(,)-407.1(S)-0.1(eriza)-10.8(wa)-406.1(I)]TJ
/F3 1 Tf
1.1988 -1.1988 TD
[(et)-325(al.)]TJ
/F2 1 Tf
2.5266 0 TD
[(\(1998\).)-324.4(The)-324(effects)-321.6(of)-323.5(anti-asthm)-10.9(a)-317(drugs)-325.5(on)-321.6(mediator)-326.2(release)]TJ
-2.5266 -1.1988 TD
[(from)-342(c)0(ultured)-340.5(human)-334.6(m)-0.1(ast)-341.6(cells.)]TJ
/F3 1 Tf
15.7897 0 TD
[(Clin)-338.3(Exp)-330.3(A)-0.1(llerg)-10.9(y)]TJ
/F10 1 Tf
7.4737 0 TD
0.0001 Tc
(28)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(1228–1236)-14.7(.)]TJ
-25.6459 -1.1988 TD
0 Tc
[(Smith)-305.5(SJ,)-296.6(Brooke)-10.2(s-Fazakerley)-309.1(S,)-294(Donnelly)-311.6(LE,)-302.4(Barnes)-297.6(PJ,)-308(B)-0.1(arnette)-303.4(MS,)]TJ
1.1988 -1.2064 TD
0.0001 Tc
[(Giemby)-9.7(cz)-249.3(MA)-251.7(\(2003\).)-256(Ubiqui)-10.7(tous)-250.1(expressi)-9.7(on)-245.6(of)-255.1(phosphod)-10.6(iesterase)]TJ
0 -1.1988 TD
[(7A)-455.6(in)-450.7(human)-455.9(proi)-10.2(nflammator)-21(y)-449.5(and)-452.9(immune)-462.3(cells.)]TJ
/F3 1 Tf
24.9023 0 TD
0 Tc
[(Am)-454.5(J)-456.1(P)-0.1(hysiol)]TJ
-24.9023 -1.1988 TD
[(Lung)-342.1(Cell)-331.5(Mol)-334.6(Physiol)]TJ
/F10 1 Tf
10.008 0 TD
0.0001 Tc
(284)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(L279–L289.)]TJ
-12.9899 -1.1988 TD
[(Smith)-715.2(SJ,)-721.4(Cieslinski)-720.3(LB,)-715.6(Newton)-717.2(R,)-720.3(Donnelly)-713.6(LE,)-719.7(Fenwick)-716.9(PS,)]TJ
1.1988 -1.1988 TD
[(Nichol)-10.6(son)-590.7(A)0(G)]TJ
/F3 1 Tf
7.4737 0 TD
0 Tc
[(et)-590.5(al.)]TJ
/F2 1 Tf
3.0654 0 TD
[(\(2004\).)-597.5(D)-0.1(iscover)-18.2(y)-586.1(o)-0.1(f)-589(B)-8.2(RL)-583.6(50481)-599.7([3-\(N,N-)]TJ
-10.5391 -1.1988 TD
[(dimethylsulf)-15.1(onamido\)-4-methyl)-15.9(-nitrobenzene],)-309.3(a)-301.9(selective)-310.3(inhibi-)]TJ
T*
[(tor)-361.7(o)-0.1(f)-353.8(phosphod)-10.7(iesterase)-362.3(7:)]TJ
/F3 1 Tf
13.2099 0 TD
[(in)-351(vitro)]TJ
/F2 1 Tf
3.5358 0 TD
[(studies)-356.5(in)-359.8(human)-357.4(mono)-10.6(cytes,)]TJ
-16.7457 -1.2064 TD
0.0001 Tc
[(lung)-327.5(macroph)-11.5(ages,)-323.9(and)-331.5(CD8)]TJ
/F7 1 Tf
13.5817 0 TD
0 Tc
()Tj
/F2 1 Tf
1.2595 0 TD
[(T)60.1(-lymph)-10.1(ocytes.)]TJ
/F3 1 Tf
7.5041 0 TD
[(Mol)-327(Pharmacol)]TJ
/F10 1 Tf
6.973 0 TD
(66)Tj
/F2 1 Tf
1.1912 0 TD
(:)Tj
-30.5095 -1.1988 TD
0.0001 Tc
[(1679–)-11.5(1689.)]TJ
-1.1988 -1.1988 TD
0 Tc
[(Spina)-399.7(D)-395.1(\(2003\).)-407.9(Phosphodiest)-12.5(erase-4)-397.8(inhibitors)-402.2(in)-397.7(the)-396.1(treat)-9.7(m)-0.1(ent)-397.5(o)-0.1(f)]TJ
1.1988 -1.1988 TD
[(inflammat)-11.9(ory)-344(l)0(ung)-335.2(disease)-9.2(.)]TJ
/F3 1 Tf
13.1264 0 TD
0.0001 Tc
(Drugs)Tj
/F10 1 Tf
2.8833 0 TD
(63)Tj
/F2 1 Tf
1.1837 0 TD
[(:)-338.7(2575–2594.)]TJ
-18.3922 -1.1988 TD
0 Tc
[(Spina)-589.4(D)-592.4(\(2004\).)-590(The)-589.6(potentia)-12.6(l)-583.3(o)-0.1(f)-589(PDE4)-591(inhibit)-10.9(o)-0.1(rs)-588.7(in)-587.4(respirator)-21.3(y)]TJ
1.1988 -1.1988 TD
[(disease)-9.2(.)]TJ
/F3 1 Tf
3.8696 0 TD
[(Curr)-338.5(D)-0.1(rug)-331.8(T)60.8(argets)-341.3(Inflamm)-341.8(A)-0.1(llergy)]TJ
/F10 1 Tf
15.6607 0 TD
(3)Tj
/F2 1 Tf
0.5918 0 TD
0.0001 Tc
[(:)-338.7(231–236.)]TJ
-21.321 -1.2064 TD
0 Tc
[(Spina)-680.5(D)-0.1(,)-680.6(H)-0.1(a)-8.2(rrison)-677.2(S)0(,)-680.9(P)-0.1(age)-684.2(C)-0.1(P)-684.5(\()0(1995\).)-681(Regulat)-10.6(ion)-677.2(b)-0.1(y)-686(phospho-)]TJ
1.1988 -1.1988 TD
[(diesterase)-1351.6(isoenzymes)-1351.8(o)-0.1(f)-1347.8(non-adrener)-10.8(gic)-1343.9(non-choli)-12.8(nergic)]TJ
T*
[(contracti)-11.6(on)-344.3(in)-352.2(guinea-pig)-349.9(iso)-9.2(lated)-346.9(main)-351.9(bronchus.)]TJ
/F3 1 Tf
24.1587 0 TD
0.0001 Tc
[(Br)-344.5(J)-349.8(Pharmacol)]TJ
/F10 1 Tf
-24.1587 -1.1988 TD
(116)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(2334–2340.)]TJ
-2.9819 -1.1988 TD
0 Tc
[(Sullivan)-336.6(P)124.3(,)-323.6(Bekir)-330.4(S,)-331.9(Jaffar)-331.8(Z,)-322.4(Page)-335.2(C,)-328.1(Jeffer)-10.4(y)-328.2(P)124.3(,)-331.2(Costello)-335.3(J)-321.3(\()0(1994\).)-339.6(Anti-)]TJ
1.1988 -1.1988 TD
[(inflammat)-11.9(ory)-670.3(effects)-663(of)-657.3(low-dose)-663(o)-0.1(ral)-658.2(theophy)-9.2(lline)-662.1(i)0(n)-655.7(atopic)]TJ
T*
[(asthma)-730.9([published)-728.3(erratum)-730(a)-0.1(ppears)-722.1(in)-724(Lancet)-729.5(1994)-724.1(Jun)-728(11;)]TJ
0 -1.2064 TD
0.0001 Tc
[(343\(8911\))-14.5(:1512].)]TJ
/F3 1 Tf
8.2704 0 TD
0 Tc
(Lancet)Tj
/F10 1 Tf
3.2019 0 TD
0.0001 Tc
(343)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(1)0(006–)-11.5(1008.)]TJ
-14.4543 -1.1988 TD
0 Tc
[(T)60.1(akahashi)-387.1(M)-0.1(,)-382.2(T)67.7(er)-17.9(williger)-381.6(R,)-379(Lane)-387.1(C,)-381.2(Mezes)-384.9(PS,)-382(Conti)-382.6(M)-0.1(,)-382.2(Duman)-384.1(R)-0.1(S)]TJ
1.1988 -1.1988 TD
[(\(1999\).)-847.9(Chronic)-843.6(a)0(ntidepressant)-848.6(a)0(dministration)-846.4(i)0(ncr)-9.2(eases)-834.2(the)]TJ
T*
[(expressi)-9.8(on)-556.8(of)-566.3(cAMP-specif)-12.3(ic)-557.1(phosphod)-10.7(iesterase)-559.6(4A)-569.5(and)-559.3(4)-0.1(B)-559.1(iso)-9.2(-)]TJ
T*
(forms.)Tj
/F3 1 Tf
3.3082 0 TD
[(J)-334.7(N)-0.1(eurosci)]TJ
/F10 1 Tf
4.7119 0 TD
0.0001 Tc
(19)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(610–618.)]TJ
-10.4101 -1.1988 TD
0 Tc
[(Timmer)-604.4(W)96(,)-611.9(L)-0.1(eclerc)-607.2(V)133.8(,)-611.9(Birraux)-614(G,)-609.9(Neuha)-9.3(user)-613.9(M,)-609.9(Hatzelmann)-614.3(A)-0.1(,)]TJ
1.1988 -1.2064 TD
[(Bethke)-535.8(T)]TJ
/F3 1 Tf
4.8105 0 TD
[(et)-529.8(al.)]TJ
/F2 1 Tf
2.944 0 TD
0.0001 Tc
[(\(2002\).)-536.7(The)-528.8(new)-533.9(phosphodie)-10.3(sterase)-529.3(4)-528.1(i)0.1(nhibitor)]TJ
-7.7545 -1.1988 TD
0 Tc
[(roflumil)-13.4(ast)-347.8(is)-351.8(efficacious)-361.9(in)-352.2(exercise-induced)-349.6(asthma)-359.1(and)-354.4(l)0(eads)-353.8(to)]TJ
T*
[(suppressi)-11.7(on)-336.7(of)-346.2(LPS-stimulated)-351.5(TNF-alpha)]TJ
/F3 1 Tf
19.5986 0 TD
[(ex)-342.8(vivo)]TJ
/F2 1 Tf
3.0426 0 TD
(.)Tj
/F3 1 Tf
0.6298 0 TD
[(J)-342.3(C)-0.1(lin)-345.9(Pharmacol)]TJ
/F10 1 Tf
-23.271 -1.1988 TD
0.0001 Tc
(42)Tj
/F2 1 Tf
1.1912 0 TD
[(:)-331.1(297–3)-11.5(0)0(3.)]TJ
-2.3901 -1.1988 TD
0 Tc
[(T)60.1(o)-0.1(rphy)-320.7(TJ)-321.8(\(1998\).)-324.4(Phosphodiestera)-13.5(se)-315.6(isozymes:)-327.5(molecular)-322.6(targets)-322.1(for)]TJ
1.1988 -1.1988 TD
[(novel)-330.8(antiasthma)-334.6(agents.)]TJ
/F3 1 Tf
12.1477 0 TD
[(Am)-325.5(J)-327.1(R)-0.1(espir)-324.2(Crit)-332.2(Care)-329.6(Med)]TJ
/F10 1 Tf
12.0187 0 TD
0.0001 Tc
(157)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(351–370.)]TJ
-27.1482 -1.1988 TD
0 Tc
[(van)-247.1(Schalkwyk)-252.7(E,)-252.3(Str)-14.6(ydom)-247.8(K,)-249.4(W)20.1(illiams)-250(Z)-0.1(,)-246.5(V)50.3(enter)-254.6(L,)-244.7(Leichtl)-258.8(S)0(,)-240.9(S)0(ch)-9(mid-)]TJ
1.1988 -1.2064 TD
[(W)20.1(irlitsch)-857.6(C)]TJ
/F3 1 Tf
6.7226 0 TD
[(et)-848.5(al.)]TJ
/F2 1 Tf
3.5889 0 TD
[(\(2005\).)-855.5(Roflumilast,)-859.6(an)-852.2(oral,)-852.8(once-d)-11.5(aily)]TJ
-10.3115 -1.1988 TD
[(phosphod)-10.7(iesterase)-1128.6(4)-1120(i)0(nhibit)-10.9(o)-0.1(r)44.8(,)-1127.9(attenuates)-1127.2(allergen-induc)-13.2(ed)]TJ
T*
[(asthma)-10.1(tic)-333.9(reactions.)]TJ
/F3 1 Tf
9.7803 0 TD
[(J)-334.7(A)-0.1(llergy)-336.1(Clin)-338.3(Immu)-9.3(nol)]TJ
/F10 1 Tf
10.486 0 TD
0.0001 Tc
(116)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(292–298.)]TJ
-23.2482 -1.1988 TD
0 Tc
[(V)50.3(estbo)-244(J)0(,)-242.7(T)60.1(an)-237.6(L,)-244.7(Atkinson)-246.9(G)-240.9(\(2007\).)-248.5(A)-238.7(6)-239.9(w)-0.1(eek)-244.2(study)-241(of)-240(th)-8.5(e)-236(efficacy)-247.9(and)]TJ
1.1988 -1.1988 TD
0.0001 Tc
[(safety)-485.3(of)-482.7(UK-500)-168.4(001)-484.2(d)0(r)-12.4(y)-479.8(powder)-483.3(f)0.1(or)-477.1(inhala)-10.4(tion)-476.6(\()0.1(DPI)-10.1(\))-472.9(i)0.1(n)-481.1(a)0.1(dults)]TJ
T*
0 Tc
[(with)-392.5(chronic)-395.6(obstructive)-400(pulmonar)-14.6(y)-388.9(d)-0.1(isease)-396.2(\(COPD\).)]TJ
/F3 1 Tf
25.5928 0 TD
0.0001 Tc
[(Eur)-388.3(R)-8.1(espir)-391.8(J)]TJ
/F2 1 Tf
-25.5928 -1.2064 TD
(612s.)Tj
-1.1988 -1.1988 TD
[(W)73.3(ang)-364.2(H,)-363.6(Peng)-363.6(MS,)-360.1(Chen)-369.9(Y)98.8(,)-369(G)0(eng)-364.6(J)0.1(,)-356.4(R)0(o)-8.6(b)0(inson)-359.8(H)0(,)-363.6(Housla)-10.1(y)-358.4(M)0(D)]TJ
/F3 1 Tf
29.7507 0 TD
0 Tc
[(et)-362.9(al.)]TJ
/F2 1 Tf
-28.5519 -1.1988 TD
[(\(2007\).)-400.3(Structures)-394.7(of)-391.8(the)-388.5(f)0(our)-394.2(subfamilies)-399.7(of)-384.2(phos)-9.5(phodiesterase-4)]TJ
T*
[(provide)-425.6(insight)-421.7(i)0(nto)-416(t)0(he)-418.9(selectivity)-421(of)-414.5(th)-8.5(eir)-411.5(inhibit)-10.9(o)-0.1(rs.)]TJ
/F3 1 Tf
26.3743 0 TD
[(Biochem)-423(J)]TJ
/F10 1 Tf
-26.3743 -1.1988 TD
0.0001 Tc
(408)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(193–201.)]TJ
-2.9819 -1.1988 TD
0 Tc
[(W)73.2(einberger)-334.3(M,)-336.7(Hendeles)-332.9(L)-330.9(\()0(1996\).)-339.6(Theophyl)-12(line)-329.2(i)0(n)-337(asthma.)]TJ
/F3 1 Tf
28.347 0 TD
[(N)-332.6(E)-0.1(ngl)-337.6(J)]TJ
-27.1482 -1.2064 TD
0.0001 Tc
(Med)Tj
/F10 1 Tf
2.1928 0 TD
(334)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-331.1(1)0.1(380–13)-13.1(88.)]TJ
-5.1747 -1.1988 TD
[(W)73.3(eston)-466.8(MC,)-462.5(Anderson)-467.2(N)0(,)-465.7(P)0(eachell)-465.9(PT)-460.3(\(1997)-13.4(\).)-462.6(Effects)-461.9(of)-467.5(phospho-)]TJ
1.1988 -1.1988 TD
0 Tc
[(diesterase)-668.7(inhibit)-10.9(o)-0.1(rs)-664.5(on)-670.6(human)-668.5(lung)-669.1(mast)-667.9(cell)-663.1(and)-673.1(b)0(asophil)]TJ
T*
0.0001 Tc
[(functi)-10.5(on.)]TJ
/F3 1 Tf
4.6739 0 TD
[(Br)-336.9(J)-327(Pharm)-12.7(acol)]TJ
/F10 1 Tf
6.9502 0 TD
(121)Tj
/F2 1 Tf
1.7831 0 TD
[(:)-338.7(287–295.)]TJ
-14.606 -1.1988 TD
[(X)16.5(u)-334.3(RX)29.4(,)-331.1(H)0(a)29.9(s)0.1(s)30.6(e)0.1(l)30.6(l)-332.8(AM)29(,)-331.1(V)65.6(a)16.9(n)0(d)23.4(e)0.1(r)20.2(w)17.2(al)25.5(l)-332.8(D)0(,)-308.8(L)0(a)27.5(m)0(b)27.8(e)0.1(r)27.8(t)-330.5(MH)30.2(,)-331.1(H)0(o)29.4(l)0.1(m)22.4(e)0.1(s)-315.4(W)20.2(D,)-316.4(L)18.2(u)0(t)25.5(h)0(e)25.6(r)]TJ
1.1988 -1.1988 TD
(MA)Tj
/F3 1 Tf
2.4811 0 TD
[(et)-833.2(al)27.9(.)]TJ
/F2 1 Tf
3.5434 0 TD
[(\()20.3(2)0(0)21.2(0)18.2(0\))23.2(.)-847(A)0(t)30.3(o)16.4(mi)22.4(c)-846.3(s)0.1(t)30(r)0.1(u)27.9(c)0.1(t)29.5(u)0(r)28(e)-850.5(of)-839.3(P)18.2(D)0(E)25.4(4)0(:)-836.4(i)16.2(ns)30.3(ig)26.1(ht)29.6(s)-853.4(i)16.2(nt)29.6(o)]TJ
-6.0245 -1.1988 TD
[(ph)23.4(o)16.4(s)0.1(p)31.3(h)0(o)27.6(d)0(i)28.4(e)0.1(s)26(t)18.5(er)27.8(as)28.4(e)-273.8(m)0(e)28.3(c)18.7(ha)28(ni)27.3(sm)-255.4(a)-271.4(s)0.1(p)23.8(e)0.1(c)33.1(i)16.2(fi)25.4(ci)27.2(t)18.5(y)81.7(.)]TJ
/F3 1 Tf
20.0463 0 TD
-0.0162 Tc
[(Sc)-16.2(i)15.5(e)-16.2(n)11.6(c)-16.2(e)]TJ
/F10 1 Tf
3.2095 0 TD
0.0001 Tc
[(28)25.3(8)]TJ
/F2 1 Tf
1.7375 0 TD
-0.03 Tc
[(:)-300.5(1)-30.1(82)-30.1(2)-8.9(–)-30(18)-30.1(25)-30.1(.)]TJ
ET
1 i 
307.842 749.367 239.131 -0.227 re
f
BT
/F1 1 Tf
5.9774 0 0 7.9702 307.8424 761.8392 Tm
-0.0001 Tc
[(PDE4)-332.8(inhibitors)-335.3(and)-325.8(respiratory)-335.9(disease)]TJ
/F9 1 Tf
0 -1.2519 TD
[(D)-328.5(Spina)]TJ
7.0982 0 0 9.4646 534.1038 751.8612 Tm
0.0001 Tc
(315)Tj
ET
307.842 40.932 239.131 -0.283 re
f
BT
/F4 1 Tf
6.0123 0 0 8.4682 405.2408 31.2378 Tm
[(British)-322.5(J)0.1(ournal)-334(of)-334.4(Pharmacolog)18.7(y)-339.1(\(2008\))]TJ
/F1 1 Tf
17.5955 0 TD
(155)Tj
/F4 1 Tf
2.0462 0 TD
(308–315)Tj
ET

 Q
q
q 1 0 0 1 0 0 cm /Xi8 Do Q
Q


Q

q
0.0 0.0 595 794 re
W
n
1 0 0 1 0 0 cm
BT
/F1-0 12 Tf
14.4 TL
ET
0.619608 0.619608 0.619608 rg
/gRLs0 gs
n
404 29 143 10 re
f*
0.619608 0.619608 0.619608 rg
n
307 751 111 19 re
f*
0.619608 0.619608 0.619608 rg
n
533 752 14 8 re
f*
0.619608 0.619608 0.619608 rg
n
573 134 14 414 re
f*
0.619608 0.619608 0.619608 rg
n
574 3 12 456 re
f*
0.156863 0.662745 0.360784 rg
n
49 137 241 585 re
f*
0.156863 0.662745 0.360784 rg
n
306 139 241 587 re
f*
1 0 0 rg
/gRLs1 gs
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 292 712 cm
BT
1 0 0 1 0 0 Tm
(1) Tj
T*
ET
Q
1 0 0 rg
BT
/F1-0 10 Tf
14.4 TL
ET
q
1 0 0 1 549 716 cm
BT
1 0 0 1 0 0 Tm
(2) Tj
T*
ET
Q
Q


endstream
endobj
258 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Name /F1
/Subtype /Type1
/Type /Font
>>
endobj
259 0 obj
<<
/BBox [ 0 0 595 794 ]
/Filter /FlateDecode
/FormType 1
/Matrix [ 1 0 0 1 0 0 ]
/Resources <<
/Font <<
/F1 120 0 R
>>
/ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ]
>>
/Subtype /Form
/Type /XObject
/Length 286
>>
stream
xœuP=oÂ0İó+Şø#)$´SKË„ÄĞHJ'¹£Äì âß×.j§vy:İé}Ü{*¾‘X°e›Ì%$ùŠÈó‚Épè“	ä]¾\d…œ!¢˜!›áÙ^LgUCZg{Æqğ÷œWƒN•gÖtÚP§+§Ü•]tGWVÛ7Vs)˜YÁ«ãÀ¢ ËDêŠµ­NÂ&`M3¼EvßRØŞ´`Şå’‹OEš}0¼a<Jr½‡2M2µ5ûÉO²ÿ‘6´yıKÛO£ÍŸö­up§<l‹“§ì¡Ü¨ë¸SğiÏäL(&¼s©aèt­ª°v¤F}ƒíûo«k2¦å1‰ÕÜ0´şR&_üT„¸
endstream
endobj
260 0 obj
<<
/BitsPerComponent 8
/ColorSpace 62 0 R
/Filter /FlateDecode
/Height 99
/Width 74
/Length 830
>>
stream
H‰ìU‹nÛ@Óÿÿ ~gX{|éÎqÚ"+ä†%®}Ö‘Åt¿Wåúa¥¿i®`üW«ğQëÏ…K|ğ»úåÔş¯uÒ2YëÛ>Kıj<şóÖ:¬QiãgwÖUáÀ¥”:®ïr|ñÕ¢ÑÍÂâÔÍ+µ(øµ7ïóF©©Å†‡¤ı4İ±Æ^1Ç°Do~ÏCõ¾µ§À0°X˜IÏÒİè:Ï‹—[¼CšXÓT¤è°m—&†Š‰Kq# lŠ«1M)m# wl<p'ºctŠ q*kf›í:T3¨Mv°QKJ@¿ŞkáÈµW5w!ÍCq‚é÷– >-Ü2*¯X÷ˆa]Íô±7ÑuaZÓØvÜ›Ñ)«…	ÛcÏ¢Yá;´Ÿ®öºŞÃÌBKzæaC›ç[!ƒ]NÒ Áß”şB(‡ãñ2Õ=@b€k²\x9€Ã)}^›®úÍeª\ô í$LÙ†°eâ›t£T[¼°…ÈêùÃÜwÒÔ­©K›óº¶’%H‰Õ“ŞuDµıøÍòççòôµe­NÇe> ÌzûYÄ"­%é=ço,B·	%“‡¦d)7c4½å0¨I¶gÁz×- aƒ>­hH«ÌìØéî´q²	˜ ôØ¸&ä[FòZ”Ë®M#Û´Å†Ko¸­8´/sòøz2±áÒ(6ôÜ3×*àeoè‹<^Ş·2äæ¹LQóôóÂ_:(7:ùñíT®iD¢%e˜Áò)ç
AÊş›Áº)Lr‘t“€jfº·DÎ	¶(I[§±ë²R„ó©%™¿ç| Lux"ßÚèYø’e]?û#x3*.ÙÉ‚4…Â&T]¡„QYô´^Ê|©É7g34°^èfB9Êx¶ëé^×š–1K&lHîQ´°5· ~‡—ÒdŸ;à‹ë¤SÙgæç5ÎøâƒŸü%7HÔÚoÚ\âo¨•¥Š“‚sƒºŠPŒ3.YJ“°´çœÍ"ÿ†ÃvÙ{`HİˆFc„ˆÚªÈ×†•"Ö0 _0ì{½×{ıÒªÇë·áıWëÏ ß¢Ck
endstream
endobj
xref
0 261
0000000000 65535 f 
0000000015 00000 n 
0000000054 00000 n 
0000000168 00000 n 
0000000217 00000 n 
0000000805 00000 n 
0000000918 00000 n 
0000001031 00000 n 
0000001143 00000 n 
0000001256 00000 n 
0000001369 00000 n 
0000001483 00000 n 
0000001595 00000 n 
0000001708 00000 n 
0000001822 00000 n 
0000001936 00000 n 
0000002050 00000 n 
0000002163 00000 n 
0000002277 00000 n 
0000002391 00000 n 
0000002505 00000 n 
0000002617 00000 n 
0000002729 00000 n 
0000002840 00000 n 
0000003116 00000 n 
0000018347 00000 n 
0000018419 00000 n 
0000019078 00000 n 
0000019570 00000 n 
0000022005 00000 n 
0000022113 00000 n 
0000022783 00000 n 
0000023527 00000 n 
0000028754 00000 n 
0000029420 00000 n 
0000029906 00000 n 
0000033655 00000 n 
0000034318 00000 n 
0000035008 00000 n 
0000038433 00000 n 
0000039096 00000 n 
0000039492 00000 n 
0000041361 00000 n 
0000041898 00000 n 
0000042136 00000 n 
0000043318 00000 n 
0000043500 00000 n 
0000043570 00000 n 
0000043809 00000 n 
0000044109 00000 n 
0000044410 00000 n 
0000044585 00000 n 
0000044653 00000 n 
0000044883 00000 n 
0000045213 00000 n 
0000045499 00000 n 
0000046168 00000 n 
0000046638 00000 n 
0000048991 00000 n 
0000049336 00000 n 
0000049537 00000 n 
0000053807 00000 n 
0000054300 00000 n 
0000054351 00000 n 
0000054761 00000 n 
0000055572 00000 n 
0000055685 00000 n 
0000055796 00000 n 
0000055910 00000 n 
0000056022 00000 n 
0000056136 00000 n 
0000056250 00000 n 
0000056364 00000 n 
0000056478 00000 n 
0000056592 00000 n 
0000056706 00000 n 
0000056820 00000 n 
0000056934 00000 n 
0000057048 00000 n 
0000057162 00000 n 
0000057275 00000 n 
0000057389 00000 n 
0000057502 00000 n 
0000057616 00000 n 
0000057730 00000 n 
0000057844 00000 n 
0000057958 00000 n 
0000058072 00000 n 
0000058186 00000 n 
0000058300 00000 n 
0000058414 00000 n 
0000058528 00000 n 
0000058642 00000 n 
0000058756 00000 n 
0000058870 00000 n 
0000058984 00000 n 
0000059098 00000 n 
0000059212 00000 n 
0000059326 00000 n 
0000059440 00000 n 
0000059554 00000 n 
0000059669 00000 n 
0000059784 00000 n 
0000059899 00000 n 
0000060013 00000 n 
0000060128 00000 n 
0000060243 00000 n 
0000060358 00000 n 
0000060473 00000 n 
0000060588 00000 n 
0000060703 00000 n 
0000060818 00000 n 
0000060933 00000 n 
0000061048 00000 n 
0000061163 00000 n 
0000061278 00000 n 
0000061393 00000 n 
0000061508 00000 n 
0000081233 00000 n 
0000081342 00000 n 
0000081879 00000 n 
0000081980 00000 n 
0000082612 00000 n 
0000083277 00000 n 
0000083391 00000 n 
0000083506 00000 n 
0000083621 00000 n 
0000083736 00000 n 
0000083850 00000 n 
0000083964 00000 n 
0000084078 00000 n 
0000084192 00000 n 
0000084307 00000 n 
0000084422 00000 n 
0000084537 00000 n 
0000084652 00000 n 
0000084767 00000 n 
0000084882 00000 n 
0000084997 00000 n 
0000085112 00000 n 
0000085227 00000 n 
0000085342 00000 n 
0000085457 00000 n 
0000085572 00000 n 
0000085687 00000 n 
0000085802 00000 n 
0000085917 00000 n 
0000086031 00000 n 
0000086146 00000 n 
0000086261 00000 n 
0000086376 00000 n 
0000086491 00000 n 
0000086606 00000 n 
0000086721 00000 n 
0000086834 00000 n 
0000086947 00000 n 
0000105502 00000 n 
0000105611 00000 n 
0000106148 00000 n 
0000106662 00000 n 
0000107274 00000 n 
0000107388 00000 n 
0000107502 00000 n 
0000107614 00000 n 
0000107728 00000 n 
0000107842 00000 n 
0000107955 00000 n 
0000108070 00000 n 
0000108185 00000 n 
0000108298 00000 n 
0000108411 00000 n 
0000108524 00000 n 
0000108636 00000 n 
0000108751 00000 n 
0000108866 00000 n 
0000108981 00000 n 
0000109095 00000 n 
0000109210 00000 n 
0000109325 00000 n 
0000109439 00000 n 
0000109554 00000 n 
0000109669 00000 n 
0000109784 00000 n 
0000109899 00000 n 
0000110012 00000 n 
0000128139 00000 n 
0000128248 00000 n 
0000128785 00000 n 
0000129293 00000 n 
0000129993 00000 n 
0000130107 00000 n 
0000130222 00000 n 
0000130337 00000 n 
0000130451 00000 n 
0000130566 00000 n 
0000130681 00000 n 
0000130794 00000 n 
0000130908 00000 n 
0000131023 00000 n 
0000131137 00000 n 
0000131251 00000 n 
0000131366 00000 n 
0000131480 00000 n 
0000131595 00000 n 
0000131708 00000 n 
0000131822 00000 n 
0000131934 00000 n 
0000132047 00000 n 
0000132158 00000 n 
0000132272 00000 n 
0000132387 00000 n 
0000132502 00000 n 
0000132617 00000 n 
0000132732 00000 n 
0000132847 00000 n 
0000132962 00000 n 
0000133077 00000 n 
0000133192 00000 n 
0000133307 00000 n 
0000133422 00000 n 
0000133537 00000 n 
0000133652 00000 n 
0000152808 00000 n 
0000152917 00000 n 
0000158116 00000 n 
0000158653 00000 n 
0000159213 00000 n 
0000159771 00000 n 
0000159886 00000 n 
0000160000 00000 n 
0000160115 00000 n 
0000160230 00000 n 
0000160345 00000 n 
0000160459 00000 n 
0000160574 00000 n 
0000160689 00000 n 
0000160802 00000 n 
0000160917 00000 n 
0000161031 00000 n 
0000161143 00000 n 
0000161257 00000 n 
0000161372 00000 n 
0000161487 00000 n 
0000161600 00000 n 
0000161712 00000 n 
0000182128 00000 n 
0000182237 00000 n 
0000182900 00000 n 
0000183208 00000 n 
0000184336 00000 n 
0000184873 00000 n 
0000185582 00000 n 
0000186004 00000 n 
0000213655 00000 n 
0000213764 00000 n 
0000214301 00000 n 
0000215341 00000 n 
0000215763 00000 n 
0000241243 00000 n 
0000241352 00000 n 
0000241889 00000 n 
trailer
<<
/Size 261
/Root 3 0 R
/Info 1 0 R
>>
startxref
242853
%%EOF
